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A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage (Purchaser’s
Guide) is an information source for employers on clinical preventive service benefit design.
This document provides guidance for the selection of clinical preventive services shown to
be effective by the U.S. Preventive Services Task Force (USPSTF), the Centers for Disease
Control and Prevention (CDC), and other authoritative organizations.
The Purchaser’s Guide builds upon the National Business Group on Health’s previous
publication, sponsored by the Robert Wood Johnson Foundation (RWJF) and reviewed by
the Agency for Healthcare Research and Quality (AHRQ): An Employer’s Guide to Clinical
Preventive Services — Improving Health. Improving Business (referred to as the Employer’s
Guide). 
The Purchaser’s Guide provides several new and important components that will assist
employers in improving coverage for clinical preventive services. Namely, the Purchaser’s
Guide includes the scientific evidence and detailed benefit language employers need to
implement comprehensive and structured clinical preventive service benefits.
Below is an annotated table of contents that describes
the information, resources, and tools provided in each
part of the Purchaser’s Guide. 
Introduction
Provides an overview of how the Purchaser’s Guide was
developed and background on the sources of its
recommendations.
Part I: The Role of Clinical Preventive
Services in Disease Prevention and Early
Detection
Provides information for employers on improving
beneficiary health and reducing healthcare costs
through the implementation of comprehensive and
structured clinical preventive service benefits within a
medical benefit plan.
A Purchaser’s Guide to
Clinical Preventive Services:
Moving Science into Coverage
Overview of a Purchaser’s Guide to 
Clinical Preventive Services
In order to protect and promote 
beneficiary health and control
healthcare costs, employers must
provide coverage for clinical 
preventive services.
Within a given benefit plan, employers
may select which preventive services
are covered and at what level. Many
preventive services are available. Some
are known to be effective; others are
known to be relatively ineffective or even
harmful; others may be effective but the
proof of effectiveness is weak. The
Purchaser’s Guide provides guidance for
the selection of clinical preventive 
services proven to be clinically effective




Part II: Summary Plan Description (SPD) Language Statements for
Recommended Clinical Preventive Service Benefits
Provides 46 condition specific summary plan description (SPD) language statements
designed to assist benefits staff as they design benefit structures, discuss clinical preventive
services with a healthcare consultant, set coverage guidelines with a health plan, or negotiate
covered services with a union or consumer group. The SPD language statements were
adapted from recommendations of the U.S. Preventive Services Task Force (USPSTF), the
Centers for Disease Control and Prevention (CDC), and other authoritative organizations. 
Each preventive service SPD statement contains detailed benefit language regarding the:
• Necessary content of the recommended clinical preventive service.
• Age at which the service should be initiated and ceased.
• Recommended frequency of the service. 
Applicable current procedural terminology (CPT) codes are provided for employers and health
plans to facilitate the implementation and reimbursement of clinical preventive service benefits.
Part III: Evidence-Statements for Recommended Clinical Preventive 
Service Benefits
Provides evidence-statements for each of the 46 recommended clinical preventive service
benefits. Each evidence-statement includes information about the:
• Prevalence and/or incidence of the condition.
• Risk factors associated with the condition.
• Economic burden of the condition and the economic benefit of early
identification/intervention.
• Cost-benefit/cost-effectiveness of the recommended intervention.
• Cost of the recommended preventive intervention. 
• Purpose of the preventive intervention.
• Benefits and risks of the preventive intervention.
Part IV: The Prioritization and Strategic Implementation of Clinical
Preventive Service Benefits 
Provides practical “how-to” information on the development and implementation of
structured clinical preventive service benefits. Real-world examples of each prioritization
method are provided. 
Part V: I Statements and C and D Recommendations and of the U.S.
Preventive Services Task Force (USPSTF) 
Provides information on clinical preventive services that were reviewed by the USPSTF, but
were not included in the Purchaser’s Guide because the USPSTF:
1. Found that there was insufficient evidence to make a recommendation either for or





2. Made no recommendation regarding the provision of the service based on an analysis
of evidence of effectiveness, benefits, and harms (C recommendation); or
3. Recommended against routine provision of the service for asymptomatic patients
based on an analysis of the evidence of effectiveness, benefits, and harms (D
recommendation).
This information may assist benefits staff in determining which clinical preventive services
currently offered in their health plan(s) should be re-evaluated and, possibly, eliminated.
Part VI: Leveraging Benefits: Opportunities to Promote the Delivery and
Use of Preventive Services
The Purchaser’s Guide is designed to help employers select and implement clinical preventive
services that are delivered by healthcare providers. Employers can strengthen prevention
efforts by supporting public health interventions that may occur in the workplace or
communities. Part VI provides information and tips for employers on promoting the
delivery and use of clinical and community-based preventive services, including:
• An overview of the Community Guide to Preventive Services. 
• A crosswalk between the recommendations proposed in the Purchaser’s Guide and the
Community Guide. 
• Case examples of large employers who have successfully implemented worksite health
promotion programs and/or supported community-based interventions.
Part VII: Resources & Tools
Provides additional information and resources on clinical preventive service benefit design,
including:
• The Life Course Charts — visual guides to clinical preventive services across the
lifespan
> Recommended Schedule of Preventive Care for Adults
> Recommended Schedule of Preventive Care for Children and Adolescents
> Recommended Schedule of Preventive Preconception, Prenatal, and 
Postpartum Care
• A crosswalk between the Purchaser’s Guide, the U.S. Preventive Services Task Force’s
A/B recommendations, the 2007 HEDIS® Measures, the NCQA State of Healthcare
Quality Report, and the U.S. Department of Health and Human Service’s Healthy
People 2010 Goals.
• Clinical Preventive Services Glossary
• Links to additional resources and cost-calculators.




An Introduction to A Purchaser’s Guide to Clinical
Preventive Services
Clinical Preventive Service Topic Selection
The clinical preventive services recommended for coverage in the Purchaser’s Guide were
selected by the National Business Group on Health with the technical assistance of experts
from two federal agencies, the Centers for Disease Control and Prevention (CDC) and the
Agency for Healthcare Research and Quality (AHRQ).
The Purchaser’s Guide coverage recommendations are mainly
based on the U.S. Preventive Services Task Force (USPSTF)
recommendations on clinical preventive services for the
general asymptomatic population. The USPSTF, sponsored by
the Agency for Healthcare Research and Quality (AHRQ)
(part of the U.S. Department of Health and Human
Services), is an independent panel of experts in primary care
and prevention that makes recommendations regarding
clinical preventive services after a careful review of the
scientific literature. The Purchaser’s Guide includes all of the
USPSTF “A” and “B”-rated recommendations published
before March 2006.
Recommendations from sources other than the USPSTF were
added to support USPSTF recommendations, or inserted in place of a USPSTF
recommendation, when:
1. No current USPSTF recommendation was available (e.g., screening for elevated
blood lead levels); or 
2. When a newer recommendation superseded the existing USPSTF recommendation
(e.g., lipids screening). 
In order to be included in the Purchaser’s Guide, clinical preventive service recommendations
were required to meet the following criteria:
1. Be based on medical evidence or recommended guidance.
2. Address a serious health threat in terms of morbidity (illness), mortality (death), or
quality of life (including risk of disability). 
3. Address a condition that results in substantial direct (e.g., treatment costs) or indirect
costs (e.g., absenteeism, lost productivity) for payers. 
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The Purchaser’s Guide also 
includes clinical preventive service 
recommendations from other 
recognized sources such as the Centers
for Disease Control and Prevention
(CDC); other Federal agencies such as
the National Health, Lung, and Blood
Institute (NHLBI), a division of the
National Institutes of Health (NIH); and
professional organizations such as the
American Academy of Pediatrics (AAP).
Forty-six (46) services met the inclusion criteria outlined on the previous page. These
services are discussed in further detail in Part II: Summary Plan Description (SPD) 
Language Statements for Recommended Clinical Preventive Service Benefits and Part III:
Evidence-Statements for Recommended Clinical Preventive Service Benefits. 
The evidence for clinical preventive services is growing. Purchasers are encouraged to
periodically check the U.S. Preventive Services Task Force (USPSTF) website
(www.ahrq.gov/clinic/uspstfix.htm) for up-to-date recommendations on clinical preventive
services.
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• Advisory Committee on Childhood Lead Poisoning Prevention (ACCLP)
• Advisory Committee on Immunization Practices (ACIP)
• Agency for Healthcare Research and Quality (AHRQ)
• Agency for Toxic Substances and Disease Registry (ATSDR)
• Alliance for Cervical Cancer Prevention; Program for the Appropriate use of Technology in 
Health (PATH)
• American Academy of Audiology
• American Academy of Bariatric Surgery
• American Academy of Family Physicians (AAFP)
• American Academy of Neurology
• American Academy of Pediatric Dentistry (AAPD)
• American Academy of Pediatrics (AAP)
• American Association of Clinical Endocrinologists (AACE)
• American Cancer Society (ACS)
• American College of Cardiology
• American College of Emergency Physicians (ACEP)
• American College of Obstetricians and Gynecologists (ACOG)
• American College of Preventive Medicine (ACPM)
• American College of Surgeons (ACS)
• American Dental Association (ADA)
• American Diabetes Association (ADA)
• American Heart Association (AHA)
• American Medical Association (AMA)
• American Psychological Association (APA)
• American Society of Addiction Medicine (ASAM)
• American Society of Clinical Oncology (ASCO)
• American Speech, Language, and Hearing Association
• Center for Medicare & Medicaid Services (CMS)
• Centers for Disease Control and Prevention (CDC)
• Committee on Educational Interventions for Children with Autism, National Research Council,
National Academies
• Directors of Speech and Hearing Programs in State Health and Welfare Agencies
• Employee Benefits Institute
• Food and Drug Administration (FDA)
• George Washington University, Center for Health Services Research and Policy
• Harvard Medical School
Figure A: Sources of Information Used in the Purchaser’s Guide 
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• Health Resources and Services Administration (HRSA)
• Healthy People 2010, U.S. Department of Health and Human Services
• Institute of Medicine (IOM)
• Internal Revenue Service (IRS), Department of Treasury
• International Agency for Research on Cancer (IARC)
• Jacobs Institute of Women’s Health (JIWH)
• Joint Committee on Infant Hearing (JCIH)
• Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure
• March of Dimes
• Maternal Child Health Bureau (MCHB)
• National Academy of Sciences (NAS)
• National Academy of Sciences, Institute of Medicine (IOM)
• National Association of Pediatric Nurse Practitioners (NAPNAP)
• National Business Group on Health
• National Cancer Institute (NCI)
• National Center for Education in Maternal and Child Health
• National Center for Health Statistics (NCHS)
• National Center for Hearing Assessment and Management (NCHAM)
• National Center for Injury Prevention and Control
• National Cholesterol Education Program (NCEP)
• National Cholesterol Education Program Adult Treatment Expert Panel-III
• National Health and Nutrition Examination Survey (NHANES)
• National Heart, Lung, and Blood Institute (NHLBI)
• National Highway Traffic Safety Administration (NHTSA)
• National Institute on Alcohol Abuse and Alcoholism (NIAAA)
• National Institutes of Health (NIH)
• National Institutes of Mental Health (NIMH)
• National March of Dimes Birth Defects Foundation
• National Osteoporosis Foundation (NOF)
• National Research Council, Committee on Educational Interventions for Children with Autism,
Division of Behavioral and Social Sciences and Education
• Partnership for Prevention
• Peer-reviewed research
• Preeclampsia Foundation
• Royal College of Obstetricians and Gynecologists
• Substance Abuse and Mental Health Services Administration (SAMHSA)
• U.S. Department of Agriculture (USDA)
• U.S. Department of Health and Human Services (USDHHS)
• U.S. Department of Transportation (DOT)
• U.S. Environmental Protection Agency (EPA)
• U.S. Preventive Services Task Force (USPSTF)
• U.S. Public Health Service (USPHS)
• U.S. Surgeon General
• World Health Organization (WHO)
Figure A:  Sources of Information Used in the Purchaser’s Guide (Continued)
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The Evidence for Clinical Preventive Services
All of the recommendations in the Purchaser’s Guide are based on science. 
The U.S. Preventive Services Task Force (USPSTF)
Most of the recommendations featured in the Purchaser’s Guide were adapted from the U.S.
Preventive Services Task Force (USPSTF). The USPSTF is recognized as the gold-standard
in clinical preventive service recommendations; it is an independent panel of experts in
primary care and prevention that conducts rigorous, impartial assessments of the scientific
evidence for the effectiveness of clinical preventive services.1
The USPSTF is mandated by Congress to evaluate preventive services and publishes
recommendations and evidence synthesis, which are the culmination of an extensive
literature review, debate, and analysis of critical comments from expert reviewers.1 USPSTF
recommendations are based on an objective process that weighs the benefits and the harms
of a preventive service. Each recommendation is given a letter grade (A-D, I) based on the
strength of evidence available to support the particular clinical preventive service and the
magnitude of net benefit for that service. The net benefit of a clinical preventive service is
defined as the benefits of the service (e.g., years of life saved through early cancer detection)
minus the harms of the service (e.g., risks associated
with false-positive test results). 
By definition, the foundational source of USPSTF
recommendations is research published in peer review
journals. USPSTF recommendations are therefore
limited to clinical preventive services that have been
systematically studied and published. Services that are
commonly provided in clinical practice but have not
been well-studied or have been poorly documented in
the literature may not be reviewed. For instance, some
interventions have not been systematically studied due
to ethical concerns (e.g., withholding treatment) or
lack of funding for research. In other cases, evidence
exists but it is conflicting. These interventions are
given an “I” rating (“I” for insufficient evidence) by
the USPSTF.
Evidence-Based Recommendations, Evidence-Based Medicine, 
and Evidence-Based Benefits
Many of the clinical preventive service recommendations presented in the Purchaser’s Guide
are evidence-based. Evidence-based services have a longer and stronger base of research to
support their efficacy, safety, and cost-effectiveness. Generally, the term “evidence-based”
refers to medical interventions that scientific studies have evaluated and determined to be
effective and to have a measurable effect on health outcomes. 
THE USPSTF publishes the annual
Guide to Clinical Preventive Services,
which includes abridged versions of the
USPSTF’s recommendations on screening,
counseling, and preventive medication
presented in a user friendly format for 
clinicians. The complete USPSTF 
recommendations and reviews are 
available on the web and provide 
information about which clinical 
preventive services should be delivered 
by prudent clinicians in the course of 
routine clinical care. For more information
on the USPSTF please visit:
www.ahrq.gov/clinic/prevenix.htm
To make the sources, types, and strength of scientific evidence used in the Purchaser’s Guide
fully transparent, each evidence-statement featured in Part III: Evidence-Statements for
Recommended Clinical Preventive Service Benefits contains an evidence-box as a summary. 
Each evidence-box contains the following information: 
• A description of where the information used in the recommendation originated from
(e.g., the American Academy of Family Physicians (AAFP), CDC, or the USPSTF).
i Introduction
8
All of the recommendations derived from the
USPSTF are evidence-based. Other recommendations
featured in the Purchaser’s Guide are based on
“recommended guidance.” Recommended guidance is
based on the best-available information for a given
topic, but lacks the scientific research support needed
to be considered evidence-based. 
Evidence-based medicine: Two common definitions of evidence-based medicine include
the following:
1. “Evidence-based medicine is the conscientious, explicit, and judicious use of current
best-evidence in making decisions about the care of individual patients. The practice of
evidence-based medicine means integrating individual clinical expertise with the best
available external clinical evidence from systematic research.”2
2. Evidence-based recommendations require, “First, good evidence that each test or pro-
cedure recommended is medically effective in reducing morbidity or mortality; second,
the medical benefits must outweigh the risks; third, the cost of each test or procedure
must be reasonable compared to its expected benefits; and finally, the recommended
actions must be practical and feasible.”2 [Note: The USPSTF does not consider cost as
a factor in its recommendations.] 
Recommended guidance: A recommendation or guideline that is based on the best
available information for a condition, disease, or health service, but that does not yet have
the scientific research support in order to be considered evidence-based (as determined
by a systematic review process). Expert opinion, expert judgment, and consensus opinion,
are considered forms of recommended guidance.
Evidence-based benefit design: Aims to promote healthcare with demonstrated 
effectiveness by providing “…more generous coverage for services supported by strong
evidence of effectiveness and less generous coverage for services that are unproven or
evidence indicates may be ineffective or unsafe, given patient characteristics and
history.”3
Definition Box B: Evidence
There is strong scientific evidence 
to support the provision of a broad
range of clinical preventive 
services for normal-risk children,
adolescents, and adults.
• The level of evidence used in constructing the recommendation:
> Evidence-based research
> Recommended guidance
• The strength of the evidence. For example, the USPSTF grades each of its clinical
preventive service recommendations on a 5-point scale (A-D, I). The grade is
determined by the strength of scientific evidence supporting a clinical preventive
service and the magnitude of net benefit (defined as benefits minus harms).4
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Figure C: Sample Evidence-Boxes
Strength of Evidence for the Clinical Preventive Service
(Colorectal Cancer Screening)
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research: 
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence) 
• The USPSTF found fair to good evidence that several screening methods
are effective in reducing mortality from colorectal cancer. The USPSTF
concluded that the benefits from screening substantially outweigh potential
harms, but the quality of evidence, magnitude of benefit, and potential
harms vary with each method.
Strength of Evidence for the Clinical Preventive Service
(Immunizations) 
The level of evidence supporting the recommendations contained in this 
chapter is described below
Recommended Guidance:
Advisory Committee on Immunization Practices (ACIP) 
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Expert Consensus
• The ACIP and CDC recommend that all children and adolescents with
no contraindications receive all routinely recommended childhood
vaccinations. Children and adolescents who fall into high-risk groups
because of health conditions, behaviors, or membership in certain
communities should receive additional immunizations.
• The ACIP and CDC recommend that all adults with no contraindications
receive three routinely recommended vaccines (age-dependent). Adults
who fall into high-risk groups because of health conditions, behaviors or
exposures, as well as those without a history of immunization for certain
diseases, should receive additional immunizations.
i Introduction
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Figure D: U.S. Preventive Services Task Force (USPSTF) Strength of Evidence Scale5
Figure E: American Academy of Family Physicians (AAFP) Strength of Evidence Scale6
A  Strongly Recommended
The USPSTF strongly recommends that clinicians provide the service to eligible
patients. The USPSTF found good evidence that the service improves important
health outcomes and concludes that the benefits substantially outweigh harms.
B Recommended
The USPSTF recommends that clinicians provide the service to eligible patients.
The USPSTF found at least fair evidence that the service improves important
health outcomes and concludes that the benefits outweigh harms.
C No Recommendation Either For or Against
The USPSTF makes no recommendation either for or against routine provision of
the service. The USPSTF found at least fair evidence that the service can improve
health outcomes but concludes that the balance of benefits and harms is too close
to justify a general recommendation.
D Recommend Against
The USPSTF recommends against routinely providing the service to asymptomatic
patients. The USPSTF found at least fair evidence that the service is ineffective or
that the harms associated with the service outweigh benefits 
I Insufficient Evidence in Order to Make a Recommendation
The USPSTF concludes that the evidence is insufficient to recommend for or
against routinely providing the service. Evidence that the service is effective is
lacking, of poor quality, or conflicting, and the balance of benefits and harms
cannot be determined.
SR Strongly Recommended
Good quality evidence exists which demonstrates substantial net benefit over
harm; the intervention is perceived to be cost-effective and acceptable to nearly all
patients. 
R Recommended
Although evidence exists which demonstrates net benefit, either the benefit is only
moderate in magnitude or the evidence supporting a substantial benefit is only
fair. The intervention is perceived to be cost-effective and acceptable to most
patients.
NR No Recommendation Either Either For or Against
Either good or fair evidence exist of at least a small net benefit. Cost-effectiveness
may not be known or patients may be divided about acceptability of the
intervention. 
RA Recommend Against
Good or fair evidence exist which demonstrates no net benefit over harm.
I Insufficient Evidence to Recommend Either For or Against
No evidence of even fair quality exists or the existing evidence is conflicting.
IHB Healthy behavior is identified as desirable, but the effectiveness of physician's
advice and counseling is uncertain.
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Prevention and Early Detection
The Role of Clinical Preventive
Services in Disease Prevention
and Early Detection
Overview:
Information for employers on
improving beneficiary health and
reducing healthcare costs 
through the implementation of  
comprehensive and structured
clinical preventive service
benefits within a medical 
benefit plan. Sections include:
• Promoting Health and
Reducing Costs 
• The Importance of Preventing
Chronic Disease









Clinical Preventive Services: Preventing Disease, 
Promoting Health, and Reducing Healthcare Costs
The goals of prevention are to:
• Encourage individuals to avoid or delay disease by practicing healthy lifestyles;
• Identify individuals who could benefit from treatment for a condition or
complication about which they are unaware; and
• Prevent further disability among individuals with established disease. 
There are three types of prevention: primary prevention, secondary prevention, and tertiary
prevention. Primary prevention is the prevention of a disease before it occurs; secondary
prevention is the early detection and treatment of disease to prevent progression; and tertiary
prevention is an intervention to reduce the amount of disability caused by a disease.1-2
The Role of Clinical
Preventive Services in
Disease Prevention and 
Early Detection
Prevention Helps Individuals Avoid Disease
Primary prevention is aimed at preventing the onset of disease. One way of doing
this is by controlling risk factors in healthy people that may lead to disease.
Examples of primary prevention include 1) immunizations to prevent communicable 
diseases such as influenza or polio, and 2) the promotion of physical activity to 
prevent conditions such as obesity that can lead to disease (e.g., type 2 diabetes).
Prevention Modifies Risk
Secondary prevention is aimed at treating a disease after its onset, but before it
causes serious complications. Secondary prevention includes 1) identifying 
individuals with established disease, and 2) treating those individuals in a timely way
so as to prevent further problems (e.g., mammography screening to detect and treat
breast cancer in its earliest stages).
Prevention Reduces Disability
Tertiary prevention is aimed at treating the late or final stages of a disease so as to
minimize the degree of disability caused by that disease (e.g., administering a foot
check to a person with diabetes to identify infections that would require amputation
if left untreated).1-2
Definition Box 1.0: Prevention
1
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1 The Role of Clinical Preventive Services in Disease Prevention and Early Detection
There are several different approaches to providing preventive services:
Clinical preventive services, the focus of this guide, include those services that are typically
performed in a clinical setting and are conducted by a health professional such as a
physician, nurse practitioner, physician assistant, or health educator. Although most clinical
preventive services should be conducted during individual face-to-face office visits, some
services may be conducted in groups, via the telephone, or by email communication.
Community-based preventive services (also known as population-based preventive services)
include any kind of planned activity or group of activities (including programs, policies, and
laws) designed to prevent disease or injury or promote health in a group of people (e.g.,
fluoridation of drinking water, bans on tobacco use in public places).3
Worksite-based preventive services are health promotion programs provided to employees
and their dependents. The expressed purpose of these services is to improve employee health
and prevent disease by providing an opportunity for employees to engage in primary
prevention activities. Examples include:
• Employer-sponsored worksite fitness centers or healthy cafeteria programs that
encourage healthy lifestyles. 
• Employer-sponsored health risk appraisals (HRAs) that identify employees at risk for
certain conditions and diseases (e.g., type 2 diabetes, heart disease, or hypertension)
and refer those employees to their health plan for continuing care.
• Employer-sponsored services such as employee assistance programs (EAPs) that can
help employees address health / lifestyle concerns, such as stress or substance use,
before the problems escalate into a clinical disorder (e.g., substance abuse, depression).
• Employer-initiated worksite smoking bans. 
• Employer-sponsored worksite influenza immunization clinics.
Preventive Interventions
There are several types of preventive interventions: screening, testing, counseling,
immunization, preventive medication, and preventive treatment. 
• Screening is best described as tests that assess the likelihood of the presence of a
disease or condition in an apparently healthy individual. Screening methods include
laboratory, X-ray, and similar technical methods; they also include questions asked by
a clinician. Screening may be targeted to people at increased risk due to age, gender,
family or personal history, or other factors. Each screening tool is different in design
and method, affecting the sensitivity (ability to correctly identify those with the
disease), specificity (ability to correctly identify those without the disease), and
positive and negative predictive values of the tool. Ideally, screening tests are rapid,
simple, and safe. It is important to note that, in most instances, screening is not a
definitive diagnostic test and that a positive result on a screening test merely indicates
that the screened individual has a higher likelihood of having the disease than a peer
with a negative result. Individuals who screen positive on such tests should have
confirmatory diagnostic tests to ensure an accurate diagnosis.4
• Testing refers to any process used to determine whether a condition is present (or not)
or to assess the status of a condition. Testing may involve questioning patients (e.g., a
mental status examination to determine whether thought processes are appropriate),
physical examination (e.g., examining a heart to detect a murmur or performing a
neurologic examination to detect nerve damage), or examining blood, body fluids, or
tissues (e.g., to detect anemia, to monitor levels of blood sugar, or to see if a cancer is
present in a biopsy sample). Testing may also require sophisticated technology, such as
CT or MRI scans and other X-rays, or invasive procedures, such as heart
catheterization to detect blockage of coronary arteries. Tests may be used to:
> Screen individuals who have risk factors, but no indication of having the
condition;
> Diagnose individuals who have symptoms and signs of a condition but where a
test will add certainty about the diagnosis; or 
> Monitor the progress of an individual who is being treated or being considered
for treatment, such as monitoring blood pressure over time.
• Counseling refers to a discussion between a clinician and patient about ways that
changes in personal behavior can reduce risk of illness or injury. The goal of
counseling is for clinicians to educate patients about their health risks as well as to
provide them with the skills, motivation, and knowledge they need to address their
risk behaviors (e.g., 5A framework for tobacco cessation: Ask, Advise, Assess, Assist,
Arrange). A special kind of counseling, “informed decision making,” recognizes that
people make different decisions even though their situations may seem to be similar.
Informed decision making is structured to give an individual all the information
needed to choose among different clinical options, such as whether or not to undergo
genetic testing.
• Immunization protects an individual from a specific communicable disease (e.g.,
measles) by exposing the individual to an antigen or a trace amount of inactivated
disease-causing agent, spurring the development of natural immunity.
• Preventive Medications are used to prevent the onset of disease (e.g., aspirin therapy
to prevent cardiovascular events).
• Preventive Treatment involves a procedure intended to prevent the occurrence of a
disease or to prevent the progression of a disease from one stage to another. Preventive
treatments usually refer to the use of prescription or over-the-counter (OTC)
medications, but they may also involve prescriptions for lifestyle changes (e.g.,
exercise, diet change) or other interventions. Some surgical procedures may be
considered “preventive treatment,” such as when polyps in the colon identified during
a screening colonoscopy are removed in order to prevent their progression to cancer
lesions.
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The Importance of Preventing
Chronic Disease
Chronic diseases result in a significant amount of
preventable morbidity and mortality in the
United States. In 2000, 46.7% of all deaths in the
United States were caused by modifiable health
behaviors (see Table 1.1).5 The U.S. Department
of Health and Human Services estimates that
approximately 33% of all deaths in the United
States are attributable to just three modifiable health behaviors: smoking, physical inactivity,
and poor eating habits.2
Chronic diseases are the leading cause of direct
healthcare costs. In fact, researchers estimate that
75% of all healthcare costs directly stem from
preventable chronic health conditions such as type 2
diabetes, hypertension, and obesity.7-8 Chronic
diseases are also a major cause of lost productivity
and disability. For example:
• In 2002, the average annual healthcare cost for
a person with diabetes was $13,243 as opposed
to $2,560 for a person without diabetes.9
• It is estimated that the indirect cost of
cardiovascular disease will total over $145 billion in 2006.10
• Each year, an estimated 39 million work days are lost to obesity-related illnesses.11
• In 1999, lost productivity due to smoking, and smoking-related illnesses cost
employers $1,897 per smoking employee.12 Excess medical expenses due to smoking
and smoking related illnesses cost employers $1,850 per smoking employee (both
figures adjusted to year 2002 dollars).12
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1 The Role of Clinical Preventive Services in Disease Prevention and Early Detection
In 2005, NCQA identified 44.5 million
sick days due to suboptimal care 
for hypertension and diabetes, two
preventable chronic diseases. The
lost productivity associated with
these disorders exceeded $7 billion.6
Each individual’s health is shaped by many factors including medical care, social 
circumstances, and behavioral choices. Increasingly, there is clear evidence that the major
chronic conditions that account for so much of the morbidity and mortality in the United States,
and the enormous direct and indirect costs associated with them, in large part are preventable
— and that to a considerable degree they stem from, and are exacerbated by, individual 
behaviors….. As Americans see healthcare expenditures continue to increase, it is important to
focus on strategies that reduce the prevalence and cost of preventable diseases.5
– U.S. Department of Health and Human Services, 2003
Prevention Makes Common “Cents”
Researchers estimate that 75% of 
all healthcare costs directly stem
from preventable chronic health 
conditions, yet only 1% of the 
$1.9 trillion dollars spent on
health care in the United States is
devoted to protecting health and
preventing illness and injury.7-8
27































Table 1.1: Percent of all Deaths in the United States Attributable to Selected Modifiable
Health Behaviors, 1990-200013
Figure 1.2: Underlying Causes of Death in the United States, 200013
Tobacco use

















Source: Mokdad A, Marks JS, Stroup DE, Gerberding JL. Actual causes of death in the United States. JAMA
2004; 291(10): 1238-1245. * Correction published: Mokdad A, Marks JS, Stroup DE, Gerberding JL.
Correction: Actual causes of death in the United States 2000. JAMA 2005; 293(3): 293-294.
Source: Mokdad A, Marks JS, Stroup DE, Gerberding JL. Actual causes of death in the United States. JAMA
2004; 291(10): 1238-1245.* Correction published: Mokdad A, Marks JS, Stroup DE, Gerberding JL.
Correction: Actual causes of death in the United States 2000. JAMA 2005; 293(3): 293-294.
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The Value of Prevention
Purchasers can avoid or reduce the costs associated with preventable conditions by offering
coverage for — and promoting the use of — clinical preventive services. 
• Clinical preventive services can help individuals avoid disease altogether (e.g., tobacco
use treatment).
• Clinical preventive services can also catch disease it in its earliest stages (e.g., cervical
cancer screening). Identifying patients with early stage disease allows clinicians to
begin treatment sooner, when interventions are generally more effective and less
expensive. Early detection and treatment of some important infectious diseases can
also prevent spread of infection to others (e.g., influenza).
• Disease avoidance and early identification have financial benefits for employers
including: 
> Averted medical costs; and
> Reductions in absenteeism, lost productivity, turnover, and disability.
Like any investment aimed at keeping a workforce
healthy and productive, clinical preventive services
offer value. The value of a preventive service is
determined by its ability to prevent a significant
amount of morbidity and mortality in relation to
the cost of offering the service. Because offering a
clinical preventive service has a real (monetary)
cost and an opportunity cost (there is a finite amount of services that can be delivered and
received in a given period of time), it is important for purchasers to quantify the value of
clinical preventive services in relation to one another when making coverage decisions.
The effectiveness of most clinical preventive services, particularly those considered evidence-
based, is well-documented. The effectiveness of clinical preventive services recommended in
the Purchaser’s Guide is detailed in Part III: Evidence-Statements for Recommended Clinical
Preventive Service Benefits. The cost-effectiveness (or economic value) of clinical preventive
services is described below. More information on the economic value of preventive
intervention can be found in each evidence-statement.
1 The Role of Clinical Preventive Services in Disease Prevention and Early Detection
Research shows that employees 
who take advantage of preventive
services have lower absenteeism,
higher productivity, and a stronger
commitment to their employer.14
Examples of Avoided Costs
The average dollar spent on:
• Alcohol misuse screening and brief counseling interventions saves $4 in healthcare costs.15-16
• The Hib vaccine (to prevent invasive bacterial infections) saves $1.40 in direct medical
costs and $2.00 in indirect costs.17
• The hepatitis B vaccine saves 50 cents in direct medical costs and $3.10 in indirect costs.17
• The varicella vaccine (to prevent chickenpox) saves 90 cents in direct medical costs and
$5.40 in indirect costs.17
• Chlamydia testing and treatment saves $12 in complications arising from chlamydia.17
Cost-Saving Clinical Preventive Services
A health intervention is cost-saving when the
intervention is 1) effective and 2) costs less in the
long run than the cost of not intervening. For
example, the cost of vaccinating all children in a
given population against measles is less than the cost of treating the children who would
contract measles without the population-wide protection of immunization. 
Cost-Effective Clinical Preventive Services
A medical intervention is considered cost-effective when the intervention provides a health
benefit at an acceptable cost. The term “acceptable cost” is not precisely defined and
involves important ethical considerations such as the value of a life. The answer to this
question boils down to a concept called “willingness-to-pay”: for example, how much is an
individual, an employer, or a society willing to pay to extend the life of one individual for
one year? Some conditions produce life- and work-altering disability, but not premature
death. Economists can use willingness-to-pay methods to assess the cost-effectiveness of
methods to prevent or modify disabilities as well. In the United States, there is no
universally accepted answer to the “willingness-to-pay” question and, thus, no universally
accepted threshold that distinguishes a cost-effective health intervention from an
intervention that is not cost-effective. 
In order to compare and rank various preventive interventions, economists use cost-
effectiveness (CE) ratios. A CE ratio is calculated as the ratio of differences in costs and
outcomes of the status quo and the proposed intervention according to the following
formula:
A CE ratio can be interpreted as the “price” of accepting a new intervention. The lower the
price, the more cost-effective the new intervention.
For more information on defining 
the value of preventive services and
prioritizing services for inclusion in a
medical benefit plan, please refer to
Part IV: The Prioritization and




(Outcome with intervention – Outcome without intervention)
(Cost with intervention – Cost without intervention)
Health economists use several terms to explain the cost, benefit, and overall value of a
clinical preventive service. The following terms are used throughout the Purchaser’s
Guide to describe the economic benefits of clinical preventive services.
Cost-saving: The reduction in healthcare costs resulting from the intervention or 
program exceeds the money required to develop, implement, and maintain the 
respective intervention or program.
Cost-effective: The net cost per unit of health generated is favorable relative to other
health services.
High-value: An intervention that prevents a substantial amount of morbidity and/or
mortality and is cost-effective.
Definition Box 1.3: Health Economics Terms
Quality Adjusted Life Years (QALY)
Outcomes in cost-effectiveness analysis (CEA) are usually measured in terms of number of
life years saved as a result of implementation of a new intervention. For interventions with
multiple health endpoints (e.g., hospitalization, treatment, death, etc) an outcome measure
needs to combine information on both morbidity (a measure of clinical illness) and
mortality (the number of deaths in the population under consideration). The best known of
these is the quality-adjusted life year or QALY. In principle, QALYs are based on the
preferences or “utilities” of respondents reflecting tradeoffs among different health states
(e.g., total cure, partial cure, disability, death). A preference or utility weight or score of 1.0
represents perfect health and 0 represents death. The number of QALYs is calculated as the
sum of the duration spent in each health state times the utility weight for that health state.
For example, if the utility weight for a chronic condition is 0.6, and an individual remains
in that health state for 1 year and then dies, the number of QALYs is 0.6. QALYs provide a
common currency that permits comparisons among different people and across different
kinds of conditions. QALYs permit comparisons of diseases that are rapidly fatal with those
that do not produce death but instead produce years of severe disability.
The results of a CEA may be interpreted to determine whether an intervention yields good
value for the investment. An intervention can be considered more or less cost-effective
relative to either another intervention or to a benchmark value. Cost-effectiveness (CE)
ratios are usually expressed in dollars per QALY. The lower the number, the more cost-
effective the intervention.
It is commonly said that an intervention that costs more than $50,000 or $100,000 per
QALY is not cost-effective, but a substantial number of healthcare interventions generally
accepted in the United States have higher CE ratios.18 The use of a fixed cost-effectiveness
threshold to define cost effectiveness ignores other determinants of social value such as
perceptions of risk. Further, the Partnership for Prevention has estimated ranges of CE ratios
using standardized methods for 25 clinical preventive services recommended for the general
population by the U.S. Preventive Services Task Force (USPSTF).19 The investigators used a
utility weight of 0.7 for chronic conditions, along with other simplifying assumptions that
make the results difficult to compare with the published CE ratios from studies that are
reported in the Purchaser’s Guide. The investigators found that one-fifth of all recommended
clinical preventive services had CE ratios between $165,000 and $450,000 per QALY in
year 2000 dollars.
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1 The Role of Clinical Preventive Services in Disease Prevention and Early Detection
High-Value Clinical Preventive Services
Many preventive services are considered to be of high-value, meaning they are both cost-
effective (they cost a “reasonable” amount of money for the added quality of life or life years
gained) and prevent a substantial proportion of disease or injury when delivered appropriately.
The National Commission on Prevention Priorities (NCPP), a blue-ribbon panel of thought-
leaders on prevention chaired by former Surgeon General Dr. David Satcher and staffed by
Partnership for Prevention, recently ranked the health impact and cost-effectiveness of 25
preventive services recommended by the U.S. Preventive Services Task Force (USPSTF) and the
Advisory Committee on Immunization Practices (ACIP). Please refer to Part IV: The Prioritization 
of Clinical Preventive Services in a Strategic Implementation Plan for more information.
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HIGH-VALUE CLINICAL       AS NOTED IN THE DESCRIPTION
PREVENTIVE SERVICE      PURCHASER’S GUIDE
CE RATIO  $0/QALY (Defined as Cost-Saving)
Aspirin Chemoprophylaxis











Aspirin Therapy for the Prevention of
Cardiovascular Disease, Counseling
Tobacco Use Treatment, Screening,
counseling, and treatment
Colorectal Cancer, Screening
Immunizations (Child, Adolescent, Adult)
Alcohol Misuse, Screening and counseling
Hypertension, Screening, counseling, 
and treatment
Cervical Cancer, Screening
Not included in the Purchaser’s Guide
Lipid Disorders, Screening, counseling, 
and treatment
Breast Cancer, Screening
Discuss the benefits/harms of daily
aspirin use for the prevention of
cardiovascular events with men  40,
women  50, and others at increased
risk.
Screen adults for tobacco use, provide
brief counseling, and offer
pharmacotherapy.
Screen adults aged  50 years routinely
with FOBT, sigmoidoscopy, or
colonoscopy.
Immunize adults aged  50 against
influenza annually. 
Screen adults routinely to identify
those whose alcohol use places them at
increased risk and provide brief
counseling with follow-up.
Measure blood pressure routinely in all
adults and treat with antihypertensive
medication to prevent incidence of
cardiovascular disease.
Screen women who have been sexually
active and have a cervix within 3 years
of onset of sexual activity or age 21
routinely with cervical cytology (Pap
smears).
Counsel adolescent and adult women
to use calcium supplements to prevent
fractures.
Routinely screen for lipid disorders
among men aged  35 and women
aged  45 and treat with lipid-
lowering drugs to prevent the incidence
of cardiovascular disease.
Screen women aged  50 routinely
with mammography alone or with
clinical breast examination, and discuss
screening with women aged 40 to 49 to
choose an age to initiate screening.
Table 1.4: Cost-Effectiveness Gradient Based on Partnership for Prevention’s Ranking of
Clinical Preventive Services Targeted to Working Age Adults19
$0/QALY  CE RATIO  $14,000/QALY
$14,000/QALY  CE RATIO  $35,000/QALY
$35,000/QALY   CE RATIO  $165,000/QALY
Relevance to Business
While economic analyses of cost-effectiveness focus on the overall costs and benefits to
society and the healthcare system, business case analyses of the value of clinical preventive
services estimate the financial return-on-investment (ROI) to individual employers,
healthcare plans, or providers. Those who pay for services are not necessarily the ones who
obtain the full financial return, however. Interventions that are cost-effective or even cost-
saving at the societal level do not necessarily yield a positive ROI from the business
perspective, although they may provide a better value than other services.20
The “Value of Prevention” in the Purchaser’s Guide
Each evidence-statement contains a “Value of Prevention” section that provides detailed
information on the economic burden, including the workplace burden, of the condition/
disease and information on the estimated cost of implementing the recommended preventive
intervention. Select chapters also include information on the cost of treatment. A sample
section is provided on the following page. 
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Obesity, Screening, counseling, and treatment
Depression, Screening
Diabetes (type 2), Screening
Healthy Diet, Counseling
Immunizations (Child, Adolescent, Adult)
Screen all adult patients routinely for
obesity and offer obese patients high-
intensity counseling about diet, exercise,
or both together with behavioral
interventions for at least 1 year.
Screen adults for depression in clinical
practices that have systems in place to
assure accurate diagnosis, treatment,
and follow-up.
Screen for diabetes in adults with high
cholesterol or hypertension, and treat
with a goal of lowering levels below
conventional target values.
Offer intensive behavioral dietary
counseling to adult patients with
hyperlipidemia and other known risk
factors for cardiovascular and diet-
related chronic disease.
Immunize adults every 10 years.
$165,000/QALY  CE RATIO  $450,000/QALY
Table 1.4: (Continued)
Source: Maciosek MV, Coffield AB, et al. Priorities among effective clinical preventive services: results of a
systematic review and analysis. Am J Prev Med 2006;31(1): 55-6.
HIGH-VALUE CLINICAL       AS NOTED IN THE DESCRIPTION
PREVENTIVE SERVICE      PURCHASER’S GUIDE
Promoting Effective and Appropriate Clinical Preventive
Services
The Underutilization of Preventive Care
Despite the documented benefits of timely preventive care, in 2002, only half of insured
adults (52%) received preventive care and screening tests according to guidelines for their
age and sex.30 The underutilization of clinical preventive services has a negative impact on
beneficiaries’ health status and on employers’ overall healthcare costs. For example, in 2004
the National Committee for Quality Assurance (NCQA) identified 7,600 excess cases of
late-stage breast cancer, 20,000 excess cases of late-stage colorectal cancer, and 21,000 excess
osteoporosis-related fractures that could have been averted if individuals received appropriate
and timely preventive care.6 Had these conditions been effectively prevented, $485.2 million
in excess medical expenses could have been avoided.6 
Reasons for the underutilization of preventive care are complex. In the past, preventive
services were poorly covered by health insurance policies in comparison to care for acute
services and medications. Differential coverage created perceived and real access barriers for















Obesity contributes significantly to medical costs in the United States. In 1998,
9.1% of total annual medical expenditures could be attributed to obesity.21
Between 1987 and 2001, 27% of the growth in inflation-adjusted per-capita
healthcare spending was associated with obesity.22 The annual cost of obesity is
estimated to range from $69 billion to $117 billion (including $61 billion for
direct medical expenses and $56 billion for indirect expenses such as lost
productivity [in year 2000 dollars]).23
The expected lifetime costs of cardiovascular disease (including coronary heart
disease, heart attack, and stroke) increase by 20% with mild obesity (class I: BMI
of 30 to 34.9), 50% with moderate obesity (class II: BMI of 35 to 39.9), and
nearly 200% with severe obesity (class III: BMI of 40 or higher).24 One large
health plan found that its yearly total medical claims were 18% higher for
overweight individuals and 32% higher for obese than for healthy-weight
individuals.25
A 2001 study found obese adults had, on average, about 37% higher healthcare
expenses per person than normal-weight adults. This excess expense increased
private healthcare spending by nearly 12% (more than $36 billion).22
The cost to employers of obesity-related health problems in 1994 was estimated
to be $13 billion per year, including $8 billion in medical claims, $2.4 billion in
paid sick leave, $1.8 billion in life insurance, and almost $1 billion in disability
insurance.24
Obesity and related illnesses are also a major cause of disability.  Each year, an
estimated 39 million work days are lost to obesity-related illnesses.22
Nutrition education, diet, and exercise counseling are effective interventions for
obesity prevention and have the potential to significantly reduce the direct and
indirect costs of obesity-related illnesses. Researchers have estimated that even a
modest reduction of 10% in body weight in an obese individual might reduce
the expected lifetime healthcare costs of major obesity-related diseases for the
individual by $2,200 to $5,300, depending on age, sex, and initial BMI.26
The cost of BMI screening is negligible when height and weight measurements
are already recorded as part of a routine physical exam. In 2004, the private-
sector cost of obesity counseling averaged $39 per session; approximately 95% of
all paid claims fell within the range of $0 to $129 per session.27
In the United States, the costs associated with treating obesity vary by location,
provider type, and treatment modality. For example, in 2006 the average wholesale
price of a 1-month supply of pharmacological therapy for obesity was $207.04 for
orlistat (Xenical“) (120 mg three times daily) and $423.60 for a 3-month supply of
sibutramine (Meridia“) (15 mg daily).28 In contrast, the average price of a surgical
procedure for obesity in 2004 ranged from $20,000 to $35,000.29
Obesity Sample
the value of prevention and the healthcare system’s
lack of capacity to effectively track, promote, and
deliver clinical preventive services. Even today, too
little time and too few resources are devoted to
prevention. In order to increase the utilization of
clinical preventive services, all stakeholders will
need to increase their investments in prevention.
Emphasizing Effective and Appropriate
Clinical Preventive Services
Not only is the underutilization of effective
preventive services a concern to employers, but so
too is the overutilization of ineffective or
unproven clinical preventive services. Providers
and patients have a limited amount of time and
purchasers have a limited amount of money to
spend on healthcare interventions. It is therefore
imperative for purchasers to cover and promote
high-impact clinical preventive services that have
proven benefit. Employers expanding their
medical benefit plan to include preventive services
should be careful to first select services with strong evidence of effectiveness. For more
information on effective clinical preventive services and the prioritization of clinical
preventive service benefits, please refer to Part IV: The Prioritization and Strategic
Implementation of Clinical Preventive Service Benefits. 
Employer Action Steps
Employers can reduce their total healthcare costs and improve the health of their beneficiaries
through the implementation and promotion of clinical preventive service benefits. For this
purpose, employers should: 
• Offer a structured set of clinical preventive service benefits through their health plan(s).
• Inform employees, dependents, and retirees about the availability of clinical preventive
service benefits and promote the consistent and appropriate use of recommended
clinical preventive services. 
• Educate employees, dependents, and retirees about the importance of preventive
services and healthy lifestyles.
• Implement programs that promote healthy lifestyles and provide opportunities for
employees to engage in disease prevention and health promotion outside of the clinical
setting (e.g., health promotion or wellness programs, disease prevention programs,
employee assistance programs).
• Support community-based and worksite-based preventive service interventions.
For more information on promoting the delivery and use of clinical preventive services,
please refer to Part VI: Leveraging Benefits: Opportunities to Promote the Delivery and Use of
Preventive Services.
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A recent study conducted by
Milliman, C-Change, and the
American Cancer Society, found that 
3 to 5 lives (per 50,000 employees)
could be saved each year if employers
fully adopted select USPSTF cancer
screening and tobacco treatment
recommendations.31 The cost to
employers of achieving 100%
compliance with USPSTF guidelines for
tobacco use treatment as well as breast,
cervical, and colorectal cancer was
estimated to be $7.50 per member/per
month (PMPM). Because most employers
already provide some type of cancer
prevention and early detection benefit,
the average incremental cost of moving
to 100% compliance would equal just
$2.95 PMPM.31
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This section presents information on 1) the purpose of structured clinical preventive service
benefits; 2) information on the federal rules and regulations surrounding the provision of
clinical preventive services and preventive medications within employer-sponsored medical
benefits; and 3) summary plan description (SPD) language for each clinical preventive
service recommended in the Purchaser’s Guide. A condition/disease-specific evidence-
statement, supporting the information contained in each SPD language example, is
provided in Part III: Evidence-Statements for Recommended Clinical Preventive Service Benefits.
The Purpose of Comprehensive and Structured Clinical
Preventive Service Benefits
Many of the clinical preventive services recommended in
the Purchaser’s Guide are covered by typical medical
benefit plans and are well-used by beneficiaries (e.g.,
cervical cancer screening). Other preventive services have
proven efficacy but are neither widely covered by
employers nor widely used by beneficiaries (e.g., tobacco
use treatment counseling).
Some types of clinical preventive services can be delivered
in the course of routine medical care, such as an annual
physical. For example, a patient who presents with
shortness of breath may be screened for obesity and
advised to lose weight. An informal screening service such as this would usually be covered
by a health plan as part of routine care, not as a unique preventive service. Informal
screening and counseling sessions serve an important function, but they are inadequate to
address some preventable conditions that
require more prevention resources. To
encourage beneficiaries to consistently and
appropriately use effective clinical preventive
services and to incentivize providers to actively
offer preventive services to their patients, it is
imperative for employers to provide a
structured and defined set of clinical
preventive service benefits within their medical
benefit plan(s) and to assure that health plans,
providers, and beneficiaries know that these






To encourage beneficiaries to 
consistently and appropriately use 
clinical preventive services and to
encourage providers to actively offer
clinical preventive services to their
patients, it is imperative for employers
to provide structured clinical 
preventive service benefits within 
their medical benefit plan(s) and to
assure that health plans, providers,
and beneficiaries know that these 
benefits exist and should be used.
As a nation, increasing our 
investment in high-impact,
cost-effective preventive services
will not only save valuable 
healthcare dollars but, more 
important, will significantly improve
the health status of the U.S.
population.1
—Sam Nussbaum, WellPoint Inc.
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An Overview of Employer-Sponsored ERISA Healthcare
Benefits
Group health plans are employee healthcare benefit plans established and maintained by
employers. These plans provide coverage for eligible employees and dependents and, often,
for retirees as well. The vast majority of employer-sponsored health plans are subject to the
provisions of the Employee Retirement Income Security Act (ERISA) of 1974.2 This Act
provides protections and assurance to plan participants, defines the information that must
be provided to beneficiaries, and defines the fiduciary responsibilities of plan administrators. 
Summary Plan Descriptions (SPDs): Communicating Health Benefits to
Beneficiaries 
ERISA requires health plan administrators to give plan participants specific information
about the benefits to which they are entitled, including covered benefits, plan rules,
financial information, and documents about the plan’s operation and management. This
information must be provided on a regular basis, either in writing or on request. 
One important document that participants are legally entitled to receive automatically is a
plan summary or summary plan description (SPD). Generally, SPDs:
• Outline healthcare services covered in the plan.
• Describe how services are provided and how the plan(s) operate.
• Describe how benefits are calculated.
• Explain the portion of costs for which the plan is responsible and the portion of 
costs for which the participant (i.e., the beneficiary) is responsible (e.g., copays,
coinsurance). 
• Include information about how participants and providers should file claims.
ERISA specifically requires that SPDs include the following types of information:
1. Annual or lifetime caps or other limits on covered benefits. 
2. Cost-sharing provisions, including premiums, deductibles, and 
coinsurance/copayment amounts for which the participant (i.e., the beneficiary) is 
responsible. 
3. The extent to which preventive services are covered under the plan.
4. Whether, and under what circumstances, existing and new drugs are covered under 
the plan.
5. Whether, and under what circumstances, coverage is provided for medical tests, 
devices, and procedures. 
6. Provisions governing the use of network providers, the composition of provider 
networks and whether, and under what circumstances, coverage is provided for out-
of-network services. 
7. Conditions or limits on the selection of primary care providers or providers of 
specialty medical care. 
The Department of Labor requires that all SPDs be written in a way that can be understood by
the average plan participant.3 Even though plan services may be complex, the use of technical
language and long, complex sentences should be avoided. Detailed technical descriptions of
clinical preventive services must be made available to beneficiaries upon request.
The ERISA Act has been amended several times; the latest revisions were released on
January 1, 2005 and reinforced previous requirements stating that SPDs must provide a
detailed schedule of benefits, including a listing of covered preventive service benefits.4
Federal Regulation and Preventive Services
Federal rules and regulations govern employer-sponsored preventive services. The
Department of Labor provides regulatory oversight of employer-sponsored healthcare
benefits. The Internal Revenue Service (IRS) offers
guidance relative to plan services and related
payments. Recently, the IRS has provided rules
regarding how preventive services may be structured
in high-deductible health plans (HDHPs) that are
used in conjunction with health savings accounts
(HSAs). 
High-Deductible Health Plans (HDHPs)
Health Savings Accounts (HSAs)
Over the past few years, employers have introduced consumer-directed healthcare (CDH)
plans as an alternative to traditional health benefit plans. The purpose of these plans is to
control cost increases by requiring beneficiaries to take responsibility for their healthcare
spending. The most common CDH plan design involves a high-deductible health plan
(HDHP) with or without an accompanying health savings account (HSA). 
Health savings accounts (HSAs) are tax-advantaged, funded accounts established to support
saving for future medical expenses. HSAs are funded by tax-free dollars and, if ultimately
used for eligible medical expenses, these dollars remain non-taxed.5
To access the tax advantages of an HSA, an individual must be covered by an IRS-defined
HDHP. These are health plans with deductibles of at least $1,100 for individual coverage
($2,200 for family coverage) and caps on allowable out-of-pocket spending ($5,500 for
individual coverage/$11,000 for family coverage). These amounts are applicable for 2007,
and are updated annually to adjust for inflation. 
Clinical Preventive Services and High-Deductible 
Health Plans: A Unique Opportunity to Promote Use
Generally, a HDHP cannot provide benefits prior to fulfillment of the required deductible.
However, the IRS has provided an exception for preventive medical care to encourage the
use of preventive services. Employers have at least four options in structuring HDHP
benefits to promote prevention:
1. Waive the plan deductible and eliminate copayment/coinsurance requirements 
(100% first-dollar coverage).
2. Waive the plan deductible and reduce required copayment /coinsurance amounts.
3. Waive the plan deductible and require the usual copayment/coinsurance amounts.
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Due to tax implications, the IRS 
has become involved in outlining
preventive services in the context of
consumer directed health care plans,
including HSA-qualified high-deductible
health plans (HDHPs), health savings
accounts (HSAs), and health reimburse-
ment arrangements (HRAs).
4. Apply the plan deductible and provide a 
separate financial benefit for preventive 
care ($500 per prevention per year, for 
example). 
Notices 2004-236 and 2004-507 from the
Department of Treasury outline a preventive care
deductible safe-harbor for HDHPs under section
223(c)(2)(C) of the IRS code. The preventive care
safe-harbor includes deductible exemptions for
clinical preventive services, preventive
medications, and treatment incidental to
preventive care. 
Clinical Preventive Services and Preventive
Medications: Notice 2004-23
I. Preventive care benefits are allowed to be
provided by a high-deductible health plan
(HDHP) without satisfying the minimum
deductible. Preventive care includes, but is not
limited to, the following6: 
• Immunizations 
• Obesity weight-loss programs
• Periodic health evaluations, including tests
and diagnostic procedures ordered in
connection with routine examinations, such as annual physicals. 
• Prenatal care
• Screening services for 
> Cancer  
> Heart and vascular diseases  
> Infectious diseases  
> Mental health conditions and substance abuse  
> Metabolic, nutritional, and endocrine conditions  
> Musculoskeletal disorders  
> Obstetric and gynecologic conditions  
> Pediatric conditions  
> Vision and hearing disorders  
• Tobacco cessation programs
• Well-child care 
II. Drugs prescribed to prevent diseases or conditions that have not yet manifested
themselves or to prevent reoccurrence of diseases or conditions [are considered
preventive] and may be covered outside of the deductible.640
2 Summary Plan Description (SPD) Language Statements for Recommended Clinical Preventive Service Benefits
Preventive care benefits such as
annual physicals, immunizations,
and screening services are
exempt from HDHP deductible
requirements. Therefore,
employers can offer HDHPs that 
provide 100% first-dollar coverage
for clinical preventive services.
This type of exemption is known 
as “safe-harbor” coverage.
Clinical preventive services and
preventive medications can be
exempted from the deductible in
HSA-qualified HDHPs. Employers
who offer traditional health plan
types (e.g., HMOs, PPOs, POS) or
CDH plans that are not HSA-qualified
may wish to consider waiving
deductibles or lowering copay or
coinsurance amounts for preventive
medical care in order to promote 
the use of preventive services by
beneficiaries in these plan types.
Notice 2004-23 recognized clinical preventive services such as screening, counseling, and
immunizations as “preventive medical care” and provided an exemption from deductible
requirements. It also deemed drugs/medications to be “preventive medications” (and
therefore excludable from deductible requirements) when taken by a person who has
developed risk factors for a disease that has not yet manifested itself or not yet become
clinically apparent (this is known as primary prevention) or to prevent the reoccurrence of a
disease from which a person has recovered. For example, the treatment of high cholesterol
with cholesterol-lowering medications (e.g., statins) to prevent heart disease may be
considered preventive. Similarly, treating an initial heart attack with angiotensin-converting
enzyme (ACE) inhibitors to prevent a reoccurrence may be considered preventive. In
addition, drugs or medications used as part of procedures providing preventive care services,
such as weight-loss programs and tobacco use treatment programs, may be considered
preventive. 
Treatment Incidental to Preventive Care: Notice 2004-50 
Treatment that is performed along with preventive care services or screening may be
provided without meeting the deductible requirements as long as it is ancillary or incidental
to preventive care.7
Notice 2004-50 extended safe-harbor coverage to treatments that are ancillary to prevention
or when a separate procedure/visit for treatment would be impractical or unreasonable. For
example, the removal of polyps is an allowable preventive treatment benefit when provided
as a part of a screening colonoscopy.7
Guidance on the Definition of “Preventive Medical Care”
Prior to the 2004 guidance and clarification notices, employers and plan administrators
requested that the Department of Labor clearly define preventive medical care. The
Department of Labor responded that services and medications may vary from plan to plan
and are best described in the context of total plan provisions and not by regulation.8 Rather
than developing a schedule of allowable services and medications, the Department of
Treasury gave employers the discretion to define them relative to need and cost within the
limits set forth in Notices 2004-23 and 2004-50. Employers interested in exempting
preventive services and medications from the deductibles of HSA-qualified and HDHP
plans must therefore decide for themselves which services and medications qualify as
preventive and which do not. 
Defining Clinical Preventive Services
The Purchaser’s Guide recommends 46 clinical preventive
services for inclusion in medical benefit plans. All of the
recommended services qualify as preventive medical care
and could be exempted from the deductible in HSA-
qualified HDHP plans and other plan types. Employers
who offer preventive service benefits should evaluate these
benefits and exempt them from the deductible on a case-
by-case basis. 
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It is especially important for 
employers who offer HDHPs to 
clearly define clinical preventive 
service benefits and to inform 
beneficiaries about safe-harbor 




The National Business Group on Health recognizes that the decisions employers must make
regarding the definition of medications as preventive are not always clear-cut particularly
because:
• Many drugs have both preventive and curative applications. For example, beta
blockers can be used to prevent stroke or treat hyperthyroidism.
• Several types of prevention exist (e.g., primary, secondary, tertiary).
A comprehensive listing of recommendations regarding preventive medication was beyond
the scope of the Purchaser’s Guide. Figure 2.0 was developed in order to provide employers
with some idea of the type of medications that may be defined as preventive. It presents
options employers have when selecting medications to consider preventive within a
pharmacy benefit. The listing draws upon evidence from regulators (such as the Food and
Drug Administration), authoritative expert groups that convene to review clinical evidence
(such as the U.S. Preventive Services Task Force), or the results of systematic literature
reviews (such as those produced by the Cochrane Collaboration, a reliable source of evidence
in health care). In the absence of such information, the sources cited are either consensus
expert opinion or important studies. The listing is intended to be a tool for benefit design
and communications; it is not a comprehensive list and is not endorsed in its entirety by any
of the referenced sources. In order to ensure compliance with IRS regulations, benefit
managers should consult with other knowledgeable sources such as health plans, consultants,
pharmacy benefit managers, and especially their internal legal departments. 
2 Summary Plan Description (SPD) Language Statements for Recommended Clinical Preventive Service Benefits
Important Note on the Difference Between the Use of the Term “Preventive
Medication” as a Category of Prevention and as a Pharmacy Benefit Definition
Several clinical preventive services recommended in the Purchaser’s Guide include the 
prescription/use of a preventive medication. Preventive medications, as recommended in
the Purchaser’s Guide, are limited to those medications that can be used to prevent a 
specific condition or disease (e.g., folic acid supplementation to prevent neural tube
defects). The prescription/use of these medications is thus a type of preventive 
intervention, in the same way that an immunization or counseling session is a type of 
preventive intervention.
There are many other types of medications that can be used to prevent the escalation of a
condition into another type of disease or disability (e.g., asthma medications to prevent
permanent damage to the airways) or to prevent a comorbidity from occurring as a result
of untreated disease (e.g., anti-diabetic agents to prevent cardiovascular disease).
Medications such as these can also be considered preventive and, according to the most
recent Department of Treasury guidance, qualify for safe-harbor coverage in HSA-qualified
HDHPs.
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COVERED DRUG RATIONALE SOURCES OF DRUGS OR THERAPEUTIC 
CATEGORY EVIDENCE            CLASSES 
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Figure 2.0: Preventive Medications that Employers May Select to Include 
in Pharmacy Benefits
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COVERED DRUG RATIONALE SOURCES OF DRUGS OR THERAPEUTIC 
CATEGORY EVIDENCE            CLASSES 
(* = Generic Available)
Figure 2.0: Preventive Medications that Employers May Select to Include 
in Pharmacy Benefits (Continued)
Abdominal Aortic Aneurysm ✔
Alcohol Misuse ✔ ✔
Aspirin Therapy for the 




Breast Cancer Genetic 
Risk Assessment and ✔ ✔ ✔
BRCA Mutation Testing





Dental Caries Prevention ✔
Lead, Elevated Blood Level ✔
Newborn Screening for 





Contraceptive Use ✔ ✔
Depression ✔
Diabetes (type 2) ✔
Healthy Diet ✔
Healthy Pregnancy
Alcohol Misuse ✔ ✔
Asymptomatic Bacteriuria ✔
Breastfeeding ✔
Folic Acid Supplementation ✔ ✔
Group B Streptococcal ✔ ✔




Figure 2.1: Intervention Chart 
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Disease (GBS)
Hepatitis B Virus (HBV) ✔ ✔ ✔




Prenatal Diagnosis of 
Chromosomal Abnormalities ✔ ✔
and Neural Tube Defects 
(NTDs)




Tobacco Use Treatment ✔ ✔
Hypertension ✔ ✔ ✔
Immunizations ✔
(Child, Adolescent, Adult)
Lipid Disorders ✔ ✔ ✔
Motor Vehicle-Related ✔
Injury Prevention




Counseling to prevent STIs ✔
Chlamydia ✔
Gonorrhea ✔
Human Immunodeficiency ✔ ✔
Virus (HIV)
Syphilis ✔
Tobacco Use Treatment ✔ ✔ ✔
Tuberculosis ✔
*Includes medical foods in addition to medications
Screening Testing Counseling Immunization Preventive (Preventive)
Medication/ Treatment
Intervention
Figure 2.1: Intervention Chart  (Continued)
Sample Summary Plan Description
(SPD) Language Statements for
Recommended Clinical Preventive 
Service Benefits
Summary Plan Description (SPD) Language 
The following pages contain condition, disease or
injury specific SPD language statements for each
clinical preventive service recommended in the Purchaser’s Guide. The SPD language
statements clearly outline the recommended benefits for each service.
The recommended benefits (and hence the SPDs), are a translation of the clinical guidelines
featured in the corresponding evidence-statements, which outline the medical evidence for
each intervention.The process of translating clinical guidelines into benefit language is
difficult. The National Business Group on Health (Business Group) has made every effort to
align benefits recommended in the Purchaser’s Guide with the most current clinical
guidelines and recommendations. However, because recommendation-making bodies (e.g.,
USPSTF, professional organizations, etc) sometimes disagree on the specifics of a particular
clinical preventive service, for example, how often a service should be provided, the Business
Group combined multiple recommendations to construct the detailed benefits described in
the SPDs. For an exact listing of the recommendations and guidelines, please refer to the
corresponding evidence-statements provided in Part III: Evidence-Statements for
Recommended Clinical Preventive Service Benefits.
Current Procedural Terminology (CPT®) Codes
Applicable current procedural terminology (CPT) codes are provided for each recommended
benefit. CPT codes are listed in alphabetical order as an appendix to the SPD language
statements. 
CPT codes are provided for employers and health plans to facilitate the implementation and
reimbursement of clinical preventive service benefits. Employers who adopt the
recommendations set forth in the Purchaser’s Guide should ensure that their health plan
administrators approve the listed CPT codes for provider reimbursement. 
CPT codes are developed by the American Medical Association (AMA) for the purpose of
providing a uniform language that accurately describes medical, surgical, and diagnostic services
provided by physicians and other clinicians. The list of codes is updated annually. For more
information on CPT codes and to view updates, please contact the CPT Information and
Education Service at 1-800-634-6922 or visit: www.ama-assn.org/ama/pub/category/3113.html
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A Note on SPDs 
Summary plan description language does not typically include the names of covered tests
or procedures. SPD language provided in the Purchaser’s Guide includes specific
information on covered tests, procedures, and medications. This information is included for
educational purposes. Some employers may wish to include this information in their SPDs;
other employers may wish to delete this information from their SPDs, and share it only
with their health plan administrators for contracting purposes.
The clinical preventive services 
benefits recommended in the
Purchaser’s Guide address a range 
of health conditions that affect people
of all ages. For a brief summary of 
clinical preventive services appropriate for
different age groups and genders, please
refer to the Life Course Charts featured in
Part VII: Resources & Tools.
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Alphabetical Listing of SPDs Page Number (CPT Codes)
Abdominal Aortic Aneurysm, Screening................................Pg. 51...............................Pg. 73
Alcohol Misuse, Screening and counseling ............................Pg. 51...............................Pg. 73
Aspirin Therapy for the Prevention of
Cardiovascular Disease, Counseling ................................Pg. 51...............................Pg. 73
Breast Cancer
Breast Cancer, Screening....................................................Pg. 52 ............................. Pg. 73
Breast Cancer Genetic Risk Assessment and 
BRCA Mutation Testing, Counseling, testing,
and preventive treatment ................................................Pg. 52 ............................. Pg. 74
Breast Cancer, Counseling and preventive medication .......Pg. 52 ............................. Pg. 75
Cervical Cancer, Screening ....................................................Pg. 53 ............................. Pg. 76
Childhood Health Promotion 
Child Development, Screening ............................................Pg. 54 ............................. Pg. 77
Dental Caries, Preventive medication..................................Pg. 54 ............................. Pg. 77
Immunizations.....................................................................Pg. 54 ............................. Pg. 88
Lead, Elevated Blood Level, Screening ...............................Pg. 54 ............................. Pg. 78
Newborn Screening for Genetic and Endocrine
Disorders, Screening, medical foods, and treatment.......Pg. 55 ............................. Pg. 78
Newborn Hearing, Screening ..............................................Pg. 55 ............................. Pg. 78
Vision, Screening.................................................................Pg. 56 ............................. Pg. 78
Colorectal Cancer, Screening..................................................Pg. 57 ............................. Pg. 79
Contraceptive Use, Counseling and 
preventive intervention........................................................Pg. 57 ............................. Pg. 79
Depression, Screening.............................................................Pg. 57 ............................. Pg. 80
Diabetes (type 2), Screening...................................................Pg. 58 ............................. Pg. 80
Healthy Diet, Counseling..........................................................Pg. 58 ............................. Pg. 81
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Summary Plan Description Language: 
Abdominal Aortic Aneurysm (Screening)
Ultrasonography of the abdomen.
One-time screening ultrasound to look for abdominal aortic aneurysm in men
aged 65 to 75 who have smoked at any time in their lives. The exact timing of
the screen is left to the discretion of the clinician.
Summary Plan Description Language: 
Alcohol Misuse (Screening) 
Screening for alcohol misuse is a covered benefit. Coverage includes the use of
validated screening tools such as:
• Single-question alcohol screens 
• Alcohol Use Disorders Identification Test (AUDIT) or AUDIT-C
• CAGE
Screening is a covered benefit beginning at age 18. Coverage is provided for
younger populations depending on risk and need. For average-risk populations,
one screen is covered annually. More frequent screening is covered for individuals
at risk for alcohol misuse, including people with a history of alcohol misuse or
alcohol-related health and social problems. 
Summary Plan Description Language: 
Alcohol Misuse (Counseling)
Counseling is a covered benefit for patients who meet criteria for alcohol misuse.
Three levels of counseling are covered:
• “Very brief ” interventions that last up to 5 minutes and have no follow-up.
• “Brief ” counseling interventions that last 15 minutes and have no follow-up.
• “Multi-contact” interventions that include one initial session lasting at least 15
minutes that is followed by several additional contacts. 
Eight (8) counseling sessions are covered per calendar year. Intervals between
counseling sessions are at the discretion of the provider. 
Summary Plan Description Language: 
Aspirin for the Primary Prevention of Cardiovascular Events
(Counseling)
Counseling to discuss the benefits and harms of aspirin therapy is a covered
benefit. 
All beneficiaries aged 30 and older are eligible for one counseling session every 5
years or whenever a cardiovascular risk factor is detected.
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Covered Counseling  
Initiation, Cessation,
and Interval
Summary Plan Description Language: 
Breast Cancer (Screening)
Breast cancer screening is a covered benefit and may include mammography and,
as an adjunct, a clinical breast exam (CBE).
Breast cancer screening is a covered benefit for average-risk women aged 40 to
80. Average-risk women are eligible for one mammography per calendar year.
Women at high risk of breast cancer may qualify for screening at a younger age,
if screening is deemed medically indicated. 
Summary Plan Description Language: 
Breast Cancer Genetic Risk Assessment and BRCA Mutation
Testing (Counseling)
Beneficiaries determined to be at high risk for breast cancer based on the results
of a clinician’s risk assessment are eligible for genetic counseling.
Counseling is provided as medically indicated, and should be conducted at least
once before and after genetic testing.
Summary Plan Description Language: 
Breast Cancer Genetic Risk Assessment and BRCA Mutation
Testing (Testing)
Beneficiaries determined to be at high risk for breast cancer based on the results
of a clinician’s risk assessment are eligible for BRCA mutation testing. 
BRCA mutation testing is covered once per lifetime.
Summary Plan Description Language: 
Breast Cancer (Counseling on Preventive Medication and
Preventive Treatment)
Beneficiaries determined to be at high-risk for breast cancer based on the results
of the clinician’s risk assessment or the results of BRCA mutation testing are
eligible for counseling on the use of preventive medication or preventive
treatments.
Counseling is provided as medically indicated.
53












Summary Plan Description Language: 
Breast Cancer (Preventive Medication)
Beneficiaries determined to be at high risk for breast cancer based on the results
of a clinician’s risk assessment are eligible for preventive medication. Coverage is
provided for all FDA-approved breast cancer preventive medications (e.g.,
tamoxifen).
Coverage is provided for 5 years. Preventive treatment may be extended, if
continued treatment is determined to be medically necessary. 
Summary Plan Description Language: 
Breast Cancer Genetic Risk Assessment and BRCA Mutation
Testing (Preventive Treatment)
Beneficiaries determined to be at high risk for breast cancer based on the results
of a clinician’s risk assessment or the results of BRCA mutation testing are eligible
for preventive treatment, which may include any of the following:
• Surgical removal of the breast(s) with or without reconstructive surgery
• Surgical removal of the ovaries
Treatment coverage includes counseling-based office visits for treatment
education, decision-making, and monitoring.
Preventive treatment is provided, as medically indicated. 
Summary Plan Description Language: 
Cervical Cancer Screening (Screening)
Conventional Pap test.
***Health plans have the discretion to provide coverage for newer screening
methods, such as liquid-based, thin-layer preparations (e.g., ThinPrep®) or
computer-assisted screening (e.g., AutoCyte®), and human papillomavirus (HPV)
tests, such as Hybrid Capture II®.
Cervical cancer screening is a covered benefit for women age 21 (or women of
any age 3 years within the onset of sexual activity) through age 65. Coverage
beyond the age of 65 is provided for women with known risk factors, recent
abnormal pap smears, inadequate previous screening, or when information about
previous screening is unavailable or when screening is unlikely to have occurred
in the past.
Coverage allows Pap tests to be performed at least once every three years, but not
more than once per calendar year.
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Summary Plan Description Language: 
Childhood Health Promotion (Screening, Immunization,
Medical Foods, and Preventive Medication)
Summary Plan Description Language: 
Child Development (Screening)
Coverage is provided for developmental screening including the use of
standardized instruments. 
Developmental screening services are covered for all children as a component of
the 9, 18, and 30-month well-child care visits.
Summary Plan Description (SPD) Language: 
Dental Caries Prevention through Oral Fluoride
Supplementation (Preventive Medication)
Oral fluoride 
Oral fluoride is covered as prescribed by the clinician according to age and need. 
Coverage for supplementation is provided from 6 months to 5 years of age and
may be extended through 16 years of age, if medically indicated. 
Summary Plan Description (SPD) Language: 
Child Immunizations (Immunization)
Please refer to the general Immunizations SPD language.
Summary Plan Description Language: 
Elevated Blood Lead Levels (Screening)
Covered screening tests for lead exposure include blood lead concentration
measured from capillary or venous samples. 
Screening is a covered benefit for children at risk for lead exposure at the
following ages: 12 months, 24 months, and 36–72 months, or at any age when
deemed medically necessary by a risk assessment, clinical signs or symptoms
consistent with elevated BLL, or when other evidence indicates possible lead
exposure. Secondary venous blood lead concentration tests, taken for
confirmation, are covered for all children identified as having an elevated BLL
through a capillary blood lead concentration screen.
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Summary Plan Description Language: 
Newborn Hearing (Screening)
Hospital-based hearing screening is a covered benefit for all newborns. Newborns
who are not screened in the hospital, or who require further screening, may be
tested in a clinician’s office. Screening may include the use of the following tests:
• Automated or semiautomated audiologic screening
• Auditory Brainstem Response (ABR) 
• Otoacoustic Emissions (OAE) 
Diagnostic audiological evaluation is a covered benefit for all infants and children
who do not pass initial screening tests.
Screening is covered for all newborns during the first 3 months of life. Additional
screening is provided for at-risk children, as determined medically necessary,
through age 3 years. Diagnostic audiological evaluation is covered, as medically
necessary.
Summary Plan Description Language: 
Newborn Screening for Genetic and Endocrine Disorders
(Screening)
Newborn blood spot screening is a covered benefit. Screening is provided for the
following conditions: phenylketonuria (PKU), congenital hypothyroidism (CH),
galactosemia, sickle cell disease (SCD) and other hemoglobin disorders,
congenital adrenal hyperplasia (CAH), biotinidase deficiency, and medium chain
acyl-coA dehydrogenase (MCAD) deficiency. Screening for other conditions is
covered, as medically indicated.
Newborn screening is covered from birth through 4 months of age. Follow-up
testing is covered, as medically indicated.
Summary Plan Description Language: 
Newborn Screening for Genetic and Endocrine Disorders
(Medical Foods)
Medical formulas and foods are covered for the purpose of preventing illness,
disability, or death among beneficiaries with genetic or endocrine disorders. 
Medical formulas and foods are covered, as medically necessary.
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Summary Plan Description Language: 
Newborn Screening for Genetic and Endocrine 
Disorders (Treatment)
Medications and other forms of treatment used to prevent illness or disability
among beneficiaries with genetic or endocrine disorders are covered. Case
management is a covered benefit and is provided, as medically necessary, for
beneficiaries with complex disorders. 
Medications and other forms of treatment are covered, as medically indicated.
Summary Plan Description Language: 
Vision (Screening) (Child)
Vision screening is a covered benefit for all children and may include use of the
following screening tests: 
• Cover test
• External inspection of the eyes and lids
• Hirschberg light reflex test
• Ocular history
• Ocular motility assessment
• Photo-screening 
• Pupil examination
• Random Dot E test
• Red reflex examination
• Titmus Fly test
• Vision assessment
• Visual acuity tests including the Snellen Acuity Chart, the Tumbling E, the
HOTV Test, Allen Cards, and LH Symbols 
Vision screening is covered in the newborn period and at all subsequent well-
child visits.
The following vision screenings are covered for children birth to 3 years of age:
ocular history, vision assessment, external inspection of the eyes and lids, ocular
motility assessment, pupil examination, and red reflex examination.
The following vision screenings are covered for children ages 3 to 5 years: age
appropriate visual acuity measurements using the Snellen Chart, Tumbling E, the
HOTV Test, Allen Cards, or LH Symbols) and ophthalmoscopy.
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Summary Plan Description Language: 
Colorectal Cancer (Screening)
• Colonoscopy   • Double-contrast barium enema. 
• Fecal occult blood testing (FOBT) (alone or combined with flexible sigmoidoscopy)
• Flexible sigmoidoscopy (alone or combined with FOBT)
Colorectal cancer screening is a covered benefit for men and women aged 50 and
older. Screening may be initiated at an earlier age if the beneficiary has certain risk
factors and a clinician determines that the individual requires early screening. 
Colorectal cancer screening intervals are based on the method of screening used: 
Screening Method Approved Interval for Coverage
Colonoscopy Every 10 years 
Flexible sigmoidoscopy Every five years 
Double-contrast barium enema Every five years 
Fecal occult blood tests (FOBT) Every year 
Combination of flexible Every five years for the flexible
sigmoidoscopy and FOBT sigmoidoscopy and annually for the FOBT
Summary Plan Description Language: 
Contraceptive Use (Counseling) 
Counseling on contraceptive use is a covered benefit.
Counseling is a covered benefit for all beneficiaries aged 13 to 55 years, whenever
it is deemed medically indicated. Counseling should be conducted at least once a
year and whenever emergency contraception is prescribed. 
Summary Plan Description Language: 
Contraceptive Use (Preventive Intervention) 
The full range of Food and Drug Administration (FDA) approved contraceptives
are covered including:
• All hormonal medications (e.g., pills and patches) including emergency contraceptives
• All contraceptive devices (e.g., IUD, diaphragm, vaginal ring)
• Voluntary sterilization (e.g., vasectomy, tubal ligation)
Hormonal medications (e.g., pills and patches) — including emergency contraceptives
— and contraceptive devices are covered as medically necessary for the prevention of
pregnancy. Voluntary sterilization (e.g., vasectomy, tubal ligation) is covered once per
lifetime. Coverage may be extended if the procedure fails. 
Summary Plan Description Language: 
Depression (Screening)
Depression screening, including the use of standardized depression screening or
informal instruments, is a covered benefit. 
Depression screening is a covered benefit for all adults age 18 and older, when deemed
medically indicated. Depression screening is covered for adolescents, as medically indicated. 
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Summary Plan Description Language: 
Diabetes (Screening)
• Fasting plasma glucose test (FBG)
• 2-hour post-load plasma glucose
• Oral glucose tolerance test (OGTT)
Diabetes screening is a covered benefit for beneficiaries of any age with
hypertension or hyperlipidemia (lipid disorders). Screening should be initiated
whenever these conditions are diagnosed. Screening should be conducted,
depending on risk, at least once every 3 years, but not more than once during
any calendar year. 
Coverage for diabetes screening among those at high risk for the disease is
provided beginning at age 30, if medically indicated. Screening should be
conducted at least once every 2 years, but not more than once during any
calendar year. 
Coverage for diabetes screening among individuals at normal risk for the disease
is provided beginning at age 45, or earlier if medically indicated. Screening may
be conducted once every 3 years.
Individuals with impaired glucose function diagnosed by any test listed in
“covered screening methods” qualify for a second screen to verify disease status.
The secondary screening should be conducted on another day in the same
calendar month.
Summary Plan Description Language: 
Healthy Diet (Counseling)
Intensive behavioral dietary counseling is covered for adult beneficiaries with
hyperlipidemia (lipid disorders) and other known risk factors for cardiovascular
and diet-related chronic diseases.
Beneficiaries who meet the criteria for counseling are eligible for 3 intensive (30-
45 minute) counseling sessions per calendar year. 
Summary Plan Description Language: 
Healthy Pregnancy (Screening, Testing, Counseling,
Preventive Medication, and Treatment)
Summary Plan Description Language: 
Alcohol Misuse (Screening)
Screening for alcohol misuse is a covered benefit. Coverage includes the use of
validated screening tools such as the:
• AUDIT
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Screening is a covered benefit during pregnancy. Normal-risk women may be
screened once per pregnancy. Patients at greater risk for alcohol problems, either
because they have a history of past alcohol misuse or report other risky behaviors,
qualify for multiple screenings during pregnancy.
Summary Plan Description Language: 
Alcohol Misuse (Counseling)
Counseling for alcohol misuse during pregnancy is a covered benefit. Three levels
of counseling are covered:
• “Very brief ” interventions that last up to 5 minutes and have no follow-up.
• “Brief ” counseling interventions that last 15 minutes and have no follow-up.
• “Multi-contact” interventions that include one initial session lasting at least 15
minutes that is followed by several additional contacts.
Eight (8) counseling sessions are covered per calendar year. Intervals between
counseling sessions are at the discretion of the provider. These covered visits are
not intended to supplant mental health or addiction treatment coverage.
Summary Plan Description Language: 
Asymptomatic Bacteriuria (Screening)
Urine culture
Screening for asymptomatic bacteriuria is a covered benefit between 12 and 16
weeks’ gestation for all pregnant women. Subsequent screenings are covered, as
medically indicated.
Summary Plan Description Language: 
Breastfeeding (Counseling)
Structured breastfeeding education and behavioral counseling is a covered benefit
for all pregnant and lactating women. Counseling may be provided in an office
setting, during hospitalization for labor/delivery, or in the patient’s home after
the birth of their child.
Counseling to promote breastfeeding initiation and continuation is a covered
benefit for all pregnant women and all lactating women. There is no maximum
number of sessions, provided that the care is medically necessary.
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Summary Plan Description Language: 
Folic Acid Supplementation (Counseling)
Counseling to promote the use of folic acid supplements (for the prevention of
neural tube defects) is a covered benefit.
Counseling on folic acid supplementation is a covered benefit for all women
considering pregnancy and all pregnant women through the first trimester of
pregnancy. 
Summary Plan Description Language: 
Folic Acid Supplementation (Preventive Medication)
• Prescription strength folic acid
• Prenatal vitamins containing folic acid
Folic acid medications of any type are covered, when used to reduce the risk of
having a pregnancy affected by a neural tube defect. 
Summary Plan Description Language: 
Group B Streptococcal Disease (Screening)
All methods of GBS isolation and identification are covered.
Screening for vaginal and rectal group B streptococcal (GBS) colonization is a
covered benefit for all pregnant women between 35 and 37 weeks gestation, or as
medically indicated.
Summary Plan Description Language: 
Group B Streptococcal Disease (Preventive Medication)
Intrapartum antibiotic prophylaxis is a covered benefit for all pregnant women. 
Intrapartum antibiotic prophylaxis to prevent GBS disease is a covered benefit
for:
• All pregnant women whose screening status is unknown at the time of labor if
they present with any of the following risk factors: delivery at < 37 weeks
gestation, membrane rupture ≥ 18 hours, or intrapartum fever ≥ 38C.
• Women who have had GBS isolated from their urine at any time during their
current pregnancy.
• All women who have previously given birth to an infant with invasive GBS
disease.
• Women who are expected to deliver preterm (< 37 weeks) and found to be at
risk for perinatal GBS disease. 
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Summary Plan Description Language: 
Hepatitis B Virus (HBV) (Screening)
Hepatitis B screening is a covered benefit for all pregnant women. Coverage
includes the use of all validated screening tools, including the HBsAg
Immunoassay and the “rapid test.”
Average-risk women should be screened once, ideally at the first prenatal care
visits. Additional screenings are covered for women at increased risk of acquiring
HBV. 
Summary Plan Description Language: 
Hepatitis B Virus (HBV) (Immunization)
All types and brands of hepatitis B immunization are covered.
Immunizations may be given at any time during pregnancy, as deemed
appropriate by the clinician. 
Summary Plan Description Language: 
Hepatitis B Virus (HBV) (Treatment)
Treatment for infants born to hepatitis B (HBV)-positive women includes:
• Postexposure hepatitis B immune globulin 
• HBV vaccination
Treatment for infants born to women with unknown HbsAg status includes:
• Single-antigen hepatitis B vaccine (without HBIG) 
Note: The hepatitis B vaccine (without HBIG) is a covered benefit for all infants,
regardless of their mother’s hepatitis status.
Immune globulin and HBV immunizations are covered, as medically indicated. 
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Summary Plan Description Language: 
Human Immunodeficiency Virus (HIV) (Screening)
All FDA-licensed screens and tests, including:
• Enzyme immunoassay (EIA)
• Western blot test
• Abbott Murex Single Use Diagnostic System HIV-1 test
• Rapid assay test
All pregnant women are eligible for HIV screening. One-time screening is
covered for normal-risk women and should be conducted as early as possible
during the pregnancy. All pregnant women with a positive screen are eligible for
confirmatory testing. Women at high risk of HIV infection are eligible for
additional screening/confirmatory testing during the third trimester, or as
medically indicated. 
Summary Plan Description Language: 
Human Immunodeficiency Virus (HIV) (Counseling)
Counseling regarding HIV screening and HIV test results, risk reduction, and
transmission reduction is a covered benefit for all pregnant women.
All pregnant women are eligible to receive counseling and educational
information on HIV and HIV screening before they are screened. 
All pregnant women who are screed for HIV are eligible for post-test counseling
on their result and risk reduction. 
Pregnant women who have behaviors that place them at high risk for acquiring
HIV infection (e.g., multiple sex partners, history of STDs, substance abuse, etc)
are eligible for a referral to an HIV risk-reduction service (e.g., HIV centers with
personnel trained in HIV counseling, drug treatment centers, etc).
Summary Plan Description Language: 
Human Immunodeficiency Virus (HIV) (Preventive Medication)
Antiretroviral chemoprophylaxis is a covered benefit for all infant beneficiaries
who are born to women who are HIV positive or whose HIV status is unknown
at the time of labor and delivery. 
All FDA-approved medications used for the prevention of perinatal HIV
transmission are covered, as prescribed by a clinician, for exposed infants during
the first 6 weeks of life (or as medically indicated).
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Summary Plan Description Language: 
Influenza (Immunization)
All brands and types of influenza immunization are covered, as medically
indicated.
Influenza immunization is a covered benefit for all women who will be pregnant
during the influenza season (October to mid-May). One influenza immunization
is covered per influenza season and women should be immunized with each
pregnancy, as indicated.
Summary Plan Description Language: 
Preeclampsia (Screening)
Conventional measure using an arm cuff and an appropriately validated aneroid
(containing no liquid) or digital sphygmomanometer (blood pressure meter). 
Blood pressure screening is covered for all pregnant women, as medically
indicated. 
Summary Plan Description Language: 
Prenatal Diagnosis of Chromosomal Abnormalities and 
Neural Tube Defects (NTDs) (Screening)
All screening tests used to detect risk for chromosomal abnormalities and neural
tube defects are covered.
The timing and frequency is determined by the screening method used. 
Summary Plan Description Language: 
Prenatal Diagnosis of Chromosomal Abnormalities and 
Neural Tube Defects (NTDs) (Testing)
Testing for chromosomal abnormalities and neural tube defects is a covered
benefit. Coverage includes the use of all validated testing tools, including, but
not limited to:
• Amniocentesis 
• Chorionic villus sampling (CVS) 
• Ultrasound
Testing for chromosomal abnormalities is covered for all pregnant women age 35
or older (and those who have equivalent risk) in place of, or in addition to,
screening services. 
Testing for neural tube defects is covered for all pregnant women at elevated risk
of neural tube defects based on a positive screen or other documented risk factor. 
Genetic counseling, when medically indicated and provided in association with
testing, is also covered.
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Summary Plan Description Language: 
Rh (D) Incompatibility (Screening)
Rh (D) blood typing and antibody testing is a covered benefit for all pregnant
women. 
All pregnant women are eligible for Rh (D) blood typing and antibody testing at
their first prenatal visit. Women known to be Rh (D)-negative and unsensitized
are eligible for repeat Rh (D) antibody test at 24 to 28 weeks’ gestation to
determine their degree of sensitivity. 
Summary Plan Description Language: 
Rh (D) Incompatibility (Preventive Medication)
Immune globulin 
Immune globulin is covered as a preventive medication for the following
populations (as medically indicated): 
• All unsensitized Rh (D)-negative women after their repeated antibody screen at
24-28 weeks’ gestation.
• Rh (D)-negative mothers within 72 hours of delivering a Rh (D)-positive
infant.
• Rh (D)-negative mothers following amniocentesis or either induced or
spontaneous abortion.
Summary Plan Description Language: 
Rubella (Screening)
Screening for rubella susceptibility is a covered benefit of all women of
reproductive age. Screening may include:
• Ascertaining an individual’s risk for rubella by way of immunization history
• Serologic test for antibodies
All women of childbearing age, including pregnant women, are eligible for
screening.
Summary Plan Description Language: 
Syphilis (Screening)
• Venereal disease research laboratory (VDRL) or the rapid plasma regain (RPR)
on serum specimens followed by a fluorescent treponemal antibody absorbed
(FTA-ABS) or T. palladium particle agglutination (TP-PA) for confirmation.
• Enzyme-linked Immunosorbent Assay (ELISA) for treponemal antibody in
serum specimens. 
• RPR point-of-care test for nontreponemal antibody in serum specimens. 
• Dark field microscope examination of lesion specimens.
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Syphilis screening is a covered benefit for all pregnant women at their first
prenatal care visit. Women with a positive screen are eligible for a confirmatory
test. Women who are at high risk for syphilis, are previously untested, or have a
positive serology in the first trimester are eligible for re-screening and
confirmatory testing during the third trimester and at delivery, or as medically
indicated.
Summary Plan Description Language: 
Tetanus (Immunization)
All brands and types of tetanus immunization are covered as medically indicated.
Coverage for tetanus vaccines is provided for all pregnant women without
adequate documentation of a completed primary tetanus series and those without
a tetanus vaccination within the past ten years. 
Summary Plan Description Language: 
Tobacco Use Treatment (Screening)
Screening for tobacco use is a covered benefit for all pregnant women.
There is no maximum limit on screening during pregnancy, provided that the
care is medically indicated.
Summary Plan Description Language: 
Tobacco Use Treatment (Counseling)
Smoking cessation counseling (5 to 15 minute sessions) is a covered benefit for
all pregnant women who smoke. Counseling may be conducted during
individual face-to-face office visits, in a group setting, or by telephone.
Pregnant women who screen positive for tobacco use should be advised to quit at
every medical encounter. There is no maximum number of counseling sessions
for eligible pregnant women.
Summary Plan Description Language:
Hypertension (Screening)
Conventional measure using an arm cuff and an appropriately validated aneroid
(containing no liquid) or digital sphygmomanometer (blood pressure meter). 
Screening is a covered benefit for all children, adolescents, and adults, and may
be conducted as medically indicated. 
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Summary Plan Description Language: 
Hypertension (Counseling and Treatment) 
Covered treatment for hypertension includes:
• Counseling to promote therapeutic lifestyle changes
• Office visits to monitor hypertension and treatment efforts
• Medications used to treat hypertension
Six (6) counseling, treatment, and monitoring sessions are covered per calendar
year. Additional counseling sessions are covered, as medically indicated.
Beneficiaries undergoing treatment with hypertension-lowering medications
qualify for additional medication management visits, as medically indicated. 
Summary Plan Description Language: 
Child, Adolescent, Adult Immunizations (Immunization)
Screening/risk assessment for vaccine-preventable disease (VPD) is a covered
benefit for all beneficiaries. Screening may include counseling by the provider.
Screening can be accomplished by a review of vaccination history, preferably
documented history, or (when appropriate) serologic testing for antibodies to
VPD using accepted laboratory tests. 
Covered immunizations (children/adolescents): Single-antigen or combination
vaccines as consistent with the most current ACIP recommendations. Currently
included vaccines are: hepatitis B, diphtheria, tetanus, pertussis, Haemophilus
influenzae type b, polio, measles, mumps, rubella, varicella, pneumococcal
disease, influenza, meningococcal disease, hepatitis A, rotavirus, human
papillomavirus. 
Covered immunizations (adults): Single-antigen or combination vaccines as
consistent with the most current ACIP recommendations. Currently included
vaccines are: diphtheria, tetanus, influenza, human papillomavirus, pneumococcal
disease. Also covered as necessary are: hepatitis A, hepatitis B, pertussis, measles,
mumps, rubella, varicella, meningococcal disease, polio.
Screening/risk assessment and immunizations are covered whenever indicated by
medical conditions or other risk factors. There are no age or frequency
limitations.
Summary Plan Description Language: 
Lipid Disorders (Screening)
9–12-hour fasting lipoprotein profile of total cholesterol, low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol, and triglycerides. 
Screening is a covered benefit for all adults aged 20 and older and may be
conducted once every 5 years, or as medically indicated. 
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Summary Plan Description Language: 
Lipids Disorders (Counseling and Treatment)
Covered treatment for a lipid disorder includes:
• Counseling to promote therapeutic lifestyle changes
• Office visits to monitor lipid disorders and treatment efforts 
• Medications used to treat lipid disorders 
Six (6) counseling, treatment, and monitoring sessions are covered per calendar
year. Additional counseling sessions are covered, as medically indicated.
Beneficiaries undergoing treatment with lipid-lowering medications qualify for
additional medication management visits, as medically indicated. 
Summary Plan Description Language:
Motor Vehicle-Related Injury Prevention (Counseling)
Counseling to reduce motor vehicle related injuries is a covered benefit. Both
brief clinician counseling (3 minutes or less) and intensive counseling are
covered.
Counseling to prevent motor vehicle-related injuries is a covered benefit for
beneficiaries of driving age. Counseling should be conducted: 1) when
beneficiaries first begin to drive (age 15, 16, or older depending on state law), 2)
when beneficiaries first become parents, 3) when beneficiaries seek other
preventive services for young children, 4) when beneficiaries present with alcohol
or other drug dependencies, and 5) when beneficiaries receive trauma care for
alcohol-related injuries.
One counseling session is covered per year. Individuals at high risk for a motor
vehicle-related injury (beneficiaries aged 18 to 33 years, parents of small children
or adolescents, and substance and alcohol abusers) may be counseled more
frequently, if medically indicated.
Summary Plan Description Language: 
Obesity (Screening)
Screening for obesity is a covered benefit and may include measurements and
calculations relating to body mass index (BMI) and waist circumference. 
Screening is covered for all beneficiaries aged 2 and above once per calendar year.
More frequent screening is covered, if medically indicated.
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Summary Plan Description Language: 
Obesity (Counseling)
Intensive counseling (2 or more person-to-person individual or group sessions per
month, for at least 3 months) is a covered benefit for beneficiaries aged 18 and
older who meet criteria for obesity (BMI > 30). 
Six (6) counseling sessions are covered per calendar year. Additional sessions are
covered, if medically indicated. 
Summary Plan Description Language: 
Obesity (Treatment)
All FDA-approved medications for the treatment of obesity or weight loss are are
covered. Coverage is reserved for beneficiaries with a BMI higher than 30 and
beneficiaries with a BMI of 27 to 29 who also have at least one additional major
risk factor for cardiovascular disease. Coverage for medication is contingent on
physician monitoring and participation in an individual or group counseling
program.
Surgical treatment procedures are covered. Coverage is reserved for beneficiaries
aged 18 and older with class III obesity (BMI exceeding 40) and beneficiaries
with class II obesity (BMI of 35 or higher) who also have at least one obesity-
related illness. All obesity-related surgical procedures are subject to pre-
authorization requirements. 
The duration of treatment is determined by the type of medication used and its
dosage. Coverage is provided for medications and surgery, as prescribed by a
clinician.
Summary Plan Description Language: 
Osteoporosis (Screening)
Screening for osteoporosis is a covered benefit. Screening may include the use of
standardized instruments such as the Osteoporosis Risk Assessment Instrument
(ORAI) and the Simple Calculated Osteoporosis Risk Estimation tool (SCORE)
and/or use of the following:
• Dual-energy x ray absorptiometry (DXA) 
• Peripheral dual-energy x-ray absorptiometry, 




Screening is provided for normal-risk women beginning at age 65. Screening is a
covered benefit for all men beginning at age 70. High-risk women and men are
eligible for screening beginning at age 60, or as otherwise medically indicated.
Screening may not be conducted more frequently than once every 2 calendar years. 
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Summary Plan Description Language: 
Osteoporosis (Treatment)
All FDA-approved medications for the treatment of osteoporosis are covered for
beneficiaries aged 60 and older who meet medical necessity criteria for the
treatment of osteoporosis. 
The duration of treatment is determined by the type of medication used and its
dosage. Coverage is provided for medications, as prescribed by a clinician.
Summary Plan Description Language: 
Sexually Transmitted Infections (Screening and Counseling)
Counseling to Prevent Sexually Transmitted Infections
(Counseling)
Counseling to prevent sexually transmitted infections (STIs) is a covered benefit.
Counseling is a covered benefit for all adolescent and adult beneficiaries. One
counseling session is covered per calendar year.
Summary Plan Description Language: 
Chlamydia (Screening)
Chlamydia screening is a covered benefit. The following tests are covered:
• Antigen detection tests 
• Culture analysis of a endocervical or urethral swab
• Culture of swab specimens from exposed sites
• Non-amplified nucleic acid hybridization tests
• Nucleic acid amplification assays
• Point-of-care antigen detection tests on genital swab specimens and leukocyte
esterase on urine.
Annual screening is a covered benefit for all women aged 25 years and younger.
Coverage is provided for women over age 25, if medically indicated.
Summary Plan Description Language: 
Gonorrhea (Screening)
Gonorrhea screening is a covered benefit. The following tests are covered:
• Culture of swab specimens from exposed sites 
• Microscopic examination of Gram-stained urethral or cervical specimen
• Non-amplified nucleic acid hybridization tests on genital swab specimens
• Nucleic acid amplification assays 
• Point-of-care antigen detection tests on genital swab specimens and urine
dipstick for leukocyte esterase (LE)
Annual screening is a covered benefit for all women aged 25 years and younger.
Coverage is provided for women over age 25, if medically indicated.










Summary Plan Description Language: 
Human Immunodeficiency Virus (HIV) (Screening)
HIV screening is a covered benefit. The following tests are covered:
• All FDA-approved home collection kits using dried blood spots
• Laboratory-based options on serum, plasma, or whole blood. 
• Rapid HIV tests (Uni-Gold Recombigen & Oraquick Advance) 
• Repeatedly reactive enzyme immunoassay 
• Western blot or immunoflourescent assay on serum or plasma
Screening is a covered benefit for all persons aged 13 to 64. The frequency of
screening should be determined by the beneficiary’s risk factors, but should be
conducted no more than once per calendar year. 
Summary Plan Description Language: 
Human Immunodeficiency Virus (HIV) (Counseling)
HIV counseling is a covered benefit. 
Counseling is a covered benefit for all beneficiaries aged 13 to 64 considering
HIV testing. Beneficiaries are eligible for pre- and post-test counseling for a total
of 3 sessions per test cycle.
Summary Plan Description Language: 
Syphilis (Screening)
Syphilis screening is a covered benefit. The following tests are covered:
• Nontreponemal tests venereal disease research laboratory (VDRL) or the rapid
plasma regain (RPR) on serum specimens followed by a fluorescent treponemal
antibody absorbed (FTA-ABS) or T. palladium particle agglutination (TP-PA)
for confirmation.
• Immunochromatographic Strip (ICS) point-of-care test on blood specimen,
when FDA approved.
• Line Immunoassay (LIA) point-of-care test on blood specimen, when FDA
approved.
• Enzyme-linked Immunosorbent Assay (ELISA) for treponemal antibody in
serum specimens. 
• RPR point-of-care test for nontreponemal antibody in serum specimens. 
• Dark field microscope examination of lesion specimens.
Annual screening is a covered benefit for all beneficiaries at risk of infection.
More frequent screening is provided, if medically indicated.
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Summary Plan Description Language: 
Tobacco Use Treatment (Screening)
Screening for tobacco use is a covered benefit beginning at age 18. Coverage is
provided for younger populations depending on risk and need. 
Screening may be conducted at every clinical encounter.
Summary Plan Description Language:
Tobacco Use Treatment (Counseling)
Brief counseling (in-person) and intensive counseling (in-person or over the
telephone) are covered benefits for tobacco use treatment.
Beneficiaries who meet criteria are eligible for 2 courses of 6 counseling sessions
per calendar year, for a total of 12 sessions per calendar year. 
Summary Plan Description Language:
Tobacco Use Treatment (Treatment)
All FDA-approved nicotine replacement products and tobacco cessation
medications are covered.
Medications are covered as prescribed by a clinician. 
Neither hypnosis nor acupuncture has been demonstrated to be effective for
tobacco cessation and these services are therefore not covered.
Summary Plan Description Language: 
Tuberculosis (Screening)
Screening for tuberculosis is a covered benefit and may include the use of the
following:
• Chest radiography
• Intracutaneous administration of purified protein derivative {PPD} tuberculin
using the Mantoux method, called the tuberculin skin test (TST) 
• Mycobacteriology services for smears, cultures
• QuantiFERON®-TB Gold (QFT-G) 
• Sputum induction
Screening is a covered benefit for all persons at high risk of tuberculosis and may
be conducted as medically indicated. Follow up re-testing is covered as medically
indicated. Note: Routine testing for TB or LTBI is not recommended for persons
who are not at high risk of TB.
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Current Procedural Terminology Codes (CPT© Codes)
Current Procedural Terminology © 2005 American Medical Association. 
Abdominal Aortic Aneurysm (Screening)
76700 Abdominal ultrasound, complete
76705 Abdominal ultrasound, limited
Alcohol Misuse (Screening) 
99420 Administration and interpretation of health risk assessment instrument
H0001* Alcohol and/or drug assessment
H0049* Alcohol and other drug screening
Alcohol Misuse (Counseling) 
96150-5 Health and behavior assessment and intervention
98960-2 Education and training for patient self-management
90804-8 Psychotherapy, including medical management for some codes
99201-5 Evaluation and management, new patient
99212-5 Evaluation and management, established patient
99381-97 Preventive services
99401-5 Preventive counseling
H0050* Brief counseling intervention
H0004* Behavioral health counseling
Aspirin for the Primary Prevention of Cardiovascular Events (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Breast Cancer (Screening)
76092 Screening mammography, bilateral
76083 Computer aided detection with further physician review for interpretation, with 
or without digitization of film radiographic images; diagnostic mammography
0060T Electrical impedance scan of the breast, bilateral (risk assessment device for 
breast cancer)
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99386 Initial preventive medicine evaluation and management, 40 to 64 years, new
patient 
99387 Initial preventive medicine evaluation and management, 65 years and older
99396 Periodic preventive medicine evaluation and management, 40 to 64 years,
established patient 
99397 Periodic preventive medicine evaluation and management, 65 years and older
S8075* Computer analysis of full-field digital mammogram and further physician 
review and interpretation, mammography 
Breast Cancer Genetic Risk Assessment and BRCA Mutation Testing (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Breast Cancer Genetic Risk Assessment and BRCA Mutation Testing (Testing)
83890 Molecular diagnostics; molecular isolation or extraction
83891 Molecular diagnostics; isolation or extraction of highly purified nucleic acid
83892 Molecular diagnostics; enzymatic digestion 
83893 Molecular diagnostics; dot/slot blot production 
83894 Molecular diagnostics; separation by gel electrophoresis
83896 Molecular diagnostics; nucleic acid probe, each 
83897 Molecular diagnostics; nucleic acid transfer
83898 Molecular diagnostics; amplification of patient nucleic acid, each nucleic acid
sequence
83900 Molecular diagnostics; amplification of patient nucleic acid, multiplex, first two
nucleic acid sequences
83901 Molecular diagnostics; amplification of patient nucleic acid, multiplex, each
additional nucleic acid
83902 Molecular diagnostics; reverse transcription
83903 Molecular diagnostics; mutation scanning by physical properties, single 
segment, each
83904 Molecular diagnostics; mutation identification by sequencing, single segment,
each segment
83905 Molecular diagnostics; mutation identification by allele specific transcription, 
single segment, each segment
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83906 Molecular diagnostics; mutation identification by allele specific translation,
single segment, each segment
83907 Molecular diagnostics; lysis of cells prior to nucleic acid extraction
83908 Molecular diagnostics; signal amplification of patient nucleic acid, each nucleic
acid sequence
83909 Molecular diagnostics; separation and identification by high resolution technique
83912 Molecular diagnostics; interpretation and report 
88271 Molecular cytogenetics; DNA probe, each
88272* Molecular cytogenetics; chromosomal in situ hybridization, analyze 3 – 5 cells
S3818* Complete gene sequence analysis; BRCA1 gene
S3819* Complete gene sequence analysis; BRCA2 gene
S3820* Complete BRCA1 and BRCA2 gene sequence analysis for susceptibility to 
breast and ovarian cancer
S3822*  Single mutation analysis (in individual with a known BRCA1 or BRCA2
mutation in the family) for susceptibility to breast and ovarian cancer
S3823*  Three-mutation BRCA1 and BRCA2 analysis for susceptibility to breast and
ovarian cancer in Ashkenazi individuals
Breast Cancer Preventive Medication and Preventive Treatment (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Breast Cancer (Preventive Medication)
S0187* Tamoxifen citrate, oral 10 mg
Breast Cancer Genetic Risk Assessment and BRCA Mutation Testing (Preventive Treatment)
19160 Mastectomy, partial
19162 Mastectomy, partial; with axillary lymphadenectomy
19180 Mastectomy, simple, complete
19182 Mastectomy, subcutaneous
19200 Mastectomy, radical, including pectoral muscles, axillary lymph nodes
19220 Mastectomy, radical, including pectoral muscles, axillary and internal mammary
lymph nodes 
19240 Mastectomy, modified radical
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19340 Immediate insertion of breast prosthesis following mastectomy
19342 Delayed insertion of breast prosthesis following mastectomy
19357 Breast reconstruction, immediate or delayed, with tissue expander, including
subsequent expansion 
19361 Breast reconstruction with latissimus dorsi flap, with or without prosthetic
implant
19364 Breast reconstruction with free flap
19366 Breast reconstruction with other technique
19367 Breast reconstruction with transverse rectus abdmoninis myocutaneous flap,
single pedicle, including closure of donor site
19369 Breast reconstruction with transverse rectus abdmoninis myocutaneous flap,
double pedicle, including closure of donor site
58661 Laparoscopy, surgical; with removal of adnexal structures
58720 Salpingo-oophorectomy, complete or partial, unilateral or bilateral 
58940 Oophorectomy, partial or total, unilateral or bilateral 
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Cervical Cancer (Screening)
88141 Cytopathology, cervical or vaginal, requiring interpretation by physician
88142 Cytopathology, cervical or vaginal, automated thin layer prep, manual screening
under physician supervision
88143 Cytopathology, cervical or vaginal, automated thin layer prep, manual screening
and rescreening under physician supervision 
88147 Cytopathology smears, cervical or vaginal, screening by automated system, 
under physician supervision
88148 Cytopathology smears, cervical or vaginal, screening by automated system with
manual rescreening under physician supervision
88150 Cytopathology slides, cervical or vaginal, manual screening under physician
supervision
88152 Cytopathology slides, cervical or vaginal, manual screening and computer-
assisted rescreening under physician supervision
88153 Cytopathology slides, cervical or vaginal, manual screening and rescreening
under physician supervision
88154 Cytopathology slides, cervical or vaginal, manual screening and computer-
assisted rescreening using cell selection and review under physician supervision 
88155 Cytopathology slides, cervical or vaginal, definitive hormonal evaluation 
88164 Cytopathology slides, cervical or vaginal (Bethesda), manual screening under
physician supervision 
88165 Cytopathology slides, cervical or vaginal (Bethesda), manual screening and
rescreening under physician supervision 
88166 Cytopathology slides, cervical or vaginal (Bethesda), manual screening and
computer-assisted rescreening under physician supervision 
88167 Cytopathology slides, cervical or vaginal (Bethesda), manual screening and
computer-assisted rescreening using cell selection and review under physician
supervision 
88174 Cytopathology, cervical or vaginal, collected in preservation fluid, automated
thin layer prep, screening by automated system under physician supervision 
88175 Cytopathology, cervical or vaginal, collected in preservation fluid, automated
thin layer prep, screening by automated system and manual rescreening or review
under physician supervision
Childhood Health Promotion (Screening, Counseling, Immunization, Preventive
Medication and Treatment)
Child Development (Screening)
96110 Developmental screening; limited with interpretation and report
96111 Developmental testing; extended with interpretation and report
99381 Initial comprehensive preventive medicine evaluation and management, infant
(under 1 year), new patient 
99382 Initial comprehensive preventive medicine evaluation and management, early
childhood (ages 1 to 4), new patient 
99391 Periodic comprehensive preventive medicine evaluation and management, infant
(under 1 year), established patient 
99392 Periodic comprehensive preventive medicine evaluation and management, early
childhood (ages 1 to 4 ), established patient 
99201– Office or outpatient visit, new patient
99205
99211– Office or outpatient visit, established patient 
99215
Dental Caries Prevention through Oral Fluoride Supplementation (Preventive Medication)
D1201 Topical application of fluoride, including prophylaxis, child 
D1203 Topical application of fluoride, excluding prophylaxis, child
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92585 Auditory evoked potentials for evoked response audiometry and/or testing of 
the central nervous system; comprehensive
92586 Auditory evoked potentials for evoked response audiometry and/or testing of the
central nervous system; limited
92587 Evoked otoacoustic emissions; limited (single stimulus level, either transient or
distortion products) 
92588 Evoked otoacoustic emissions; comprehensive or diagnostic evaluation
(comparison of transient and/or distortion product otoacoustic emissions at
multiple levels and frequencies) 
Newborn Screening for Genetic and Endocrine Disorders (Screening)
Screening for genetic and endocrine disorders is a covered benefit. Purchasers
should refer to their health plan administrators for a current list of applicable
CPT codes.
Newborn Screening for Genetic and Endocrine Disorders (Medical Foods)
CPT code not applicable
Newborn Screening for Genetic and Endocrine Disorders (Treatment)
Medications and other forms of treatment used to prevent illness or disability 
among beneficiaries with genetic or endocrine disorders are covered. Case 
management is a covered benefit and is provided, as medically necessary, for 
beneficiaries with complex disorders. Purchasers should refer to their health 
plan administrators for a list of applicable CPT codes.
Vision (Screening) (Child)
92081 Visual field exam, unilateral or bilateral, limited exam 
92082 Visual field exam, unilateral or bilateral, intermediate exam 
92083 Visual field exam, unilateral or bilateral, extended exam 
99172 Visual function screening, automated or semi-automated bilateral, quantitative 
99173 Visual acuity screening, quantitative, bilateral 
92002 Ophthalmological medical exam and evaluation, intermediate, new patient 
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92004 Ophthalmological medical exam and evaluation, comprehensive, one or more
visits, new patient
92012 Ophthalmological medical exam and evaluation, intermediate, established
patient 
92014 Ophthalmological medical exam and evaluation, comprehensive, one or more
visits, established patient 
0065T Ocular photoscreening, interpretation and report, bilateral
Colorectal Cancer (Screening)
45378 Colonoscopy 
45330 Sigmoidoscopy, flexible 
74270 Barium enema, with/without KUB
74280 Radiological exam, colon, air contrast with specific high-density barium,
with/without glucagon 
82270 Fecal occult blood for colorectal neoplasm screening, by peroxidase activity,
consecutive collected specimens with single determination
Contraceptive Use (Counseling)
99384 Initial preventive medicine evaluation and management, adolescent (12 to 17
years), new patient
99385 Initial preventive medicine evaluation and management, 18 to 39 years, new
patient 
99386 Initial preventive medicine evaluation and management, 40 to 64 years, new
patient 
99394 Periodic preventive medicine evaluation and management, adolescent (12 to 17
years), established patient 
99395 Periodic preventive medicine evaluation and management, 18 to 39 years,
established patient 
99396 Periodic preventive medicine evaluation and management, 40 to 64 years,
established patient
Contraceptive Use (Preventive Intervention)
11975 Insertion implantable contraceptive capsules
58300 IUD insertion
58565 Hysteroscopy; with bilateral fallopian tube cannulation to induce occlusion by 
placement of permanent implants
58600 Ligation or transection of fallopian tube(s), abdominal or vaginal approach, 
unilateral or bilateral
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58605 Ligation or transection of fallopian tube(s), abdominal or vaginal approach, 
postpartum, unilateral or bilateral, during same hospitalization 
(separate procedure)
58611 Ligation or transection of fallopian tube(s) when done at the time of cesarean 
delivery or intra-abdominal surgery (not a separate procedure) (List separately in 
addition to code for primary procedure)
58615 Occlusion of fallopian tube(s) by device (e.g, band, clip, Falope ring) vaginal or 
suprapubic approach
58661 Laparoscopy; with removal of adnexal structures (partial or total oophorectomy 
and/or salpingectomy)
58671 Laparoscopy, surgical; with occlusion of oviducts by device (e.g., band, clip, or 
Falope ring)
58700 Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)
55250 Vasectomy, unilateral or bilateral (separate procedure), including postoperative 
semen examination(s)
S4993 Contraceptive pills for birth control
Depression  (Screening)
99420 Administration and interpretation of health risk assessment instrument
Diabetes (Screening)
82947 Glucose, blood (except reagent stript)
82948 Glucose, blood, reagent strip 
82950 Glucose, post glucose dose
82951 Glucose tolerance test, 3 specimens
82952 Glucose tolerance test, each additional specimen beyond 3 
82962 Glucose, blood, by monitoring device FDA-approved for home use
36415 Venipuncture
99385 Initial preventive medicine evaluation and management, 18 to 39 years, new
patient 
99386 Initial preventive medicine evaluation and management, 40 to 64 years, new
patient 
99394 Periodic preventive medicine evaluation and management, adolescent (12 to 17
years), established patient 
99395 Periodic preventive medicine evaluation and management, 18 to 39 years,
established patient 
99396 Periodic preventive medicine evaluation and management, 40 to 64 years,
established patient
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Healthy Diet  (Counseling)
99402 Preventive medicine counseling/risk factor reduction, individual, 30 minutes 
99412 Preventive medicine counseling/risk factor reduction, group, 60 minutes
99403 Preventive medicine counseling/risk factor reduction, individual, 45 minutes
99411 Preventive medicine counseling/risk factor reduction, group, 30 minutes
98960 Education and training for patient self-management by a qualified, nonphysician
healthcare professional using a standardized curriculum, face-to-face with the 
patient (could include caregiver/family) each 30 minutes; individual patient
S9470* Nutritional counseling, dietician visit
Healthy Pregnancy (Screening, Testing, Counseling, Preventive Medication, and Treatment)
Alcohol Misuse (Screening)
99420 Administration/interpretation health risk assessment instrument
Alcohol Misuse (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Asymptomatic Bacteriuria (Screening)
87077 Culture, bacterial; aerobic isolate, additional methods required for definitive
identification, each isolate
87086 Culture, bacterial; quantitative colony count, urine
87088 Culture, bacterial; with isolation and presumptive identification of isolates, urine
87187 Susceptibility studies, antimicrobial agent; microdilution or agar dilution,
minimum lethal concentration (MLC), each plate 
Breastfeeding (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
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98960 Education and training for patient self-management by a qualified, non-physician
health care professional using a standardized curriculum, face-to-face with the patient
(could include caregiver/family) each 30 minutes; individual patient
Folic Acid Supplementation (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Folic Acid Supplementation (Preventive Medication)
CPT code not applicable 
Group B Streptococcal Disease (Screening)
87081 Culture, presumptive, pathogenic organisms, screening only
Group B Streptococcal Disease (Preventive Medication)
CPT code not applicable
Hepatitis B Virus (HBV) (Screening)
36415 Venipuncture
87340 Hepatitis B surface antigen (HBsAg) 
Hepatitis B Virus (HBV) (Immunization)
90471 Immunization administration (includes percutaneous, intradermal, 
subcutaneous, or intramuscular injections); one vaccine (single or combination 
vaccine/toxoid)
90740 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose
schedule), for intramuscular use
90743 Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use
90744 Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for
intramuscular use
90746 Hepatitis B vaccine, adult dosage, for intramuscular use
90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose
schedule), for intramuscular use
Hepatitis B Virus (HBV) (Treatment)
90471 Immunization administration (includes percutaneous, intradermal, 
subcutaneous, or intramuscular injections); one vaccine (single or combination 
vaccine/toxoid)
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90740 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose
schedule), for intramuscular use
90743 Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use
90744 Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for
intramuscular use 
90746 Hepatitis B vaccine, adult dosage, for intramuscular use
90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose
schedule), for intramuscular use 
90371 Hepatitis B immune globulin (HBIg), human, for intramuscular use
90772 Therapeutic, prophylactic or diagnostic injection (specify substance or drug);
subcutaneous or intramuscular
Human Immunodeficiency Virus (HIV) (Screening)
36415 Venipuncture 
86689 HTLV or HIV antibody, confirmatory test
86701 HIV-1 antibody
86702 HIV-2 antibody
86703 HIV-1 and HIV-2 antibody, single assay 
87390 Infectious agent antigen detection, HIV-1
87391 Infectious agent antigen detection, HIV-2
S3645* HIV antibody testing of oral mucosal transudate 
Human Immunodeficiency Virus (HIV) (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
Human Immunodeficiency Virus (HIV) (Preventive Medication)
J3485 Zidovudine, injection, 10 mg 
S0104* Zidovudine, oral, 100 mg 
Influenza (Immunization)
90471 Immunization administration (includes percutaneous, intradermal, 
subcutaneous, or intramuscular injections); one vaccine (single or combination 
vaccine/toxoid)
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90656 Influenza virus vaccine, split virus, preservative free, for use in individuals 
3 years and above, for intramuscular use
90658 Influenza virus vaccine, split virus, for use in individuals 3 years of age and
above, for intramuscular use
Preeclampsia (Screening)
CPT code not applicable 




84702 Gonadotropin, chorionic (hCG); quantitative
84703 Qualitative
86336 Inhibin A
83632 Lactogen, human placental (HPL) human chorionic somatomammotropin
59000 Amniocentesis
76946 Ultrasound guidance for amniocentesis
59015 Chorionic villus sampling
76945 Ultrasound guidance for chorionic villus sampling 
59012 Cordocentesis
76941 Ultrasonic guidance for cordocentesis
89290 Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-
implantation genetic diagnosis); less than or equal to 5 embryos




82677 Quantitative Estriol 
83020 Hemoglobin Electrophoresis 
83896 Nucleic Acid Probe (each) 
83898 Nucleic Acid Probe w/Amplication (PCR) 
83912 DNA Interpretation and Report 
86316 Cancer Antigen Immunoassay 
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88230 Cell Culture, Lymphocytes 
88233 Cell Culture, Tissue 
88235 Cell Culture, Amnio/CVS 
88237 Cell Culture, Bone Marrow 
88239 Cell Culture, Other Tissue 
88245 Blood Chromosomes, Bloom syndrome
88248 Blood Chromosomes, Fanconi syndrome 
88250 Blood Chromosomes, Fra(X) 
88261 Chromosome Analysis, 5 Cell, Karyotype 
88262 Chromosome Analysis, Routine 
88262 Chromosome Analysis, Post BMT 
88262 Additional Tissue 
88267 Chromosome Analysis, Mosaic 
88267 Chromosome Analysis/Karyotype (Amnio) 
88267 Chromosome Analysis/Karyotype (CVS) 
88269 Chromosomal Analysis/Karyotype (In situ) 
88280 Additional Karyotype 
88283 Additional Banding 
88285 Additional Cells Counted 
88289 Additional High Resolution 
88271 X 5 Molecular cytogenetics, DNA probe, each (code applied 5 times, once for
each probe in the assay)
88275 Interphase in situ hybridization, count 100 to 300 cells
88291 Molecular cytogenetics, interpretation and report 
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
S3828* Complete gene sequence analysis; MLH1 gene
S3830* Complete mlh1 and mlh2 gene sequence analysis for hereditary nonpolyposis
colorectal cancer (HNPCC) genetic testing
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S3831* Single-mutation analysis (in individual with a known MLH1 and MLH2
mutation in the family) for hereditary nonpolyposis colorectal cancer (HNPCC)
genetic testing
S3833* Complete APC gene sequence analysis for susceptibility to familial adenomatous
polyposis (FAP) and attenuated FAP
S3834* Single-mutation analysis (in individual with a known APC mutation in the family)
for susceptibility to familial adenomatous polyposis (FAP) and attenuated FAP 
S3835* Complete gene sequence analysis for cystic fibrosis genetic testing
S3837* Complete gene sequence analysis for hemochromatosis genetic testing
S3840* DNA analysis for germline mutations of the ret proto-oncogene for
susceptibility to multiple endocrine neoplasia type 2 
S3841* Genetic testing for retinoblastoma
S3842* Genetic testing for von Hippel-Lindau disease
S3843* DNA analysis of the F5 gene for susceptibility to Factor V Leiden thrombophilia 
S3844* DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital,
profound deafness 
S3845* Genetic testing for alpha-thalassemia 
S3846* Genetic testing for hemoglobin E beta-thalassemia 
S3847* Genetic testing for Tay-Sachs disease 
S3848* Genetic testing for Gaucher disease
S3849* Genetic testing for Niemann-Pick disease 
S3850* Genetic testing for sickle cell anemia 
S3851* Genetic testing for Canavan disease 
S3853* Genetic testing for myotonic muscular dystrophy
Prenatal Diagnosis of Chromosomal Abnormalities and Neural Tube Defects (NTDs) (Testing)
9000 Amniocentesis
76946 Ultrasound guidance for amniocentesis
59015 Chorionic villus sampling
76945 Ultrasound guidance for chorionic villus sampling 
76801 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation, first trimester (14 weeks 0 days), transabdominal approach;
single or first gestation
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76802 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation, first trimester (14 weeks 0 days), transabdominal approach;
each additional gestation (List separately in addition to code for primary
procedure)
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation, after first trimester ( or = 14 weeks 0 days),
transabdominal approach; single or first gestation
76810 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation, after first trimester ( or = 14 weeks 0 days),
transabdominal approach; each additional gestation
76811 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation plus detailed fetal anatomic examination, transabdominal
approach; single or first gestation
76812 Ultrasound, pregnant uterus, real time with image documentation, fetal and
maternal evaluation plus detailed fetal anatomic examination, transabdominal
approach; each additional gestation
76815 Ultrasound, pregnant uterus, real time with image documentation, limited (eg,
fetal heart beat, placental location, fetal position, and/or qualitative amniotic
fluid volume), one or more fetuses
76816 Ultrasound, pregnant uterus, real time with image documentation, follow-up
(e.g., re-evaluation of fetal size by measuring standard growth parameters and
amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed
to be abnormal on a previous scan), transabdominal approach, per fetus
76817 Ultrasound, pregnant uterus, real time image documentation, transvaginal
76818 Fetal biophysical profile; with non-stress testing
76819 Fetal biophysical profile; without non-stress testing
Rh(D) Incompatibility (Screening)
36415 Venipuncture 
86901 Blood typing, Rh(D)
Rh(D) Incompatibility (Preventive Medication)
90384 Rho(D) immune globulin (RhIg), human, full-dose, for intramuscular use
90385 Rho(D) immune globulin (RhIg), human, mini-dose, for intramuscular use
90386 Rho(D) immune globulin (RhIgIV), human, for intravenous use
90772 Injection, intramuscular 
90774 Injection, IV push
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90765 Intravenous infusion, up 1 hour 







86593 Syphilis, quantitative 
86781 Treponema pallidum, confirmatory test (e.g., FTA-abs)
86403 Particle agglutination; screen, each antibody
86406 Particle agglutination; titer, each antibody\
Tetanus (Immunization)
90471 Immunization administration (includes percutaneous, intradermal, 
subcutaneous, or intramuscular injections); one vaccine (single or 
combination vaccine/toxoid)
90703 Tetanus toxoid adsorbed, for intramuscular use
90714 Tetanus and diphtheria toxoids (Td) adsorbed, preservation free, for use in 
individuals sever years or older, intramuscular use
90718 Tetanus and diphtheria toxoids (Td) adsorbed for use in individuals 7 years or
older, for intramuscular use
Tobacco Use Treatment (Screening)
99420 Administration/interpretation health risk assessment instrument
Tobacco Use Treatment (Counseling)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
S9075* Tobacco use treatment
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Hypertension (Screening)
CPT code not applicable
Hypertension (Counseling, Treatment)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
99201 Office/outpatient evaluation and management visit, new patient, level 1
99202 Office/outpatient evaluation and management visit, new patient, level 2
99203 Office/outpatient evaluation and management visit, new patient, level 3
99204 Office/outpatient evaluation and management visit, new patient, level 4
99205 Office/outpatient evaluation and management visit, new patient, level 5
99211 Office/outpatient evaluation and management visit, established patient, level 1
99212 Office/outpatient evaluation and management visit, established patient, level 2
99213 Office/outpatient evaluation and management visit, established patient, level 3
99214 Office/outpatient evaluation and management visit, established patient, level 4
99215 Office/outpatient evaluation and management visit, established patient, level 5
Immunizations (Child, Adolescent, Adults) 
This list is complete and up-to-date as of July 11, 2006.  Please refer to your 
appropriate state or local agency, providers, or partner organizations (e.g., 
Medicaid, AAP, AAFP, etc.) regarding use of these codes.  Please refer to 
AMA/CPT publications as the current, authoritative source.  AMA/CPT 
publication information can be found online at (www.ama-assn.org/ama/pub/ 
category/3113.html). Errata for the most recent CPT print edition can also be 
found online (www.ama-assn.org/ama/pub/category/3896.html). Please refer 
to (www.ama-assn.org/ama/pub/category/10902.html) for additional “early 
release” codes.
Vaccines (Toxoids)
90281 Immune globulin (Ig), human, intramuscular use
90283 Immune globulin (IgIV), human, intravenous use
90296 Diphtheria antitoxin, equine, any route
90371 Hepatitis B immune globulin (HBIg), human, intramuscular use
90389 Tetanus immune globulin (TIg), human, intramuscular use
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90396 Varicella-zoster immune globulin, human, intramuscular use
90399 Unlisted immune globulin
90632 Hepatitis A vaccine, adult dosage, intramuscular use
90633 Hepatitis A vaccine, pediatric/adolescent dosage-2 dose schedule, intramuscular
use
90634 Hepatitis A vaccine, pediatric/adolescent dosage-3 dose schedule, intramuscular
use
90636 Hepatitis A and hepatitis B (HepA-HepB), adult dosage, intramuscular use
90645 Hemophilus influenza b vaccine (Hib), HbOC conjugate (4 dose schedule),
intramuscular use
90646 Hemophilus influenza b vaccine (Hib), PRP-D conjugate, for booster use only, 
intramuscular use
90647 Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), 
intramuscular use
90648 Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4 dose schedule),
intramuscular use
90649 Human papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent) 
3 dose schedule, intramuscular use.
90655 Influenza virus vaccine, split virus, preservative free, for children 6-35 months 
of age, intramuscular use
90656 Influenza virus vaccine, split virus, preservative free, for use in individuals 
3 years of age and above, intramuscular use
90657 Influenza virus vaccine, split virus, for children 6-35 months of age,
intramuscular use
90658 Influenza virus vaccine, split virus, for use in individuals 3 years of age and
above, intramuscular use
90660 Influenza virus vaccine, live, intranasal use
90669 Pneumococcal conjugate vaccine, polyvalent, for children under five years,
intramuscular use
90680 Rotavirus vaccine, pentavalent, 3 dose schedule, live, oral use.
90698 Diphtheria, tetanus toxoids, and acellular pertussis vaccine, haemophilus
influenza Type B, and poliovirus vaccine, inactivated (DTaP - Hib - IPV),
intramuscular use
90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), for use in
individuals younger than seven years, intramuscular use
90701 Diphtheria, tetanus toxoids, and whole cell pertussis vaccine (DTP),
intramuscular use
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90702 Diphtheria and tetanus toxoids (DT) adsorbed for use in individuals younger
than seven years, intramuscular use
90703 Tetanus toxoid adsorbed, intramuscular use
90704 Mumps virus vaccine, live, subcutaneous use
90705 Measles virus vaccine, live, subcutaneous use
90706 Rubella virus vaccine, live, subcutaneous use
90707 Measles, mumps and rubella virus vaccine (MMR), live, subcutaneous use
90708 Measles and rubella virus vaccine, live, subcutaneous use
90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, subcutaneous use
90712 Poliovirus vaccine, (any type(s)) (OPV), live, oral use
90713 Poliovirus vaccine, inactivated, (IPV), subcutaneous or intramuscular use
90714 Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, for use in
individuals seven years or older, intramuscular use
90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), for use in
individuals 7 years or older, intramuscular use
90716 Varicella virus vaccine, live, subcutaneous use
90718 Tetanus and diphtheria toxoids (Td) adsorbed for use in individuals seven years
or older, intramuscular use
90719 Diphtheria toxoid, intramuscular use
90720 Diphtheria, tetanus toxoids, and whole cell pertussis vaccine and Hemophilus
influenza B vaccine (DTP-Hib), intramuscular use
90721 Diphtheria, tetanus toxoids, and acellular pertussis vaccine and Hemophilus
influenza B vaccine (DTaP-Hib), intramuscular use
90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and
poliovirus vaccine, inactivated (DTaP-HepB-IPV), intramuscular use
90732 Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed
patient dosage, subcutaneous or intramuscular use
90733 Meningococcal polysaccharide vaccine (any group(s)), subcutaneous use
90734 Meningococcal conjugate vaccine, serogroups A, C, Y and W-135 (tetravalent),
intramuscular use
90740 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose
schedule), intramuscular use
90743 Hepatitis B vaccine, adolescent (2 dose schedule), intramuscular use
90744 Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), 
intramuscular use
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90746 Hepatitis B vaccine, adult dosage, intramuscular use
90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose
schedule), intramuscular use
90748 Hepatitis B and Hemophilus influenza b vaccine (HepB-Hib), intramuscular use
90749 Unlisted vaccine/toxoid
Vaccines (Administration and Counseling)
90465 Immunization administration under 8 years of age (includes percutaneous,
intradermal, subcutaneous, or intramuscular injections) when the physician
counsels the patient/family; first injection (single or combination
vaccine/toxoid), per day
90466 Each additional injection (single or combination vaccine/toxoid), per day (List
separately in addition to code for primary procedure)
90467 Immunization administration under 8 years of age (includes intranasal or oral
routes of administration) when the physician counsels the patient/family; first
administration (single or combination vaccine/toxoid), per day
90468 Each additional administration (single or combination vaccine/toxoid), per day
(List separately in addition to code for primary procedure)
90471 Immunization administration (includes percutaneous, intradermal, 
subcutaneous, or intramuscular injections); one vaccine (single or combination 
vaccine/toxoid)
90472 Each additional vaccine (single or combination vaccine/toxoid) (List separately 
in addition to code for primary procedure)
90473 Immunization administration by intranasal or oral route; one vaccine (single or
combination vaccine/toxoid)
90474 Each additional vaccine (single or combination vaccine/toxoid) (List separately 
in addition to code for primary procedure)
Lipid Disorders (Screening)
82465 Cholesterol, serum or whole blood, total
83721 Lipoprotein, direct measurement, LDL cholesterol
83719 Lipoprotein, direct measurement, VLDL cholesterol 
83718 Lipoprotein, direct measurement, high density cholesterol 
84478 Triglycerides
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Lipid Disorders (Counseling and Treatment)
99401 Preventive medicine counseling/risk factor reduction, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, 60 minutes
99201 Office/outpatient evaluation and management visit, new patient, level 1
99202 Office/outpatient evaluation and management visit, new patient, level 2
99203 Office/outpatient evaluation and management visit, new patient, level 3
99204 Office/outpatient evaluation and management visit, new patient, level 4
99205 Office/outpatient evaluation and management visit, new patient, level 5
99211 Office/outpatient evaluation and management visit, established patient, level 1
99212 Office/outpatient evaluation and management visit, established patient, level 2
99213 Office/outpatient evaluation and management visit, established patient, level 3
99214 Office/outpatient evaluation and management visit, established patient, level 4
99215 Office/outpatient evaluation and management visit, established patient, level 5
Motor Vehicle-Related Injury Prevention (Counseling)
99401 Preventive medicine counseling and/or risk factor reduction, 15 minutes
99402 Preventive medicine counseling and/or risk factor reduction, 30 minutes
99403 Preventive medicine counseling and/or risk factor reduction, 45 minutes 
99404 Preventive medicine counseling and/or risk factor reduction, 60 minutes 
Obesity (Screening)
99420 Administration and interpretation of health risk assessment instrument
Obesity (Counseling)
99401 Preventive medicine counseling/risk factor reduction, individual, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, individual, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, individual, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, individual, 60 minutes
99411 Preventive medicine counseling/risk factor reduction, group, 30 minutes
99412 Preventive medicine counseling/risk factor reduction, group, 60 minutes
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Obesity (Treatment)
43842 Gastric restrictive procedure, without gastric bypass, for morbid obesity; 
vertical-banded gastroplasty
43843 Gastric restrictive procedure, without gastric bypass, for morbid obesity; other
than vertical-banded gastroplasty
43845 Gastric restrictive procedure with partial gastrectomy, pylorus-preserving
duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit
absorption
43846 Gastric restrictive procedure, with gastric bypass for morbid obesity; with short
limb (150 cm or less) Roux-en-Y gastroenterostomy
43847 Gastric restrictive procedure, with gastric bypass for morbid obesity;With small
intestine reconstruction to limit absorption
43848 Revision, open, of gastric restrictive procedure for morbid obesity, other than
adjustable gastric band
43886 Gastric restrictive procedure, open; revision of subcutaneous port component
only
43887 Gastric restrictive procedure, open; removal of subcutaneous port component
only
43888 Gastric restrictive procedure, open removal and replacement of subcutaneous
port component only
43770 Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable
gastric band 
43771 Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric
band component only
43772 Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric
band component only
43773 Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of
adjustable gastric band component only
43774 Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric
band and subcutaneous port components
43644 Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and 
Roux-en-Y gastroenterostomy 
43645 Laparoscopy, surgical, gastric restrictive procedure with gastric bypass and small
intestine reconstruction to limit absorption
Osteoporosis (Screening)
99420 Administration and interpretation of health risk assessment instrument
76071 Computerized tomography, bone mineral density study, one or more sites;
appendicular skeleton 
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76076 Dual energy x-ray absorptiometry (DXA), bone density study, one or more sites;
appendicular skeleton 
76077 Dual energy x-ray absorptiometry (DXA), bone density study, one or more sites;
vertebral fracture assessment 
76078 Radiographic absorptiometry (e.g., photodensitometry, radiogrammetry), one or
more sites
76977 Ultrasound bone density measurement and interpretation, peripheral site(s), any
method
78350 Bone density (bone mineral content) study, one or more sites; single photon
absorptiometry
78351 Bone density (bone mineral content) study, one or more sites; dual photon
absorptiometry, one or more sites 
Osteoporosis (Treatment)
CPT code not applicable
Sexually Transmitted Infections (Screening and Counseling)
Counseling to Prevent Sexually Transmitted Infections (STI)
99401 Preventive medicine counseling/risk factor reduction, individual, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, individual, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, individual, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, individual, 60 minutes
Chlamydia (Screening)
87270 Infectious agent antigen detection by immunofluorescent technique, Chlamydia
trachomatis 
87320 Infectious agent antigen detection by enzyme immunoassay technique,
qualitative or semi-quantitative, Chlamydia trachomatis 
87320 Chlamydia, culture, any source
87810 Infectious agent detection by immunoassay with direct optical observation,
Chlamydia trachomatis 
87490 Infectious agent detection by nucleic acid; Chlamydia trachomatis, direct probe
technique
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified
probe technique
87800 Infectious agent detection by nucleic acid, multiple organisms; direct probe
technique
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87801 Infectious agent detection by nucleic acid, multiple organisms; amplified probe
technique
81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any
number of these constituents; non-automated, with microscopy
81001 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any
number of these constituents; automated, with microscopy
81002 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any
number of these constituents; non-automated, without microscopy
81003 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any
number of these constituents; automated without microscopy 
Gonorrhea (Screening)
87081 Culture, presumptive, pathogenic organisms, screening only
87205  Smear, primary source with interpretation; Gram or Giemsa stain for bacteria,
fungi, or cell types
87800 Infectious agent detection by nucleic acid, multiple organisms; direct probe
technique
87801  Infectious agent detection by nucleic acid, multiple organisms; amplified probe
technique
87590 Infectious agent detection by nucleic acid (DNA or RNA); Neisseria 
gonorrhoeae, direct probe technique
87591 Infectious agent detection by nucleic acid (DNA or RNA); Neisseria 
gonorrhoeae, amplified probe technique
81003 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin,
ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any
number of these constituents; automated without microscopy
Human Immunodeficiency Virus (HIV) (Screening)
36415 Venipuncture 
86689 HTLV or HIV antibody, confirmatory test
86701 HIV-1 antibody
86702 HIV-2 antibody
86703 HIV-1 and HIV-2 antibody, single assay 
87390 Infectious agent antigen detection, HIV-1
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87391 Infectious agent antigen detection, HIV-2
S3645* HIV antibody testing of oral mucosal transudate 
Human Immunodeficiency Virus (HIV) (Counseling)
99401 Preventive medicine counseling/risk factor reduction, individual, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, individual, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, individual, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, individual, 60 minutes
Syphilis (Screening)
36415 Venipuncture
86592 Syphillis test, qualitative 
86781 Antibody, treponemal pallidum, confirmatory test 
87164 Dark field examination, any source, includes specimen collection 
87166 Dark field examination, any source, without collection
Tobacco Use (Screening)
99420 Administration/interpretation health risk assessment instrument
Tobacco Use (Counseling)
99401 Preventive medicine counseling/risk factor reduction, individual, 15 minutes
99402 Preventive medicine counseling/risk factor reduction, individual, 30 minutes 
99403 Preventive medicine counseling/risk factor reduction, individual, 45 minutes
99404 Preventive medicine counseling/risk factor reduction, individual, 60 minutes
S9075* Smoking cessation treatment 
Tobacco Use (Treatment)
CPT code not applicable
Tuberculosis (Screening)
71010 Chest xray, single view 
71020 Chest xray, two views, frontal and lateral 
71030 Chest xray, complete, minimum of four views 
86580 Skin test, tuberculosis, intradermal
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86480 Tuberculosis test, cell mediated immunity measurement of gamma interferon
antigen response
94640 Sputum induction for diagnostic purposes 
87116 Culture, tubercle or other acid-fast bacilli (eg, TB, AFB, mycobacteria) any
source, with isolation and presumptive identification of isolates
36415 Venipuncture 
Source:
CPT codes, descriptions, and numeric modifiers only are copyrighted 2006 American Medical Association.
All Rights Reserved.  
This publication contains CPT codes to offer information regarding coding of medical services using the CPT
coding system.  The CPT codes presented are based on the experience and interpretations of the publisher.
The material in this manual is to assist in obtaining correct and appropriate coverage and reimbursement for
healthcare goods and services. To the best of our knowledge, the information contained in the manual was
correct as of the date of publication. However, there can be no assurances that it will not become outdated
without notice or that the government or other payers may differ with the guidance contained in the manual.
The responsibility for coding correctly lies with the healthcare provider, and we urge you to consult with your
coding advisors to resolve any billing questions that you might have.  Though all of the information has been
carefully researched and checked for accuracy and completeness, the publisher does not accept any
responsibility or liability with regard to errors, omissions, misuse or misinterpretation.  Please note that CPT
codes change annually, the most current CPT is available from the American Medical Association.
No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no
liability for the data contained herein. Applicable FARS/DFARS restrictions apply to government use.
Notes:
*“S” codes are national Permanent Level II HCPCS Codes that are maintained by the HCPCS National
Panel, a group comprised of representatives from the Blue Cross/Blue Shield Association (BCBSA), the
Health Insurance Association of America (HIAA), and the Centers for Medicare and Medicaid Services
(CMS). Permanent Level II HCPCS Codes provide a standardized coding system that is managed jointly by
public and private insurers, thus providing a stable system for claims processing. These codes can be used by
all private and public insurers.
*“H” codes are used by Medicaid and other plans in order to identify mental health services such as alcohol
and drug screening.
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Overview: 
The scientific evidence behind each of the 46 screening, testing, counseling, immunization,
preventive medication, and (preventive) treatment benefit recommendations.
Evidence-Statements for Recommended
Clinical Preventive Service Benefits
Abdominal Aortic Aneurysm, Screening
Alcohol Misuse, Screening and counseling
Aspirin Therapy for the Prevention of Cardiovascular Disease, Counseling
Breast Cancer
Breast Cancer, Screening
Breast Cancer Genetic Risk Assessment and BRCA Mutation Testing, Counseling, testing,
and preventive treatment




Dental Caries, Preventive medication
Immunizations 
Lead, Elevated Blood Level, Screening
Newborn Hearing, Screening
Newborn Screening for Genetic and Endocrine Disorders, Screening, medical foods, and treatment
Vision, Screening
Colorectal Cancer, Screening
Contraceptive Use, Counseling and preventive intervention
Depression, Screening
Diabetes (type 2), Screening
Healthy Diet, Counseling
Healthy Pregnancy
Alcohol Misuse, Screening and counseling
Asymptomatic Bacteriuria, Screening
Breastfeeding, Counseling
Folic Acid Supplementation, Counseling and preventive medication
Group B Streptococcal Disease (GBS), Screening and preventive medication
Hepatitis B Virus (HBV), Screening, immunization, and treatment
Human Immunodeficiency Virus (HIV), Screening, counseling, and preventive medication
Influenza, Immunization
Preeclampsia, Screening
Prenatal Diagnosis of Chromosomal Abnormalities and Neural Tube Defects (NTDs), Screening 
and testing




Tobacco Use Treatment, Screening and counseling
Hypertension, Screening and treatment
Immunizations (Child, Adolescent, Adult)
Lipid Disorders, Screening, counseling, and treatment
Motor Vehicle-Related Injury Prevention, Counseling
Obesity, Screening, counseling, and treatment
Osteoporosis, Screening and treatment
Sexually Transmitted Infections (STIs)
Counseling to Prevent STIs, Counseling
Chlamydia, Screening
Gonorrhea, Screening
Human Immunodeficiency Virus (HIV), Screening and counseling
Syphilis, Screening






Evidence Statements for Recommended Clinical
Preventive Service Benefits
The following is a complete list of clinical preventive services covered in the Purchaser’s
Guide. These recommended clinical preventive services address a range of health conditions
that affect people of all ages. For a brief summary of clinical preventive services appropriate
for different age groups and genders, please refer to the Life Course Charts featured in Part
VII: Resources & Tools.
Evidence-statements are organized in alphabetical order. Each evidence-statement has an
accompanying SPD language statement. Please refer to Part II: Summary Plan Description
(SPD) Language Statements for Recommended Clinical Preventive Service Benefits, for
additional information.
Estimating the Cost of Preventive Interventions 
The information provided in the “Cost of Preventive Intervention” subsection of the “Value
of Prevention” section of each evidence-statement was adapted from the 2004 Medstat
Marketscan health insurance claims database. The analysis used claims paid by preferred
provider organizations (PPOs) to calculate average reimbursement rates and 95% confidence
intervals for preventive screenings and procedures. The Medstat Marketscan database is
compiled from health insurance claims of 40 self-insured employers. All 50 states are
represented in the database, which captured 6 million covered life-years during 2004.
Information in the “Cost of Treatment” subsection of the “Value of Prevention” section of
each evidence-statement was adapted from peer-reviewed journal articles and other sources.
This information may not be exclusive to commercially-insured beneficiaries. 
It is important to note that the Medstat Marketscan database is a compilation of data from a
commercially-insured population and does not reflect the costs or charges of patients in
other populations (e.g., Medicare, Medicaid, self-insured). Medstat Marketscan data is
valuable because it reflects what purchasers actually pay for healthcare and not what
providers bill for their services. Paid claims data can help purchasers estimate the cost of
implementing coverage for a preventive service. In some instances a billed service is not
reimbursed by a payer; in these instances the Medstat Marketscan database contains a $0
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Updating Cost Estimates in the “Value of Prevention” Section to Current
Year Dollars
The dollar figures presented in the “Value of Prevention” section of each evidence-statement
are not directly comparable because the figures were taken from sources that were developed
in different years. A proper updating of information related to the value of prevention for
each disease/condition should take into account the changes in both real and monetary
factors over time. For example, to update the costs of alcohol abuse from 1992 to 1998,
researchers adjusted for both changes in incidence/prevalence of alcohol abuse and changes
in the population over the time interval and used the consumer price index (CPI), medical
care price index (MCPI), and wage compensation index to respectively update 1992 non-
medical care costs, medical care costs, and productivity loss estimates to year 1998 dollars.1
Because earnings do not increase or decrease at the same rates as the prices of goods and
services, productivity losses associated with lost workdays should not be updated by CPI.
Instead, the employment cost index (ECI) should be used as it is able to accurately measure
relative changes in wages, benefits, and bonuses of workers over time and thus can be used
to update productivity loss estimates to current dollars.
Table 3.1 lists annual values of CPI, MCPI, and ECI for civilian workers for the period
1985 to 2005. The table can be used to quickly update past dollar values without
undertaking a detailed analysis based on changes in both real and monetary factors. For
example, the total cost of obesity is estimated to be $117 billion in year 2000 U.S. dollars
including $61 billion in medical care expenses and $56 billion in indirect costs (i.e., lost
productivity). To get the updated value of direct medical care costs in 2005, $61 billion of
direct medical care costs should be multiplied by 1.24, the ratio of 2005 MCPI and 2000
MCPI (323.2/260.8) to yield $75.6 billion. Similarly, assuming that the total number of
lost work hours due to obesity stayed the same between 2000 and 2005, the $56 billion of
productivity loss in 2000 would translate to approximately $67.2 billion in 2005 ($56
billion multiplied by a factor of 1.2, the ratio of 2005 ECI and 2000 ECI [100/83.6]).
Thus, the total cost of obesity would sum to $142.8 billion in year 2005 dollars. For many
diseases/conditions, there may be significant non-health related outcomes. The costs of these
outcomes need to be updated by the general CPI. For example, the cost of crime and
property damage due to alcohol abuse should be updated by general CPI. Depending on the
information available, it is possible to improve the updates by using appropriate categories
of CPI, MCPI, and ECI. For example, within the medical care category, separate price
indices are available for medical care goods and medical care services. Similarly, separate
ECIs can readily be obtained for workers in different occupations. 
Updated Direct Cost
Figure 3.0: Current Year Value Equations
Current Year Value of 
Direct Medical Care Cost
Data Year
Direct Medical Care Cost
= X
Updated Indirect Cost
Current Year Value of 
Indirect Cost Due to
Productivity Lost

















Table 3.1: Consumer Price Index (CPI), Medical Care Price Index (MCPI), and Employment
Cost Index (ECI)
Base Period 1982-84=100 1982-84=100 December 2005=100
1985 107.6 113.5 48.2
1986 109.6 122.0 49.9
1987 113.6 130.1 51.7
1988 118.3 138.6 54.2
1989 124.0 149.3 56.9
1990 130.7 162.8 59.7
1991 136.2 177.0 62.3
1992 140.3 190.1 64.4
1993 144.5 201.4 66.7
1994 148.2 211.0 68.7
1995 152.4 220.5 70.6
1996 156.9 228.2 72.6
1997 160.5 234.6 75.0
1998 163.0 242.1 77.6
1999 166.6 250.6 80.2
2000 172.2 260.8 83.6
2001 177.1 272.8 87.0
2002 179.9 285.6 90.0
2003 184.0 297.1 93.5
2004 188.9 310.1 96.9
2005 195.3 323.2 100.0
References: 
1. Harwood, H. Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates,
Update Methods, and Data. Report prepared by The Lewin Group for the National Institute on Drug 
Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 
Department of Health and Human Services. NIH Publication No. 98-4327. Rockville, MD: National 
Institutes of Health, 1998.
2. Series Id: CUUR0000SA0, Not Seasonally Adjusted, Area: U.S. City Average. Bureau of Labor Statistics. 
[cited 2006 Sep 27]. Available from: http://data.bls.gov/cgi-bin/surveymost?cu. 
3. Series Id: CUUR0000SAM, Not Seasonally Adjusted, Area: U.S. City Average. Bureau of Labor Statistics. 
[cited 2006 Sep 27]. Available from: http://data.bls.gov/cgi-bin/surveymost?cu. 
4. Employment Cost Index: Historical Listing: Current-dollar 1975-2005. Not Seasonally Adjusted. Bureau 
of Labor Statistics. [cited 2006 Sep 27]. Available from: http://www.bls.gov/web/echistry.pdf. 
Note: civilian workers include private industry and State and local government workers and excludes farm, 
household, and Federal government workers.
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Abdominal Aortic Aneurysm, Screening .........................................................................Pg. 107
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• An abdominal aortic aneurysm (AAA) is a potentially fatal abnormal swelling
(often balloon-like) of a segment of the body’s largest artery, the aorta. The
wall of the artery bulges out rather than remaining straight.1
• Abdominal aortic aneurysms affect 4% to 8% of older men and 0.5% to 1.5%
of older women.2-6
• Older age, smoking, male sex, and family history are the most significant AAA
risk factors.2-6
• Approximately 69% of men in the United States age 65 to 74 years have a
history of smoking (defined as lifetime consumption of more than 100
cigarettes) and are therefore at risk for AAA.7
• Although AAAs may be asymptomatic for years, as many as 1 in 3 eventually
rupture if left untreated.8
• Voluntary AAA screening may reduce AAA-related mortality by 43% in men
age 65 to 75 years.9 Therefore, it is particularly important that employers who
provide retiree health care coverage or who have active employees over the age
of 65 provide coverage for AAA screening. 
• In 2003, AAA (without rupture) was responsible for $2.7 billion in hospital
charges and AAA rupture was responsible for an additional $639.71 million.
Each patient treated for AAA (without rupture) costs more than $59,000; each
hospital-treated patient with an AAA rupture costs more than $93,000.10
• The average cost of elective surgery following AAA screening is $25,000; the
average cost of emergency AAA surgery following a rupture is approximately
$50,000.11
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends one-time
screening for abdominal aortic aneurysm (AAA) by ultrasonography in men aged
65 to 75 who have ever smoked.12
The USPSTF found good evidence that screening for AAA and surgical repair of
large AAAs (5.5 cm or more) in men aged 65 to 75 who have ever smoked
(current and former smokers) leads to decreased AAA-specific mortality. There is
good evidence that abdominal ultrasonography, performed in a setting with
adequate quality assurance (i.e., in an accredited facility with credentialed
technologists), is an accurate screening test for AAA. There is also good evidence
of important harms of screening and early treatment, including an increased
number of surgeries with associated clinically-significant morbidity and mortality,
and short-term psychological harms. Based on the moderate magnitude of net
benefit, the USPSTF concluded that the benefits of screening for AAA in men
aged 65 to 75 who have ever smoked outweigh the harms.12
The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Healthcare Research and Quality (AHRQ)
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• American College of Cardiology
• Harvard Medical School
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
An abdominal aortic aneurysm (AAA) is a potentially fatal abnormal swelling
(often balloon-like) of a segment of the body’s largest artery, the aorta. The wall
of the artery bulges out rather than remaining straight.1
Abdominal aortic aneurysms are found in 4% to 8% of older men and 0.5% to
1.5% of older women.2-6 Aortic aneurysms account for approximately 15,000
deaths in the United States annually; of these, 9,000 are AAA-related and the
remainder are due to thoracic aortic aneurysms.13-14
Once an aortic aneurysm develops, it is a lifelong condition. Most abdominal
aortic aneurysms grow larger with time, expanding at an average rate of .33
centimeters to .5 centimeters each year. As many as 1 in 3 AAAs eventually
rupture if left untreated.8 In about 20% of cases, an undiscovered abdominal
aneurysm ruptures without warning and the patient collapses and dies from
massive bleeding inside the abdomen. Most AAAs do not cause any symptoms,
however when present, symptoms may include:
• Pain in the abdomen, back, or the fleshy part of sides between the bottom ribs
and the hips.
• A feeling of fullness after eating a small meal.
• Nausea and vomiting.
• A pulsating mass in the abdomen.
Older age, smoking, male sex, and family history are the most significant AAA
risk factors.2 Other risk factors include high blood pressure, high blood
cholesterol levels, and obesity.15 Approximately 69% of men in the United States
age 65 to 74 years are current or former smokers and are therefore at risk for
AAA.7 A former smoker, also called an “ever smoker” is defined as anyone with a
lifetime consumption of more than 100 cigarettes.7
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An estimate of the total societal economic burden of AAA is not available.
However, hospital discharge data from Health Cost and Utilization Project
(HCUP) show that, in 2003, 45,986 patients were discharged with AAA
(without rupture) with a mean length of stay of 6.7 days and aggregate charges of
$2.7 billion.10 Therefore, the average AAA patient staying in the hospital cost
more than $59,000. Hospital discharge data also show that in 2003, 6,815
patients were discharged with a ruptured AAA with a mean length of stay of 10.7
days and total charges of $639.71 million. The average cost per discharge for a
ruptured AAA exceeded $93,000. Men accounted for 75% of all discharges and
80% of aggregate charges.10
The economic burden of AAA would be much larger if lost productivity,
premature mortality, and morbidity costs were accounted for.
Detailed data on the workplace burden of AAA is not available. The workplace
burden of AAA is likely to increase due to the rapidly aging workforce.
Early detection and appropriate management of AAA through screening can
prevent costs resulting from rupture or leakage. The average cost of emergency
surgery for AAA is approximately $50,000, while elective surgery (following AAA
screening) is only $25,000.11
In 2004, the private-sector cost of screening for AAA averaged $115;
approximately 95% of all paid claims fell within the range of $35 to $336.16
The average cost of surgery for AAA is between $25,000 and $50,000 (in year
2004 dollars).11
The Oregon Evidence-Based Practice Center (EPC) conducted an evidence
synthesis of AAA screening studies.17-20 Their principal findings point to a cost-
effectiveness ratio for population-based AAA screening (compared with no
screening) that lies in the range of $14,000 to $20,000 per quality-adjusted life
year (QALY).15 In comparison to other preventive interventions and to
commonly accepted cost-effectiveness benchmarks, screening for AAA is cost-
effective. 
Preventive Intervention Information
Screening for AAA allows clinicians to identify affected patients and those who
require preventive surgery and can thereby prevent rupture or leakage of the
aneurysm. 
Early intervention reduces AAA-specific mortality9 and is more cost-effective than
emergency surgery.11 
Ultrasonography of the abdomen is accurate21-22 and reliable23 in detecting AAAs
and it does not expose patients to radiation. One-time AAA ultrasound screening
and the surgical repair of large AAAs (5.5 centimeters or more) in men aged 65
to 75 who have ever smoked reduces AAA-related mortality by as much as 43%.9
The USPSTF found good evidence of important harms associated with screening
and early treatment, including an increased number of surgeries with clinically-
significant morbidity and mortality, and short-term psychological harms. Based
on the moderate magnitude of net benefit, the USPSTF concluded that the
benefits of screening for AAA in men aged 65 to 75 who have ever smoked
outweigh the harms.12
The USPSTF recommends a one-time screening ultrasound to look for
abdominal aortic aneurysm in men aged 65 to 75 who have smoked at any time
in their lives. The exact timing of the screen is left to the discretion of the
clinician.12
Ultrasonography of the abdomen is used to screen for AAA. Ultrasonography
should be performed in an accredited facility with credentialed technologists.
Treatment depends on the size of the aneurysm. The larger the aneurysm, the
more likely it is to burst (rupture). Death rates for ruptured aneurysms and
emergency surgery are higher than rates for scheduled repair of unruptured
aneurysms. Surgery is almost always recommended for an aneurysm that is
leaking. Surgery is generally recommended for people with aneurysms larger than
5.5 centimeters in diameter unless another illness makes surgery unusually risky.
Even with no symptoms, a person with an aneurysm larger than 6.5 centimeters
would almost always have urgent surgery to repair the problem. People with
smaller aneurysms may be monitored with ultrasound tests (every 12 months for
anyone with an aneurysm smaller than 3.5 centimeters and every six months for
those with aneurysms larger than 3.5 centimeters) to determine if the aneurysm
is growing larger.1 
Health benefits should include provisions for follow-up and treatment.
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this
chapter is described below.
Evidence-Based Research:
U.S. Preventive Service Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF recommends one-time screening for abdominal aortic
aneurysm (AAA) by ultrasonography in men aged 65 to 75 who have ever
smoked.12
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• Alcohol misuse contributes to illnesses and injuries and is the third most
common behavior-related cause of death in the United States. Alcohol misuse
was associated with 75,000 deaths and 2.3 million years of potential life lost
(30 years per premature death) in 2001.1
• Alcohol misuse results in a variety of adverse health and social outcomes. These
include increased risk of unintentional injuries, violence, liver disease,
hypertension, certain cancers, and diseases of the central nervous system.
Individuals who misuse alcohol are also at increased risk of a variety of adverse
reproductive health outcomes.1-7
• Alcohol misuse is associated with high costs to employers in the form of
increased absenteeism, decreased productivity and lost productivity, and
increased employer-sponsored healthcare expenditures. Overall, 15.3% of U.S.
workers report using or being impaired by alcohol at work at least one time
during the previous year, including 9% of workers who report being hung over
at work.8 Lost productivity accounted for 73% of the total costs resulting from
alcohol misuse in 1998.9 
• Alcohol misuse is costly for health insurers and society. The cost of alcohol
misuse in the United States was estimated to be $185 billion in 1998.9 About
$16 billion of this amount was spent on medical care for alcohol-related
complications (not including fetal alcohol syndrome [FAS]), $7.5 billion was
spent on specialty alcohol treatment services, and $2.9 billion was spent on
FAS treatment. The remaining costs ($134) billion were due to lost
productivity. 
• Randomized trials demonstrate that brief counseling leads to reduced alcohol
consumption among excessive drinkers and to reductions in adverse alcohol-
related health outcomes, including excess mortality.10-13
• Screening and counseling for alcohol misuse reduces both societal and
healthcare costs. Each $1 invested in screening and brief counseling
interventions saves approximately $4 in healthcare costs.12,14 
• Coverage for screening and brief counseling is currently offered by only 20%
of employer-sponsored health plans, despite the fact that such services are
among the most cost-effective clinical preventive services and have a proven
impact on health outcomes.10,15
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening and
behavioral counseling interventions to reduce alcohol misuse by adults, including
pregnant women, in primary care settings.16
The USPSTF found good evidence that screening in primary care settings can
accurately identify patients whose levels or patterns of alcohol consumption do
not meet criteria for alcohol dependence but place them at risk for increased
morbidity or mortality. The USPSTF also found good evidence that brief
behavioral counseling interventions with follow-up produce small-to-moderate
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reductions in alcohol consumption that are sustained over 6 to 12 month periods
or longer.16
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) recommends
incorporating screening for alcohol misuse and counseling into routine medical
practice.17
Expert Consensus
The American Academy of Pediatrics (AAP) encourages clinicians to ask
adolescents about their alcohol use and refer adolescents with suspected drinking
problems for age-appropriate treatment.18 It also encourages including substance
abuse prevention counseling in routine and episodic office visits.19
Expert Consensus (Committee on Substance Abuse)
The American Medical Association (AMA) recommends that primary care
physicians establish routine alcohol screening and be trained to conduct brief
intervention counseling and motivational interviewing.20
Expert Consensus (Office of Alcohol, Tobacco and Other Drug Abuse
Prevention)
The American College of Surgeons (ACS) recommends alcohol screening with
brief counseling or referral, as appropriate, for all injured patients.21
Expert Consensus (Committee on Trauma)
The American College of Emergency Physicians (ACEP) recommends that
physicians mitigate the consequences of alcohol abuse through screening, brief
interventions, and appropriate referral.22
Expert Consensus (Board of Directors)
The American Society of Addiction Medicine (ASAM) recommends routine
screening for alcohol misuse in primary care settings, with appropriate counseling
and referral.
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Healthcare Research and Quality (AHRQ)
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP) 
• American College of Emergency Physicians (ACEP)
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Epidemiology of
Condition/Disease
• American College of Surgeons (ACS)
• American Medical Association (AMA) 
• American Society of Addiction Medicine (ASAM)
• Center for Medicare and Medicaid Services (CMS)
• National Business Group on Health 
• National Institute on Alcohol Abuse and Alcoholism (NIAAA) 
• Peer-reviewed research 
• Substance Abuse and Mental Health Services Administration (SAMHSA)
• U.S. Preventive Services Task Force (USPSTF)
The information contained in this document is based on a compilation of
research findings. Information presented in this document should be attributed
to its referenced source and should not be considered a reflection of the opinions
of other organizations cited in the text. 
Condition/Disease-Specific Information
The term “alcohol misuse” is used to describe alcohol consumption that puts
individuals at increased risk for adverse health and social consequences. The
NIAAA defines alcohol misuse (which the Institute calls “at-risk drinking”) as
either excessive daily consumption (more than four drinks for men or more than
three drinks for women), excessive total consumption (more than 14 drinks per
week for men or more than 7 drinks per week for women), or both.17 Alcohol
abuse, which is a subset of alcohol misuse, is defined on the basis of having
suffered negative consequences from drinking (e.g., legal problems, job loss, or
family problems). Alcohol dependence (i.e., alcoholism) is also a subset of alcohol
misuse and is defined on the basis of having suffered negative consequences from
drinking and some combination of experiencing withdrawal symptoms, loss of
control, or alcohol tolerance. Other types of alcohol misuse include alcohol
consumption among high-risk populations (e.g., pregnant women, youth) and
drinking prior to or during certain activities (e.g., driving a motor vehicle,
operating heavy equipment). 
Among adults in the United States, approximately 30% of current drinkers
exceed NIAAA’s daily or weekly alcohol consumption limits. Of these excessive
drinkers, more than 90% report past-month binge drinking (consuming 5 or
more drinks during one or more occasions),23 approximately 15% abuse alcohol,
and approximately 10% are dependent on alcohol.24
Alcohol misuse contributes to illnesses and injuries and is the third most
common behavior-related cause of death in the United States. Alcohol misuse
was associated with 75,000 deaths and 2.3 million years of potential life lost
(30 years per premature death) in 2001.1 Alcohol misuse is a risk factor for:
unintentional injuries (e.g., motor vehicle crashes, falls); violence (e.g.,
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homicide, suicide); liver disease; diseases of the central nervous system (e.g.,
stroke, dementia); hypertension; and various cancers (e.g., breast, neck,
stomach, colon, and liver). Alcohol misuse is also associated with a variety of
adverse reproductive health outcomes (e.g., unintended pregnancy, sexual
assault, sexually transmitted infections), fetal alcohol spectrum disorders (e.g.,
fetal alcohol syndrome), low birth weight, and sudden infant death syndrome
(SIDS). Finally, alcohol misuse often coexists with mental health problems as
well as other substance abuse problems.1-7
There are multiple risk factors for alcohol misuse.2 These include environmental
and regulatory factors such as the price and availability of alcohol, marketing
exposure, and the provision of alcohol in public facilities. Social factors include
familial country of origin, peer group norms, religious affiliation, and other
socio-cultural factors. Intrinsic (internal or personal) risk factors for alcohol
misuse include personality characteristics and genetic factors. 
Value of Prevention
The direct and indirect costs of alcohol misuse in the United States were
estimated to at $185 billion in 1998.9 About $16 billion of this amount was
spent directly on medical care for alcohol-related complications (excluding FAS),
$7.5 billion was spent on specialty alcohol treatment services, and $2.9 billion
was spent on the treatment of FAS. The remaining costs (73% of all costs) were
due to lost productivity and costs incurred by law enforcement agencies and the
criminal justice system.9
Lost productivity due to alcohol-related deaths and disabilities impose a greater
economic burden than do healthcare costs. Lost productivity is due to 1)
absenteeism and 2) to poor job performance among those who come to work
drunk, hungover, or who drink on the job. Over 15% of workers in the United
States report drinking on the job or being hungover at work at least once during
the previous year.8
The economic benefits of screening and treatment of alcohol misuse are
measured in terms of savings from future reductions in medical costs and future
reductions in productivity losses. These costs are considerable. For example, in
1998, the estimated cost of the medical consequences of alcohol misuse was $18
billion, lost future earnings due to premature deaths from alcohol-related causes
totaled $36.5 billion, lost earnings due to alcohol-related illness totaled $86.4
billion, lost earnings due to FAS totaled $1.3 billion, and lost earnings due to
alcohol-related crimes and lost productivity of incarcerated persons totaled $10
billion.9
Implementing screening and brief counseling programs for alcohol misuse is
relatively inexpensive compared with other clinical preventive services. Costs
depend on the number of sessions, the mode of delivery (in office or by
telephone), and the type of provider that delivers the counseling. 
Screening for alcohol misuse using standard questions is a brief clinical activity
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Benefits and Risks of
Intervention
that is not typically reimbursable.  Approximately 10% of patients in primary care
settings can be expected to screen positive for alcohol misuse and accept brief
counseling.  In 2004, the private-sector cost of alcohol misuse counseling averaged
$22 per session when counseling was provided in a separate visit and a preventive
service code was used; approximately 95% of paid claims fell within the range of
$0 to $81.25 Brief counseling bundled in a primary care visit would cost less.
The vast majority of people with alcohol misuse are not alcohol dependent. For
those who are alcohol dependent, referral for specialty treatment might be
appropriate. Costs of treatment for alcohol dependence are beyond the scope of
this document, but treatment is generally cost-saving.
In economic evaluation studies of screening and counseling for alcohol misuse,
outcomes are commonly converted from natural units (e.g., reduced
hospitalizations) to dollars to enable direct comparison of benefits and costs. Several
cost-benefit analyses of screening and brief counseling have been conducted, all of
which demonstrated cost-savings. One of these studies, the Trial for Early Alcohol
Treatment (Project TrEAT), was a randomized clinical trial of screening and brief
counseling conducted in 64 primary care clinics in Wisconsin; study participants
had non-dependent alcohol misuse. Over the study’s 48-month follow-up period,
each $1.00 invested in the intervention saved $4.30 by reducing future health care
costs.12 Another study assessed the cost-effectiveness of alcohol screening and
counseling for injured patients treated in U.S. emergency department settings or
admitted to the hospital. The cost analysis, which was restricted to medical costs,
identified $3.81 in savings for each $1 spent on the intervention.14
Treatment of alcohol dependence also saves money when downstream medical
care costs associated with non-treatment are considered. For example, a 14-year
longitudinal follow-up study found that healthcare costs for alcoholics who
underwent treatment declined substantially over time, while costs rose among
untreated alcoholics.26 After adjusting for the pre-treatment status of the two
groups, those whose alcoholism that had been treated experienced a 25% decline
in medical care costs compared to those whose alcoholism had not been treated.
Preventive Intervention Information
The purpose of screening and counseling for alcohol misuse is to identify patients
who drink excessively and to assist them in reducing their consumption to safer
levels. Screening and counseling can also identify patients with more severe
alcohol problems who may require intensive substance abuse treatment. However,
most individuals with positive screening results do not meet the criteria for
alcohol dependence and are thus eligible for brief counseling interventions that
can be delivered in primary care settings and by telephone.
Most recommended screening instruments reliably identify alcohol misuse. A
majority of these instruments have a sensitivity of 70% to 90% for detecting alcohol
dependence, and single-question screens can detect milder forms of alcohol misuse
with similar sensitivity levels. In primary care settings, 10% to 25% of patients screen
positive for alcohol misuse, depending on the setting and patient population.16,27-28
Brief counseling with appropriate follow-up results in moderate reductions
(approximately 13% to 34%) in alcohol consumption lasting 6 to 12 months or
longer.16,29 Studies also show that the extent of reductions in alcohol-related health
problems may exceed the extent of reductions in alcohol consumption itself. For
example, one randomized study that assessed long-term effects (48-month follow-
up) of screening and brief counseling found that the intervention group had 20%
fewer emergency department visits, 33% fewer nonfatal injuries, 37% fewer
hospitalizations, 46% fewer arrests, and 50% fewer motor vehicle crashes than
the controls.12 These reductions exceeded the reductions experienced by these
participants in alcohol consumption; the intervention group experienced a 20%
reduction in binge drinking episodes, a 10% reduction in drinks per week, and a
4% increase in reporting no binge drinking episodes relative to controls. A meta-
analysis found that counseling interventions also reduced mortality.13
The USPSTF identified two theoretical harms from regular screening and
counseling for alcohol misuse: those who drink moderate amounts of alcohol
might abstain from drinking alcohol altogether, thus losing any of the potential
health benefits of light or moderate drinking, and those who abuse alcohol or are
dependent on alcohol might under-treat their condition by drinking moderately
rather than quitting. However, the USPSTF found no data showing that
screening and counseling for alcohol misuse are likely to produce either of these
theoretical harms. Furthermore, it should be noted that no randomized trial has
demonstrated that moderate alcohol consumption reduces mortality of any type.
Although the benefits of screening for alcohol misuse (including early
identification of misuse and treatment with behavioral counseling) outweigh the
potential harms associated with screening,16 fewer than half of patients in primary
care settings are screened for alcohol misuse,30 making it one of the least
commonly performed of the clinical preventive services recommended by the
USPSTF.31 In the absence of screening, clinicians cannot reliably identify patients
with alcohol misuse.32
The USPSTF recommends that screening begin in adulthood (i.e., at age 18).
The USPSTF found insufficient evidence to recommend for or against screening
in younger populations. However, alcohol misuse is frequent among adolescents,
has severe consequences in this population, and is an important predictor of
adult alcohol misuse. The AAP encourages clinicians to ask adolescents about
their alcohol use and refer adolescents with suspected drinking problems for age-
appropriate treatment.18
Alcohol misuse among all women of childbearing age, whether pregnant or not,
should be appropriately assessed, counseled, and treated. Furthermore, women of
childbearing age should be advised to use an effective form of contraception until
alcohol intake can be reduced or eliminated because pregnancy is often not
recognized until a woman has been pregnant for at least a month (particularly
among women who have unintended pregnancies) and fetal damage can occur
during the pre-recognition period.33 Finally, pregnant women should be screened
118




for alcohol use and should be advised to refrain from drinking alcohol altogether
during their pregnancies.34
The optimal frequency of screening is unknown. The NIAAA recommends
annual screening, with more frequent screening and counseling for high-risk
individuals such as those with a history of previous alcohol misuse.17
Those who screen positive on an alcohol screen should be counseled as medically
indicated. Eight (8) counseling sessions are covered per calendar year. 
The NIAAA and USPSTF recommend that clinicians use the screening strategy
most appropriate to their own patient population, clinical practice style, or
general setting. Examples of effective screening tools include:
• Single-question screens, which address alcohol consumption that exceeds
recommended daily limits. The question typically asks patients to identify the
last occasion, if any, when they consumed five or more drinks (or four or more
drinks for a woman). Drinking at such levels within a specified time period
(e.g., three months) constitutes a positive screening result. Single-question
screens are recommended by the NIAAA because of their high sensitivity for
detecting both severe and less severe forms of alcohol misuse, and because
having fewer questions streamlines the screening process, thereby improving its
acceptability in busy practices.17,35-37
• The Alcohol Use Disorders Identification Test (AUDIT), which is a 10-item
questionnaire that is designed to detect alcohol misuse by asking about
frequency, quantity, and consequences of drinking. The AUDIT is sensitive
and specific for detecting all forms of alcohol misuse. The first three questions
(referred to as the AUDIT-C) comprise a validated screening approach that is
less time consuming than the full AUDIT; it too has a high sensitivity for
detecting all forms of alcohol misuse. The third AUDIT question can also be
used as a single-question screen, although it uses a threshold of 6 or more
drinks that is slightly higher than the threshold used by some other single-
question screens.28,36,38-39
• The CAGE (feeling the need to Cut down, Annoyed by criticism, Guilty
about drinking, and need for Eye opener in the morning), which is a four-item
risk assessment instrument. The CAGE is reasonably sensitive and specific for
detecting alcohol abuse and dependence. However, it is relatively insensitive for
detecting less severe forms of alcohol misuse.28,36,39
Clinicians should provide counseling interventions for patients who meet the
criteria for alcohol misuse (i.e., patients who drink in excess of NIAAA
guidelines). The USPSTF identifies three levels of counseling intervention,
differentiated by level of intensity, for these patients. Multi-contact counseling is
more effective than single-contact counseling interventions, but providers should
tailor counseling intensity to address individual patient needs. Intensity is
determined by the duration of the initial contact and whether any follow-up
occurs. “Very brief ” interventions last up to 5 minutes and have no follow-up.
“Brief ” counseling interventions last 15 minutes and have no follow-up. “Multi-
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Treatment
Information
contact” interventions include one initial session lasting at least 15 minutes and
several follow-up contacts.16
Effective counseling for alcohol misuse in the primary care setting includes
feedback, advice, goal setting, and follow-up. Alcohol misuse counseling should
follow the counseling framework known as the “5 As”17: 
• Providers should assess the degree of a patient’s drinking, including any
problems caused by alcohol and whether the person is alcohol dependent or
not. 
• Providers should advise patients to reduce their alcohol consumption to safer
levels or to abstain altogether from drinking. 
• Providers should agree with patients on their goals for reducing alcohol
consumption. 
• Providers should assist patients in acquiring personal motivation, self-help
skills, or outside resources necessary to achieve behavior change. 
• Finally, providers should arrange for patients to receive appropriate follow-up
support services and counseling, depending on the nature of their alcohol
misuse.
Interventions for those with alcohol dependence are more intense and time
consuming. Addiction treatment was not discussed in the USPSTF document.16
Counseling interventions for non-dependent alcohol misuse are described above.
A detailed description of treatment for alcohol dependence is beyond the scope
of this chapter but such treatment is accepted medical practice. The benefits of
alcohol dependence treatment include a 50% reduction in alcohol consumption
compared with those who do not undergo treatment. 
Health benefits should include provisions for diagnostic follow-up and treatment
services.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/ At Least Fair Evidence)
• The USPSTF found good evidence to support screening and behavioral
counseling interventions to reduce alcohol misuse by adults, including
pregnant women, in primary care settings.16
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Recommended Guidance:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Strength of Evidence: Expert Recommendation
• The NIAAA recommends incorporating screening for alcohol misuse and
counseling into routine medical practice.17
American Academy of Pediatrics (AAP)
Strength of Evidence: Expert Consensus (Committee on Substance Abuse)
• The AAP encourages clinicians to ask adolescents about their alcohol use and
refer adolescents with suspected drinking problems for age-appropriate
treatment.18 It also encourages including substance abuse prevention in routine
and episodic office visits.19
American Medical Association (AMA)
Strength of Evidence: Expert Consensus (Office of Alcohol, Tobacco, and Other
Drug Abuse Prevention)
• The AMA recommends that primary care physicians establish routine alcohol
screening and be trained to conduct brief intervention counseling and
motivational interviewing.20
American College of Surgeons (ACS)
Strength of Evidence: Expert Consensus (Committee on Trauma)
• The ACS recommends alcohol screening with brief counseling or referral, as
appropriate, for all injured patients.21
American College of Emergency Physicians (ACEP)
Strength of Evidence: Expert Consensus (Board of Directors)
• The ACEP recommends that physicians mitigate the consequences of alcohol
abuse through screening, brief interventions, and appropriate referral.22
American Society of Addiction Medicine (ASAM)
Strength of Evidence: Not Specified
• The ASAM recommends routine screening for alcohol misuse in primary care
settings, with appropriate counseling and referral.
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• Heart disease is the leading cause of death in the United States.1
• Each year, over 1 million Americans experience new or recurrent myocardial
infarction (heart attack) or fatal coronary heart disease (CHD). Most events
occur in older people and those with recognized risk factors for cardiovascular
disease, including high blood cholesterol levels, hypertension, diabetes, or a
history of smoking.2
• Coronary heart disease (CHD), which is the most common type of heart
disease in the United States, is a leading cause of death and disability in the
working population.
• Heart disease and stroke are expected to cost more than $403 billion in 2006.3
• Aspirin therapy may decrease the risk of CHD in adults who are at increased
risk for heart disease, although aspirin is contraindicated for some individuals.2
• Adults who are at increased risk for heart disease may wish to consider aspirin
therapy, but only after consultation with their medical providers.2
• Aspirin, when used as a preventive medication by men at average risk for
cardiovascular events (men whose 10-year risk of CHD is 7.5% or higher), is
both cost-saving and life-saving. A recent study found that average risk men
who took therapeutic aspirin gained 15 quality-adjusted days of life at a cost
that was $215 less than no therapy at all.4
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that
clinicians discuss aspirin chemoprevention with adults who are at increased risk
for coronary heart disease (CHD). Discussions with patients should address both
the potential benefits and harms of aspirin therapy.2
The USPSTF found good evidence that aspirin decreases the incidence of
coronary heart disease in adults who are at increased risk for heart disease. They
also found good evidence that aspirin increases the incidence of gastrointestinal
bleeding and fair evidence that aspirin increases the incidence of hemorrhagic
strokes. The USPSTF concluded that the balance of benefits and harms is most
favorable in patients at high risk of CHD (5-year risk of greater than or equal to
3%) but is also influenced by patient preferences.2
The American Diabetes Association (ADA) recommends that physicians consider
aspirin therapy in diabetic patients between that ages of 30 and 40 years,
particularly when there is the presence of other cardiovascular risk factors.5
The ADA has designated an “E” rating as a standard of care based on expert
opinion.
The ADA recommends that use of aspirin therapy (75-162mg/day) as a primary
prevention strategy in those with either type 2 diabetes (A rating) or type 1
diabetes (B rating) who are over 40 years of age or have additional risk factors
(family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria.).5
EVIDENCE-STATEMENT:















An “A” rating is based upon clear evidence from randomized control trials.
A “B” rating is based upon supportive evidence from well-controlled cohort studies.
The American Heart Association (AHA) recommends aspirin use, if not
contraindicated, for patients who have had a myocardial infarction (heart attack),
unstable angina, ischemic stroke (caused by blood clot), or transient ischemic
attacks (TIAs or “little strokes”). This recommendation is based on sound
evidence from clinical trials showing that aspirin helps prevent the recurrence of
such events. Studies show aspirin also helps prevent these events from occurring
in people at high risk.6
The AHA also concluded that aspirin may be warranted for patients at high risk
for myocardial infarction but that health care providers must consider a patient’s
particular cardiovascular risk profile, the demonstrated benefits of aspirin on
reducing risk for a first myocardial infarction, and known as well as unknown
side effects of aspirin.7
Evidence from clinical trials.
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Diabetes Association (ADA)
• American Heart Association (AHA)
• Peer reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Heart disease and stroke are the most common types of cardiovascular disease
and are the first and third leading causes of death for both men and women in
the United States.8 In 2002, the age-adjusted death rate was 241 per 100,000
people, equating to almost 700,000 deaths per year.9
Each year, over 1 million Americans experience new or recurrent myocardial
infarction (heart attack) or fatal coronary heart disease. Most events occur in
older people and those with recognized risk factors for cardiovascular disease. In
2003, approximately 37% of adults reported having at least 2 of 6 risk factors for
heart disease and stroke (high blood pressure, high cholesterol, diabetes, current
smoking, physical inactivity, and obesity).10
Decisions about aspirin therapy should take into account the overall risk for
coronary heart disease. Risk assessment should include asking about the presence
and severity of the following risk factors: age, sex, diabetes, elevated blood
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pressure, family history (in younger adults), smoking,2 elevated total cholesterol
levels, low levels of high density lipoprotein (HDL-C) cholesterol, and high levels
of low density lipoprotein (LDL-C) cholesterol.3
Value of Prevention
In 2006, cardiovascular disease is expected to cost more than $403 billion,
including expenses related to healthcare services, medications, and lost
productivity.3 The total (direct and indirect) cost of coronary heart disease was
estimated at $142 billion in 2006.3
The workplace burden of heart diseases and stroke in 2006 included $35.6
billion in lost productivity due to morbidity and an additional $109.9 billion
dollars in lost future earnings due to premature mortality.3 Already a leading
cause of death and disability in the United States working population, the
workplace burden of cardiovascular diseases is expected to grow as a result of the
aging workforce.3
The economic benefit of counseling primarily results from the improved quality
of life and the averted cost of illness with successful aspirin therapy. Most trials
demonstrate a 15% to 40% reduction in cardiovascular events with chronic
aspirin use.11
The annual cost of an aspirin regimen is $18 and ranges from $3 to $55 per year
in 2004 dollars.12
In 2004, the private-sector cost of prevention counseling averaged $39 per
session; approximately 95% of paid claims fell within the range of $0 to $129
per session.13
In 2004, the cost of treatment for all conditions with myocardial infarction as the
principal diagnosis was $45,076 per discharge.14 
Aspirin, when used as a preventive medication by men at average risk for
cardiovascular events (men whose 10-year risk of CHD is 7.5% or higher), is
both cost-saving and life-saving. A recent study found that average risk men who
took therapeutic aspirin gained 15 quality-adjusted days of life at a cost that was
$215 less than no therapy at all.4
According to one study, increasing the use of aspirin therapy (so that all eligible
patients with coronary heart disease over 35 years of age take aspirin for 25 years)
would have an estimated cost-effectiveness ratio of about $11,000 per quality-
adjusted year of life gained.15 In comparison to other preventive interventions and
to commonly accepted cost-effectiveness benchmarks, the increased prescription
of aspirin for secondary prevention of CHD is cost-effective.
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There is good evidence that aspirin decreases the incidence of coronary
heart disease in adults who are at increased risk for heart disease.
Therefore, clinician discussion of the benefits and harms with their
patients who are at increased risk for heart disease is indicated.2
Aspirin can prevent myocardial infarctions but adds to the risk of
gastrointestinal bleeding and increases the risk of hemorrhagic stroke,
especially among older people and people with hypertension. The net
benefit of aspirin increases with growing cardiovascular risk.16 Although
older patients may derive greater benefits because they are at higher risk
for CHD and stroke, their risk of bleeding may also be higher.
Uncontrolled hypertension may attenuate the benefits of aspirin in
reducing CHD,2 and, uncontrolled hypertension and concomitant use of
non-steroidal anti-inflammatory agents or anticoagulants increase risk for
serious bleeding.16
Here is an illustration of the relationship between the benefits and risks
of the preventive intervention:  For 1,000 patients with a 5% risk of
CHD event(s) over 5 years, aspirin would prevent 14 myocardial
infarctions (range 6 to 20), but would cause one hemorrhagic stroke
(range 0 to 2), and 3 major gastrointestinal bleeds (range 2 to 4). In
contrast, for patients with CHD risk of only 1% over 5 years, aspirin
would prevent 3 myocardial infarctions (range 1 to 4), but would cause 1
hemorrhagic stroke (range 0 to 2) and 3 major gastrointestinal bleeding
events (range 2 to 4).7
According to the USPSTF, physicians should inform adults who are at
increased risk for CHD of the benefits and risks of aspirin therapy.2 The
AHA’s recommendation is primarily based on physician discretion. 
Although the optimal timing and frequency of discussions related to
aspirin therapy are unknown, reasonable options include every 5 years in
middle-aged and older people or whenever cardiovascular risk factors are
detected.16
Counseling and discussion methods are left to the discretion of the
clinician. Discussions about aspirin therapy should focus on potential
CHD benefits, such as prevention of myocardial infarction, and potential
harms, such as gastrointestinal and intracranial bleeding. Discussions
should take into account individual attitudes and risk preferences about
myocardial infarction, stroke, and gastrointestinal bleeding.2
When it is determined that the benefits of intervention outweigh the
risks of intervention, physicians should encourage patients to take aspirin
for the prevention of cardiovascular disease events. The optimum dose of
aspirin for prevention is not known. Primary and secondary prevention
trials have demonstrated benefits with a variety of regimens, including 75
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mg per day, 100 mg per day and 325 mg every other day. Doses of approximately
75 mg per day appear as effective as higher doses17 whether doses below 75 mg
per day are effective has not been established. Enteric-coated or buffered
preparations do not clearly reduce adverse gastrointestinal effects of aspirin.16
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF strongly recommends that clinicians discuss aspirin
chemoprevention with adults who are at increased risk for coronary heart disease
(CHD).2
Recommended Guidance:
American Diabetes Association (ADA)
Strength of Evidence: A, B, E 
E (Based on Expert Opinion)
• The ADA recommends that physicians consider aspirin therapy in patients
between that ages of 30 to 40 years, particularly when there is the presence of
other cardio-vascular risk factors.5
A (Based upon clear evidence from randomized control trials)
B (Based upon supportive evidence from well-controlled cohort studies)
• The ADA recommends the use of aspirin therapy (75-162 mg/day) as a
primary prevention strategy in those with either type 2 diabetes (A rating) or
type 1 diabetes (B rating) who are over 40 years of age or have additional risk
factors (family history of CVD, hypertension, smoking, dyslipidemia, or
albuminuria).5
American Heart Association (AHA)
Strength of Evidence: Evidence from clinical trials
• The AHA recommends aspirin use for patients who have had a myocardial
infarction (heart attack), unstable angina, ischemic stroke (caused by blood
clot) or transient ischemic attacks (TIAs or “little strokes”), if not
contraindicated. This recommendation is based on sound evidence from
clinical trials showing that aspirin helps prevent the recurrence of such events.
Studies show aspirin also helps prevent these events from occurring in people
at high risk.6
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• Breast cancer is the most commonly diagnosed non-skin cancer and the second
leading cause of cancer death among women in the United States.1
• In 2005, 211,000 women are expected to be diagnosed with breast cancer and
40,000 women are expected to die as a result of breast cancer.1
• Women aged 40 to 64 years accounted for 61% of in situ cases, 54% of
invasive breast cancer cases, and 40% of breast cancer deaths in 2005.1 The
direct medical care costs for breast cancer treatment were estimated to exceed
$6 billion in 1996.2
• Breast cancer accounts for up to one-quarter of all cancer-related costs.3
• The risk of breast cancer increases with age.4 Population aging in the next three
decades is expected to increase the number of breast cancer cases and the
economic burden of the disease.
• Mammography screening is a valuable early detection tool because it can
identify breast cancer at an early stage, usually before physical symptoms or
complications develop, when treatment is more effective and less expensive.
• Women with certain specific family history patterns have an increased risk for
developing breast or ovarian cancer associated with mutations in genes known
as BRCA1 and BRCA2. Although these mutations are uncommon, public
interest in testing is growing.5 Further, for women who are positive for a
BRCA1 or BRCA2 genetic mutation, prophylactic surgery at a young age
significantly improves survival and is cost-effective in comparison to other
interventions.6
• For the minority of women with a clear, high risk for breast cancer, preventive
medication can reduce the risk of certain types of breast cancer although such
treatment can also produce serious side effects.7 For women at low or average
risk for breast cancer, the potential harms of preventive medication may
outweigh the potential benefits.
Breast Cancer (Screening)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening
mammography, with or without clinical breast examination (CBE), every 1 to 2
years for women aged 40 and older.8
The USPSTF found fair evidence that screening for breast cancer every 12 to 33
months significantly reduces mortality from breast cancer and that the benefits of
screening outweigh the associated risks, for women aged 40 and older.8
EVIDENCE-STATEMENT:
BREAST CANCER (Screening, Counseling, Testing,
Preventive Medication, and Treatment)
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Breast Cancer: Genetic Risk Assessment and
BRCA MutationTesting (Counseling, Testing, and
Preventive Treatment)
The U.S. Preventive Services Task Force (USPSTF) recommends that women
whose family history is associated with an increased risk of deleterious mutations
in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for
BRCA testing.9
The USPSTF found fair evidence that women with certain specific family history
patterns (increased-risk family history) have an increased risk for developing
breast or ovarian cancer associated with BRCA1 or BRCA2 mutations. The
USPSTF determined that these women would benefit from genetic counseling
that allows informed decision making about testing and further prophylactic
treatment. This counseling should be done by suitably trained healthcare
providers. There is fair evidence that prophylactic surgery significantly decreases
breast and ovarian cancer incidence in women who test positive for deleterious
BRCA1 or BRCA2 mutations, although there is insufficient evidence to
determine other health-outcome benefits from intensive screening or preventive
medication in such women.9
Note: The U.S. Preventive Services Task Force (USPSTF) recommends against
routine referral for genetic counseling or routine breast cancer susceptibility gene
(BRCA) testing for women whose family history is not associated with an
increased risk for deleterious mutations in breast cancer susceptibility. The
USPSTF concluded that the potential harms of routine referral for genetic
counseling or BRCA testing in these women outweigh the benefits.9
The American College of Medical Genetics (ACMG) recommends risk
assessment and genetic counseling before testing for BRCA1/BRCA2 mutations
in individuals at increased risk, based on a personal or family history of breast
cancer, ovarian cancer or both.10 In a previous guideline published in 1996, the
ACMG recommended testing for BRCA1 mutations in high-risk families and
population screening of Ashkenazi Jews after discussion of test limitations and
appropriate informed consent.11
Expert Opinion
The American Society of Clinical Oncology (ASCO) recommends that genetic
testing be offered when an individual has a personal or family history that
suggests a genetic cancer susceptibility, the test can be adequately interpreted, and
its results will influence diagnosis or management of the patient or family
members at risk for hereditary cancer.12
Not Specified
The National Comprehensive Cancer Network recommends offering genetic
susceptibility testing (after risk assessment and counseling) to individuals who
meet the criteria for hereditary breast or ovarian cancer or both.13
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Breast Cancer: (Counseling and Preventive
Medication)
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
discuss preventive medication with women at high risk for breast cancer and at
low risk for adverse effects of preventive medication use. Clinicians should
inform patients of the potential benefits and harms of preventive medication.14
The USPSTF found fair evidence that treatment with tamoxifen can significantly
reduce the risk of invasive estrogen-receptor-positive breast cancer in women at
high risk for breast cancer and that the likelihood of benefit increases as the risk
for breast cancer increases. Although raloxifene is not now FDA-approved for this
use, the USPSTF found consistent, but less abundant, evidence for its benefit as
well. The USPSTF found good evidence that estrogen antagonists (e.g.,
tamoxifen) increase the risk for thromboembolic events (for example, stroke,
pulmonary embolism, and deep vein thrombosis) and symptomatic side effects
(for example, hot flashes) and that tamoxifen increases the risk of endometrial
cancer.14
The USPSTF concluded that the balance of benefits and harms may be favorable
for some high-risk women but will depend on breast cancer risk, risk from
potential harms and individual patient preferences.14
Note: The U.S. Preventive Services Task Force (USPSTF) recommends against
routine use of tamoxifen or raloxifene for the primary prevention of breast cancer
in women at low or average risk for breast cancer.14
The American Society of Clinical Oncology (ASCO) suggests that women with
sufficient risk, based on the Gail Index, be offered tamoxifen to reduce their risk
of breast cancer.15 The Gail Index is a breast cancer risk tool developed by the
National Cancer Institute, and is available online (http://cancer.gov/bcrisktool/)
or by telephone (800-4-CANCER).
Expert Opinion
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Cancer Society (ACS)
• American College of Medical Genetics (ACMG)
• American Society of Clinical Oncology (ASCO)
• Centers for Disease Control and Prevention (CDC)
• International Agency for Research on Cancer (IARC)
• National Cancer Institute (NCI)
• National Committee for Quality Assurance (NCQA)
• National Comprehensive Cancer Network
134
EVIDENCE-STATEMENT: Breast Cancer (Screening, Counseling, Testing, 





• National Heart, Lung, and Blood Institute (NHLBI)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Breast cancer is the most commonly diagnosed non-skin cancer and the
second leading cause of cancer death among women in the United States.1 In
2005, 211,000 women are expected to be diagnosed with breast cancer and
40,000 women are expected to die as a result of breast cancer.1
Risk factors for breast cancer (reported by the USPSTF) include16:
• A family history of breast cancer (especially a mother or sister with breast
cancer)
• Atypical hyperplasia
• Having a first child after the age of 30
• Increasing age 
Risk factors reported by other organizations include17-19: 
• Early age at menarche
• Late age at menopause
• Overweight/obesity
• Physical inactivity
• Hormone replacement therapy
• Exposure to radiation
Another risk factor for breast cancer is the presence of genetic markers for the
BRCA1 or BRCA2 genes.19 However, only a small proportion of breast cancer
cases are attributable to genetic susceptibility. Approximately 2% of adult
women in the United States have a family history indicating they are at
increased risk of a deleterious mutation in the BRCA1 or BRCA2 gene, and
about1 in 10 women with these histories (2 to 3 per 1,000 adult US women)
actually have a mutation.5 Among women with a deleterious BRCA1 or
BRCA2 mutation, 35% to 84% may develop breast cancer by age 70.5
Value of Prevention
The direct medical care costs for breast cancer treatment were estimated to exceed
$6 billion in 1996.2 The total economic burden of breast cancer would be much
higher if breast cancer related mortality and morbidity costs were included in this
figure. In 2004, for example, the overall cost of cancer (including direct and
indirect cots) was estimated to be almost $190 billion20, and breast cancer could
account for up to one-quarter of this total.3 A small proportion of the economic
burden of breast cancer is attributable to genetically-related breast cancers.
The risk of breast cancer increases with age.4 Population aging in the coming
decades is expected to increase the number of breast cancer cases and the
economic burden of the disease. 
Women aged 40 to 64 years accounted for 61% of in situ cases, 54% of invasive
breast cancer cases, and 40% of breast cancer deaths in 2005.1 The breast cancer
medical care costs, productivity losses, and mortality costs among working
women in this group is substantial. 
Screening may reduce breast cancer treatment costs by identifying tumors in their
earliest stages when treatment is more successful and less expensive. For example,
a study that examined the cancer-care costs among members of a health
maintenance organization (HMO) found that the net cost of initial care for
breast cancer was $7,093 when the cancer was identified at the carcinoma in situ
stage and to $10,900 when it was identified at the regional stage (both figures in
year 1992 dollars).21
The recognition of BRCA mutations through testing allows for early intervention
and treatment. This is important because women who receive early treatment
generally have better outcomes. For example, in one research model, a 30-year-
old BRCA1 and 2 positive woman could prolong her life by about 1 year by
having bilateral oophorectomy, 3.4 years by having bilateral mastectomy, and 4.3
years by having both procedures instead of surveillance alone.7
The use of preventive medication in carefully-selected, high-risk women can
reduce their risk of breast cancer or delay the onset of breast and ovarian cancers.
It is estimated that for every 100 women treated with tamoxifen for 5 years,
1.665 expected cancers are delayed or prevented. If breast cancer death is fully
prevented by this strategy, then the use of preventive medication (compared to no
intervention) would cost $8,479 per year of life gained.22
In 2004, the private-sector cost of a screening mammography averaged $51
(range $0 to $122).23 A diagnosis of breast cancer is more costly ($451 to $2,520
in year 2002 dollars) as it requires additional tests, interpretations, and office
visits.4
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In 2004, the private-sector cost of BRCA mutation testing averaged $53 per test;
approximately 95% of all paid claims fell within the range of $12 to $201 per
test.23 The cost of genetic counseling averaged $39 per session; approximately 95%
of all paid claims fell within the range of $0 to $129 per session.23 The cost of a
preventive mastectomy or oophorectomy varies by location and facility type. 
The average wholesale price (AWP) of a 1-month supply of tamoxifen citrate is
between $58.38 (generic) and $128.62 (brand — Nolvadex®).24
The cost of breast cancer treatment depends on the stage of disease at diagnosis
and the procedures or treatments selected. Treatment costs have been reported to
range from $21,287 to $45,220 per patient. However, terminal care costs for
Medicare patients were reported to be as high as $63,455 (all figures in year 2002
dollars).4
The cost-effectiveness of breast cancer screening depends on the age of the
population screened. Many cost-effectiveness analyses have shown that screening
for breast cancer in women 65 years of age and younger reduces mortality at a
reasonable cost.1 A systematic review of cost-effectiveness analyses performed for
the USPSTF noted that biennial screening after the age of 65 also reduces
mortality at a reasonable cost. However, screening becomes more costly in
women with significant comorbidities, such as dementia, or comorbidities that
limit life expectancy. For example, the incremental costs per life-year saved for
screening beyond age 65 were found to range from $34,000 to $88,000 in year
2002 dollars4, which compare favorably with most other preventive interventions
and to commonly accepted cost-effectiveness benchmarks.1
One study, using modeling techniques, concluded that BRCA1 and BRCA2
testing is cost-effective only if women who screen positive proceed with
prophylactic surgery.25 The model further suggested that, per life-year saved,
combined surgery cost $20,717, mastectomy cost $29,970, and oophorectomy
cost $72,780 (all figures in year 1995 dollars).25 Another study, which also used
modeling techniques, concluded that for women who are positive for a BRCA1
or BRCA2 genetic mutation, prophylactic surgery at a young age significantly
improves survival and is cost-effective in comparison to other interventions.8
Tamoxifen is cost-effective for women aged 40 to 50 years who are at significant
risk for breast cancer.26 Tamoxifen costs $46,619 per life-year saved for women
who begin taking the medication at age 35. For women over the age of 50, the
intervention costs more than $50,000 per life-year saved.27
Preventive Intervention Information
Mammography screening is a valuable early detection tool because it can identify
breast cancer at an early stage, usually before physical symptoms or complications
develop, and when treatment is more effective and less expensive.
The purpose of family history assessment, counseling, and BRCA mutation-
testing is to identify women with certain specific family history patterns that are
associated with an increased risk for deleterious mutations in the BRCA1 or
BRCA2 gene and an increased risk of breast or ovarian cancer. With the
assistance of genetic counseling, women at risk can make an informed decision
on testing and treatment options. 
The purpose of preventive medication counseling is to educate women at high
risk of breast cancer on the benefits and risks associated with tamoxifen. 
Screening allows for the early detection of breast cancer. Screening is estimated to
reduce breast cancer mortality by 20% to 25% during the 10-year period
following screening.8 The risk of breast cancer increases with age. Therefore, the
absolute benefit of screening also increases as a woman ages, at least from age 40
through age 70.16 Because the risk of breast cancer is higher after age 70,
mammography may offer important benefits to older women. However, these
benefits may be offset by the fact that many older women, especially the very old
and those with other illnesses, will die from other causes before they experience
the benefits of early cancer detection.16 Risks associated with screening include
false-positive test results, which may cause undue anxiety, and the inconvenience,
occasional complications, and costs associated with biopsies.  False-positive test
results are common among all types of cancer screening, including
mammography; 80% to 90% of abnormal mammogram or clinical breast exam
results are false-positive.16
The USPSTF determined that women with certain specific family history
patterns benefit from genetic counseling that allows informed decision making
about testing and preventive treatment (e.g., removal of the breasts and/or
ovaries).9 The USPSTF found fair evidence that prophylactic surgery significantly
decreases the incidence of breast and ovarian cancer among women with a BRCA
mutation. Thus, the potential benefits of referral and discussion of testing and
prophylactic treatment for these women may be substantial. The inherent risk
associated with preventive treatment and surgery, such as patient anxiety and
medical errors, may be substantial for some individuals.
The USPSTF concluded that for women whose family history is not associated
with an increased risk of deleterious mutations, the harms of routine referral for
counseling and testing outweigh the benefits.9
Among women at high risk for breast cancer, an estrogen antagonist (i.e.,
tamoxifen) has been found to reduce the incidence of invasive breast cancer by
approximately one-half.14, 28 Estrogen antagonists increased survival by 1.6 years
(range 1.0 to 2.1 years) and 2.2 years (range 1.3 to 2.8 years), respectively.
Research shows that preventive medication yields more quality-adjusted life years
than does prophylactic surgery, even when treatment is delayed to age 40 or 50
years.9
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Estrogen antagonists are associated with an increased risk of venous
thromboembolic disease (deep vein thrombosis and pulmonary embolism);
tamoxifen is also associated with an increased risk of endometrial cancer.14, 28
The balance between benefits and harms varies among subgroups of women,
depending on age, predicted risk of breast cancer, and hysterectomy status. In
general, the balance of benefits and harms of preventive medication is more
favorable for women in their 40s who are at increased risk for breast cancer and
have no predisposition to thromboembolic events or women in their 50s who are
at increased risk for breast cancer, have no predisposition to thromboembolic
events, and do not have a uterus. Women are at lower risk for adverse effects
from preventive medication if they are younger; have no predisposition to
thromboembolic events such as stroke, pulmonary embolism, or deep venous
thrombosis; or do not have a uterus.
The USPSTF concluded that routine use of estrogen antagonists for the primary
prevention of breast cancer in women at low or average risk for breast cancer
would cause more harm than benefit.14
According to the USPSTF women aged 40 and above should be screened for
breast cancer with mammography, with or without CBE (clinical breast
examination), every 1 to 2 years.16 The USPSTF notes that the precise age is not
known when the benefits of breast cancer screening first outweigh the associated
risks and costs; thus, the specific ages at which screening should begin and cease
should consider patient preferences.16
Patients identified as high-risk through a clinician risk assessment should be
referred for genetic counseling and, if appropriate, follow-up genetic mutation
testing. The initiation, cessation, and frequency of counseling is left to the
discretion of the clinician. A onetime BRCA test should be administered to at-
risk patients who request testing. Preventive treatment including mastectomy
and/or ophorectomy should be conducted, as medically necessary, at the
discretion of the clinician. 
Note: The USPSTF realizes that clinical decisions about patients involve more
complex considerations that the evidence alone; clinicians should always
understand the evidence but individualize decision making to the specific patient
and situation.
The initiation and cessation of preventive medication therapy with an estrogen
antagonist is left to the discretion of the clinician (in discussion with the patient).
In general, preventive medication is more favorable for women in their 40s who
are at increased risk for breast cancer and have no predisposition to
thromboembolic events or women in their 50s who are at increased risk for
breast cancer, have no predisposition to thromboembolic events, and do not have
a uterus.14 Women younger than 40 years of age have a lower risk for breast
cancer, and thus will not experience as large an absolute benefit from beast cancer
preventive medication as older women.14 Women 60 years of age and older, who
have the highest risk for breast cancer also have the highest risk for complications
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from preventive medication/chemoprevention with a less favorable balance of
benefits and harms.14
The standard course of preventive medication with tamoxifen in clinical trials is
5 years.29
Approved screening methods for breast cancer include mammography and, as an
adjunct, a clinical breast exam. CBE is a low-cost screening method that provides
an opportunity for health professionals to discuss breast health with women.30
Although CBE is not explicitly recommended by the USPSTF, many experts
encourage routine CBE.30 However, clinicians who perform routine CBE should
understand that there is currently insufficient evidence to determine whether CBE
affects breast cancer mortality and that they are likely to increase the incidence of
clinical assessments and biopsies.16 Coverage should also include diagnostic follow-
up. Coverage should also include diagnostic follow-up (e.g., biopsies).
The clinician should assess the patient's family history of breast cancer to
determine the likelihood that the patient has a deleterious BRCA mutation.9 If
the assessment is positive, the woman should be referred for genetic counseling to
help determine if she wishes to have genetic testing. Women may require further
counseling after test results are received. A positive test for a deleterious mutation
may result in a decision to have the surgical removal of her breasts and/or ovaries.
Coverage should include clinician time to evaluate family history for possible
referral to a genetic counselor, counseling on the harms and benefits of genetic
testing by a qualified practitioner, and preventive treatment (e.g., complete
mastectomy with or without reconstructive surgery, ophorectomy).
Clinicians should assess a patient’s risk for breast cancer and the risk for adverse
preventive medication effects when identifying women who may be candidates
for preventive medication therapy. Clinicians can assess a patient’s risk of
developing breast cancer within the next 5 years using risk-factor information
from the National Cancer Institute Breast Cancer Risk Tool (the “Gail Index”).
Clinicians should discuss the results of the risk assessment, inform the patient of
the risks associated with breast cancer, and counsel about the benefits and risks
associated with the use of preventive treatment. Clinicians should counsel on the
harms and benefits of preventive medication use and prescribe an FDA-approved
preventive medication to eligible women who choose to use preventive
medication. Coverage should include clinician time to monitor the potential
harms/adverse effects associated with preventive medication use and the cost of
the preventive medication approved for use by the FDA.
Health benefits should include provisions for diagnostic and treatment services. 
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Strength of Evidence for the Clinical Preventive Service
Breast Cancer (Screening)
The level of evidence supporting the recommendations contained in this section
is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence) 
• The USPSTF found fair evidence to recommend screening mammography,
with or without clinical breast examination (CBE), every 1 to 2 years for
women aged 40 and older.8
Strength of Evidence for the Clinical Preventive Service 
Breast Cancer Genetic Risk Assessment and BRCA Mutation
Testing (Counseling, Testing and Preventive Treatment)
The level of evidence supporting the recommendations contained in this section
is described below.
Evidence-Based Research:
The U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found fair evidence that women with certain specific family
history patterns (increased risk family history) have an increased risk for
developing breast or ovarian cancer associated with BRCA1 or BRCA2
mutations.9
Note: The USPSTF recommended against routine referral for genetic counseling
or gene testing for women whose family history is not associated with an
increased risk of deleterious mutations as the USPSTF concluded that the
potential harms of routine referral for genetic counseling or BRCA testing in
these women outweigh the benefits.9
Recommended Guidance: 
The American College of Medical Genetics (ACMG) 
Strength of Evidence: Expert Opinion
• The ACMG recommends risk assessment and genetic counseling before testing
for BRCA1/BRCA2 mutations in individuals at increased risk, based on a
personal or family history of breast cancer, ovarian cancer or both.10 In a
previous guideline published in 1996, the ACMG recommended testing for
BRCA1 mutations in high risk families and population screening of Ashkenazi
Jewish individuals after discussion of test limitations and appropriate informed
consent.11
The American Society of Clinical Oncology (ASCO)
Strength of Evidence: Not Specified
• The American Society of Clinical Oncology recommends that genetic testing
be offered when: an individual has a personal or family history that suggests a
genetic cancer susceptibility and the test can be adequately interpreted and its
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results will influence diagnosis or management of the patient or family
members at risk for hereditary cancer.12
The National Comprehensive Cancer Network 
Strength of Evidence: Not Specified
• The National Comprehensive Cancer Network recommends offering genetic
susceptibility testing (after risk assessment and counseling) to individuals who
meet the criteria for hereditary breast or ovarian cancer or both.13
Strength of Evidence for the Clinical Preventive Service
Breast Cancer (Counseling and Preventive Medication)
The level of evidence supporting the recommendations contained in this section
is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
B (Recommended/At Least Fair Evidence);
• The USPSTF recommends that clinicians discuss preventive medication with
women at high risk for breast cancer and at low risk for adverse effects of
chemoprevention. Clinicians should inform patients of the potential benefits
and harms of chemoprevention.14
Note: The USPSTF recommends against routine use of tamoxifen for the
primary prevention of breast cancer in women at low or average risk for breast
cancer.14
Recommended Guidance: 
American Society of Clinical Oncology (ASCO)
Strength of Evidence: Expert Opinion
• The American Society of Clinical Oncology suggests that women with
sufficient risk, based on the Gail Index, be offered tamoxifen to reduce their
risk of breast cancer.16
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• Cervical cancer was once the most common cause of cancer death among
women in the United States. Screening, earlier detection, and more effective
treatment methods reduced the death rate from cervical cancer 74% between
1955 and 1992.1
• Nevertheless, cervical cancer remains a concern. In 2005, it was estimated that
10,370 women would be diagnosed with cervical cancer and 3,710 women
would die as a result of the disease.1
• The direct medical care costs associated with cervical cancer were estimated to
equal $1.7 billion in year 1996 dollars.2
• Screening can prevent cervical cancer by allowing clinicians to identify and
remove precancerous lesions before they develop into cancer. Screening can
also identify cancer early in the course of the disease when treatment is more
effective and the chance of recovery is high.3
• The cost of screening is typically less than the cost of treating cancer and,
when screening identifies a lesion in its early stages, the cost of treatment is
often much less expensive than if the lesion was identified at a later stage.
Clinical Preventive Service Recommendations for Screening
The U.S. Preventive Services Task Force (USPSTF) strongly recommends cervical
cancer screening for all women who have been sexually active and have a cervix.3
The USPSTF found good evidence that the benefits of screening for cervical
cancer substantially outweigh the risks associated with screening.3
The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Immunization Practices (ACIP)
• Alliance for Cervical Cancer Prevention; Program for the Appropriate use of
Technology in Health (PATH)
• American Cancer Society (ACS)
• National Cancer Institute (NCI)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Cervical cancer was once the most common cause of cancer death among women
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Condition/Disease
Risk Factors
between 1955 and 1992, due to screening, earlier detection and treatment, and
more effective treatment methods.1 Despite this progress, cervical cancer remains
a major cause of premature morbidity and mortality among women in the
United States.
In 2005, it was estimated that 10,370 women would be diagnosed with cervical
cancer and 3,710 women would die as a result of the disease.1 Cervical cancer is
most common among women in their 40s to 60s, although some women develop
cancer in their 30s.4
Cervical cancer screening has been conducted using the conventional Pap test
screening method since 1940; the Pap test has proven to be one of the most
successful methods of cancer prevention and early detection available.5 More than
50% of women who develop cervical cancer have never been screened for cervical
cancer and 60% of women who develop cervical cancer have not been screened
in the previous 5 years.5-6 The dose-response relationship between the number of
times a woman is screened during her lifetime and her likelihood of developing
cervical cancer is illustrated in the following table: 
Source: Alliance for Cervical Cancer Prevention. Cervical cancer prevention fact sheet. Seattle,
WA: Program for the Appropriate use of Technology in Health (PATH); 2003.
The major risk factor for cervical cancer is infection with the human
papillomavirus (HPV), a common sexually transmitted infection (STI). Clinical
research shows that 95% to 100% of all squamous cell cervical cancers and 75%
to 95% of all cervical intraepithelial neoplasia (CIN) lesions (a precursor to
cervical cancer) can be linked to infection with HPV.7
HPV is the most common sexually transmitted disease in the United States; over
50% of adults contract an HPV infection during their lifetime.8 In most women
infected with HPV, the virus remains asymptomatic and does not progress to
precancerous lesions (CIN or dysplasia) or cervical cancer.9-10 However,
approximately 5% to 10% of women with persistent HPV infection develop
cervical cancer during their lifetimes if they do not have a Pap test to detect
precancerous lesions and do not receive appropriate follow-up care.10
In 2006, the Food and Drug Administration (FDA) licensed a vaccine to reduce
the risk of cervical cancer. The Advisory Committee on Immunization Practices
(ACIP) has issued provisional recommendations for use of this vaccine.11 The
Frequency of Screening Reduction in Cancer Rate
At least every three years
*Screening interval recommended by the USPSTF
75%-88%
Five times per lifetime 61%-75%
Three times per lifetime 35%-55%
Twice per lifetime 29%-42%
Once per lifetime 17%-32%
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vaccine is not a substitute for recommended screening services: screening is still
the primary method of cervical cancer prevention.11 Additional information on
the HPV vaccine is provided in the Immunization Evidence-Statement.
Although cervical cancer precursor lesions only develop after HPV infection, other
factors—such as age, being a smoker, starting sexual intercourse at an early age,
having a large number of sexual partners, using oral contraceptives, and having
seven or more live births—increase a woman’s risk of cervical cancer.9 Some
research suggests that diet; a woman’s immune status and genetic predisposition;
and co-infection with chlamydia, HIV/AIDS, or other sexually transmitted
infections (STIs) may also influence risk of developing cervical cancer.9, 12
Value of Prevention
The direct medical care costs associated with cervical cancer were estimated to
equal $1.7 billion in year 1996 dollars based on SEER (Surveillance,
Epidemiology, and End Results) and Medicare-linked data.2
The cost of cervical cancer ($1.7 billion) would be significantly higher if work
loss and premature deaths were included in the analysis. For example, 25.9 years
of life are lost, on average, by each woman who dies of cervical cancer. These lost
years of life—which often occur during the prime working years—translate into
lost earnings for women and their families, worker-replacement costs for
businesses, and are a significant cost to society.13
As with most preventive services, screening for and treating cervical cancer in its
early stages is much less expensive than intervening at later stages in the disease
process. For example, the cost of treating a single case of localized (early-stage)
cervical cancer averages $20,255, while the cost of treating a single case of distant
(late-stage) disease averages $36,912 (both figures in year 2000 dollars).14 In
addition to reduced medical care costs, the years of life gained from early
detection and treatment are valuable to families, businesses, and the community
at large.13
The cost of a conventional Pap smear test will vary depending on location, type
of provider, and the patient’s age. In 2004, the private-sector cost of screening for
cervical cancer among women under age 65 averaged $31 including specimen
collection, laboratory processing, and interpretation; approximately 95% of all
paid claims fell within the range of $9 to $64.15 For Medicare eligible women,
cervical cancer screening cost an average of $28 and approximately 95% of all
paid claims fell within the range of $0 to $62.15
Costs of vaccination are in addition to the costs for recommended screening
services. 
The costs associated with an abnormal Pap test as a result of HPV infection,
including the cost of physician visits, laboratory tests, colposcopies, and
treatment of cervical neoplasia if present, were estimated to be $1,281 per patient
in year 2000 dollars.14
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The cost of treating established cervical cancer varies. Localized (early-stage)
cervical cancer costs and average of $20,255 to treat and distant (late-stage)
disease costs an average $36,912 to treat (both figures in year 2000 dollars).14
The relative costs and benefits of screening will vary depending on the age of
patients screened and the screening interval. A recent study (that included
patient-time costs) estimated that the cost-effectiveness ratio of a conventional
Pap test repeated every three years up to the age of 75 was $11,830 per quality-
adjusted life year (QALY) saved (in year 2000 dollars).7 In comparison to other
preventive interventions and to commonly accepted cost-effectiveness
benchmarks, cervical cancer screening is highly cost-effective.16
Preventive Intervention Information 
The purpose of screening for cervical cancer is twofold. First, screening reduces
the risk of cervical cancer by identifying women with precancerous conditions
that can be treated before the conditions progress to cancer. The primary
precursor lesions of cervical cancer, CIN III and carcinoma in situ, progress
slowly, often over more than 8 to 9 years. Pap test screening detects these lesions
before they develop into invasive cancers and, with appropriate and timely
treatment, a full recovery is likely. Second, screening can identify women with
cervical cancer before symptoms appear. Early detection, which allows for early
treatment, improves outcomes.3
The benefits of cervical cancer screening are substantial. Screening reduces
cervical cancer incidence and mortality. When Pap test screening programs are
introduced into populations for the first time, the risk of developing cervical
cancer is typically reduced by 60% to 90% within 3 years.12 Mathematical
models suggest that population-wide screening with the Pap test every 3 years
reduces the rate of invasive cervical cancer by 91%; screening with the Pap test
every 5 years reduces the rate by 84%.6, 12 In North America and Europe, the
introduction of screening programs was associated with reductions in cervical
cancer mortality of between 20% and 60%.12
The harms of screening for cervical cancer are small compared to the benefits.
False-positive screening results may lead to unnecessary treatment of low-grade
lesions, unnecessary evaluations and biopsies, and psychological stress.12
Screening is of little or no value among women who have undergone a
hysterectomy for benign disease. The USPSTF suggests that clinicians obtain a
full and accurate surgical history to confirm indication for hysterectomy and that
a total hysterectomy has been performed before deciding against screening.12
The USPSTF recommends that screening begin within 3 years of the onset of
sexual activity or the age of 21, whichever occurs first, and continue until the age
of 65 for adult women of normal risk. Some professional organizations
recommend more frequent Pap tests, but the USPSTF found no direct evidence
that annual screening achieves better outcomes than screening every 3 years.
Further, although screening women who are not sexually active has little value,





many professional organizations recommend that clinicians screen all women
over the age of 21 for cervical cancer because women may not always accurately
report their history of sexual activity.12
Because the risk of cervical cancer decreases after the age of 65 in women who
have a history of normal Pap test results, the risks associated with screening,
including false-positive results and inconvenience, outweigh the benefits of
screening for older women.3 Screening is recommended in older women who
have not been previously screened, when information about previous screening is
unavailable, or when screening is unlikely to have occurred in the past (e.g.,
among women from countries without screening programs).3 Evidence is limited
to define “adequate recent screening.” The American Cancer Society (ACS)
guidelines recommend that older women who have had three or more
documented, consecutive, technically satisfactory normal/negative cervical
cytology tests, and who have had no abnormal/positive cytology tests within the
last 10 years, can safely stop screening.1
Note: In addition to screening, coverage should be provided for immunization
with the HPV vaccine in accordance with recommendations by the Advisory
Committee on Immunization Practices (ACIP). For more information on the
HPV vaccine, please refer to the Immunization Evidence-Statement.
The approved screening method for cervical cancer is the conventional Pap test.
Newer screening methods, such as liquid-based, thin-layer preparations (e.g.,
ThinPrep®), computer-assisted screening (e.g., AutoCyte®), and human
papillomavirus (HPV) tests, such as Hybrid Capture II®, are available. Purchasers
may choose to cover these screening tests in addition to the conventional Pap
test.5
Health coverage should include provisions for diagnostic and treatment services.
Strength of Evidence for the Clinical Preventive Service
(Screening)
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Service Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to recommend cervical cancer screening for
all women who have been sexually active and have a cervix.3
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• Approximately 17% of children age 17 years and younger in the United States
have at least one developmental disability, and 30% of children with a
developmental disability have comorbid or multiple developmental disorders.1
• Children with developmental delays and disabilities are at increased risk for
poor health and social outcomes and added medical and education costs. 
• The lifetime direct and indirect costs for persons born in 2000 with
developmental disabilities were estimated to equal $51.2 billion for persons
with mental retardation, $11.5 billion for persons with cerebral palsy, $2.1
billion for persons with hearing loss, and $2.5 billion for persons with vision
impairment (all figures in year 2003 dollars).2
• The added time and stress associated with caring for a child with a
developmental disability may result in employees experiencing higher medical
claims (due to increased health problems or depression), lower productivity,
increased absenteeism, or an early exit from the workforce. The mothers of
children with disabling conditions are estimated to lose an average of
approximately 5 hours of work per week equaling 250 hours per year.3
Assuming an hourly cost of $12 to $20 (including fringe benefits), that implies
a lost productivity cost of $3,000 to $5,000 per child, per year.3
• Children with developmental delays and disabilities who are identified and
treated early have better long-term outcomes.
Dental Caries Prevention Through Oral Fluoride Supplementation 
(Preventive Medication):
• Dental caries (tooth decay) is an infectious, transmissible disease in which
bacterial by-products (i.e., acids) dissolve the hard surfaces of teeth. It is the
most common chronic disease of childhood; up to 27% of children aged 2 to
5 years and 49% of children aged 6 to 11 years have experienced dental caries.4
• Dental caries can result in pain and loss of tooth structure or teeth and can
progress to acute systemic infection.
• Dental disease is particularly prevalent among young children of lower
socioeconomic status.
• Fluoride supplementation prevents 32% to 81% of caries lesions in primary
teeth or tooth surfaces.5
• Expenditures for dental services in the United States in 2004 totaled $81.5
billion, which was slightly more than 4% of the amount spent on health care
that year. Private health insurance paid for $40.5 billion, or about half, of this
amount.6
• Preventing tooth decay can reduce school absenteeism7 and therefore reduce
lost productivity among adult caregivers.
• Many preschool-aged children never visit a dentist. Primary care physicians are
often the first and only health care professionals that children visit and are
therefore in a unique position to address dental disease in this population.8
EVIDENCE-STATEMENT:
CHILD HEALTH PROMOTION (Screening, Counseling,
Immunization, Preventive Medication, and Treatment)
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Immunizations for Children and Adolescents (Immunization):
• Approximately 11,000 babies born each day in the United States will need
vaccination against fourteen diseases before age two.
• All vaccines are cost-effective, and most child and adolescent vaccines are cost-
saving. The routine childhood vaccination program saves nearly $10 billion in
direct medical costs and $43 billion in societal costs for every birth cohort (all
children born in one year).9
• Approximately 24% of toddlers may be vulnerable to serious illnesses,
including polio, measles, mumps, rubella, diphtheria, tetanus, pertussis,
invasive Haemophilus influenzae type b infection, hepatitis B, and varicella
because they have not completed the recommended vaccination series.10
Lead, Elevated Blood Lead Levels (Screening):
• The dangers of lead are well documented for all age groups, and high levels of
lead exposure produce serious neurologic complications that can result in
permanent disability or death. Lead affects multiple organ systems such as the
cardiovascular, renal, and hepatic systems.11-12 Lead can also reduce growth,
resulting in restricted height.13-14 Among children, elevated BLLs are associated
with behavioral and reaction (attention) deficits15-19 and intellectual
impairments (lowered IQ).20-25
• Approximately 310,000 children between the ages of 1 and 5 years have
elevated blood lead levels.26
• An estimated 24 million housing units have significant lead-based paint hazards
and pose a serious threat to children’s health. These units include 1.2 million
homes occupied by low-income families with children under the age of 6 years.26
• Between 1988 and 1992, childhood lead poisoning was estimated to result in
53,400 hospitalization days and $41 million in inpatient treatment costs.27
• Screening for elevated blood lead levels helps identify children who are exposed
to lead and need interventions to reduce their blood lead levels. The higher a
child's BLL and the longer it persists, the greater the chance that the child will
experience serious adverse neurologic effects or other problems. 
• Only 33% of children ages 1 to 5 years in the United States receive
recommended screening.28
• In most states, case identification and treatment is the responsibility of health
care providers and is therefore dependent on private insurance coverage.
Environmental management and education of affected families remains the
responsibility of local public health departments.
Newborn Hearing (Screening):
• Congenital hearing loss affects approximately 3 per 1,000 children.29 Hearing
loss, even loss that is mild in magnitude or unilateral (only one ear affected),
can affect a child’s potential to develop speech, language, and social skills, and
school performance.30
• The average lifetime cost for one person with early childhood-onset hearing
loss is estimated to be $417,000 (in year 2003 dollars).31 It is estimated that
the lifetime cost for all people born with congenital hearing loss in the year
2000 will total $2.1 billion (in year 2003 dollars).31
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• Screening newborn infants for hearing loss identifies most children with
congenital hearing loss prior to the onset of language development, allowing
their parents to access support services much earlier than otherwise.
Newborn Screening for Genetic and Endocrine Disorders 
(Screening, Medical Foods, and Treatment):
• Newborn screening using dried blood spot specimens collected from newborn
infants’ heels can detect a number of disorders such as phenylketonuria (PKU),
congenital hypothyroidism (CH), galactosemia, and sickle cell disease (SCD).
All states require newborn screening for at least some genetic and endocrine
disorders, but the required tests differ among various jurisdictions.
• At least 4 million babies in the United States undergo newborn blood spot
screening each year. Severe disorders are detected in about 3,000 newborns.
Accurate screening: 
– Identifies affected babies quickly.
– Ensures that cases are not missed. 
– Helps start treatment early to reduce negative and irreversible health
problems for affected newborns. 
• Disorders identified by newborn screening programs require treatment in order
to prevent serious and sometimes fatal complications. Lifelong medical
management (including specialized medical foods or access to specialty clinics)
is required to prevent serious medical complications associated with newborn
metabolic disorders.
• The economic value of the prevention of mental retardation due to just two
metabolic conditions (PKU and CH) exceeds $400 million per year, more than
twice the amount of money spent on all newborn screening.32-33
• Sickle cell disease is a major cause of hospitalizations. During 1989 to 1993,
hospitalization costs for children and adults with SCD averaged $475 million
per year (in year 1996 dollars).34
Vision (Child) (Screening):
• Visual impairment is a common condition that affects 7% to 8% of children.35
The most common forms of visual impairment in children are refractive errors
(nearsightedness, farsightedness, anisometropia, and astigmatism), amblyopia
(reduced visual acuity without a detectable organic lesion of the eye), and
strabismus (ocular misalignment). 
• Uncorrected amblyopia may be a risk factor for future blindness in later
childhood and adulthood36 and may harm school performance, ability to learn,
and later, adult self-image.37 Further, the lack of binocular vision disqualifies
individuals with amblyopia from many occupations. 
• The estimated lifetime cost (in year 2003 dollars) for persons born in 2000
with vision impairment is $2.5 billion.38
• Early detection and treatment is essential for amblyopia, as treatment is highly
effective in early childhood.
• Because visual impairment in children is common and believed to have an
early sensitive period when interventions lead to better outcomes, much
interest has focused on primary care vision screening tools for early detection,
referral, and treatment.
Child Development (Screening)
Clinical Preventive Service Recommendations
In 2006, the U.S. Preventive Services Task Force (USPSTF) found that
evidence was “insufficient” to recommend for or against routine use of
brief, formal screening instruments in primary care to detect speech and
language delay in children up to 5 years of age.1
The USPSTF was unable to find studies that addressed the overarching
question of whether screening for speech and language delay with brief,
formal instruments improves long-term speech, language, and other non-
speech-and-language outcomes. However, the USPSTF did find fair
evidence to suggest that interventions can improve the results of short-
term assessments of speech and language skills. The USPSTF could not
find studies that addressed the potential harms of screening or
interventions for speech and language delays. The USPSTF could not
determine the balance of benefits and harms of screening with brief,
formal screening instruments.1
The USPSTF did not examine other aspects of developmental screening. 
The American Academy of Pediatrics (AAP) recommends regular,
universal developmental screening of infants and young children by
primary pediatric healthcare providers at 9, 18, and 30 months, using
standardized screening tools with high specificity and sensitivity, to
identify children in need of further assessment and diagnosis, and
appropriate referral for early intervention and education services as
indicated.2
Not Specified
Other professional organization such as the National Association of
Pediatric Nurse Practitioners (NAPNAP)3 and the American Academy of
Neurology4 recommend screening for developmental disorders. 
The recommendations and supporting information contained in this
document came from several sources, including the:
• American Academy of Child and Adolescent Psychiatry
• American Academy of Neurology
• American Academy of Pediatrics (AAP)
• American Psychological Association (APA)
• Centers for Disease Control and Prevention (CDC)
• Committee on Educational Interventions for Children with Autism,
National Research Council, National Academies of Science
• Maternal Child Health Bureau (MCHB)
154
EVIDENCE-STATEMENT: Child Health Promotion (Screening, Counseling, Immunization, 













• National Association of Pediatric Nurse Practitioners (NAPNAP)
• National Research Council, Committee on Educational Interventions for
Children with Autism, Division of Behavioral and Social Sciences and
Education
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
A developmental delay, disorder, or disability refers to the presence of one or
more of a diverse group of chronic conditions that hinders a child from
developing age-appropriate cognitive, emotional, social, behavioral, psychological,
or motor skills such as learning, communicating with adults, playing with other
children, or walking. Developmental disabilities can begin at any time during
childhood and, depending on the severity of the condition, can result in delayed
learning (such as a speech impediment that can be overcome with speech
therapy), a physical or mental impairment (such as dyslexia), or a permanent
disability (such as cerebral palsy or mental retardation). 
Examples of developmental disabilities include: 
• Attention deficit/Hyperactivity disorder (ADD/ADHD)
• Autism spectrum disorders 
• Cerebral palsy
• Depressive or anxiety disorders
• Epilepsy
• Hearing loss




• Tourette syndrome and other tic disorders
• Vision impairment
Approximately 6.6% of children (aged 5 to 17 years) in the United States have
ADD, 3.6% have a developmental delay (DD), 8.2% have a learning disability
(LD), and 13.6% have a mental health problem.5
Children with developmental disabilities have poorer health outcomes, a lower
level of education attainment, and higher rates of delinquency and incarceration
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than do children without disabilities. Poor outcomes associated with
developmental delays and disabilities include: 
Reduced educational attainment
• Poor school performance
• Reduced school attendance
Poor overall health status
• Increased rate of injuries
• Increased rate of emergency room visits, doctor visits, and hospitalizations
• Longer hospital stays
• Higher rates of mental illness and behavioral problems
Social problems
• Poor peer relationships
• Increased risk of substance abuse
• Increased risk of delinquency and violence in adolescence and adulthood
There are multiple risk-factors for developmental delays, disabilities, and
disorders.6-8
Value of Prevention
The economic and social burden of developmental disabilities is great. The poor
health and social outcomes of children with developmental disabilities result in
excess medical, education, and criminal justice system costs for families,
employers, and communities. The lifetime direct and indirect costs for persons
born in 2000 with developmental disabilities were estimated to equal $51.2
billion for persons with mental retardation, $11.5 billion for persons with
cerebral palsy, $2.1 billion for persons with hearing loss, and $2.5 billion for
persons with vision impairment (all figures in year 2003 dollars).9 Indirect costs
for the developmentally disabled person include the value of productivity losses
in the workplace and household because of premature death, inability to work, or
limitation in the amount and type of work that can be performed. 
The excess medical costs associated with developmental disabilities are well-
documented. For example, children with ADHD have higher health-related
expenses than do children without developmental delays and disabilities. In fact,
compared to children who develop normally, children with ADHD have 2.6
times as many medical claims and average nearly $1,000 per year in added
medical costs (the average annual per patient cost for a child with ADHD in
1998 was $1,574 compared to $541 for a child without ADHD).10 Further,
family members of children with ADHD have per-capita annual direct and
indirect costs nearly twice that of the family members of children without
ADHD ($2,728 compared to $1,440).10
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Similarly, results from Washington State Medicaid claims data show that,
compared to children who develop normally, children with developmental delays:
• Are at least 5 times more likely to have chronic health conditions such as
gastrointestinal disorders, central nervous system disorders, and conditions of
the ear, nose, and throat;
• Have 1.5 times as many physician visits during their first 5 years of life;
• Have more hospitalizations during their first 5 years of life, even when factors
such as health status are controlled; and
• Have more than 10 times the number of visits to specialty practitioners such as
physical and occupational therapists, speech therapists, and audiologists.11
This additional need for healthcare translates into added costs for employers. 
While employers are not directly impacted by the societal costs of
developmentally disabled children, the added cost to the healthcare system
should be of major concern to employers. Further, children with developmental
delays and disabilities are a source of indirect costs to employers due to the fact
that affected children experience more health problems and therefore require
more substantial parental caregiving than do children without developmental
problems. The added time and stress associated with intensive caregiving may
result in employees experiencing higher medical claims themselves (due to
increased health problems or depression), and lower productivity, increased
absenteeism, or an early exit from the workforce. For example, the mothers of
children with disabling conditions are estimated to lose an average of
approximately 5 hours of work per week equaling 250 hours per year.12 Assuming
an hourly cost of $12 to $20 (including fringe benefits), that implies a lost
productivity cost of $3,000 to $5,000 per child, per year.12
Screening and early intervention services may reduce long-term societal costs.
However, there is no direct evidence to support cost-savings associated with
screening or early detection.13
In 2004, the private-sector cost of a well-child visit that included developmental
screening averaged $83; approximately 95% of all paid claims fell within the range
of $30 to $127 dollars. The private-sector cost of a limited developmental screen
(e.g., Developmental Screening Test II, Early Language Milestone Test) averaged $27
and 95% of all paid claims fell within the range of $0 to $95. The private-sector cost
of an extended developmental test (i.e., assessment of motor, language, social,
adaptive, and/or cognitive functioning by standardized assessment instruments)
averaged $144 and 95% of all paid claims fell within the range of $0 to $466.13
The cost of treatment will vary widely depending on the type and severity of the
condition. 
Screening and early intervention services may reduce long-term societal costs.
However, there is no direct evidence to support cost-savings associated with
screening or early detection.13
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Screening tools are designed to identify children who may have a delay or
disability and thus need more intensive diagnostic assessment and possible
intervention or treatment. The purpose of screening is to identify children
affected by developmental delays and disabilities when they are still
developmentally receptive and malleable and therefore most responsive to
interventions.
Research has shown substantial benefits to early recognition and intervention,
especially for certain conditions. For example, children with autism who are
identified early in life and receive specialized interventions have significantly
improved cognitive, language, and motor skills and attain a higher level of
education than do autistic children who are identified later in life.14-15 Early
intervention can also improve the cognitive developmental trajectories of children
with developmental disabilities and decrease conduct problems at home and in
the classroom (resulting in an increased rate of high school graduation and
decreased juvenile and adult arrests).16-17
The risks of screening for developmental delays and disabilities include the
possibility of a negative influence on the parent’s perception of their child, the
added time and costs associated with screening and—as with all screenings—the
risk of false-positives which can produce anxiety and subject the child and parent
to unneeded tests and evaluations. Research has found that false-positive rates can
reach 15% to 30% for developmental screening.13 False-positive results can place
an extraordinary burden on the healthcare system, erode trust in the system, and
potentially influence parents’ perception of their child.18 However, some research
has found children with false-positives perform substantially lower than do
children with true-negative scores on measures of intelligence, language, and
academic achievement indicating that while these children do not have a
developmental disability they may nonetheless benefit from further assessment
and referral to services such as Head Start and specialized day care.18-19
The benefits of early recognition and the opportunity for early intervention are
expected to outweigh the risks and costs associated with screening.
Research is insufficient to determine the most efficacious age at which to screen
for, diagnose, and treat specific developmental disorders. The AAP recommends
screening all infants and young children due to the availability and importance of
1) early intervention services for children birth to 3 years of age, and 2) early
childhood education services for children age 3 to 5 years. 
Developmental concerns should be addressed among other health topics at each
preventive care visit during the first 5 years of life. Developmental surveillance,
asking for example, “Do you have any concern about your child’s development,
learning, or behavior?” is important at each visit. 
Structured screening should occur at the 9, 18, and 30-month visits.2
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Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to
Clinical Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group
on Health; 2006.
Developmental screening consists of a brief assessment conducted by a parent
and/or health care provider that can include direct observation, patient (child)
elicitation (i.e., asking the child to name three colors), interviewing parents of a
child expressing usual behavior, and physical testing (e.g., measuring a child’s
ability to visually track objects). Screening tools help a clinician assess a child’s
attainment of developmental milestones—the physical, cognitive, and behavioral
skills that are necessary components of a child’s development. Developmental
screening is best conducted by a primary care provider who has knowledge of the
child’s health and consistent contact with the child. 
Providers should refer children with development disabilities to Early
Intervention (EI) services and other developmentally appropriate services, as
medically indicated. Health benefits should include provisions for diagnostic
follow-up and treatment services. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this section
is described below.
Recommended Guidance:
American Academy of Pediatrics (AAP)
Strength of Evidence: Not Specified
• The AAP recommends regular, universal developmental screening of infants
and young children by primary pediatric healthcare providers at 9, 18, and 30
months, using standardized screening tools with high specificity and
sensitivity,to identify children in need of further assessment and diagnosis, and
appropriate referral for early intervention and education services, as indicated.2
Note: In 2006, the U.S. Preventive Services Task Force (USPSTF) found that
evidence was “insufficient” to recommend for or against routine use of brief,
formal screening instruments in primary care to detect speech and language delay
in children up to 5 years of age.1 The USPSTF did not examine other aspects of
developmental screening.20
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Dental Caries Prevention Through Oral
Fluoride Supplementation 
(Preventive Medication)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that primary
care clinicians prescribe oral fluoride supplementation at currently recommended
doses to preschool children older than 6 months of age whose primary water
source is deficient in fluoride.1
The USPSTF found fair evidence that the service improves important health
outcomes and concluded that the benefits of oral fluoride supplementation
outweigh the harms. The USPSTF found fair evidence that, in preschool children
with low fluoride exposure, prescriptions of oral fluoride supplements by primary
care clinicians lead to reduced dental caries. The USPSTF concluded that the
benefits of caries prevention using oral fluoride supplementation outweigh the
potential harms of dental fluorosis, which in the United States are primarily in
the form of mild discoloration of the teeth.1
The Centers for Disease Control and Prevention (CDC) has developed
recommendations for preventing tooth decay while reducing the risk of enamel
fluorosis, or the hypo-mineralization of the tooth’s enamel surface that results
from ingesting fluoride during tooth formation. The CDC recommends the
judicious prescription of fluoride supplements in preschool-aged children, and for
those at risk, supplementation may continue through 16 years of age. Fluoride
supplements may be prescribed for children who are at high risk for tooth decay
and whose primary source of drinking water has low fluoride concentration,
based on the child’s risk of developing decay without fluoride supplements; the
benefit of decay prevention; the potential for enamel fluorosis; and the child's
sources of fluoride, especially drinking water. Parents and caregivers should be
informed of both the benefits and the risks associated with fluoride
supplementation. The dosage of prescribed fluoride supplements should be
consistent with the schedule established by American Dental Association (ADA),
American Academy of Pediatric Dentistry (AAPD), and American Academy of
Pediatrics (AAP) which is available online (www.cdc.gov/fluoridation/other/
spplmnt_schdl.htm). Fluoride supplements may be prescribed for specific
children (as appropriate) or they may be given through school-based programs.
When practical, supplements should be prescribed as chewable tablets or lozenges
to maximize the topical effects that aid with enamel remineralization.2
The American Dental Association (ADA), American Academy of Pediatrics
(AAP), and American Academy of Pediatric Dentistry (AAPD) concur with the
USPSTF and CDC recommendations described above.
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Pediatric Dentistry (AAPD)
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• American Academy of Pediatrics (AAP)
• American Dental Association (ADA)
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information in this document is based on
research findings. All information presented in this document should be
attributed to its referenced source and should not be considered a reflection of
the opinions of other organizations cited in the text. 
Condition/Disease-Specific Information
Dental caries (tooth decay) is an infectious, transmissible disease in which bacterial
by-products (i.e., acids) dissolve the hard surfaces of teeth.3 It is the most common
chronic disease of childhood and is five times more common than asthma and
seven times more common than hay fever.4 Dental caries can result in pain and loss
of tooth structure or teeth, and can progress to acute systemic infection. 
Populations believed to be at increased risk of dental caries are those with low
socioeconomic status or low levels of parental education, those that do not obtain
regular dental care, and those without dental insurance or access to dental
services.5-7 Persons can be at high risk of dental caries even if they do not have
any recognized risk factors. Individual factors that might increase risk include
active dental caries; a history of high levels of caries in older siblings or caregivers;
high levels of infection with cariogenic bacteria; impaired ability to maintain oral
hygiene; malformed enamel or dentin; reduced salivary flow because of
medications, radiation treatment, or disease; low salivary buffering capacity (i.e.,
decreased ability of saliva to neutralize acids); and the wearing of space
maintainers or dental prostheses. Risk can increase if any of these factors are
combined with dietary practices conducive to dental caries, such as frequent
consumption of refined carbohydrates, while risk decreases with adequate
exposure to fluoride.5,8 An individual’s risk of developing caries can vary over time
as his or her risk factors change.
Value of Prevention
Expenditures for dental services in the United States in 2004 totaled $81.5 billion,
which was slightly more than 4% of the amount spent on healthcare that year.
Private health insurance paid for $40.5 billion, or about half, of this amount.9
In 1996, 3.7 days of restricted activity per 100 employed people aged 18 years
and older were reported to be associated with an acute dental conditions and over
2.4 million work days (1.9 days per person) were lost because of an acute dental
conditions.10 These statistics do not include days that parents were absent from
work to care for children with dental conditions. Parental caregiving
requirements associated with child dental problems can be extensive as children
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Benefits and Risks of
Intervention
miss a significant number of school days due to dental problems. In 1996, U.S.
schoolchildren missed 1.6 million days of school as a result of acute dental
conditions. Preventing tooth decay can reduce school absenteeism10 and therefore
reduce lost productivity among adult caregivers. 
Fluoride modalities are most cost-effective for persons at high risk of dental
caries. Limited benefit is gained by providing additional caries-preventive
modalities to persons consuming fluoridated water. 
In 2004, the private-sector cost of fluoride supplementation averaged $33;
approximately 95% of all paid claims fell within the range of $0 to $42).11 This
cost does not include the cost of physician time for counseling and risk
assessment.
The ADA has estimated per-capita dental care expenditures (in year 1995 dollars)
at $174 per person, per year.12 The Health Care Financing Administration (now
called the Centers for Medicare and Medicaid Services) came up with a similar
estimate of $164 per person, per year.13
The USPSTF found consistent evidence showing that fluoride supplementation
prevents 32% to 81% of caries lesions in primary teeth or tooth surfaces.14 No
long-term cost-benefit analyses are available. 
Preventive Intervention Information
Appropriate fluoride supplementation can prevent dental caries, infections, and
other complications, thereby improving overall oral and physical health.
Preventing tooth decay in preschool children can have a positive impact on oral
health and quality of life in later years. 
Fluoride controls early dental caries by both preventing caries from occurring and
controlling caries when they do occur. Fluoride has a pre-eruptive effect on
developing tooth enamel and a post-eruptive topical effect. Although community
water fluoridation is recommended as the ideal way to provide fluoride’s benefits
to both children and adults, fluoride supplements are an effective alternative for
children who lack access to fluoridated drinking water.2
However, fluoride ingested during tooth development can result in a range of
changes in the appearance of teeth, broadly known as enamel fluorosis. Certain
extremes of enamel fluorosis are cosmetically unacceptable. Severe forms of this
condition occur only when young children ingest excess fluoride, from any
source, during critical periods of tooth development. The use of dietary
supplements in areas with fluoridated drinking water, which is inconsistent with
the recommended supplement schedule, might increase the risk of enamel
fluorosis.15 Although the studies assessing the appropriateness of primary care
clinicians’ prescription of fluoride supplements have uncertain external and
internal validity, they indicate that the majority of physicians in the United
163
EVIDENCE-STATEMENT: Child Health Promotion (Screening, Counseling, Immunization, 








States, especially pediatricians, prescribe oral fluoride supplements for at least
some of their patients.2 Research shows that many physicians do not know the
fluoride status of their patients or the fluoridation level of their patients’ water
supplies, raising the possibility of inappropriate fluoride supplement prescriptions
that may lead to excessive fluoride intake.1
When healthcare providers identify preschool children who live in non-
fluoridated areas as being at high risk of dental caries, they should consider
prescribing dietary fluoride supplements for these children. These supplements
are normally taken once per day and are not recommended for children younger
than 6 months of age. Depending on the child’s level of risk, supplementation
may continue from age 6 months to 16 years.2 Fluoride supplements should not
be initiated or should be discontinued if the assessed risk of dental caries
decreases to a low level or if the child obtains access to fluoride through other
sources, especially drinking water. 
When prescribing any pharmaceutical agent, primary care providers should
attempt to maximize benefit and minimize harm.16 Although fluoride's
posteruptive action can benefit the primary (i.e., “baby”) teeth of children aged 1
to 6 years and provide some protection for developing permanent teeth, fluoride
supplements can also increase the risk of enamel fluorosis.17-18 Before prescribing
fluoride supplements, clinicians should verify that the patient is not obtaining
fluoride from any source of drinking water, medications, or swallowed
toothpaste.2
Dietary fluoride supplements in the form of tablets, lozenges, or liquids
(including fluoride-vitamin preparations) have been used throughout the world
since the 1940s. Sodium fluoride is the active ingredient in most supplements.
Tablets and lozenges typically contain 1.0, 0.5, or 0.25 mg of fluoride. To
maximize the topical effect of the fluoride, tablets and lozenges should be chewed
or sucked for 1 to 2 minutes before being swallowed. For infants, supplements
are available in liquid form and are dispensed with a dropper.
Health benefits should include provisions for routine dental care and the
treatment of dental caries and other forms of dental disease.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this section
is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found at least fair evidence to recommend oral fluoride
supplementation for preschool children older than 6 months of age whose
primary water source is deficient in fluoride.1
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Recommended Guidance:
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Expert Panel
• The CDC recommends the judicious prescription of fluoride supplements in
preschool-aged children, and for those at risk, supplementation may continue
through 16 years of age. Fluoride supplements may be prescribed for children
who are at high risk for tooth decay and whose primary source of drinking
water has low fluoride concentration, based on the child’s risk of developing
decay without fluoride supplements; the benefit of decay prevention; the
potential for enamel fluorosis; and the child's sources of fluoride, especially
drinking water. Parents and caregivers should be informed of both the benefits
and the risks associated with fluoride supplementation. The dosage of
prescribed fluoride supplements should be consistent with the schedule
established by American Dental Association (ADA), American Academy of
Pediatric Dentistry (AAPD), and American Academy of Pediatrics (AAP).2
Immunizations for Children and Adolescents
(Immunization)
Please refer to the Immunizations Evidence-Statement on page 337.
Lead, Elevated Blood Lead Levels
(Screening)
Clinical Preventive Service Recommendations
In 1996, the U.S Preventive Services Task Force recommended that clinicians
screen children at risk for lead exposure for elevated blood lead levels. Given the
availability of new evidence, the USPSTF has decided to update its 1996
recommendation. This work is currently in progress. 
The Centers for Disease Control and Prevention (CDC) recommends blood lead
testing for children at high risk for exposure from lead paint, from house dust
and soils contaminated by lead paint, from industrial sources of lead (e.g.,
smelters), and from imported cosmetics, traditional remedies, and cultural items
that contain lead.1 
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The Centers for Medicare and Medicaid Services (CMS) requires blood lead
testing of all Medicaid enrolled children at 1 and 2 years of age or at 3 years of
age if not previously tested.2
CMS Mandate
The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Childhood Lead Poisoning Prevention (ACCLP)
• Agency for Toxic Substances and Disease Registry (ATSDR)
• Center for Medicare and Medicaid Services (CMS)
• Centers for Disease Control and Prevention (CDC)
• National Health and Nutrition Examination Survey (NHANES)
• Peer-reviewed research
• U.S. Department of Health and Human Services (USDHHS)
• U.S. Environmental Protection Agency (EPA)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
The dangers of lead are well-documented for all age groups. High levels of lead
exposure produce serious neurologic complications that can result in permanent
disability or death. Lead affects multiple organ systems such as the cardiovascular,
renal, and hepatic systems.3-4 Lead can also reduce growth, resulting in restricted
height.5-6 Among children, elevated blood lead levels (BLLs) are associated with
behavioral and reaction (attention) deficits7-11 and intellectual impairments
(lowered IQ).12-17 Neurologic complications associated with lead exposure and
lead poisoning are irreversible, even with treatment. The association between
elevated BLLs and reduced intellectual capacity is strong and has a dose-response
relation, meaning that the more lead present in the blood, the more severe the
impairments become.18-19 For example, a rise in blood lead from 10 to 20 µg/dL
reduces a child’s score on an IQ test by an average of 2 points.18 No “safe” BLL in
children has been specified.15-16,19
It is estimated that 310,000 children between the ages of 1 and 5 years have
elevated BLLs.20 An estimated 24 million housing units have significant lead-
based paint hazards, including 1.2 million homes occupied by low-income
families with children under the age of 6 years. These units pose a serious threat
to children’s health.20
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The prevalence of elevated BLLs among young children in the United States has
declined 98% since 1976-1980.20 A critical factor in reducing children’s BLLs has
been the reduction in the number of homes with lead-based paint, which fell
from 64 million in 1990 to approximately 38 million in 2000.20 Despite the
dramatic reduction in elevated BLLs, lead exposure and lead poisoning remain
serious public health problems in the United States, especially for young children,
who are most susceptible to the harmful effects of lead. 
Reducing BLLs and eliminating BLLs higher than 10 µg/dL in children are two
of the nation’s Healthy People 2010 objectives.21
Racial and ethnic minorities (particularly African-Americans), individuals with
low incomes, children living in housing built before 1950, and those living in
urban centers and in the Northeast bear the highest rates of lead exposure.22-23
Major sources of lead exposure include dilapidated housing with lead-based paint
(commonly used until 1950) and paint dust, lead-soldered pipes, and lead found
in dust or soil from peeling paint, leaded gasoline, or industrial emissions. Other
sources of lead exposure include lead waste brought into the home from
industry,24 ethnic remedies,25–27 or from lead in consumer products.28–31
Value of Prevention
The costs of providing medical care and public health services to treat adverse
health outcomes constitute the immediate direct costs of lead exposure and lead
poisoning. Between 1988 and 1992, childhood lead poisoning was estimated to
result in 53,400 hospitalization days and $41 million in inpatient treatment
costs.32 The longer term burden to taxpayers includes the costs of special
education and lost tax revenues from the lower wages of workers with intellectual
deficits due to childhood lead exposure or lead poisoning. The total economic
burden would be much higher if lifetime productivity losses due to cognitive
impairment and premature mortality were included in cost analyses.
Lead poisoning results in dose-related reductions in IQ which, in turn,
contributes to lower wages and diminished lifetime earning power. The present
value of economic losses attributable to lead exposure in the birth cohort of
current 5-year-olds was estimated to be $43.4 billion in 1997.33 
Reducing lead exposure yields economic benefits by avoiding healthcare and
special education costs and by preventing reductions in children's intelligence,
academic achievement, and future productivity. A recent study quantified
economic benefits from projected improvements in worker productivity that
resulted from the reduction in children's exposure to lead in the United States
since 1976. It was estimated that, because of falling BLLs in the United States,
preschool-aged children in the late 1990s had IQs that were, on average, 2.2 to
4.7 points higher than they would have been if they had the blood lead
distribution observed among United States preschool-aged children in the late
1970s. It was also estimated that each IQ point raises worker productivity 1.76%
to 2.38%. With discounted lifetime earnings of $723,300 for each 2-year-old in
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2000 dollars, the estimated economic benefit for each year's cohort of 3.8 million
2-year-old children ranges from $110 billion to $319 billion.34
In 2004, the private-sector cost of blood lead screening (venous sample test)
averaged $22 per specimen for shipping, handling, and laboratory analysis;
approximately 95% of all paid claims fell within the range of $8 to $55.35
Including the blood draw, which costs an average of $9, the total cost for blood
lead level screening averaged $31. Approximately 95% of all paid medical claims
fell within the range of $10 to $69.35
Chelation therapy, the standard treatment, which leeches lead from the body,
costs an estimated $2,046 (in year 2001 dollars) for each child treated.36
A study based on mathematical simulations of a blood lead screening program,
estimated that, compared with no screening, universal screening of all 1-year old
children for elevated BLLs would produce economic benefits exceeding program
costs in communities where at least 11% to 17% of children had elevated BLLs.37
Preventive Intervention Information
Identifying children with elevated BLLs allows parents to make necessary
environmental changes to limit the child’s exposure to lead and allows clinicians
to begin medical treatment with chelating agents (if necessary), before lead
poisoning and its serious complications occur. Environmental changes, such as
lead-paint abatement and removal of lead-soldered pipes, can have beneficial
effects on both exposed children and other children who live in the home.
Risks associated with BLL screening include increased anxiety among parents,
discomfort to the child of repeated blood draws, and the inconvenience
associated with office visits. As with all screening tests, a false-positive test result
can lead to unnecessary treatment. However, the benefits of screening, including
early identification of lead exposure and the prevention of lead poisoning,
outweigh the costs and risks associated with screening.
Chelating agents can cause adverse effects, which may be severe. Thus, the benefits
and risks associated with lead poisoning treatment should be carefully weighed. 
Children at risk for lead exposure should be screened at or before age 12 months.
Clinicians should note that, on average, blood levels peak in exposed children
between 18 and 24 months of age. Screening for elevated BLLs should cease
when the clinician determines the child is no longer at risk for exposure based on
age or environmental risk profile.
At a minimum, blood lead testing for at-risk populations should be conducted at
the following ages: 
• 12 months
• 24 months 
• 36–72 months
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Children of any age should be screening when deemed medically necessary by a
clinician’s risk assessment, when clinical signs or symptoms consistent with
elevated BLL are present, or when other evidence indicates possible exposure. 
Children with symptoms consistent with increased intracranial pressure should
also be considered for screening.
Recently resettled refugee, immigrant, and internationally adopted children 6
months to 16 years of age should be tested upon arrival and again 3 to 6 months
after resettlement if local conditions warrant.38
State screening plans can be found on the CDC Childhood Lead Poisoning
Prevention Branch website (www.cdc.gov/nceh/lead).
Screening for lead exposure is conducted by measuring the amount of lead
circulating in the blood through either a capillary or venous blood sample.
Venous samples are more accurate and are thus the preferred method of testing.
However, because of the added discomfort and cost of venous samples, clinicians
often screen low-risk populations by taking a capillary blood sample and by
performing a confirmatory venous blood lead concentration test on samples that
show elevated BLLs. 
The main treatment for lead exposure is to stop the exposure by removing
environmental or dietary sources of lead. Lead exposure reduction may include
full lead abatement in the home, special cleaning techniques, the removal of
contaminated objects, or the removal of the child from the home.40 Treatment for
lead poisoning (a BLL of 45 µg/dL or higher) requires pharmacologic
intervention. Chelation therapy is the most common form of lead poisoning
treatment and may prevent further damage by reducing the amount of lead
circulating in the blood. Clinicians may choose to begin chelation therapy for
children with BLLs lower than 45 µg/dL if the children have persistently elevated
BLLs that do not respond to environmental risk reduction.39
Health benefits should include provisions for diagnostic, surveillance, and
treatment services.
Strength of Evidence for the Clinical Preventive Service
The evidence supporting the recommendations contained in this section is
described below.
Recommended Guidance:
Centers for Disease Control and Prevention’s (CDC) Advisory Committee on
Childhood Lead Poisoning Prevention
Strength of Evidence: Not Specified
• The CDC supports routine blood lead testing for children at high risk for
exposure from lead paint, from house dust and soils contaminated by lead
paint, from industrial sources of lead (e.g., smelters), and from imported
cosmetics, traditional remedies, and cultural items that contain lead.1
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Brown MJ, Chattopadhyay S. Lead, elevated blood lead level evidence-statement: screening. In:
Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to
Clinical Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group on
Health; 2006.
Center for Medicare and Medicaid Services (CMS)
Strength of Evidence: CMS Mandate
• The Centers for Medicare/Medicaid Services (CMS) requires blood lead testing
of all Medicaid enrolled children at 1 and 2 years of age or at 3 years of age if
not previously tested.2
Newborn Hearing (Screening)
Clinical Preventive Service Recommendations
In 2001, the U.S. Preventive Services Task Force (USPSTF) issued an “I”-rating
for “insufficient” evidence to recommend for or against routine newborn hearing
screening. The USPSTF found inconclusive evidence to determine whether
earlier treatment resulting from screening leads to clinically important
improvement in speech and language skills at  3 years of age.1 However, the
USPSTF did note that there is evidence that the average age of diagnosis is
significantly reduced with newborn hearing screening.
The CDC recommends screening all children for hearing loss at birth.
The CDC recommendation for screening at birth is based on evidence from
observational studies that children who receive intervention services for hearing
loss before the age of 6 months develop significantly better language skills.2-4 This
is supported by expert opinion of those who care for children with hearing loss
and parents of children with hearing loss, who report that children with hearing
loss detected as infants have better language skills than older siblings with later-
diagnosed hearing loss.
The Joint Committee on Infant Hearing (JCIH) endorses early detection of and
intervention for infants with hearing loss (early hearing detection and
intervention, EHDI) through integrated, interdisciplinary state and national
systems of universal newborn hearing screening, evaluation, and family-centered
intervention. Thus, all infants’ hearing should be screened using objective,
physiologic measures in order to identify those with congenital or neonatal onset
hearing loss. Audiologic evaluation and medical evaluations should be in progress
before 3 months of age. Infants with confirmed hearing loss should receive
intervention before 6 months of age from health care and education professionals
with expertise in hearing loss and deafness in infants and young children.5
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A 1993 National Institutes of Health (NIH) Consensus Development
Conference Statement on Early Identification of Hearing Impairment in Infants
and Young Children recommended that universal newborn hearing screening be
implemented.6
Expert Consensus
At present, 38 states and territories have enacted legislation on universal
screening of all infants for hearing loss, and all states have programs to promote
newborn hearing screening.7
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Audiology
• American Academy of Pediatrics (AAP)
• American Speech, Language, and Hearing Association
• Centers for Disease Control and Prevention (CDC)
• Directors of Speech and Hearing Programs in State Health and Welfare
Agencies
• Joint Committee on Infant Hearing (JCIH)
• Health Resources and Services Administration (HRSA)
• National Center for Hearing Assessment and Management (NCHAM) 
• National Institutes on Health (NIH)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Congenital hearing loss affects approximately 3 per 1,000 children.8 About 30%
of children with hearing loss have another condition at birth. Hearing loss, even
loss that is mild in magnitude or unilateral (only one ear affected), can affect a
child’s potential to develop speech, language, social skills, and school performance,
including grade retention.9 Hearing loss may be present at birth or may occur
later.
About 40% to 60% of hearing loss is due to genetic or gene-environment factors.
The causes of hearing loss for many children are poorly defined, and infants may
have no identifiable risk factors to prompt targeted screening. But assorted risk
factors are known. Some cases occur in families with a history of permanent
childhood hearing loss. Infections such as bacterial meningitis or in utero
cytomegalovirus (CMV), herpes, toxoplasmosis, and rubella are associated with
hearing loss. Anatomical anomalies, caused either by birth defects or trauma or
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other factors are also associated with hearing loss. Finally, a variety of other
predispositions such as severe neonatal hyperbilirubinemia (jaundice) requiring
exchange transfusion or persistent otitis media are associated with hearing loss.10
Value of Prevention
Many people with hearing loss need long-term services. The average lifetime cost
for one person with early-childhood-onset hearing loss is estimated to be
$417,000 (in year 2003 dollars).11 It is estimated that the lifetime cost for all
people with congenital hearing loss who were born in 2000 will total $2.1 billion
(in year 2003 dollars).11 These costs include both direct and indirect costs. Direct
medical costs, such as doctor visits, prescription drugs, and inpatient hospital
stays, make up 6% of these costs. Non-medical expenses, such as home
modifications and special education, make up 30% of the costs. These estimates
do not include other expenses, such as hospital outpatient visits, sign language
interpreters, and family out-of-pocket expenses. 
Indirect costs of hearing loss, which include the value of lost wages when a
person either cannot work or is limited in the amount or type of work possible,
make up 63% of total costs.11
The economic benefits of newborn hearing screening include reduced special
education costs associated with improved hearing and language and also lower
social and community services. A new study from England has reported that
average education costs among 7 to 9 year-old children with bilateral hearing loss
were lower by 22% among children born in districts with universal newborn
hearing screening.12
The cost of screening for hearing loss depends on the location (inpatient or
outpatient setting), provider type, and the screening instrument used. In 2004,
the private-sector cost of screening for hearing loss in the hospital (recommended
setting) averaged $84 if billed and paid separate from the labor and delivery
charge; approximately 95% of paid claims fell within the range of $0 to $200.13
If the screening was missed before discharge or needed to be repeated on an
outpatient basis, the average private-sector cost was $98 (in this scenario 95% of
paid claims fell within the range of $0 to $235).13 Both figures include the cost of
staff time, consumables, and the cost of the equipment. When screening is billed
as a part of labor and delivery charges the incremental cost is lower.
The cost of treatment will vary widely depending on the type and severity of the
hearing loss and the kinds of interventions chosen.
Screening programs detect approximately 3 children with hearing loss for every
1,000 infants screened. Assuming an average cost of $30, the cost per infant
detected may be as low as $10,000. In comparison to other preventive
interventions and to commonly accepted cost-effectiveness benchmarks, newborn
hearing screening is cost-effective. 
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The cost-effectiveness of early detection depends on long-term outcomes. To the
extent that improved language leads to lower special education costs and to
improved learning potential, the monetary benefits of screening are likely to
exceed the costs.14-15 The savings in special education costs are likely to exceed the
costs of screening within 5 years.12
Preventive Intervention Information
Screening newborn infants for hearing loss identifies most children with
congenital hearing loss prior to the onset of language development, allowing their
parents to access services much earlier than otherwise. In the absence of
screening, the majority of children with congenital hearing loss do not receive a
diagnosis until 2 to 3 years of age, by which point language development is
usually seriously delayed.16 The average deaf or hard-of-hearing adult reads at
only a 4th grade level.17 The average language development score of children who
are deaf or hard of hearing in the absence of early identification is two standard
deviations below the mean.2
Certain children have later-onset or progressive hearing loss that cannot be
detected during the newborn period. Clinicians and parents should be alert to
hearing, speech, language, or developmental delay and should have children
tested for hearing function if they are concerned about delays regardless of
previous hearing screenings. 
With screening, most cases of hearing loss can be detected prior to 3 to 4 months
of age. With early identification, parents have the opportunity to communicate
with their child beginning early in infancy. This aids language development for
the child and strengthens the parent-child bonding. Research suggests that most
preschool-age children with hearing loss will have language development within
the normal range if intervention beginnings by 6 to12 months of age.2-4 It is
widely believed that this will lead to improved school performance and
occupational success.12,14-15
The main risk of screening is that false-positive results can lead to additional
screening or evaluation, incurring unnecessary costs and inconvenience for
families and providers. The expected number of newborns who do not pass the
hearing screen is 40 per 1,000 births, of which 3 will have hearing loss.
Following and re-testing the remaining 37 incur costs and challenge follow-up
systems. On the other hand, a number of surveys of families whose children
screened positive for hearing loss found that most parents support hearing
screening and consider the inconvenience to be minor compared to the benefits
of early recognition.18
Hearing screening for newborn infants is mandated in many jurisdictions, and
CDC recommends it for all infants. 
Since hearing loss may develop or first become apparent later, infants and
children and should also be screened when a clinician suspects that language or
developmental delay may be related to hearing loss. Physicians should be
encouraged to see that patients at high-risk for late-onset or progressive hearing
loss be screened in accordance with recommendations set forth by the Joint
Committee on Infant Hearing (JCIH).5
It is recommended by the JCIH that infants with risk indicators for progressive
or delayed-onset hearing loss should receive audiologic monitoring before age 3
years.5 In addition, an infant who does not pass a newborn screening should get a
diagnostic audiological evaluation before 3 months age at the latest. 
Hospital-based screening programs should use automated audiologic screening
instruments approved for use with newborn infants. This type of instrumentation
is also appropriate for use in pediatrician and other provider offices, but very few
of these offices provide this type of screening. Those offices that do not have the
appropriate instrumentation and training should refer to audiological practices
that do provide this service. Infants who are suspected to have hearing loss on the
basis of the initial screening test should be referred for comprehensive audiologic
assessment and specialty medical evaluations to confirm the presence of hearing
loss and to determine type, nature, options for treatment, and (whenever
possible) etiology of the hearing loss.5 Audiological diagnosis requires a test-
battery approach to cross-check results of multiple physiologic and
developmentally-appropriate behavioral measures. Early audiologic assessments
rely on physiologic measures of auditory function including: Auditory Brainstem
Response (ABR), Otoacoustic Emissions (OAE), acoustic immittance measures,
and acoustic reflexes.19
Auditory Brainstem Response (ABR) is a test that checks the brain's response to
sound and is measured by placing electrodes on the head to record the brain’s
response to sound. Older babies, as well as those who do not routinely sleep well
after eating, frequently require sedation to attain accurate ABR test results.19
Otoacoustic Emissions (OAE) is a test that checks the inner ear response to
sound and is measured by placing a very sensitive microphone in the ear canal to
measure the ear’s response to sound. Either type of instrument can be used alone
or in sequence. Evidence is mixed as to what instrument or method is most
effective in accurately identifying children with hearing loss, but most
instruments seem to have an adequate level of sensitivity and specificity.19
Health benefits should include provisions for diagnostic, surveillance, and
treatment services. 
Infants with a diagnosed hearing loss should receive appropriate services before 6
months of age, including medical services, early intervention services (i.e., Part C
services or other state approved intervention services), and audiologic services.5,20
Every infant with confirmed hearing loss should be referred for an otolaryngology
medical evaluation to determine the etiology of hearing loss, to identify related
physical conditions, and to provide recommendations for treatment as well as
referral for other services, including genetics evaluation and counseling. The
clinician should refer families to a source of information about qualified early
intervention service providers and the state Universal Newborn Hearing
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Screening (UNHS)/Early Hearing Detection and Intervention (EHDI) program.
In many states, clinicians are required to report children with hearing loss to the
state program. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Observational Studies, Expert Opinion
• The CDC found evidence to support universal newborn hearing screening at
birth. The CDC recommendation is based on evidence from observational
studies that children who receive intervention services for hearing loss before
the age of 6 months develop significantly better language skills. This is
supported by expert opinion of those who care for children with hearing loss
and parents of children with hearing loss, who report that children with
hearing loss detected as infants have better language skills than older siblings
with later-diagnosed hearing loss.2-4
The Joint Committee on Infant Hearing (JCIH) 
Strength of Evidence: Expert Opinion
• JCIH endorses early detection of and intervention for infants with hearing loss
(early hearing detection and intervention, EHDI) through integrated,
interdisciplinary state and national systems of universal newborn hearing
screening, evaluation, and family-centered intervention. Thus, all infants’
hearing should be screened using objective, physiologic measures in order to
identify those with congenital or neonatal onset hearing loss. Audiologic
evaluation and medical evaluations should be in progress before 3 months of
age. Infants with confirmed hearing loss should receive intervention before 6
months of age from health care and education professionals with expertise in
hearing loss and deafness in infants and young children.5
National Institutes of Health (NIH)
Strength of Evidence: Expert Consensus
• A NIH Consensus Development Conference Statement on Early Identification
of Hearing Impairment in Infants and Young Children recommended that
universal newborn hearing screening be implemented.6
State Legislation
Strength of Evidence: Not Specified
• At present, 38 states and territories have enacted legislation on universal
screening of all infants for hearing loss, and all states have programs to
promote newborn hearing screening.7
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Grosse S. Newborn hearing evidence-statement: screening. In: Campbell KP, Lanza A, Dixon R,
Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical Preventive Services:
Moving Science into Coverage. Washington, DC: National Business Group on Health; 2006.
Note: In 2001, the U.S. Preventive Services Task Force (USPSTF) issued an “I”-
rating for “insufficient” evidence for newborn hearing screening, as a result of a
lack of randomized controlled trials evaluating outcomes from newborn hearing
screening.1 However, the USPSTF did note that there is evidence that the average
age of diagnosis is significantly reduced with newborn hearing screening. 
Newborn Screening for Genetic and
Endocrine Disorders
(Screening, Medical Foods, and Treatment)
Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force recommended screening
newborns for phenylketonuria (PKU), congenital hypothyroidism (CH), and
hemoglobin disorders.1 It did not considered other disorders included in state
newborn screening panels. 
Given the availability of new evidence, the USPSTF has decided to update its
1996 recommendation on phenylketonuria (PKU). This review is currently
underway. Please refer the USPSTF website for further information
(www.ahrq.gov/clinic/uspstf/uspsspku.htm).
The American Academy of Pediatrics (AAP) recommends that all food for special
dietary use with accepted benefit for treatment of a medical condition be
reimbursed [covered] as a medical expense, provided that the costs are over and
above usual foods. All expenses for medical equipment and medical supplies
necessary for the delivery of foods for special dietary use should be reimbursed
[covered]. Reimbursement [coverage] for foods for special dietary use should be
mandatory for the following2: 
1. Any medical condition for which specific dietary components or the
restriction of specific dietary components is necessary to treat a physical,
physiologic, or pathologic condition resulting in inadequate nutrition.
2. An inherited metabolic disorder, including but not limited to disorders of
carbohydrate metabolism, lipid metabolism, vitamin metabolism, mineral
metabolism, or amino acid and nitrogen metabolism.
3. A condition resulting in impairment of oral intake that affects normal
development and growth. 
Expert Consensus (Committee on Nutrition)
An expert group convened by the American College of Medical Genetics
(ACMG) with support from the Health Resources and Services Administration
(HRSA) recently recommended a core panel of 29 disorders to be screened for in
newborn blood spot specimens.3 This screening panel has been endorsed by a
Department of Health and Human Services (DHHS) Secretary’s Advisory
Committee on Heritable Disorders and Genetic Diseases in Newborns and
Children4 and by professional organizations, including the American Academy of
Pediatrics (AAP).5
PKU Management
Screening newborns is just a first step. In 2000, a NIH Consensus Statement on
Phenylketonuria Screening and Management stated that a “multidisciplinary
approach to lifelong care…for the treatment of PKU with….continuity of care
from infancy through adulthood is considered medically necessary for optimal
outcomes for individuals with PKU.” Treatment includes access to appropriate
medical services at specialized multidisciplinary treatment centers and provision
of medical formula and foods.6
SCD Management
NIH guidelines on the management of SCD, last revised in 2002, call for
comprehensive management by a team that includes physicians, nurses, health
educators, and medical social workers, as well as access to a number of specialists.
NIH recommends that a mid-level practitioner coordinate preventive and
primary care, pain management, transfusion and chelation therapy compliance,
and education of patients and other health care providers.7
The recommendations and supporting information contained in this document
came from several sources, including the: 
• American Academy of Pediatrics (AAP)
• American College of Medical Genetics (ACMG) 
• DHHS Secretary’s Advisory Committee on Heritable Disorders and Genetic
Diseases in Newborns and Children
• Government Accountability Office (GAO)
• National Institutes of Health (NIH)
• National Newborn Screening and Genetics Resource Center, funded by the
Health Resources and Services Administration (HRSA)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text.
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All states require that providers collect dried blood spot specimens from infants
soon after birth and send them to be tested at an approved screening laboratory
for a panel of disorders specified by the state. All states require screening for a
minimum of four disorders: phenylketonuria (PKU), congenital hypothyroidism
(CH), galactosemia, and sickle cell disease (SCD) and other hemoglobin
disorders. Other disorders that are mandated by the majority of states include
congenital adrenal hyperplasia (CAH), biotinidase deficiency, and medium chain
acyl-CoA dehydrogenase (MCAD) deficiency.8-9 Most states are moving to adopt
the core panel of disorders recommended by the ACMG. 
The most common newborn genetic disorders are congenital hypothyroidism
(CH), with a prevalence at birth of 1 in 2,500 newborns, and sickle cell disease
(SCD), which is diagnosed in 1 in 2,600 newborns.9 The birth prevalence of
phenylketonuria (PKU) in the United States is 1 in 20,000 newborns. 
If untreated, phenylketonuria (PKU) results in severe mental retardation in most
children. Congenital hypothyroidism (CH) results in mental retardation as well
as other forms of cognitive impairment and physical and behavioral problems in
many untreated infants. Sickle cell disease (SCD) results in repeated bouts of
severe pain, disability, and can increase susceptibility to blood-borne infections
that can cause sepsis, meningitis, and death. SCD also results in frequent, painful
crises. In addition, children with SCD are at risk of stroke, which can cause brain
damage and cognitive impairment. 
Most disorders detected by newborn blood spot screening are genetic disorders,
except for congenital hypothyroidism, an endocrine disorder which is primarily
non-genetic.
Value of Prevention
In the absence of screening and treatment, almost all children with
phenylketonuria (PKU) (about 200 births per year) would develop mental
retardation. The average lifetime direct and indirect cost per child born with
mental retardation is $1 million (in year 2003 dollars).10 This indicates a lifetime
burden of at least $200 million for each birth cohort. Prior to screening, at least
1 in every 20,000 children developed mental retardation due to congenital
hypothyroidism (CH).11 This indicates that CH and PKU have similar economic
burdens and, when combined, cost at least $400 million per year.
Sickle cell disease is a major cause of hospitalizations. During 1989 to 1993,
hospitalization costs for children and adults with SCD averaged $475 million per
year (in year) 1996 dollars.12
Family caregivers for children with disabling sequelae such as mental retardation
or painful sickle cell crises are liable to miss days of work, cut back hours, or
leave the workforce altogether. Mothers of children with disabling conditions are
estimated to lose an average of approximately 5 hours of work per week, or 250
hours per year.13 Assuming an hourly cost between $12 and $20 (including fringe
benefits), that implies an economic cost from $3,000 to $5,000 per child, per year.13
Screening for two disorders, phenylketonuria (PKU) and congenital
hypothyroidism (CH), has been demonstrated to be cost-saving to public payers,
with the averted costs of care exceeding the costs of providing screening and
diagnostic services and treatment.14
The cost of newborn screening for genetic and endocrine disorders depends on
the conditions tested for, the screening instruments used, the number of
specimens tested, and the type of follow-up conducted.15
A study by the General Accountability Office (GAO) concluded that, in 2001,
state newborn screening programs spent over $120 million, or an average of
$29.44 per infant.16 All except 5 states charge a fee to birthing centers or other
providers to cover the cost of providing laboratory screening and, to a varying
extent, follow-up services. Some states also use the fee to subsidize the costs of
providing specialist services and/or medical foods. These fees vary from $10 to
over $100 per infant.17
Children with phenylketonuria (PKU) require treatment from specialized
metabolic disease clinics. Dietary treatment for PKU, which is recommended for
life, entails special phenylalanine-free formula that is supplemented with tyrosine
and medical foods. The cost for one year of formula and medical foods can reach
$10,000.18 In contrast, congenital hypothyroidism (CH) can be treated by
primary care providers using inexpensive thyroid hormone medications. 
Children with sickle cell disease (SCD) may be prescribed antibiotics as
prophylaxis against infections, and vaccination against selected bacterial
infections may also be needed. Although many children with SCD are treated by
primary care providers, outcomes such as survival are improved among children
who receive care from a comprehensive SCD center.19 Federally-insured children
with SCD in 1992-1993 had mean expenditures 9 times higher than other
similarly insured children.20 Most of the costs were associated with hospital and
emergency department admissions, although optimal pain management has been
shown to reduce those costs substantially.21 New interventions such as
hydroxyurea, transfusions, and bone marrow transplantation offer promise in the
prevention of painful crises, morbidity, disability, and mortality but, those
treatments require significant expertise and specialized clinical experience to be
utilized appropriately.22
The cost-effectiveness of newborn screening is well established. In particular,
screening for phenylketonuria (PKU) and congenital hypothyroidism (CH) is
cost-saving, with the averted costs of care exceeding the costs of providing
screening, diagnostic services, and treatment.14 Screening for other disorders is
generally cost-effective, if not cost-saving. For example, one analysis of screening
for sickle cell disease (SCD) concluded that screening all newborns for SCD
results in a cost of $10,000 per discounted life year saved.23 Another analysis of
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newborn screening for medium chain acyl-CoA dehydrogenase (MCAD)
deficiency found that the cost per quality-adjusted life year (QALY) is likely less
than $30,000.24
Preventive Intervention Information
Newborn screening allows treatment to be initiated within the first few weeks of
life thereby preventing some of the complications associated with genetic and
endocrine disorders. 
Newborn screening for phenylketonuria (PKU) and congenital hypothyroidism
(CH) has been a major public health success in preventing numerous cases of
intellectual disability and assuring normal development of thousands of children.
Newborn screening for other disorders has saved the lives of many children who
would otherwise have died in early childhood.
Studies have shown that treatment for phenylketonuria (PKU) and congenital
hypothyroidism (CH), if begun in the first 3 weeks and adhered to subsequently,
can prevent mental retardation and assure normal cognitive functioning.25-26 Risks
resulting from discontinuation or lack of adherence to treatment vary with the
age of the individual and the severity of the disorder. Newborn screening for
sickle cell disease (SCD), in association with parent and provider education,
clinical management, and vaccine and antibiotic prophylaxis, has been shown to
prevent most deaths associated with SCD in the first 3 to 4 years of life. Early
identification of SCD does not prevent pain crises and strokes, and long-term
outcomes are less clear.27 Treatments for other disorders that are included in some
state screening panels also have benefits and risks. For example, a recent CDC report
evaluated benefits and risks of screening and early treatment for cystic fibrosis.28
The effectiveness of newborn screening is dependent on access to appropriate
medical services and treatments, including medical foods for disorders such as
PKU. Failure of payers to cover medical foods can result in serious adverse
consequences, including, for example, severe intellectual disability and
devastating birth defects among children born to mothers with inadequately
treated PKU.29 Similarly, access to specialized, multidisciplinary treatment centers
may be needed in order to minimize mortality and medical complications. 
The main risk of screening is false-positive results, which can lead to unnecessary
testing and unneeded treatment. False-negative screening results, as well as missed
cases, may lead to delays in diagnosis and treatment. 
Screening should be initiated upon birth, or as soon thereafter as possible, because
initiation of treatment within the first few months of life may be required to
prevent adverse outcomes. Some states require or recommend the collection of
another blood spot specimen between 1 and 4 weeks of age. Families adopting
children from other countries should consult their child’s healthcare provider. 
Medical foods and preventive treatment should be provided as medically necessary.
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A variety of types of equipment, reagents, and protocols are used to screen
newborns. All newborn screening laboratories are CLIA-certified, use approved
technologies, and participate in a rigorous proficiency testing and quality
assurance program maintained by CDC in collaboration with the Association of
Public Health Laboratories.
Children with positive screening test results need to be followed up with further
testing. For disorders for which early treatment is urgent, treatment may be
initiated based on presumptive positive results pending final confirmation.
Children with genetic and endocrine disorders may require one or more of the
following:
• Medical formula or medical foods 
• Medications 
• Treatment from specialized metabolic clinics 
Health benefits should include provisions for case management services, access to
specialty clinics, medical formulas/foods, and medications — as medically
indicated — for the purpose of preventing illness or disability among
beneficiaries with genetic or endocrine disorders. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
Medical Foods
The American Academy of Pediatrics (AAP) 
Strength of Evidence: Expert Consensus
• AAP recommends that all food for special dietary use with accepted benefit for
treatment of a medical condition be reimbursed [covered] as a medical
expense, provided that the costs are over and above usual foods. All expenses
for medical equipment and medical supplies necessary for the delivery of foods
for special dietary use should be reimbursed [covered].2
Screening
American College of Medical Genetics (ACMG) 
Strength of Evidence: Expert Opinion
• An expert group convened by the American College of Medical Genetics
(ACMG) recently recommended a core panel of 29 disorders to be screened
for in newborn blood spot specimens.3
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Grosse S. Newborn screening for genetic and endocrine disorders evidence-statement: screening,
medical foods, and treatment. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA,
editors. A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington,
DC: National Business Group on Health; 2006.
Management and Preventive Medication
National Institutes on Health (NIH)
Strength of Evidence: Not Specified
• NIH PKU treatment guidelines stipulate that treatment should include access
to appropriate medical services at specialized multidisciplinary treatment
centers and provision of medical formula and foods.6
• NIH guidelines on the management of SCD call for comprehensive
management by a team that comprises doctors, nurses, health educators, and
medical social workers, as well as access to a number of specialties. The NIH
recommends coordination of care by a mid-level practitioner, including
preventive and primary care, pain management, transfusion and chelation
therapy compliance, and education of patients and other health care providers.7
Vision (Child) (Screening)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening to
detect amblyopia, strabismus, and defects in visual acuity in children younger
than age 5 years.1-2
The USPSTF found at least fair evidence that the service improves important
health outcomes and concludes that benefits outweigh harms. The USPSTF
found no direct evidence that screening for visual impairment in children leads to
improved visual acuity. However, studies from Sweden and Israel suggest that
early screening for visual impairment may reduce the prevalence of amblyopia in
children.1 Also, the USPSTF found fair evidence that screening tests have
reasonable accuracy in identifying strabismus, amblyopia, and refractive error in
children with these conditions; that more intensive screening compared with
usual screening leads to improved visual acuity; and that treatment of strabismus
and amblyopia can improve visual acuity and reduce long-term amblyopia.1-2
The American Academy of Pediatrics (AAP) recommends the following vision
screening be performed at all well-child visits for children starting in the newborn
period to 3 years: ocular history, vision assessment, external inspection of the eyes
and lids, ocular motility assessment, pupil examination, and red reflex examination.
For children ages 3 to 5 years, the AAP recommends the aforementioned screening
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in addition to age-appropriate visual acuity measurement and ophthalmoscopy. All
children who fail the vision assessment or who have an ocular abnormality should
be referred to a pediatric ophthalmologist or an eye care specialist appropriately
trained to treat pediatric patients.3
Expert Opinion
The Center for Medicare and Medicaid Services (CMS) requires that Early and
Periodic Screening, Diagnostic, and Treatment (EPSDT) services be provided to
all individuals under age 21 enrolled in Medicaid. The EPSDT benefit, at a
minimum, must include diagnosis and treatment of defects in vision, including
eyeglasses. Vision services must be provided according to a distinct periodicity
schedule developed by the state and at other intervals as medically necessary.4
CMS Mandate
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Pediatrics (AAP)
• Centers for Disease Control and Prevention (CDC)
• Center for Medicare and Medicaid Services (CMS)
• National Institutes of Health (NIH)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Visual impairment is a common condition that affects 7% to 8% of children.1
Relatively severe bilateral visual impairment with a best corrected visual acuity in
the better eye of 20/70 or worse occurs in about 1 per 1,000 children ages 6 to
10 years, and blindness (visual acuity worse than 20/400) occurs in about 4 per
10,000 children.5
Causes of visual impairment in children include amblyopia, refractive error not
associated with amblyopia, and strabismus. Significant refractive errors are the
most common and easily corrected vision disorder, affecting up to 20% of young
children.6 Refractive errors are eye disorders in which the shape of the eye does
not allow the light that enters the eye to be focused properly, resulting in blurred
vision. Types of refractive errors include myopia (nearsightedness), hyperopia
(farsightedness), anisometropia (a difference in refractive error between eyes), and
astigmatism (an unequal curvature of the cornea that prevents light rays from
focusing clearly at one point on the retina). Refractive errors are strong risk
factors for amblyopia.
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Amblyopia refers to reduced visual acuity in one or both eyes that is not due to
ocular structure anomalies and that is not eliminated when refractive error is
corrected. The disorder is most frequently caused by uncorrected anisometropia
or strabismus and can also be caused by cataracts.1 The best estimate of the
prevalence of ambylopia is 3% to 4%.1 An untreated amblyopic eye does not
develop normal vision, and the individual has impaired binocular function
(ability to use the eyes together, such as in depth perception). In addition,
uncorrected amblyopia may be a risk factor for future blindness in later
childhood and adulthood and may harm school performance, ability to learn,
and later, adult self-image. 
Strabismus is present in 3% to 4% of the population.1 It is a deviation or
misalignment of the eyes resulting from the failure of the eye muscles to work
together. Most strabismus develops in early childhood and some types may not
be cosmetically obvious. Strabismus results in poor to absent binocular function
(ability of the eyes to work together) and can result in amblyopia.1
Prematurity and low birth weight are risk factors for amblyopia and strabismus.7-8
Risk factors for other visual impairment disorders are not well understood. 
Value of Prevention
The estimated lifetime cost (in year 2003 dollars) for persons born in 2000 with
vision impairment is $2.5 billion. This is a conservative estimate because it
applies only to the 1 in 1,000 children with corrected visual acuity of 20/70 or
worse. The cost estimate includes both direct and indirect costs and refers to all
excess costs for individuals with vision impairment. 
An estimate of the excess costs attributable specifically to vision impairment in
children in the United States is not available.
The workplace burden of visual impairment in children has not been effectively
measured. Indirect costs of visual impairment, which include the value of lost
wages when a person either cannot work or is limited in the amount or type of
work he or she can do, may be substantial.
No economic evaluation of vision screening in preschool-age children has been
published. A primary benefit of screening is the early detection of amblyopia,
which allows for earlier treatment and improvement of visual acuity in the
affected eye. 
The cost of conducting vision screening in young children varies depending on
the methods used, the setting, and the type of staff performing the screening. In
2004, the private-sector cost of vision screening averaged $71; approximately
95% of paid claims fell within the range of $5 to $133.9
Treatment for visual impairment varies depending on the type, cause, and
severity of impairment. For amblyopia, treatment and associated costs (in year
2001 dollars) are10: 
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• Nonsurgical amblyopia therapy – $1,452
• Nonsurgical amblyopia therapy and ocular alignment – $2,190
• Nonsurgical amblyopia therapy and cataract extraction – $2,628
• Nonsurgical amblyopia therapy and ptosis repair – $1,853
The weighted average cost of surgical and nonsurgical treatment was $1,623 in
year 2001 dollars.10
One cost-effectiveness analysis of treatment for amblyopia in preschool-age
children has been published.6 That study reported that treatment was associated
with a mean improvement in visual acuity from 20/80 to 20/32, and an
associated improvement of health-related quality of life. The estimated cost per
QALY (a measure of health impact) gained from treatment was $2,281 in year
2001 dollars.6 In comparison to other preventive interventions and to commonly
accepted cost-effectiveness benchmarks, vision screening is highly cost-effective. 
Preventive Intervention Information
Visual impairment in children is believed to have an early sensitive period when
interventions lead to better outcomes. Screening for visual impairment allows
clinicians to identify affected patients early and initiate treatment.
The USPSTF found no evidence of harms associated with screening, judged the
potential for harms to be small, and concluded that the benefits of screening are
likely to outweigh any potential harms.2
Based on their review of current evidence, the USPSTF was unable to determine
the optimal periodicity of screening. They recommend screening beginning in
infancy with the methods of screening depending on the child. 
Based on expert opinion, the American Academy of Pediatrics (AAP)
recommends the following vision screening be performed at well-child visits for
children starting in the newborn period to 3 years: ocular history, vision
assessment, external inspection of the eyes and lids, ocular motility assessment,
pupil examination, and red reflex examination. Between the ages of 3 and 5
years, visual acuity can be screened using simple recognition charts.3 After age 5,
standard visual acuity charts such as the Snellen Acuity Chart can generally be
added to the screening.11
Various tests are used widely in the United States to identify visual defects in
children, and the choice of tests is influenced by the child’s age. Beginning in the
first year of life, strabismus can be screened for by using the cover test, the
Hirschberg light reflex test, and the red reflex test. Screening children younger
than age 3 years for visual acuity is more challenging than screening older
children and typically requires testing by specially trained personnel. Newer
automated techniques can be used to screen these children. Photo-screening and
autorefractors can detect amblyogenic risk factors such as significant refractive
error and media opacities; however, these techniques do not provide acuity
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Treatment
Information
information on the children screened. In children older than 3 years, stereopsis
(ability of both eyes to function together) can be assessed with the Random Dot
E test or Titmus Fly. Some of these tests have better test characteristics than others. 
Recent results from a large, rigorous evaluation of commonly used preschool
vision screening tests supported by the National Institutes of Health (NIH)
indicate that some tests outperform others. The Vision in Preschoolers Study
(VIP) found that the best tests were able to detect two-thirds of children with
vision disorders and that select objective and subjective screening tests can be
effective.11-12
Health benefits should include provisions for follow-up and treatment services. 
Significant refractive errors are easily corrected with eyeglasses and some
amblyopia and strabismus may be prevented by early detection and correction of
significant refractive errors.
Most amblyopia can be treated nonsurgically. Treatment strategies include
covering the sound eye with patching or using pharmacologic agents such as eye
drops. Amblyopia associated with refractive errors may also be treated with
eyeglasses. Select types of amblyopia do require surgical treatments, such as ocular
alignment and cataract extraction, in addition to nonsurgical therapy. 
Treatment of strabismus largely consists of correction with eyeglasses, surgical
correction, and orthoptics (optometric vision therapy). Large constant deviations
present in the first few years usually require surgical intervention, while
intermittent or accommodative esotropia, which most commonly develops at 2
to 3 years of age, can almost always be corrected with eyeglasses.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this section
is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found at least fair evidence to recommend screening to detect
amblyopia, strabismus, and defects in visual acuity in children younger than
age 5 years.2
Recommended Guidance:
American Academy of Pediatrics (AAP)
Strength of Evidence: Expert Opinion
• The American Academy of Pediatrics (AAP) found good evidence to support
the following components of vision screening at all well-child visits for
children starting in the newborn period to 3 years: ocular history, vision
assessment, external inspection of the eyes and lids, ocular motility assessment,
pupil examination, and red reflex examination. For children ages 3 to 5 years,
the AAP recommends the aforementioned screening in addition to age
appropriate visual acuity measurement and ophthalmoscopy.3
Center for Medicare and Medicaid Services (CMS)
Strength of Evidence: CMS Mandate
• The Center for Medicare and Medicaid Services (CMS) requires that Early and
Periodic Screening, Diagnostic, and Treatment (EPSDT) services be provided
to all individuals under age 21 enrolled in Medicaid. The EPSDT benefit, at a
minimum, must include diagnosis and treatment of defects in vision, including
eyeglasses. Vision services must be provided according to a distinct periodicity
schedule developed by the state and at other intervals as medically necessary.4
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• Colorectal cancer is the second leading cause of cancer death.1
• Routine screening can reduce the number of people who die of colorectal
cancer. While estimates of mortality reduction due to screening vary by type of
screening test, the range is approximately 15% to 60%.2-3
• The estimated annual national expenditure for colorectal cancer treatment is
$5.5-$6.5 billion; inpatient hospital care accounts for 80% of this cost.4
• Because colorectal cancer is a disease of middle and old age, the costs related to
colorectal cancer treatment are likely to increase as the population ages. For
example, hospital admissions for colorectal cancer are expected to double by
2050.4
• Screening can prevent colorectal cancer by allowing clinicians to identify and
remove precancerous polyps before they develop into cancer. Screening can
also identify cancer early in the course of the disease when treatment is more
effective and the chance of recovery is high.2-5
• The cost of screening is typically less than the cost of treating cancer. When
screening identifies a colorectal tumor in its early stages, the cost of treatment
is often much less expensive than if the tumor is detected later in the course of
disease.4
Clinical Preventive Service Recommendations
The USPSTF strongly recommends that clinicians screen men and women 50
years of age or older for colorectal cancer.2
The USPSTF found fair to good evidence that several screening methods are
effective in reducing mortality from colorectal cancer. The USPSTF concluded
that the benefits from screening substantially outweigh potential harms, but the
quality of evidence, magnitude of benefit, and potential harms vary with each
method.2
The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Healthcare Research and Quality (AHRQ)
• American Cancer Society (ACS)
• International Agency for Research on Cancer (IARC)
• National Academy of Sciences (NAS)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a

















Colorectal cancer is the second leading cause of cancer death in the United
States.  It is also a major cause of premature mortality; patients who die of
colorectal cancer lose 13 years of life, on average.1 The American Cancer Society
(ACS) estimated that there would be 104,950 colon and 40,340 rectal cancer
cases in the United States in 2005. Although mortality rates have continued to
decline over the past 15 years, an estimated 56,290 deaths from colorectal cancer
were predicted to occur in 2005, comprising about 10% of all cancer deaths.1
Risk factors for colorectal cancer include being male, being older, having a family
history of colorectal cancer, having a personal history of inflammatory bowel
disease, being overweight or obese, being physically inactive, having certain
genetic conditions3, and (possibly) consuming inadequate amounts of fruits and
vegetables.6
Value of Prevention
The annual expenditure for colorectal cancer was conservatively estimated to
equal $5.3 billion in 2000.5 However, other investigators estimated that inpatient
costs alone exceeded $5 billion in 1994 and their analysis also indicated that
colon cancer-related admissions were twice as long and twice as expensive as the
average hospital admission in the United States.4
Because colorectal cancer is a disease of middle and old age, the costs related to
colorectal cancer treatment are likely to increase as the population ages. Based on
census projections, the annual number of colon cancer-related hospital
admissions among persons aged 50 years is expected to increase from 215,000 in
1992 to 471,000 in 2050. Similarly, among persons aged 60 years and older
hospital admissions for colorectal cancer are expected to increase from 192,000 in
1992 to 448,000 in 2050.4
Besides the health, disability, and life insurance costs for employees affected by
colorectal cancer, lost productivity associated with morbidity and premature
mortality contributes to significant additional costs. During 1998, colorectal patients
were hospitalized for 2.3 million days — a work loss equivalent of $70.9 million in
lost wages among the working-age population. This figure would increase to $106.1
million if time away from work due to care in all settings was considered.5
Screening can prevent colorectal cancer by allowing clinicians to identify and remove
precancerous polyps before they develop into cancer. Screening can also identify
cancer early in the course of the disease when treatment is more effective and the
chance of recovery is high. The cost of screening is typically less than the cost of
treating cancer and, when screening identifies a colorectal tumor in its early stages,
the cost of treatment is often much less expensive. For example, one study, which
looked at the cancer care costs among members of a health maintenance organization
(HMO), found that the net costs of initial care for colon cancer were $7,002 at the
carcinoma in situ stage and $11,624 at the local stage compared to $13,367 at the
regional stage, and $15,276 at the distant stage (all figures in year 1992 dollars).7
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The average cost of colorectal cancer screening varies by location and provider.
The 5 recommended methods of screening for colorectal cancer have very
different initial costs, with FOBT and colonoscopy being the least and most
expensive methods respectively. However, because they are typically used at
different time intervals and because colonoscopy is required to confirm results of
the other methods, the 10-year overall cost for screening methods that include
diagnostic colonoscopy are similar. Table 1 lists the average price of colorectal
cancer screening, by type. Cost estimates are based on 2004 data from privately-
insured beneficiaries.8
Table 1: Average Private-Sector Cost of Colorectal
Cancer Screening Methods (in year 2004 dollars)8
Screening Technique Average Price Recommended Average Price 
per Procedure Number of Over  Over a 10-year 
a 10-Year Period Interval
Colonoscopy $557 1 $557
(range $150 to (range $150 to 
$1,112)* $1,112)*
Flexible sigmoidoscopy; $174 2 $348
requires a follow-up (range $54 (range $108 to 
colonoscopy if polyps to $392)* $784)*
are found
Double-contrast barium $126 2 $252
enema; may require follow-up (range $38 (range $76
colonoscopy to $399)* to $798)*
Fecal occult blood test $7 10 $70  
(FOBT); may require  (range $2 (range $20
follow-up colonoscopy to $16)* to $160)*
Combination of flexible $181 2/10 $418
sigmoidoscopy and FOBT (range $56 (range $128
to $408)* to $944)*
Source: Thompson Medstat. Marketscan. 2004.*Approximately 95% of paid claims fell within
the stated range.
Not Provided
A systematic review of cost-effectiveness analyses for different colorectal cancer
screening methods found that most common screening strategies for adults aged
50 years or more would result in an average cost-effectiveness ratio ranging from
$10,000 to $30,000 per life-year saved (year 2000 dollars) compared to no
screening.9 In comparison to other preventive interventions and to commonly
accepted cost-effectiveness benchmarks, screening for colorectal cancer is cost-
effective.
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The purpose of screening for colorectal cancer is to find precancerous
polyps so that they can be removed before they turn cancerous, thus
preventing the development of a tumor. Screening can also identify
cancer early in the course of the disease when treatment is more effective
and the chance of recovery is high.  
Unfortunately, screening rates for colorectal cancer are low; fewer than
half of men and women over age 50 are screened at the recommended
intervals.10
The benefits of screening are substantial. Routine screening can reduce
the number of people who die of colorectal cancer by preventing cancer
or identifying it in its earliest stages when treatment is most effective.
While estimates of mortality reduction due to screening vary by type of
screening test, the range is approximately 15% to 60%.2 
The risks associated with screening depend on the type of screening
method used.  All of the recommended tests can produce false-positive
results, which may lead to unnecessary procedures with resultant harms.
Flexible sigmoidoscopy, colonoscopy, and double-contrast barium enema
may cause perforation and bleeding. However, the benefits of colorectal
cancer prevention and early detection outweigh the risks of every
screening method.2
Screening for colorectal cancer should be initiated at age 50 for both men
and women. For individuals who are determined by their physicians to be
at higher risk of the disease, screening may be initiated at an earlier age.11
Screening has been found to be effective for people up to age 80.
However, randomized trials suggest that life expectancy of at least 5 years
may be required to realize the benefits of screening, so the risks and costs
of screening may outweigh the benefits for people with reduced life
expectancy because of age or illness.5
The optimal interval between screenings depends on the screening
method used and is illustrated in Table 2.
Table 2: Colorectal Cancer Screening Methods and 
Recommended Intervals5
Screening Method Recommended Interval
Colonoscopy 10 years
Flexible sigmoidoscopy 5 years
Double-contrast barium enema 5 years
Fecal occult blood tests (FOBT) 1 year
Combination of flexible 5 years for the flexible 
sigmoidoscopy and FOBT sigmoidoscopy and one year for 
the FOBT





Approved methods of screening for colorectal cancer include colonoscopy, flexible
sigmoidoscopy, fecal occult blood testing (FOBT), and double-contrast barium
enema. FOBT may be combined with flexible sigmoidoscopy to improve the
sensitivity of the tests. The approved FOBT test uses specimens collected in the
patient’s home.2-3
Health benefits should include provisions for diagnostic and treatment services.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research: 
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence) 
• The USPSTF found fair to good evidence that several screening methods are
effective in reducing mortality from colorectal cancer. The USPSTF concluded
that the benefits from screening substantially outweigh potential harms, but
the quality of evidence, magnitude of benefit, and potential harms vary with
each method.2
Authored by: 
Campbell KP, Coates RJ, Chattopadhyay S. Colorectal cancer evidence-statement: screening. In:
Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to
Clinical Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group on
Health; 2006.
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• Unintended pregnancy is a significant problem in the United States.
Approximately 3 million unintended pregnancies occur each year1 and roughly
half of all pregnancies and 31% of all live births are unintended.2
• During the course of a singe menstrual cycle (28 days) a fertile couple has a
25% chance of pregnancy with repeated unprotected sexual intercourse.1
Among women ages 19 to 26 (when fertility is at its peak) the chance of
pregnancy following a single act of unprotected intercourse around the time of
ovulation is approximately 50%.1
• Contraceptives, when consistently and appropriately used, effectively prevent
pregnancy.
• Approximately 50% of all unintended pregnancies occur among women who
do not use contraception.3
• Contraception counseling increases the consistent and correct use of
contraceptives, which in turn leads to lower rates of unintended pregnancy,
fewer induced abortions, and better pregnancy outcomes.4-5 In fact, it is
estimated that halving the number of women not using contraception would
reduce the number of unintended pregnancies (per year) by one-third. The
reduction in unintended pregnancies would in turn reduce the number of
abortions by 500,000 per year.6
• Comprehensive contraceptive coverage is relatively inexpensive. The average
cost of adding coverage for all reversible methods of contraception is $25.31
per employee, per year.7
• Researchers estimate that over a 5-year period, employers can save $9,000 to
$14,000 (in year 1993 dollars) by providing comprehensive contraceptive
coverage.8 Experts suggest that employers may begin to see some savings in the
first year of coverage.8
Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that
clinicians counsel all men and women at risk for unintended pregnancy on
effective contraceptive methods. This recommendation is archived and is no
longer active. 
The American Academy of Family Physicians (AAFP) recommends that primary
care providers obtain a history of sexual practices and provide counseling on the
prevention of unintended pregnancy and contraceptive options to all sexually
active women who do not want to become pregnant and men who do not want
to have a child.9
Although evidence exists which demonstrates the net benefit of counseling to
prevent unintended pregnancy, either the benefit is only moderate in magnitude
or the evidence supporting a substantial benefit is only fair. The intervention is
perceived to be cost-effective and acceptable to most patients.9
EVIDENCE-STATEMENT:
CONTRACEPTIVE USE (Counseling and 
Preventive Interventions)
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The American College of Obstetricians and Gynecologists (ACOG) strongly
recommends that combination or progestin-only oral contraceptives for
emergency contraception should be offered to women who have had unprotected
sexual intercourse within 72 hours of intercourse.10
ACOG found good and consistent scientific evidence to support their
recommendation of emergency contraception following unprotected
intercourse.10
The American Academy of Pediatrics (AAP) notes that the comprehensive health
care of adolescents should include counseling on the prevention of sexually
transmitted infections (STIs), education on contraceptive methods, and family
planning services for the sexually active patient.11 Specifically:
1. Adolescents should be strongly encouraged to postpone the initiation of sexual
intercourse.
2. For patients already engaged in sexual intercourse or who are contemplating
having sexual intercourse, a discussion of contraceptive methods and
prevention of sexually transmitted infections (STIs) (including HIV) is
essential. 
3. The pediatrician should support compliance, manage side effects, change the
method of contraception as circumstances require, and provide referrals and
frequent follow-up with periodic screening for STIs. 
Not Specified
ACOG recommends that when a woman is prescribed emergency contraception,
she should be counseled about effective contraceptive methods, sexually
transmitted infections, and safe-sex practices.10
ACOG’s recommendation that women receive contraceptive counseling post
emergency contraception use is based on consensus and expert opinion.10
The American Medical Association (AMA) recommends that healthcare
professionals12:
1. Help women plan for pregnancy.
2. Support age-appropriate education in esteem building, decision-making and
family life, ultimately introducing the concept of planning for childbearing
into the educational process. 
Not Specified
Due to the side-effect profile of some medications and devices, the difference in
permanence and reversibility of contraceptives, and women’s personal preferences,
employers/health plans should [cover] the full range of Food and Drug
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Administration (FDA) approved contraceptive methods including, but not
limited to7:
• Hormonal medications (e.g., pills and patches) including emergency
contraceptives
• Contraceptive devices (e.g., IUD, diaphragms, vaginal rings)
• Sterilization (e.g., vasectomy, tubal ligation)
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP)
• American College of Obstetricians and Gynecologists (ACOG)
• American Medical Association (AMA)
• Centers for Disease Control and Prevention (CDC)
• Employee Benefits Institute 
• Food and Drug Administration (FDA)
• Healthy People 2010, U.S. Department of Health and Human Services
• Institute of Medicine (IOM)
• Internal Revenue Service (IRS), Department of Treasury
• Jacobs Institute of Women’s Health
• March of Dimes
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Unintended pregnancy is a significant problem in the United States.
Approximately 3 million unintended pregnancies occur each year1 and roughly
half of all pregnancies and 31% of all live births are unintended.2
The risk of pregnancy (unintended or intended) is high. Women in the United
States, on average, are fertile from ages 15 to 44.13 During the course of a singe
menstrual cycle (28 days) a fertile couple has a 25% chance of pregnancy with
repeated unprotected intercourse.1 Among women ages 19-26 (when fertility is at
its peak) the chance of pregnancy following a single act of unprotected
intercourse around the time of ovulation is 50%.1 Approximately 50% of all
unintended pregnancies occur among women who do not use contraception. It is
estimated that the overall rate of unintended pregnancy could be cut in half if
these women were to use a highly effective method of contraception.3
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A wide range of effective contraceptives are available. They include reversible
methods (e.g., hormonal pills and patches, IUDs, condoms, etc.) and irreversible
methods (e.g., vasectomy, tubal ligation). Nearly all women (98%) who have had
sexual intercourse have, at some point, used contraception to either avoid or
delay pregnancy. Approximately 82% of women have used the oral contraceptive
pill and about 90% have had a partner use the male condom.4 The birth control
pill, which is used by 11.6 million women, is the most common form of birth
control in the United States.14
Despite the availability and effectiveness of contraception, women continue to
experience unintended pregnancies. Most unintended pregnancies occur as a
result of contraceptive nonuse, misuse, or a noticeable contraceptive failure (i.e.,
condom breaks).1 In 2001, 5% of women of reproductive age experienced an
unintended pregnancy.15 Contrary to popular belief, unintended pregnancy is not
only a problem of adolescence: women of all ages experience unintended
pregnancies.8
Healthy People 2010, the national health agenda, has set the following goals for
reducing the rate of unintended pregnancy is the United States6:
1. To increase the proportion of pregnancies that are intended to 70%.
2. To reduce the proportion of births occurring within 24 months of a previous
birth to 6%.
3. To increase to 100% the proportion of females at risk of unintended
pregnancy (and their partners) who use contraception.
4. To reduce the proportion of females that get pregnant despite using a reversible
contraceptive method.
5. To increase male involvement in pregnancy prevention and family planning
efforts.
All women who are aged 13 to 44, are sexually active and fertile, and who are not
trying to become pregnant are at risk of an unintended pregnancy.2
Approximately 10.7% of women in the United States who are at risk for an
unintended pregnancy do not use contraception.2 Certain groups are at an
elevated risk for unintended pregnancy, they include: teenagers and young
women age 20 to 24, women age 40 years and older, black women, women with
lower levels of education, unmarried women, and women with low incomes.2
Value of Prevention
The economic burden of unintended pregnancy is substantial, both to employers
and the society at large. The economic cost of an unintended pregnancy to an
employer includes either A) the cost of termination or B) the cost of prenatal,
delivery, and postpartum care for the woman and the cost of continuing medical
care for the infant as long as s/he remains a beneficiary. 
Unplanned pregnancies, compared to planned pregnancies, often result in higher
total medical claims costs and lost productivity costs because women whose
pregnancies are unintended are less likely to have proper folic acid intake, are less
likely to breastfeed, and are more likely to continue smoking during pregnancy.16
The adverse health outcomes associated with these behaviors lead to higher
obstetric medical claims.14
Unintended pregnancies result in substantial excess direct medical claims costs17
and indirect costs such as disability, employee replacement costs, lost
productivity, and presenteeism.14
Providing coverage for contraceptive counseling and contraceptive medications
and devices improves access and use, thereby avoiding the substantial direct and
indirect costs associated with unintended pregnancies, abortions, and unwanted
births. The average cost of a 1-year supply of prescription birth control pills is
$240 to $300 (in year 2005 dollars) and the cost of a single prescription of
emergency contraception is $20 to $150. These costs are lower than the
“treatment” costs for an unintended pregnancy.7 For example, the average cost to
employers of: 
• A first term abortion is approximately $468 (in year 2003 dollars).7
• A normal vaginal delivery (without complications) is $7,340 (in year 2005
dollars).7
• A cesarean delivery (without complications) is $12,257 (in year 2005 dollars).7
• The delivery and first year care of a premature infant is $41,610 (in year 2001
dollars).18
Comprehensive contraceptive coverage is relatively inexpensive. The average total
cost (including administrative costs) of adding coverage for all reversible methods
of contraception is $25.31 per employee, per year.7 The added cost to employers
of providing contraception coverage (assuming 20% employee cost sharing) is
$1.69 per employee, per month (all figures from 1998, adjusted to year 2005
dollars using the NASA Inflation Calculator).7
In 2004, the private-sector cost of preventive medicine evaluation and
management averaged $107 per session; approximately 95% of paid claims fell
within the range of $45 to $165 per session.19
Treatment costs of an unintended pregnancy include the cost of termination
($428)7 or the cost of prenatal, delivery, and postpartum care and the ongoing
cost of care for the infant. The cost of labor and delivery alone ranges from
$7,3406 to $41,610 (figures in year 2003, 2005, 2001 dollars, respectively).18 The
cost of prenatal care and ongoing infant/child care varies substantially, but it can
be assumed to be significant if the child remains a beneficiary until 18 to 25
years of age.
Researchers estimate that over a 5-year period, employers can save $9,000 to
$14,000 (in year 1993 dollars) by providing comprehensive contraceptive
coverage.8 Experts suggest that employers may begin to see some savings in the
first year of coverage.8
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Contraceptive counseling is a key component of family planning. The purpose of
contraceptive counseling is to educate at-risk men and women about ways of
effectively preventing an unintended pregnancy. 
Contraceptive medications and devices reduce the occurrence of pregnancy. This
allows women and their partners to avoid, limit, or delay pregnancy. 
There are several documented benefits of contraceptive use. First, women/couples
who use contraceptives and engage in family planning have lower rates of
induced abortion. It is estimated that halving the number of women not using
contraception would reduce the number of unintended pregnancies (per year) by
one-third. The reduction in unintended pregnancies would in turn reduce the
number of abortions by 500,000 per year.6 Second, planned and properly spaced
pregnancies are associated with improved maternal and infant health outcomes:
women who wait 18 to 23 months between delivery and subsequent conception
lower their risk of adverse perinatal outcomes, including low birth weight,
preterm birth, and small for size gestational age.4-5 Finally, women who are able to
limit their fertility have improved opportunities to seek education and thus
higher earning employment. This improves individual, family, and societal
economic status.4
Contraceptives are effective and safe when used as directed (see discussion of side
effects below). Immediate use of an emergency contraceptive following
unprotected sex or a contraceptive failure can reduce the risk of unintended
pregnancy to 1% to 2%.1
Risks associated with family planning counseling have not been well
documented, but may include partner discord. There are a number of side effects
associated with contraceptives. Vaginal irritation is the most common side effect
associated with cervical condoms, caps, diaphragms, shields, spermicides, and
sponges. Other rare side effects may include urinary tract infections, vaginal
infections, and toxic shock syndrome (with prolonged use). Side effects associated
with birth control pills include headaches, breast tenderness, nausea, vomiting,
bloating, decreased sex drive (libido), and depression. Women who take birth
control pills, especially those who smoke, are also at an increased risk of heart
disease, high blood pressure, and blood clots. The major side effects of
intrauterine devices (IUDs) are abnormal vaginal bleeding and pelvic infection.20
According to the American Academy of Family Physicians (AAFP) and the
American College of Obstetricians and Gynecologists (ACOG):
• Clinicians should regularly ask all patients of reproductive age (men and
women) about contraception needs, even at office visits initiated for other
reasons.9-10 
• Clinicians should offer emergency contraception to all women who have had
unprotected sexual intercourse within 72 hours of intercourse or as otherwise
indicated.9-10 Emergency contraception should be offered in advance of need (as
a back-up method) to all women, particularly those using barrier methods of
contraception.10
Counseling should target both men and women and be inclusive of natural and
artificial, permanent and reversible techniques. Contraceptive methods
recommended by a clinician should be suited to the needs and lifestyle of
patients. 
Specific counseling methods are left to the discretion of the clinician. 
The American Academy of Family Physicians (AAFP) recommends that
clinicians9:
• Use a patient-centered strategy to help patients choose a contraceptive method,
acknowledging concerns that can interfere with adherence. 
• Inform patients about efficacy rates for different methods and recommend use
of high-efficacy options. 
• Encourage patients to call or return to the office if they experience problems
with the method chosen. 
The American Academy of Pediatrics (AAP) notes that the comprehensive health
care of adolescents should include counseling on the prevention of sexually
transmitted infections (STIs), education on contraceptive methods, and family
planning services for the sexually active patient.11 Adolescents should be strongly
encouraged to postpone the initiation of sexual intercourse. For patients already
engaged in sexual intercourse or who are contemplating having sexual
intercourse, a discussion of contraceptive methods and prevention of sexually
transmitted infections (STIs) (including HIV) is essential. For these patients the
pediatrician should support compliance, manage side effects, change the method
of contraception as circumstances require, and provide referrals and frequent
follow-up with periodic screening for STIs.11
Clinicians should prescribe contraceptive medications (e.g., birth control pill) or
devices (e.g., IUDs) or provide the appropriate surgery or intervention (e.g.,
vasectomy) to men and women who wish to limit their fertility. Because research
indicates that women and couples are more likely to use contraception
successfully if given their contraceptive method of choice,21-22 coverage of a wide
range of contraceptive options is optimal. Employers are therefore encouraged to
provide coverage for the full range of Food and Drug Administration (FDA)
approved methods of contraception including, but not limited to7:
• Hormonal medications (e.g., pills and patches) including emergency
contraceptives
• Contraceptive devices (e.g., IUD, diaphragms, vaginal rings)
• Sterilization (e.g., vasectomy, tubal ligation)
Note: Condoms play an important role in unintended pregnancy prevention and
STI prevention. Because condoms do not require a prescription they are not
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Treatment
Information
typically covered in employer-sponsored health insurance plans. While condoms
are not addressed in the 2005 IRS23 statement of qualified medical expenses for
flexible spending arrangements (FSAs), some flexible spending administrators do
consider condoms a qualified medical expense.24 Birth control pills and
sterilization are designated as qualified medical expenses by the IRS.23 Employers
who offer FSAs should alert beneficiaries to their administrator’s rules and
regulations regarding birth control, condoms, and sterilization.
Treatment for an unintended pregnancy may include either prenatal, delivery,
and postpartum care or abortion.
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
The American Academy of Family Physicians (AAFP)
Strength of Evidence: R (Recommended)
• AAFP recommends that primary care providers obtain a history of sexual
practices and provide counseling on the prevention of unintended pregnancy
and contraceptive options to all sexually active women who do not want to
become pregnant and men who do not want to have a child. Counseling
should also be provided regarding high-risk sexual behavior and the prevention
of sexually transmitted diseases and human immunodeficiency virus (HIV)
infection.9 Although evidence exists which demonstrates the net benefit of
counseling to prevent unintended pregnancy, either the benefit is only
moderate in magnitude or the evidence supporting a substantial benefit is only
fair. The intervention is perceived to be cost-effective and acceptable to most
patients.9
The American College of Obstetricians and Gynecologists (ACOG) 
Strength of Evidence: A (Recommended/Good Evidence)
• ACOG found good and consistent scientific evidence to support the provision
of emergency contraception following unprotected intercourse.10
Recommended Guidance:
The American Academy of Pediatrics (AAP)
Strength of Evidence: Not Specified
• The American Academy of Pediatrics (AAP) notes that the comprehensive
health care of adolescents should include counseling on the prevention of
sexually transmitted infections (STIs), education on contraceptive methods, and
family planning services for the sexually active patient.11 Adolescents should be
strongly encouraged to postpone the initiation of sexual intercourse. For
patients already engaged in sexual intercourse or who are contemplating having
sexual intercourse, a discussion of contraceptive methods and prevention of
sexually transmitted infections (STIs) (including HIV) is essential. For these
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patients the pediatrician should support compliance, manage side effects,
change the method of contraception as circumstances require, and provide
referrals and frequent follow-up with periodic screening for STIs.11
American College of Obstetricians and Gynecologists (ACOG)
Strength of Evidence: C (Evidence Based on Expert Opinion)
• ACOG recommends that when a woman is prescribed emergency
contraception, she should be counseled about effective contraceptive methods,
sexually transmitted diseases, and safe-sex practices.10
American Medical Association (AMA)
Strength of Evidence: Not Specified
• The AMA recommends that healthcare professionals:
1. Help women plan for pregnancy.
2. Support age-appropriate education in esteem building, decision-making
and family life, ultimately introducing the concept of planning for
childbearing into the educational process.12
Jacobs Institute of Women’s Health
Strength of Evidence: Not Specified
• Due to the side effect profile of some medications and devices, the difference
in permanence and reversibility of contraceptives, and women’s personal
preferences, employers/health plans should [cover] the full range of Food and
Drug Administration (FDA) approved contraceptive methods including, but
not limited to7:
– Hormonal medications (e.g., pills and patches)
– Contraceptive devices (e.g., IUD, diaphragms, vaginal rings, condoms)
– Sterilization (e.g., vasectomy, tubal ligation)
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• In a given year, 18.8 million American adults (9.5% of the adult population)
will suffer from a depressive illness.1
• Routine, systematic screening can successfully identify patients who are
depressed, allowing them to access care earlier in the course of their illnesses.2
• Depression is a major cause of disability, absenteeism, and productivity loss
among working-age adults.1 Depression is estimated to cause 200 million lost
workdays each year at a cost to employers of $17 to $44 billion.3
• Research suggests that 80% of patients with depression will improve with
treatment.4
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening all
adults for depression in clinical practices that have systems in place to assure
accurate diagnosis, effective treatment, and adequate follow-up.5 Although not
explicitly stated in the USPSTF recommendation statement, screening adults for
depression should be part of an overall system to improve depression recognition
and outcomes. Important system aspects include feedback, treatment advice,
education, case management, access to mental health care, telephone follow-up,
and an institutional commitment to quality improvement.5
The USPSTF found good evidence that screening 1) improves the accurate
identification of depressed patients in primary care settings and 2) that treating
depressed adults identified in primary care settings reduces clinical morbidity.
The USPSTF concluded the benefits of screening are likely to outweigh any
potential harms.5
The American Academy of Family Physicians (AAFP) concurs with the U.S.
Preventive Services Task Force recommendation.6
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• National Institutes of Mental Health (NIMH)
• U.S. Preventive Services Task Force (USPSTF)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Depression is a serious condition that affects 5% to 9% of adult patients
presenting at primary care in the United States.2 In a given year, 18.8 million

















illness. Approximately 5% to 12% of men and 10% to 25% of women will
experience a major depressive episode at some point during their lives.1
Depression is a major cause of morbidity in the United States, and it is projected
to become the leading cause of disability worldwide by 2020.3
Risk factors for depression include a family history of depression, female sex,
unemployment, and chronic disease.2
Value of Prevention
In 2000, over $83.1 billion dollars were spent on depression in the United States;
$26.1 billion dollars (31%) for direct medical costs, $5.4 billion dollars (7%) for
suicide-related mortality costs, and $51.5 billion dollars (62%) for workplace
costs.7
Depression is a major cause of disability, absenteeism, and productivity loss
among working-age adults. In a 3-month period, patients with depression miss
an average of 4.8 workdays and suffer 11.5 days of reduced productivity.1 In
total, depression is estimated to cause 200 million lost workdays each year at a
cost to employers of $17 to $44 billion.3
In addition to its direct medical and workplace costs, depression also increases
healthcare costs and lost productivity indirectly by contributing to the severity of
other costly conditions such as heart disease, diabetes, and stroke.
The economic benefits of screening mainly result from averting the lost
productivity costs associated with the disease.8 Some studies suggest that
treatment of depression may lead to decreased general medical costs, however,
conclusive evidence is not available. 
The cost of screening for depression depends on the location, provider type, and
the screening instrument used. In 2004, the private-sector cost of depression
screening averaged $23; approximately 95% of paid claims fell within the range
of $0 to $81.9
Treatment of depression in the primary care setting (based on one initial physician
visit and one follow-up visit within 3 months) costs an average of $99.68 (in year
2001 dollars). The cost of medication to treat depression varies substantially based
on the type of medication chosen. Average wholesale price (AWP) figures are noted
below for a 1-month supply of a few varieties of the FDA-approved selective-
serotonin-reuptake-inhibitors (SSRIs) commonly used to treat depression.10
Drug Name 2006 Average Wholesale Price (AWP)
Generic Brand
fluoxetine/Prozac® $74.35 (20 mg) $138.91 to $277.82
paroxetine/Paxil® $92.50 to $105.02 $72.90 to $81.00

















The total cost of treatment should consider treatment-related cost-offsets due to
the reduction of lost productivity, absenteeism, and other factors. For example,
the indirect cost associated with an employee who is treated for depression
(extrapolated from lost work days/time for medical appointments, etc) over a 3
month period averages $400, whereas the indirect cost associated with a
depressed employee who does not receive treatment (extrapolated from sick days,
etc) averages $840 over a 3 month period.1 If benefits of treatment on work
impairment are taken into account, the estimated cost-savings would exceed the
average treatment cost of depression.8
The cost-effectiveness of screening is sensitive to screening costs and achievable
depression remission rates. Based on an economic modeling approach, one study
found that one-time depression screening had a relatively low cost per quality-
adjusted life year gained compared to no screening. However, neither annual nor
periodic screening for depression were found to be cost-effective in comparison
to preventive service benchmarks.1
Preventive Intervention Information
Screening for depression identifies patients suffering from depression, allowing
them to access care earlier in the course of their illness. Research suggests that
80% of patients with depression will improve with treatment.4 The USPSTF
found evidence that patient outcomes improve significantly when depression
recognition and management are integrated.2 Yet despite the value of screening, it
is infrequently conducted, and hence, primary care physicians fail to identify
30% to 50% of patients suffering from depression.5
Risks of screening include false-positive results, which can lead to additional
testing, incurring further costs and inconvenience. Patients may also suffer some
negative effects after being labeled as depressed. However, the USPSTF felt that
these potential risks were likely outweighed by the benefits of screening.11
There is insufficient evidence to determine the optimal ages at which to begin
and cease depression screening. Thus, experts agree that depression screening
should be initiated and stopped when deemed appropriate by the clinician. 
Evidence is also insufficient to determine the optimal interval of screening. Thus,
clinicians are encouraged to use their judgment in deciding how frequently to
screen patients for depression. The USPSTF notes that recurrent screening is
most likely to benefit patients with a history of depression, unexplained somatic
symptoms, chronic pain or other comorbid psychological conditions such as
anxiety, panic attack, or substance abuse.11
The USPSTF found insufficient evidence to recommend for or against
depression screening among children or adolescents in primary care settings.
However, the USPSTF encourages physicians to remain alert for signs of
depression in these populations and to treat or refer to specialty care as
appropriate.2
While the USPSTF did not recommend screening adolescents for depression,
new evidence shows that the benefits of screening in the adolescent population
may outweigh the risks involved. A recent randomized controlled trial of high-
school students showed that screening adolescents for depression with a
standardized screening instrument did not increase suicidal ideation (thoughts or
fantasies about committing suicide) or increase feelings of discomfort.
Surprisingly, depressed students reported less distress at being asked questions
about suicidal ideation than did non-depressed students. Identifying adolescents
with suicidal ideation is an important part of youth suicide prevention.12
Providers need to be aware that the signs and symptoms of depression in
adolescents are different from those in adult populations.
Several depression screening tools, called instruments, are currently available for
use in the primary care setting. These instruments are composed of standardized
questions that assess the number and severity of a patient’s depression symptoms.
Clinicians can then interpret the results to make a diagnosis of depression and to
develop a treatment plan. Evidence is mixed as to what instrument or method is
most effective in accurately identifying patients with depression, but most
instruments seem to have an adequate level of sensitivity and specificity.
Commonly used instruments, such as the Patient Health Questionnaire-9, are
simple to administer and take less than 5 to 10 minutes for a patient or provider
to complete.5
The USPTF recommends that physicians choose their preferred method of
screening based on their patient population and practice setting.2 Clinicians who
do not use a standardized instrument to screen for depression may want to ask
their patients the two questions below to assess their mental health status. These
may be as effective as using longer screening tools.2
1. Over the past two weeks, have you ever felt down, depressed, or hopeless? 
2. Over the past two weeks, have you felt little interest or pleasure in doing
things?
Positive responses to these questions or positive responses to questions on a short
standardized screening test should trigger a full diagnostic interview by the
clinician so that they may identify the specific depressive symptoms experienced
by the patient and make an accurate diagnosis.2 The USPSTF recommends that
clinicians use standard diagnostic criteria, such as those featured in the
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).11
The process used in screening patients for depression is important. Screening
adults for depression in clinical practices that have well functioning systems in
place to assure accurate diagnosis, effective treatment, and careful follow-up, are
more likely to produce benefits.2 The USPSTF found several other clinically
relevant factors pertinent to successful depression screening processes. For
information on these factors please refer the USPSTF website
(www.ahrq.gov/clinic/uspstf/uspsdepr.htm).
Implementing a systematic depression screening program in a clinical practice




of patients treated for depression. It is important to remember that not all of the
patients who screen positive for depression will be diagnosed with depression. 
Considering the prevalence of depression in the primary care setting, it can be
expected that 25% to 40% of patients who screen positive for depression will
actually have depression.2
• Many screened patients will have screened false-positive, meaning that
although they screened positive for depression, they are not actually depressed.
These patients do not require treatment. 
• Some patients who screen positive for depression may suffer from depressive
illnesses other than major depression, such as adjustment reactions with
depression or grief reactions, and these patients may benefit from monitoring.  
• Some of the patients who screen positive for depression may have, in addition
to or in place of depression, another psychological disorder such as anxiety
disorder, panic attack, post-traumatic stress disorder (PTSD), obsessive-
compulsive disorder (OCD), a substance abuse disorder, or another type of
mental health condition. Physicians should refer these patients to a mental
health specialist. 
Because of the complexities involved in screening for depression, the USPSTF
recommends that clinicians follow-up all positive screens with further diagnostic
work, including a full diagnostic interview such as that featured in the DSM-IV.11
Health benefits should include provisions for diagnostic and treatment services.
Most patients with depression present and are treated in the primary care setting.
While depression is one of the most common disorders seen by primary care
providers, research shows that the standard of care delivered is poor. In the
primary care setting, 35% to 70% of patients with depression do not receive an
appropriate diagnosis or adequate treatment.1
Patients who screen positive for depression and are diagnosed with depression as
confirmed by the DSM-IV diagnostic interview should 1) begin treatment in the
primary care or specialty mental healthcare setting or 2) be referred for treatment
to a mental health professional. A primary care treatment plan can include
pharmacological therapy (tricyclic anti depressants and selective-serotonin-
reuptake-inhibitors [SSRIs], are proven to be effective in the treatment of major
depression) psychotherapy, or a combination of the two.11
Current research points to a number of successful identification and disease-
management techniques for addressing depression in primary care. Experts note
that routine, systematic screening can successfully identify patients who are
depressed. Patients who are identified in primary care settings as suffering from
depression or other mental health conditions, can often benefit from referral to a
mental health specialist. Depressed patients may also benefit from collaborative
care; an approach to care that pairs a mental health specialist with a primary care
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EVIDENCE-STATEMENT: Depression (Screening)
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found good evidence to support screening all adults for
depression in clinical practices that have systems in place (such as a referral
system, on-site mental health provider, or other mental health resources) to
assure accurate diagnosis, effective treatment, and adequate follow-up.5 
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• Diabetes affects over 21 million Americans, 7% of the United States
population.1 In addition, 41 million adults aged 40 to 74 have prediabetes, a
condition that increases the risk of diabetes, heart disease, and stroke.1-2
• Alarmingly, the prevalence of type 2 diabetes and gestational diabetes has
increased 61% in United States since 1990.3
• Diabetes is a major cause of premature morbidity, disability, and death. In
addition to being a direct cause of death, uncontrolled diabetes can cause heart
disease, stroke, blindness, kidney failure, pregnancy complications, and
amputations of toes, feet, or legs.
• The total annual economic burden of diabetes in the United States exceeds
$132 billion dollars.4
• Diabetes is among the top 10 most costly physical health conditions for
employers in various industries in terms of direct medical expenditures,
absenteeism, short-term disability, and presentism.5
• In 2002, the average annual healthcare cost for a person with diabetes was
$13,243 as opposed to $2,560 for a person without diabetes.4
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening for
type 2 diabetes in adults with hypertension (high blood pressure) or
hyperlipidemia (high cholesterol).6
The USPSTF found good evidence that, in adults who have hypertension and
clinically detected diabetes, lowering blood pressure below conventional target
blood pressure values reduces the incidence of cardiovascular events and
cardiovascular mortality; this evidence is considered fair when extrapolated to
cases of diabetes detected by screening. Among patients with hyperlipidemia,
there is good evidence that detecting diabetes substantially improves estimates of
individual risk for coronary heart disease, which is an integral part of decisions
about lipid-lowering therapy.6
Note: the USPSTF found insufficient evidence to support a recommendation for
or against universal screening of adults for diabetes. 
The American Diabetes Association (ADA) recommends that adults at normal
risk for diabetes be screened at 3-year intervals for prediabetes and diabetes
beginning at age 45.  Adults at high risk (based on a family history of the disease,
overweight or obesity, or other factors; see condition/disease risk factor section
below) should be screened at a younger age or screened more frequently (1 to 2
year intervals).7
Expert Opinion 
The American Association of Clinical Endocrinologists (AACE) recommends










The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Healthcare Research and Quality (AHRQ)
• American Association of Clinical Endocrinologists (AACE)
• American Diabetes Association (ADA)
• Centers for Disease Control and Prevention (CDC)
• Center for Medicare & Medicaid Services (CMS)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Diabetes is divided into 3 types: type 1 diabetes (previously referred to as
“juvenile” diabetes), type 2 diabetes (previously referred to as “adult-onset”
diabetes), and gestational diabetes (a form of diabetes that occurs only during
pregnancy). 
In the past, type 1 diabetes typically affected young people who had few
symptoms or signs of the disease before experiencing an abrupt onset, type 2
diabetes primarily affected adults, and gestational diabetes affected pregnant
women and indicated a higher-than-average risk for type 2 diabetes. While the
epidemiological profiles of type 1 diabetes and gestational diabetes have remained
constant, the profile of type 2 diabetes has changed dramatically in recent years.
Type 2 diabetes used to be an adult-onset disorder; now type 2 diabetes affects
children, adolescents, and young adults as well.
Since the onset of type 1 diabetes is usually relatively sudden and associated with
symptoms that require care, screening for type 1 diabetes has not been considered
useful. 
Type 2 diabetes, on the other hand, has a longer asymptomatic phase. Early
recognition and intervention can forestall its onset and may even prevent its
emergence. For reasons not completely understood, but seemingly related (at
least in part) to obesity, changing dietary habits, and levels of physical activity,
the incidence of type 2 diabetes is increasing. It is also being identified at
younger and younger ages.
Type 2 diabetes (hereafter referred to as diabetes) affects over 21 million Americans
(7% of the United States population) and more than 6 million Americans with







prediabetes, a condition that increases the risk of diabetes, heart disease, and
stroke.1-2 People with prediabetes have a high blood sugar level but not high
enough to be classified as diabetes. Many people with prediabetes will develop
clinical diabetes.  Alarmingly, the prevalence of type 2 diabetes (including
gestational diabetes) in the United States has increased 61% since 1990.3
Diabetes is a major cause of premature morbidity and disability, and
uncontrolled diabetes can cause death. Diabetes is the sixth leading cause of
death in the United States — each year 200,000 Americans die of complications
resulting from the disease.1
Death rates are about 2 to 4 times higher for adults with diabetes than for those
without the disease.2 Heart disease and stroke are leading causes of diabetes-
related deaths. Uncontrolled diabetes can also cause blindness, neurologic
problems, kidney failure, pregnancy complications, and amputations of toes, feet,
or legs. Persons with diabetes are at higher risk of acquiring influenza and
pneumonia, which are additional causes of disproportionate death among
diabetics. Each year, 12,000 to 24,000 people become blind, 42,813 have kidney
failure, and 82,000 have leg, foot, or toe amputations.2
Diabetes disproportionately affects women, older adults, and certain racial and
ethnic groups, such as African-Americans, Hispanics, and American Indians/
Alaska Natives. One in five adults older than 65 has diabetes.
The risk of developing type 2 diabetes increases with8:
• Cardiovascular disease, high cholesterol levels, or both
• Hypertension
• High levels of triglycerides
• Low concentrations of high-density lipoprotein
• Family history of diabetes
• Impaired glucose tolerance or impaired fasting glucose
• Hispanic, African-American, Asian American, Native American, or Pacific
Islander race or ethnicity
• BMI over 25kg/m2 and/or central obesity
• History of gestational diabetes
• Delivery of a baby weighing more than 9 pounds (4 kg)
• Polycystic ovary syndrome
• Sedentary lifestyle
Value of Prevention*
The estimated direct and indirect costs for diabetes care in 2002 totaled $132
billion4, 11% of the national health care expenditures for 2002. Diabetes is among
the costliest physical health conditions in terms of total medical costs9-11 and
productivity losses.4,9,12 In 2002, the average annual healthcare cost for a person
with diabetes was $13,243 as opposed to $2,560 for a person without diabetes.4
Diabetes is among the top 10 most costly physical health conditions for
employers in various industries in terms of direct medical expenditures,
absenteeism, short-term disability, and presentism.5 If pharmaceutical
expenditures, costs related to absenteeism, and claims for short-term disability are
combined with medical expenditures, diabetes ranks as the third most costly
physical health condition for employers.13 In addition, diabetes-related
prescriptions rank in the top 2 treatment expenses for employers based on 1997-
1999 claims data for inpatient and outpatient costs.13
Employees with diabetes who reduce their glycemic levels (the way your body’s
sugar level responds to certain foods) demonstrate short-term (4 to 5 months)
health outcomes (quality of life improvements), work-related outcomes (reduced
absenteeism and increased productivity), and cost-savings through reduced
hospital visits.14 Sustaining reduced glycemic levels for 1 year reduces primary and
specialty care visits and is associated with (longer-term) cost-savings within 1 to 2
years of improvement.15 Therefore, reduced glycemic levels in persons with
diabetes has short- and long-term direct and indirect economic benefits. 
More than 30% of employer costs associated with employees who have diabetes
are attributable to medically related absences or disability.16 Diabetes may affect
the number of disability claims and the length of disability claims.16-18 When
stratified by age, total medical and productivity costs for beneficiaries with
diabetes range from $2,589 for those younger than 18 years to $8,568 for those
aged 56 through 64 years (in year 1998 dollars).16
People with diabetes lose income as a result of missing work and disability.  The
average annual earnings loss (in year 1994 dollars) for a person with diabetes is
estimated at $4,306 for men and $1,865 for women.12 In 1998 dollars, medically
related work loss cost employees with diabetes an estimated $1,121 for those
aged 18 through 35 years, $1,448 for those aged 36 through 45 years, $1,467 for
those aged 46 through 55 years, and $1,095 for those aged 56 through 64 years.16
The Diabetes Prevention Program (DPP) showed that lifestyle interventions
delayed the development of diabetes by 11 years and reduced the absolute
incidence by 20%.19 Metformin, an oral medication, delayed the development of
diabetes by 3 years and reduced the absolute incidence by 8% (compared to a
placebo). The cost was $1,100 per quality-adjusted life year (QALY) for the lifestyle
intervention and $31,300 for the metformin intervention. The lifestyle
intervention included a weight reduction goal of at least 7% of initial body weight
through a healthy, low-fat, lower calorie diet; and physical activity of moderate
intensity (brisk walking) for at least 150 minutes/week. A 16 lesson curriculum was
developed and group and individual sessions were designed to reinforce changes.19
The cost of screening for type 2 diabetes varies by location and provider.  In
2004, the private-sector cost of diabetes screening averaged $15 (range $0 to
$40).20 However, this is a rough average: one or two follow-up visits may be
























Benefits and Risks 
of Intervention
From the health system perspective, the cost of a metformin intervention
(compared to placebo) is $2,191/participant over 3 years; the cost of a lifestyle
intervention (compared to placebo) is $2,269/participant over 3 years.19 It is
significant to note that although the lifestyle intervention costs about 37% more
than the metformin in year 1, the lifestyle intervention costs about 12% and 7%
less than metformin intervention in years 2 and 3. Therefore, the cost of lifestyle
intervention relative to metformin intervention would decrease with follow-up
beyond 3 years.19
It is cost-effective to screen people with hypertension in all age groups for type 2
diabetes. It is even more cost-effective to screen people with hypertension aged
55 to 75 years.21 In year 1997 dollars, the cost per quality-adjusted life year
(QALY) for targeted screening (compared to no screening) at age 55 was
estimated to be $34,375. In comparison to other preventive interventions and to
commonly accepted cost-effectiveness benchmarks, diabetes screening is cost-
effective.22 In general, opportunistic screening (i.e., screening patients during
routine healthcare encounters) is more cost-effective than universal or population
screening, and targeted screening (i.e., screening people with particular health
risk factors, such as hypertension) is the most cost-effective.21
Preventive Intervention Information
Screening is meant to identify individuals with diabetes and individuals at high
risk of diabetes. Intervention may delay the onset of diabetes and its
complications among individuals at high-risk.1 Early detection by screening
allows clinicians to suggest a variety of interventions during the preclinical
period, including tight glycemic control; intensive use of antihypertensive agents;
aggressive use of lipid treatment and aspirin; foot care programs; and
improvements in diet, increases in physical activity, and cessation of tobacco use.
The efficacy of early interventions is affected by numerous variables, such as the
relationship between the intervention and the timing of the specific
complication: some complications typically occur early in the disease process
(e.g., cardiovascular disease) and some occur late in the process (e.g., blindness).23
The USPSTF found that people at risk for cardiovascular disease benefit most from
diabetes screening. Screening people with hypertension or hyperlipidemia for type
2 diabetes allows the disease to be diagnosed and treated before it causes certain
complications. Evidence shows that people with hypertension and type 2 diabetes
can reduce their risk of cardiovascular disease by reducing their blood pressure to a
level below that recommended for people with hypertension but without diabetes.
People with hyperlipidemia and type 2 diabetes can lower their risk of cardiovascular
disease by beginning lipid-lowering therapy in combination with diabetes treatment.24
Few studies have examined the harmful effects of screening asymptomatic people
for diabetes. As with all screening tests, there is a risk of false-positive results.
False-positive results have the potential to cause harmful effects including a
negative change in self-perception, undue stress and anxiety, risk of loss of
insurability (life insurance or health insurance), and the risk of beginning




The USPSTF found insufficient evidence in order to determine whether adults
without hypertension or hyperlipidemia should be screened for diabetes.
Therefore, when to screen individual patients is a matter of clinical judgment and
patient preference. 
Patients at increased risk for cardiovascular disease may benefit the most from
screening for type 2 diabetes, since effective management of cardiovascular risk
factors leads to reductions in major adverse cardiovascular events. For adult
patients with diagnosed hypertension or hyperlipidemia, diabetes screening
should be part of an integrated approach to reduce cardiovascular risk.24
American Diabetes Association
While acknowledging the insufficiency of evidence regarding the benefits of
screening, the ADA recommends (on the basis of expert opinion) that adults at
normal risk for diabetes should be screened at 3-year intervals for prediabetes and
diabetes beginning at age 45.  Adults at high risk (based on a family history of
the disease, overweight or obesity, or other factors) should be screened at a
younger age or screened more frequently (1 to 2 year intervals).7
There is no universally accepted interval for type 2 diabetes screening of healthy
adults or adults with hypertension or hyperlipidemia. The ADA recommends
that adults at normal risk for diabetes undergo screening every 3 years and adults
at high-risk of diabetes undergo screening every 1 to 2 years.7
CMS Coverage 
As of September 2006, the Centers for Medicare and Medicaid Services (CMS)
covers screening tests for diabetes. This is significant because CMS’s decisions
frequently influence other managed care policies. Some employers also provide
healthcare insurance to retirees eligible for Medicare.  The CMS policy covers the
following25:
• Two screening tests per year for individuals with diagnosed prediabetes (not
less than 6 months apart).
• For those who are not diabetic or have not previously been diagnosed as pre-
diabetic, Medicare covers one diabetes screening test within a 12-month period
(or that at least 11 months have passed following the month in which the last
Medicare covered diabetes screening test was performed).
Covered tests are the fasting blood glucose (FBG) test and the Oral Glucose
Tolerance Test (OGTT). 
Individuals who have any one of the following risk factors for diabetes are eligible
for the CMS benefit:
• Hypertension (high blood pressure)









• Obesity (a body mass index equal to or greater than 30 kg/m2)
• Elevated impaired fasting glucose intolerance
Also eligible for the CMS benefit are individuals who have at least two of the
following characteristics: 
• Overweight (a body mass index >25 but <30 kg/m2
• A family history of diabetes
• Age 65 or older
• A history of gestational diabetes
• Delivery of a baby weighing more than 9 lbs
Screening requires a blood glucose test. Several tests are appropriate and should
be used at the discretion of the physician, they include the fasting plasma glucose
test (FPG), the 2-hour post-load plasma glucose test, and the oral glucose
tolerance test (OGTT). 
Health benefits should include provisions for diagnostic, follow-up, and
treatment services. 
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found at least fair evidence that the benefits of screening adults
with hypertension or hyperlipidemia for diabetes outweigh the associated risks
and costs. 
Recommended Guidance:
The American Diabetes Association (ADA) 
Strength of Evidence: Expert Opinion
• The ADA recommends that adults at normal risk for diabetes be screened at 
3-year intervals for prediabetes and diabetes beginning at age 45. Adults at
high risk (based on a family history of the disease, overweight or obesity, or
other factors) should be screened at a younger age or screened more frequently
(1-2 year intervals).7
The American Association of Clinical Endocrinologists (AACE) 
Strength of Evidence: Expert Opinion
• The AACE recommends targeted screening, beginning at age 30, for people at
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• Four of the 10 leading causes of death in the United States — coronary heart
disease, some types of cancer, stroke, and type 2 diabetes — are associated with
an unhealthy diet.1 More than half of all deaths in 1994 were attributable to
these four diseases.
• Diet also contributes significantly to the development of high cholesterol, high
blood pressure, and overweight. These health conditions are associated with
considerable medical expenses, disability, and premature deaths.2
• The total cost attributable to diet-associated coronary heart disease, cancer,
stroke, and diabetes is estimated to be $70.9 billion (in year 1995 dollars).2-3
Direct medical costs account for nearly half (47%) of this total; premature
deaths account for 39% and lost productivity accounts for 13% of the
remainder.2-3 Diet-related osteoporosis and hip fractures cost an additional $5.1
to $10.6 billion each year (in year 1995 dollars).4
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force recommends intensive behavioral dietary
counseling for adults with hyperlipidemia (lipid disorders) and other known risk
factors for cardiovascular and diet-related chronic diseases. Intensive counseling
can be delivered by primary care clinicians or specialists such as nutritionists and
dieticians.3
The USPSTF found good evidence that medium- to high-intensity counseling
interventions can produce medium to large changes in average daily intake of the
core components of a healthy diet (including reduced consumption of saturated
fat and increased consumption of fiber, fruits, and vegetables) in adult patients at
increased risk of diet-related chronic diseases.3
Controlled clinical trials have assessed intensive counseling interventions for at-
risk adult patients. The trials involved combined nutrition education with
behavioral dietary counseling provided by a nutritionist, dietician, or specially
trained primary care clinician. The USPSTF concluded that such counseling is
likely to improve important health outcomes and that its benefits outweigh its
potential harms. No controlled trials of intensive counseling in children or
adolescents were identified that measure effective dietary counseling in the
primary care setting.3
Dietary guidelines for the general population have been issued by the U.S.
Department of Agriculture and the Department of Health and Human Services5
and specific dietary objectives for the nation are outlined in Healthy People 2010.6
Guidelines from the American Heart Association7 address diets that lower the
risks for heart disease, and the American Cancer Association8 has issued
guidelines on diet and cancer. All of these agencies and organizations recommend
a diet that includes a variety of fruits, vegetables, and grains; is low in saturated
fat and cholesterol and moderate in total fat; and balances calories with physical
activity to maintain a healthy weight.




EVIDENCE-STATEMENT: Healthy Diet (Counseling)
Information Sources
patients at average risk of chronic disease, including the American College of
Preventive Medicine (ACPM), American Academy of Family Physicians (AAFP),
American Academy of Pediatrics (AAP), and American College of Obstetricians
and Gynecologists (ACOG).9-12 These recommendations are based primarily on
the benefits of a healthy diet rather than on evaluations of counseling efficacy.13
Recommendations on nutritional counseling for patients at risk of diet-related
chronic diseases (e.g., persons with hypertension or hyperlipidemia) have been
issued by the American Dietetic Association and two panels sponsored by the
National Heart, Lung and Blood Institute (NHLBI). The American Dietetic
Association recommends that primary care providers screen all patients for
nutrition-related illnesses and, for patients with positive screening results,
prescribe diets, provide preliminary counseling on specific nutritional needs,
follow up with the patients, and refer them to appropriate dietetic professionals
when necessary.14 Similarly, the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of High Blood Pressure recommends that
dietary assessments be included in routine medical histories and that patients at
risk of diet-related chronic diseases should be counseled about  lifestyle
modifications to prevent and treat high blood pressure; the lifestyle changes
emphasize weight loss for those overweight, limiting alcohol intake, reducing
sodium consumption, and reducing intake of saturated fat and cholesterol.15
The National Cholesterol Education Program (NCEP) recommends that 
persons with elevated levels of low-density lipoprotein limit their intake of fats,
particularly saturated fats and cholesterol, and increase their intake of dietary
fiber.16
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics  (AAP)
• American College of Obstetricians and Gynecologists  (ACOG)
• American College of Preventive Medicine (ACPM)
• American Dietetic Association 
• American Heart Association (AHA)
• Healthy People 2010
• Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure 
• National Cancer Institute (NCI)
• National Cholesterol Education Program (NCEP)
• National Institutes of Health  (NIH)
• National Heart, Lung, and Blood Institute (NHLBI)
• Peer-reviewed Research
• U.S. Department of Agriculture (USDA)
• U.S. Department of Health and Human Services (USDHHS)
• U.S. Preventive Services Task Force (USPSTF)
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The background and supporting information in this document is based on a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of the opinions of other organizations cited in the text. 
Condition/Disease-Specific Information
The relationship between dietary patterns and health outcomes has been examined
in a wide range of observational studies and randomized trials with patients at risk
of diet-related chronic disease. The majority of these studies have shown that
people who consume diets that are low in fat, saturated fat, trans-fatty acids, and
cholesterol and high in fruits, vegetables, and whole-grain products containing
fiber have lower rates of morbidity and mortality from coronary heart disease and,
possibly, several forms of cancer than those who consume unhealthy diets.17 In
fact, 4 of the 10 leading causes of death — coronary heart disease, some types of
cancer, stroke, and type 2 diabetes — are associated with unhealthy diets.1
Lipid Disorders 
Nearly 107 million American adults (50.7% of the adult population) have a total
blood cholesterol value of 200 mg/dl or above, and 37.7 million of these adults
(18.3%) have a total blood cholesterol level of 240 mg/dl or above.18 A reading of
less than 200 mg/dl is considered desirable and a reading of 240 mg/dl or more is
considered high.
Obesity
Obesity is epidemic in the United States. Between 1976 to 1980 and 1999 to
2002, the proportion of obese adults doubled, the proportion of overweight
children (aged 6 to 11) doubled, and the proportion of overweight adolescents
(aged 12 to 19) tripled.19 Approximately half to two-thirds of obese adults have
diabetes, high blood pressure, coronary artery disease, high cholesterol, or a
combination of these conditions.20
Both lipid disorders and obesity are risk factors for cardiovascular diseases,
including coronary heart disease and coronary artery disease.
Cardiovascular Disease
Coronary heart disease, a cardiovascular disease, is caused by arteriosclerosis (a
thickening or hardening of the arteries) and can lead to angina pectoris (heart pain),
heart attack, or both. An estimated 1.5 million adults have a heart attack each year
in the United States. The American Heart Association estimates that 13.9 million
adults have a history of coronary heart disease and about every minute, someone
dies from a heart attack.18 Arteriosclerosis is particularly sensitive to lipid levels. 
Alcohol and caffeine use and insufficient calcium or vitamin D intake are also
risk factors for osteoporosis. Please refer to the Osteoporosis Screening and
Treatment Evidence-Statement for additional information. 
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The American Cancer Society estimates that almost 1.4 million new cases of
cancer will develop in 2006.8 About one-third of the 564,830 deaths expected to
result from cancer in 2006 are related to diet, physical inactivity, and overweight
or obesity and are thus preventable.8
To reduce the risk of morbidity and mortality from coronary heart disease and to
maintain a healthy weight, it is necessary to eat a healthy diet and to balance
calories consumed with physical activity.3 A healthy eating plan is one that
emphasizes fruits, vegetables, whole grains, and fat-free or low-fat milk and milk
products; includes lean meats, poultry, fish, beans, eggs, and nuts; is low in
saturated fats, trans-fats, cholesterol, salt (sodium), and added sugars; and balances
caloric intake with caloric needs. The Federal publication, Nutrition and Your
Health: Dietary Guidelines for Americans provides a good source of dietary advice21:
• Consume a variety of nutrient-dense foods and beverages within and among
the basic food groups while choosing foods that limit the intake of saturated
and trans-fats, cholesterol, added sugars, salt, and alcohol. 
• Meet recommended intake of calories within energy needs by adopting a
balanced eating pattern, such as the U.S. Department of Agriculture’s Food
Guide or the Dietary Approaches to Stop Hypertension (DASH) eating plan.
• Maintain a diet with less than 10% of calories from saturated fat, no more than
30% of calories from total fat, and limited consumption of trans-fatty acids.
Consuming a healthy diet is associated with a reduced risk of chronic disease
morbidity and mortality. 
Value of Prevention
Unhealthy diets contribute to several diseases that impose a heavy economic
burden on employers and employees. 
The total cost attributable to diet-associated coronary heart disease, cancer,
stroke, and diabetes is estimated to be $70.9 billion (in year 1995 dollars).2-3
Direct medical costs account for nearly half (47%) of this total; premature deaths
account for 39% and lost productivity accounts for 13% of the remainder.2-3
Diet-related osteoporosis and hip fractures cost an additional $5.1 to $10.6
billion each year (in year 1995 dollars).4
Productivity losses due to unhealthy diet-associated morbidity from coronary
heart disease, cancer, stroke, and diabetes cost $9.3 billion (in 1995 dollars) per
year.2-3
The cost to employers of obesity-related health problems in 1994 was $13 billion
per year, including $8 billion in medical claims, $2.4 billion in paid sick leave,
$1.8 billion in life insurance, and almost $1 billion in disability insurance.22 In
addition, an estimated 39 million workdays are lost to obesity-related illnesses
each year.23
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Benefits and Risks 
of Intervention
A randomized controlled trial of a low-cost healthy nutrition education program
in the California Public Employee’s Retirement System found a cost savings of
20% over 12 months.24
The Massachusetts Dietetic Association found that diet modification and
counseling for hypercholesterolemia by a registered dietitian saved an estimated
$1,300 per patient, per year.25
In 2004, the private-sector cost of preventive medicine counseling by a physician
averaged $39 per session; approximately 95% of all paid claims fell within the
rage of $0 to $129 per session.26 Nutritional counseling by a dietician averaged
$61 per session and approximately 95% of all paid claims fell within the range of
$0 to $150 per session.26
Nutrition education from the expanded Food and Nutrition Education Program,
administered by the U.S. Department of Agriculture, helps limited-resource
populations acquire the knowledge, skills, and attitudes, and make the behavior
changes necessary for nutritionally sound diets. The benefit-to-cost ratio of
$10.64/$1.00 for a Food and Nutrition Education Program in Virginia27 and
$10.75/$1.00 in Iowa28 shows that nutrition counseling can produce a significant
return-on-investment (ROI).
Another study found that an intensive nutrition intervention in patients with
type 2 diabetes had a cost-effectiveness ratio of $4.20, while the cost-effectiveness
ratio of usual nutrition care was $5.32.29-30
Some evidence indicates that lifestyle interventions may be more cost-effective
than drug treatments for some diet-related chronic illnesses.31
Preventive Intervention Information
Behavioral counseling can help persons at high risk of cardiovascular disease and
other diet-related chronic diseases improve their diets and thereby reduce their
risk of the poor outcomes and complications associated with obesity, lipid
disorders, and coronary heart disease.3
Medium- to high-intensity behavioral interventions appear to produce consistent,
sustained, and clinically important changes in dietary intake of total fat, saturated
fat, fruits, vegetables, and fiber.3 It is important to note that the studies
supporting these benefits were conducted in patients with known risk factors for
diet-related chronic disease or in special clinics with select patients and specially
trained providers. The most effective interventions generally combined education,
behavior-oriented counseling, patient reinforcement, and follow-up. More
intensive interventions and those of longer duration were associated with greater
benefits and more sustained changes in diet.3 The largest effects of dietary
counseling in asymptomatic adults with hyperlipidemia or hypertension and
those at increased risk of diet-related chronic disease have been observed with
more intensive interventions (multiple sessions lasting 30 minutes or longer).3
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Two other approaches appear promising for adult patients in primary care
settings3: 
1. Medium-intensity face-to-face dietary counseling (two to three group or
individual sessions) delivered by a dietitian or nutritionist or by a specially
trained primary care physician or nurse practitioner. 
2. Lower intensity interventions that involve 5 minutes or less of counseling by a
primary care provider and are supplemented by patient self-help materials,
telephone counseling, or other interactive health communications.
However, more research is needed to assess the long-term efficacy of these
treatments and to balance the benefits and harms.3
Possible harms of dietary counseling have not been well-defined or measured.
Some researchers have suggested that a focus on reducing total fat intake but not
reducing caloric intake might lead to an increased intake of carbohydrates (in the
form of reduced-fat or low-fat food products), which could result in weight gain,
elevated triglyceride levels, or insulin resistance.3
Little is known about effective dietary counseling for children or adolescents in
the primary care setting. Most studies of nutritional interventions in these
populations have focused on non-clinical settings, such as schools, or have used
physiologic outcomes, such as cholesterol level or weight reduction, rather than
indicators of a healthy diet, such as intakes of total and saturated fats.32-33
The USPSTF was not able to determine the ideal frequency of counseling. Other
research has indicated that intensive counseling (30 to 45 minutes in duration)
can reasonably be conducted at baseline, 3 months after the initial intervention,
and every 6 months thereafter, as medically indicated. Thus, in any given
calendar year, 3 counseling sessions could be provided.34
Decisions about behavioral counseling should take into account the overall risk
for coronary heart disease. Risk assessment should consider age, sex, and the
presence and severity of the following risk factors: diabetes, elevated total
cholesterol levels, low levels of high density lipoprotein cholesterol, elevated
blood pressure, family history (in younger adults), and smoking.3
Effective interventions include individual or group counseling, which can be
delivered by nutritionists, dietitians, specially trained primary care practitioners
and health educators in the primary care setting, or in other clinical settings by
referral.3
Effective interventions combine nutrition education with behavior-oriented
counseling to help patients acquire the skills, motivation, and support needed to
alter their daily eating and food preparation practices. Examples of behavior-
oriented counseling interventions include teaching self-monitoring, training
patients to overcome common barriers to selecting a healthy diet, helping
patients set their own goals, providing guidance in shopping and food
preparation, engaging in role playing with patients, and arranging for social










• Assess dietary practices and related risk factors.
• Advise patients to change dietary practices.
• Agree on individual diet change goals.
• Assist patients in changing their dietary practices or addressing motivational
barriers.
• Arrange regular follow-up and support or refer patients to more intensive
behavioral nutritional counseling (e.g., medical nutrition therapy) if needed.5,20
Systems supports (prompts, reminders, and counseling algorithms) for primary
care clinicians have been found to significantly improve their delivery of
appropriate dietary counseling.36-38
Initial assessments and follow-up monitoring can be conducted using any of
several brief dietary assessment questionnaires, which have been validated for use
in the primary care setting.39 These instruments identify dietary counseling needs,
guide interventions, and monitor changes in patients’ dietary patterns. Since
patients enrolled in diet-change programs may exaggerate their adherence the
programs, clinicians may not wish to rely on brief dietary assessment
questionnaires but may find them useful to verify self-reported information.21, 40-42
Not Applicable
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research: 
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/ At Least Fair Evidence)
• The U.S. Preventive Services Task Force found good evidence to recommend
intensive behavioral dietary counseling for adult patients with hyperlipidemia
(lipid disorders) and other known risk factors for cardiovascular and diet-
related chronic disease. Intensive counseling may be delivered by primary care
clinicians or by referral to other specialists, such as nutritionists or dieticians.3
Recommended Guidance:
American Dietetic Association
Strength of Evidence: Not Specified
• The American Dietetic Association recommends that primary care providers
screen all patients for nutrition-related illnesses and, for patients with positive
screening results, prescribe diets, provide preliminary counseling on specific
nutritional needs, follow up with the patients, and refer them to appropriate
dietetic professionals when necessary.14
Joint National Committee on Prevention, Detection, Evaluation and Treatment
of High Blood Pressure
Strength of Evidence: Not Specified
• The Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure recommends that dietary assessments be
included as part of a routine medical history and that physicians counsel
patients on lifestyle modifications for the prevention and treatment of high
blood pressure (lose weight if overweight, limit alcohol intake, reduce sodium
intake, reduce saturated fat and cholesterol intake).15
The National Cholesterol Education Program (NCEP)
Strength of Evidence: Not Specified
• The National Cholesterol Education Program recommends that persons with
elevated levels of low-density lipoprotein limit their intake of fats, particularly
saturated fats, and cholesterol and increase their intake of dietary fiber.16
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Alcohol Misuse (Screening and Counseling): 
• Fetal exposure to alcohol during pregnancy is one of the leading causes of
preventable birth defects, mental retardation, and developmental disorders in
the United States.1
• In 2003, 10% of pregnant women reported alcohol use, including 4% who
reported binge drinking.2 Approximately 55% of women of childbearing-age
age drink alcohol and 12% report binge drinking on one or more occasions in
the past month.2 Because half of all pregnancies in the United States are
unintended, many women of childbearing-age who use or abuse alcohol are at
risk of an alcohol-exposed pregnancy. 
• The direct and indirect costs of alcohol misuse in the United States were
estimated to equal nearly $185 billion in 1998. Medical consequences of fetal
alcohol syndrome (FAS) accounted for approximately $2.9 billion of this
amount.3
• Researchers estimate that the excess medical costs for a child with fetal alcohol
syndrome (FAS) are $2,342 per year (in year 1997 dollars).4
• Randomized trials demonstrate that brief counseling leads to reduced alcohol
consumption among excessive drinkers and to reductions in adverse alcohol-
related health outcomes, including excess mortality.5-7
• It is estimated that each $1 invested in screening and brief counseling
interventions saves approximately $4 in healthcare costs.6,8
Asymptomatic Bacteriuria (Screening):
• Urinary tract infections (UTIs) are the most common bacterial infections
among pregnant and non pregnant women; each year 8 million women visit a
physician for evaluation of a UTI.9
• Physiologic changes that occur during pregnancy make pregnant women more
susceptible to UTIs, including asymptomatic bacteriuria (infection in the
urine), cystitis (infection in the bladder), and pyelonephritis (infection in the
kidneys).9
• Asymptomatic bacteriuria occurs in approximately 2% to 14% of pregnant
women and 80,000 to 400,000 cases occur each year in the United States.9
• Bacteriuria increases the risk for preterm delivery twofold.9 It also increases the
risk of low birth weight and fetal and perinatal mortality.9-10 
• Without treatment, asymptomatic bacteriuria can progress to pyelonephritis, a
serious kidney infection. Pyelonephritis complicates 1% to 2% of all
pregnancies and affects 100,000 women each year.9
• Early identification and treatment of asymptomatic bacteriuria improves
pregnancy outcomes as it reduces the incidence of pyelonephritis and
premature births.
Breastfeeding (Counseling):
• Human milk is universally recognized to be the optimal food for infants and is
nutritionally superior to formula: breast milk confers immunity and protects
infants from infections and allergens. 
EVIDENCE-STATEMENT:
HEALTHY PREGNANCY (Screening, Testing, Counseling,
Immunization, and Preventive Medication)
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• Research shows that children who were breastfed are at significantly lower risk
for childhood obesity as well as type 1 and type 2 diabetes compared to their
non-breastfed peers.11
• Breastfeeding also has important short- and long-term health benefits for the
mother. A woman’s risk of breast cancer is decreased 4.3% for every 12-month
increment of breastfeeding over her lifetime. Her risk of ovarian and
endometrial cancer is decreased through breastfeeding as well.12
• Data from 2005 show that 72.9% of all new mothers initiated breastfeeding;
but only 39.1% continued to breastfeed for 6 months and only 20.1%
continued to breastfeed for the recommended 12-month period.13
• A 2001 U.S. Department of Agriculture (USDA) study estimated that at least
$500 million (in year 1998 dollars) could be saved in healthcare costs if
breastfeeding rates were increased to match those recommended by the
Surgeon General/Healthy People 2010 goals.14
• Research indicates that working outside the home reduces the initiation and
duration of breastfeeding.15 Therefore, employers should support women
returning to work by offering lactation benefits (such as counseling) and
programs. 
Folic Acid Supplementation (Counseling and Preventive Medication):
• Neural tube defects (NTD), such as spina bifida and anencephaly, result from
a failure of the neural cord to properly fuse. 
• Each year, approximately 3,000 pregnancies are affected by neural tube defects
(NTDs) and approximately 2,200 infants are born with NTDs.16
• Folic acid, a B vitamin, helps prevent NTD. Consuming the recommended
daily amount of folic acid (0.4mg) can reduce a woman’s chance of having a
NTD-affected pregnancy by 40% to 80%.17
• Despite the benefits of supplementation, only 33% of women of childbearing
age report taking vitamins that contain folic acid.18
• NTD rates are highest among the Hispanic population. Efforts to ensure
supplementation among this population are important for eliminating health
disparities.19
• The economic impact of NTDs is substantial. The average lifetime cost for a
child born with spina bifida is estimated to be $636,000 (in year 2002
dollars).20 Costs associated with NTDs are shared by parents, employers, and
communities.
Group B Streptococcal Disease (Screening and Preventive Medication): 
• Group B streptococcus (GBS), a bacterium, has been a leading cause of
infection-related infant deaths in the United States since the 1970s. 
• GBS disease is a serious infection that causes sepsis (blood poisoning),
pneumonia, and meningitis in newborns. 
• Each year in the United States between 1,300 and 1,600 infants contract early-
onset GBS and 65 to 80 infants die from it.21 Those who survive are often left
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with lifelong disabilities such as hearing loss, vision impairments, and/or
learning disabilities. 
• While most women colonized with GBS are asymptomatic (meaning that they
can pass the disease to their children, but are not affected by it themselves),
some women become infected with GBS and are at risk of womb infections,
bladder infections, and stillbirth.21
• By identifying women who carry group B streptococcal bacteria, clinicians can
administer antibiotic prophylaxis during labor, thus preventing transmission of
bacteria to the infant. 
• The average neonatal intensive care cost of a GBS-infected infant was
estimated to be $30,100 in 2001.22 The cost of treating an infant with early-
onset group B streptococcal sepsis (a severe form of the disease) is estimated to
exceed $123,000 (in year 1993 dollars).23
• In 1993, researchers estimated that treating high-risk women identified
through screening with intrapartum antibiotic prophylaxis could prevent 3,300
cases of GBS annually; saving approximately $16 million in direct medical
costs.24
Hepatitis B Virus (HBV) (Screening, Immunization, and Treatment): 
• Over 1 million people in the United States are chronic HBV carriers.25
• In 2003, 73,000 new HBV infections were reported.25
• Screening pregnant women for HBV, and treating the infants of HBV-positive
women with post-exposure hepatitis B immune globulin prophylaxis and HBV
vaccination can dramatically reduce the incidence of perinatal HBV
transmission and thus the number of infants who become chronically infected
with hepatitis B.26
• The economic burden of hepatitis B infection can be substantial depending on
whether the infection is acute or chronic and what treatment is required.
• From a societal perspective, prevention of perinatal HBV infection was estimated
to save $41.8 million (in year 1993 dollars) in medical and work-loss costs.27
Human Immunodeficiency Virus (HIV) (Screening, Counseling, and
Preventive Medication)
• Approximately 120,000 to 160,000 HIV-infected women live in the United
States, 80% of whom are of childbearing age. Each year between 1985 and
1995, approximately 6,000 to 7,000 HIV-infected women gave birth.28
• Mother-to-infant HIV transmission, called perinatal transmission, can occur
during pregnancy, during labor and delivery, or through breastfeeding.
Perinatal HIV transmission is almost entirely preventable.
• Despite screening and treatment advances, perinatal HIV transmission
continues to occur; CDC estimates that 280 to 370 infants are born with HIV
each year in the United States.28
• In 2000, there were 4,107 hospitalizations among HIV-infected children in the
United States, which accounted for approximately $100 million in hospital
charges and more than 30,000 hospital days.29
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• The estimated average lifetime healthcare-related cost of a perinatal
HIV infection is estimated to range between $100,000 and $117,000.30
Influenza (Immunization):
• Pregnant women are considered to be at increased risk for
complications from influenza infections. 
• Influenza immunization has many benefits. Foremost, when a pregnant
woman is immunized during pregnancy, antibodies can be passed to
her fetus and can also be passed in breast milk.31
• Researchers estimate that an average of 1 to 2 hospitalizations can be
prevented for every 1,000 pregnant women vaccinated.32
• Despite the seriousness of influenza infection and the fact that the
inactivated influenza vaccine is safe and effective, only 12% to 13% of
pregnant woman are inoculated against influenza.31,33
• Immunization of healthy working adults is cost-effective and may
result in cost-savings in some years.34 Economic results are likely to be
as favorable for pregnant women since they are at high risk for
influenza-related complications.
Preeclampsia (Screening):
• Preeclampsia (pregnancy-related high blood pressure) affects 5% to 7%
of all pregnancies.35 If preeclampsia is not effectively treated it can lead
to eclampsia, a severe condition that is characterized by maternal
seizure activity, coma, and death. 
• Preeclampsia/eclampsia is the third leading cause of maternal death
worldwide36 and is responsible for 18% of all maternal deaths in the
United States.37
• Spending on pregnancy-related hypertension totaled nearly $2.3 billion
in the United States in 2003.38
• In 2003, approximately 204,868 pregnant women were admitted to
the hospital for hypertension, staying on average 3.5 days. The average
per-person charge for such hospital admissions totaled $11,208.38
• Screening, which involves minimal cost, and early treatment can
minimize and prevent otherwise costly medical conditions.
Prenatal Diagnosis of Chromosomal Abnormalities and Neural Tube
Defects (NTDs) (Screening and Testing): 
• Down syndrome (trisomy 21) is the most common chromosomal
abnormality in the United States, affecting 1 in every 800 to 1,000
live-born babies.39
• Spina bifida and anencephaly are common, permanent, and potentially
fatal birth defects. Both are neural tube defects (NTD) resulting in
failure of the neural cord to properly fuse. Each year in the United
States, approximately 3,000 pregnancies are affected by NTDs and
approximately 2,200 infants are born with neural tube defects.16
• The purpose of screening and testing is to identify affected
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pregnancies. Early identification of an affected pregnancy allows parents and
providers to prepare for the birth of a special needs infant or to terminate the
pregnancy.40
• Chromosomal abnormalities and NTDs have a substantial economic impact.
For example, the average lifetime cost for a child born with spina bifida is
estimated to be $636,000 (in year 2002 dollars).41
• Employers also face productivity losses associated with workdays lost by
employees who must care for affected infants and children.42
Rh(D) Incompatibility (Screening and Preventive Medication): 
• Rh(D) incompatibility occurs in 9% to 10% of all pregnancies, depending on
the race of the pregnant woman and fetus, and may cause severe destruction of
an affected fetus’s red blood cells.43
• Without treatment, 25% to 30% of affected fetuses will experience hemolytic
anemia and hyperbilirubinemia (jaundice) and an additional 20% to 25% will
be hydropic and will either die in the womb or shortly after birth.43
• Early identification of Rh(D) incompatibility allows clinicians to begin
treatment before damage is done to the fetus. This prevents otherwise
expensive medical treatment, lifelong disability, and even death.
Rubella (Screening):
• When contracted during early pregnancy, rubella can cause serious
complications including miscarriage, stillbirth, and congenital rubella
syndrome (CRS) – a constellation of birth defects that includes hearing
impairment, growth retardation, developmental delays, and heart and eye
defects.44
• CRS and its complications have substantial health consequences and economic
costs. A large rubella outbreak in 1964-65 cost an estimated $840 million.45 In
2006, the estimated lifetime cost of treating a child born with CRS exceeded
$200,000.45
• Screening allows clinicians to identify childbearing-age women who are at risk
for rubella and to immunize them before they become pregnant. Screening
pregnant women allows clinicians to identify at-risk women and to encourage
them to be immunized immediately after delivery, thereby offering protection
during subsequent pregnancies. 
Syphilis (Screening):
• In addition to sexual transmission, syphilis can be passed from an infected
pregnant woman to her infant during pregnancy and delivery.
• Congenital syphilis is particularly severe and results in fetal or infant death in
40% of cases.46
• In 2002, 451 cases of congenital syphilis were reported in the United States.47
• The average annual national cost of treating infants with congenital syphilis is
approximately $18.4 million (in year 1995 dollars).48
• Screening for syphilis allows clinicians to identify affected patients and begin
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treatment earlier in the course of disease, thereby improving outcomes and
avoiding the health and economic consequences of latent disease. Further,
ensuring that all women receive prenatal care and are screened for syphilis
during pregnancy will reduce the incidence of congenital syphilis.47
Tetanus (Immunization): 
• Neonatal tetanus is a severe and often fatal disease; it accounted for an
estimated 200,000 deaths worldwide in 200049 but is extremely rare in the
United States.50
• Nearly all neonatal tetanus occurs in infants born to women who are not
adequately immunized against tetanus. Therefore, it is important for all
pregnant women to be vaccinated against tetanus.51
• There are few economic data on the burden of tetanus disease and no data
about the costs of neonatal tetanus in the United States. A recent economic
evaluation of the 7-vaccine routine childhood immunization schedule in the
United States estimated that, if there had not been a tetanus vaccination
program in the U.S., 153 cases of tetanus and 23 deaths from tetanus would
have occurred in each birth cohort (all children born in one year) at a total
cost of $29 million (direct and indirect costs in year 2001 dollars).52
• Tetanus immunization offers long-term protection against tetanus for the
vaccinated woman, and maternal vaccination confers significant protection to
the fetus.53
Tobacco Use Treatment (Screening and Counseling):
• Twenty-five percent (25%) of all childbearing-age women in the United States
smoke. Depending on demographic factors, between 11% and 20% of all
pregnant women in the United States smoke.54
• Women who smoke during their pregnancies are 83% more likely to deliver a
low-birth-weight infant, 129% more likely to deliver an infant that will die of
SIDS, 30% more likely to deliver an infant with respiratory distress syndrome,
and 41% more likely to deliver an infant with a perinatal respiratory condition
than are women who do not smoke during pregnancy.
• Each pregnant smoker incurs an additional $704 in healthcare costs (in year
1996 dollars)55 and, annually, smoking-attributable neonatal costs (defined as
all costs related to labor/delivery and the care of infants within the first few
months of life) are estimated to meet or exceed $367 million in the United
States.56-57
• Tobacco use treatment is considered to be one of the most cost-effective
preventive services.54 Clinical trials have shown that $6 are saved in healthcare
costs for every $1 invested in smoking cessation programs for pregnant
women.58
• A smoking cessation program that could achieve an annual drop of 1 percentage
point in smoking prevalence has been estimated to produce an economic
benefit of $21 million in direct medical costs solely by reducing the number of
low-birth-weight live births. In 7 years, the cumulative undiscounted saving in
direct medical costs would become $572 million through the prevention of
57,200 low-birth-weight infants (all figures in year 1995 dollars).59
243
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 














Alcohol Misuse (Screening and Counseling)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends screening and
behavioral counseling interventions to reduce alcohol misuse by adults, including
pregnant women, in primary care settings.1
The evidence on the effectiveness of counseling to reduce alcohol consumption
during pregnancy is limited; however, studies in the general adult population show
that behavioral counseling interventions are effective among women of childbearing
age. The USPSTF concluded that the benefits of behavioral counseling
interventions to reduce alcohol misuse by adults outweigh any potential harms.1
The USPSTF recommendation is supported by the American Academy of Family
Physicians (AAFP).2
The Surgeon General of the United States recommends that clinicians 1) screen
pregnant women for alcohol use, 2) inform them of the risks of alcohol
consumption, and 3) advise them not to drink alcohol during their pregnancy.3
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• Centers for Disease Control and Prevention (CDC)
• National Institute of Alcohol Abuse and Alcoholism (NIAAA)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
• U.S. Surgeon General
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
No amount of alcohol can be considered safe during pregnancy: alcohol
consumed during any stage of pregnancy increases the risk of alcohol-related
birth defects.3 Fetal exposure to alcohol during pregnancy is one of the leading
causes of preventable birth defects, mental retardation, and developmental
disorders in the United States.4
Despite the documented risks associated with fetal alcohol exposure 10% of
pregnant women reported consuming alcohol in 2003.5 Annually, 55% of
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women of childbearing age report alcohol use, and 12% report binge drinking.5
This statistic is of particular concern because half of all pregnancies in the United
States are unplanned and are at particular risk of unintentional prenatal alcohol
exposure. Therefore, experts recommend that women of childbearing age consult
their physicians and take steps to reduce the possibility of an alcohol-exposed
pregnancy by either 1) using an effective form of contraception or 2) reducing or
eliminating alcohol use.5 
Prenatal alcohol use can lead to one or more fetal alcohol spectrum disorders
(FASD). FASD is characterized by permanent disabilities of varying degrees of
severity. FASD may result in subtle defects, such as learning disabilities or mild
physical abnormalities, or it may result in fetal alcohol syndrome (FAS), the most
severe form of FASD, which is characterized by mental retardation, abnormal
facial features, growth retardation, and central nervous system complications.3
FASD is identified in 2 of every 1,000 live births, and FAS is identified in
between 0.5 to 2 of every 1,000 live births.3 Because many alcohol-related deficits
are not identified at the time of birth, the actual prevalence of alcohol-related
disorders is much higher. In fact, researchers estimate that, for every case of FAS
documented at birth, there are 3 additional cases that are not identified until
later in life.3
Alcohol misuse (in the form of binge drinking, heavy drinking, alcohol abuse, or
alcohol dependence) before pregnancy is highly predictive of continued use.4
Value of Prevention
The direct and indirect costs of alcohol misuse in the United States were
estimated to equal nearly $185 billion in 1998. Medical consequences of fetal
alcohol syndrome (FAS) accounted for about $2.9 billion of this amount and
approximately $1.3 billion were attributed to lost earnings due to FAS.6
Data are limited about presenteeism and absenteeism stemming from parental
caregiving requirements for FASD/FAS-affected children, but parents are likely to
take time off from work to attend to special needs children. 
The economic benefits of screening and counseling mainly result from:
• The averted costs of medical care for FAS and related disorders.
• Cost-savings in neonatal care and the management of developmental delays
and birth defects.
• Cost-savings associated with special education, the criminal justice system,
alcohol and/or drug abuse treatment, and mental health services. 
Interventions directed toward alcohol misuse that occur during pregnancy may
also improve a pregnant woman’s long-term drinking behavior. A permanent or
long-term reduction/elimination of alcohol use would generate additional cost-
savings due to averted long-term healthcare costs.
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Screening patients for alcohol misuse in primary care settings is relatively
inexpensive. The cost of follow-up counseling sessions depends on the number of
sessions, their mode of delivery (in-office or by telephone), and on the type of
provider who delivers the counseling. In 2004, the private-sector cost of the
initial health risk assessment and counseling averaged $23; approximately 95% of
all paid claims fell within the range of $0 to $81.7
Treatment costs for pregnant women who misuse alcohol should not differ from
general alcohol treatment costs unless there are other pregnancy-related
complications.
Screening and counseling for alcohol misuse have a greater impact and are more
cost-effective than most clinical preventive services.8 Screening and counseling for
alcohol misuse among all adults (not just pregnant women) reduce both societal
and healthcare costs. It is estimated that each $1 invested in screening and brief
counseling interventions saves approximately $4 in healthcare costs.9-10
Furthermore, researchers estimated that the excess medical costs for a child with
fetal alcohol syndrome (FAS) are $2,342 per year (based on North Dakota
Health Claims data for 1996 and 1997). This suggests that a alcohol-reduction
program that costs $50,000 and is able to prevent one case of FAS each
year would have paid for itself in 6 years by generating healthcare savings. The
benefits are returned even faster if the prevention of alcohol-related conditions
other than FAS are included in the analysis.11
Preventive Intervention Information
Screening for alcohol misuse allows clinicians to identify women who misuse
alcohol early in the course of pregnancy (or during the pre- or interconception
periods). Pregnant women who misuse alcohol can be counseled to reduce or
eliminate their use and referred to treatment services as needed. 
The benefits of screening and intervention include the prevention of FASD and
FAS in addition to the maternal benefits accrued from identifying and
intervening with their alcohol misuse. Randomized trials demonstrate that brief
counseling leads to reduced alcohol consumption among excessive drinkers and
to reductions in adverse alcohol-related health outcomes, including excess
mortality.9, 12-13 The USPSTF found little direct evidence regarding harms of
screening for alcohol misuse or behavioral counseling interventions to reduce or
eliminate alcohol use in general populations.14
All women should be screened for alcohol use with each pregnancy. Because the
optimal frequency of screening is unknown, screening is left to the discretion of
the clinician. Patients at greater risk for alcohol problems, either because they
have a history of past alcohol misuse or may report other risky behaviors, may
benefit from re-screening during pregnancy.14 Counseling should be conducted as
medically indicated. A total of 8 counseling sessions are covered each calendar
year.
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There are several effective screening tools currently available for assessing alcohol
use in primary care settings. Non-pregnant women of childbearing age seen in
primary care settings should be screened with general tools such as a single
questions screen (e.g., AUDIT or AUDIT-C).15 Pregnant women seen in primary
care settings should be screened with a pregnancy-specific tool such as the
TWEAK or T-ACE. The TWEAK, a 5-question tool, and the T-ACE, a 4-
question tool, were specifically designed to screen pregnant women for “risky
drinking”, “harmful drinking”, and alcohol abuse disorders. The T-ACE is very
sensitive and has been shown to outperform unaided clinicians in identifying
pregnant women who use alcohol.
All pregnant women and women considering pregnancy should be advised of the
harmful effects of alcohol on the fetus. Because safe levels of alcohol
consumption during pregnancy are unknown, pregnant women should be
advised to refrain from drinking alcohol altogether.5,14 Non pregnant women
should also be advised to use contraception until their drinking can be reduced
or eliminated.
Clinicians should provide counseling interventions for patients who meet the
criteria for alcohol misuse. The USPSTF identifies 3 levels of counseling
intervention, differentiated by level of intensity, for these patients. Multi-contact
counseling is more effective than single-contact counseling interventions, but
providers should tailor counseling intensity to address individual patient needs.
Intensity is determined by the duration of the initial contact and whether any
follow-up occurs. “Very brief ” interventions last up to 5 minutes and have no
follow-up. “Brief ” counseling interventions last 15 minutes and have no follow-
up. “Multi-contact” interventions include one initial session lasting at least 15
minutes and several follow-up contacts.1 More intensive interventions are
typically recommended for those meeting criteria for alcohol dependence.
Effective counseling for alcohol misuse in the primary care setting includes
feedback, advice, goal setting, and follow-up. Alcohol misuse counseling should
follow the counseling framework known as the “5 As”15: 
• Providers should assess the degree of a patient’s drinking, including any
problems caused by alcohol and whether the person is alcohol dependent or
not. 
• Providers should advise patients to reduce their alcohol consumption to safer
levels or to abstain altogether from drinking. 
• Providers should agree with patients on their goals for reducing alcohol
consumption. 
• Providers should assist patients in acquiring personal motivation, self-help
skills, or outside resources necessary to achieve behavior change. 
• Finally, providers should arrange for patients to receive appropriate follow-up
support services and counseling, depending on the nature of their alcohol
misuse. 
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Treatment
Information
Health benefits should include provisions for diagnostic assessment, follow-up,
and treatment services.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research: 
The U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found at least fair evidence to support screening and behavioral
counseling all adults, including pregnant women, for alcohol misuse.1
This recommendation is supported by the:
• American Academy of Family Physicians (AAFP)2
Recommended Guidance:
The U.S. Surgeon General
Strength of Evidence: Not Specified
• The U.S. Surgeon General recommends that clinicians should routinely 1)
screen pregnant women for alcohol use, 2) inform them of the risks of alcohol
consumption, and 3) advise them not to drink alcohol during their pregnancy.3
Authored by: 
Campbell KP, Naimi T, Chattopadhyay S. Alcohol misuse during pregnancy evidence-statement:
screening and counseling. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA,
editors. A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington,
DC: National Business Group on Health; 2006.
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Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends
screening for asymptomatic bacteriuria with urine culture for pregnant women at
12 to 16 weeks’ gestation.1
The USPSTF found good evidence that screening pregnant women for
asymptomatic bacteriuria with urine culture significantly reduces symptomatic
urinary tract infections, low birth weight, and preterm delivery. The benefits of
screening and treatment substantially outweigh any potential harm.1
The American Academy of Family Physicians (AAFP) strongly recommends that
all pregnant women be screened for asymptomatic bacteriuria using urine culture
at 12 to 16 weeks’ gestation or at the first prenatal visit if after that time.2
Good quality evidence exists which demonstrates the substantial net benefit of
screening for asymptomatic bacteriuria over harm; the intervention is perceived
to be cost-effective and acceptable to nearly all patients.2
The American College of Obstetricians and Gynecologists (ACOG) recommends
that clinicians screen all pregnant women for asymptomatic bacteriuria by taking
a urine culture at the first prenatal visit. They further recommend that a repeat
urine culture be obtained during the third trimester.3
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American College of Obstetricians and Gynecologists (ACOG)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
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Asymptomatic bacteriuria in pregnancy is defined at the presence of a significant
amount of bacterial growth in a urine culture taken from a urine sample4 and the
absence of symptoms of a urinary infection such as pain or urgency.5
Asymptomatic bacteriuria occurs in approximately 2% to 14% of pregnant
women and 80,000 to 400,000 cases occur each year in the United States.6
Without treatment, 20% to 40% of asymptomatic bacteriuria cases among
pregnant women progress to pyelonephritis, a serious kidney infection.
Pyelonephritis complicates 1% to 2% of all pregnancies and affects 100,000
women each year.6 It is also a leading cause of antepartum hospitalization.1 With
appropriate screening and treatment, only 3% of bacteriuria cases will progress to
pyelonephritis.6
Bacteriuria increases the risk for preterm delivery and low birth weight and may
also increase the risk of fetal and perinatal mortality.1,6 If fact, the risk of preterm
delivery is twice as high among women who had asymptomatic bacteriuria at
some point during pregnancy compared to those who did not.6
Risk factors for asymptomatic bacteriuria during pregnancy include low
socioeconomic urinary tract infections (UTIs) in childhood. Other risk factors
include preexisting medical conditions such as diabetes, sickle cell disease,
immunosuppression (e.g., HIV/AIDS), urinary tract anatomic anomalies, and
spinal cord injuries. UTIs experienced before pregnancy are predictive of the
diagnosis of asymptomatic bacteriuria at the first prenatal visit.6
Value of Prevention
Specific data about the economic burden of UTIs among pregnant women are
not available. The annual cost of all community-acquired urinary tract infections
in 1995 was estimated to be approximately $1.6 billion, including $659 million
in direct costs and $936 million in indirect costs.7 The direct and indirect costs of
acute pyelonephritis were estimated to be $2.14 billion (in year 2000 dollars).8
Lost productivity due to absenteeism associated with pregnancy-related
complications of UTIs among working women (in addition to the increased
medical care costs of such complications) has important financial ramifications
for employers. Specific data on the workplace burden of pregnancy-related UTIs
are not available. 
The preventive treatment of asymptomatic bacteriuria during pregnancy
produces economic benefits such as preventing cases of cystitis, pyelonephritis,
and premature births. In addition, preventing cases of mild and serious
pyelonephritis produce significant improvements in quality of life.9
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In 2004, the private-sector cost of screening for bacteriuria averaged $17 per screen;
approximately 95% of all paid claims fell within the range of $1 to $45 per screen.10
One cost-effectiveness study estimated the cost of antibiotic treatment to be $11,
based on a 7-day course of the generic form of commonly used antibiotics for the
treatment of asymptomatic bacteriuria (in year 1994 dollars).7
Research shows that screening for asymptomatic bacteriuria using urine culture,
when compared with use of dipstick analysis, is cost-effective among populations
where the prevalence of asymptomatic bacteriuria is at least 9%.6
Preventive Intervention Information
The purpose of screening for and treating asymptomatic bacteriuria in pregnancy
is the prevention of poor maternal and infant outcomes associated with infection
including pyelonephritis and prematurity. 
Good evidence exists that screening pregnant women for asymptomatic
bacteriuria with urine culture (rather than urinalysis) — and treating those with
the infection — significantly reduces symptomatic urinary tract infections, low
birth weight, and preterm delivery. A urine specimen obtained at 12 to 16 weeks’
gestation will detect approximately 80% of patients with asymptomatic
bacteriuria.6,11
The USPSTF did not identify any information on the potential harms of
screening for asymptomatic bacteriuria.11
All pregnant women should be screened for asymptomatic bacteriuria at 12 to 16
weeks’ gestation.1,3 The optimal frequency of subsequent urine testing during
pregnancy is uncertain and is thus left to the discretion of the clinician. The
American College of Obstetricians and Gynecologists (ACOG) recommends that
clinicians re-screen all pregnant women for asymptomatic bacteriuria by
performing a urine culture during the third trimester.3
Urine culture is the gold standard for detecting asymptomatic bacteriuria.1 Other
types of screening tests commonly used in the primary care setting (such as
dipstick analysis and direct microscopy) are not as accurate for detecting
bacteriuria in asymptomatic persons.1
Asymptomatic bacteriuria can be treated with a range of antibiotics. A Cochrane
Collaboration review of 14 randomized trials of asymptomatic bacteriuria in
pregnant women showed that antibiotic treatment was significantly associated
with decreased incidence of pyelonephritis. The review also determined that
antibiotic treatment reduced the rate of preterm delivery and low birth weight.12
Health benefits should include provisions for diagnostic and treatment services.
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Authored by: 
Campbell KP, Chattopadhyay S. Asymptomatic bacteriuria evidence-statement: screening.
In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s 
Guide to Clinical Preventive Services: Moving Science into Coverage. Washington, DC: National Business
Group on Health; 2006.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The U.S. Preventive Services Task Force (USPSTF) strongly recommends
screening for asymptomatic bacteriuria with urine culture for pregnant women
at 12 to 16 weeks’ gestation.1 The USPSTF found good evidence that
screening pregnant women for asymptomatic bacteriuria with urine culture
significantly reduces symptomatic urinary tract infections, low birth weight,
and preterm delivery. The benefits of screening and treatment substantially
outweigh any potential harm.1
The American Academy of Family Physicians (AAFP) 
Strength of Evidence: SR (Strongly Recommended)
• AAFP strongly recommends that all pregnant women be screened for
asymptomatic bacteriuria using urine culture at 12 to16 weeks’ gestation or at
the first prenatal visit if after that time. Good quality evidence exists which
demonstrates the substantial net benefit of screening for asymptomatic
bacteriuria over harm; the intervention is perceived to be cost-effective and
acceptable to nearly all patients.2
Recommended Guidance:
American College of Obstetricians and Gynecologists (ACOG)
Strength of Evidence: Not Specified
• The American College of Obstetricians and Gynecologists (ACOG)
recommends that clinicians screen all pregnant women for asymptomatic
bacteriuria by taking a urine culture at the first prenatal visit. They further
recommend that a repeat urine culture be obtained during the third trimester.3
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Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
provide structured breastfeeding education and behavioral counseling to all
pregnant and postpartum women to promote the initiation and continuation of
breastfeeding.1
The USPSTF found fair evidence that programs which combine breastfeeding
education with behaviorally-oriented counseling increase the rates of the
initiation and continuation of breastfeeding for up to 3 months. The USPSTF
notes that effective programs involve at least one in-person session; are usually 
30 to 90 minutes in duration; follow structured protocols; and include practical
behavioral skills training, problem-solving, and didactic instruction.1
The USPSTF also found fair evidence to suggest that continued support via 
in-person visits or telephone contact with a clinician or counselor increases the
proportion of women who continue breastfeeding their infants for 6 months.1
The CDC Guide to Breastfeeding Interventions recognizes the critical role
returning to work plays in women’s infant feeding decisions, and identifies a
strong need to establish lactation support in the workplace.2
Not Specified
The American Academy of Family Physicians (AAFP) recommends structured
breastfeeding education and behavioral counseling programs to promote
breastfeeding.3
Although evidence exists which demonstrates the net benefit of counseling to
promote breastfeeding, either the benefit is only moderate in magnitude or the
evidence supporting a substantial benefit is only fair. The intervention is
perceived to be cost-effective and acceptable to most patients.3
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• Centers for Disease Control and Prevention (CDC)
• Healthy People 2010, U.S. Department of Health and Human Services
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
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should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Breastfeeding provides protective immune globulins from the mother to the
infant, completing the development of the infant’s immune system after birth
and thereby reducing the risk that the infant will acquire some serious infections.
This immunologic protection is impossible to replicate with infant formula.
Infants who are breastfed are thus better prepared to fight off infections and
allergens than their non-breastfed counterparts. Additionally, human breast milk
is universally recognized to be the optimal food for infants and is nutritionally
superior to formula. Evidence suggests that breastfed infants are less likely to
develop obesity, and type 1 and type 2 diabetes than bottle-fed infants.2 Further,
children who were breastfed have lower rates of otitis media (ear infections),
respiratory infections, gastroenteritis, and eczema (a skin disorder).2
Despite the benefits of breastfeeding for both women and infants, breastfeeding
rates in the United States remain suboptimal, especially among certain
subpopulations. Data from 2005 show that 72.9% of all new mothers initiated
breastfeeding and 39.1% continued to breastfeed for 6 months.4 However, only
63.5% of low income mothers and 55.4% of African-American mothers initiated
breastfeeding. Further, only 29.7% of low income mothers and 24.8% of
African-American mothers continued to breastfeed their infants for the
recommend 6-month period.4
The Healthy People 2010 goals for breastfeeding aim to increase breastfeeding
rates so that 75% of all new mothers initiate breastfeeding, 50% continue
breastfeeding for at least 6 months postpartum, and 25% continue to breastfeed
at least 1 year postpartum.5
Breastfeeding rates should be of paramount importance to employers as working
outside the home negatively affects initiation and duration of breastfeeding.6
Furthermore, one-third of working mothers return to work within 3 months of
the birth of their child, and two-thirds return within 6 months, the exact time
period when breastfeeding is most critical.6
The mothers at highest risk for not breastfeeding are first-time mothers, those
who have less formal education, those who are non-white, and those who are ill
postpartum.7
Value of Prevention
Healthcare costs of treating respiratory tract infections, ear infections, and
gastrointestinal illnesses represent the majority of healthcare expenses for children
less than one year of age.8 Because all of these illnesses are significantly more
common among formula-fed infants than breastfed infants, support of
breastfeeding initiation and continuation saves healthcare dollars.8 Indirect costs
include time and income lost from work to take care of a sick child.
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Benefits and Risks 
of Intervention
Children who are not breastfed contribute to huge additional healthcare
expenditures for the employers of their parents. Their parents are also responsible
for significant productivity losses in the workplace associated with absenteeism
and presenteeism. A study that compared infant feeding among employed
mothers found that 75% of all 1-day maternal absences were among formula-
feeding mothers.9 The study also found that infants who were formula fed were
much more likely to fall ill. In fact, only 14% of infants with no illnesses were
formula-fed (comparatively 86% of infants with no illnesses were breastfed).9
Breastfeeding offers important economic benefits to families, employers, and
society at large. Breastfeeding allows the family to save the money that otherwise
would be spent on infant formula, other human milk substitutes, and feeding
equipment. 
Further, a 2001 U.S. Department of Agriculture (USDA) study estimated that at
least $3.6 billion (in year 1998 dollars) would be saved if  breastfeeding rates
were increased from the current rates to those recommended by the U.S. Surgeon
General (75% in-hospital and 50% at 6 months). This estimate includes $3.1
billion is savings from prevented premature deaths, $500 million in savings from
reduced healthcare costs (e.g., hospital visits, etc), and savings from averted
indirect costs such as forgone earnings of parents.8
In 2004, the private-sector cost of counseling to promote breastfeeding initiation
and continuation averaged $23 per session; approximately 95% of all paid claims
fell within the range of $0 to $81 per session.10
Not Applicable
A study based on 1993-1994 data from the Special Supplemental Nutrition
Program for Women, Infants, and Children (WIC) in Colorado found that
compared with formula-feeding, breastfeeding each infant enrolled in WIC saved
$478 in WIC costs and Medicaid expenditures during the first 6 months of the
infant’s life, or $161 after consideration of the formula manufacturers’ rebate.11
The cost saving was realized by the averted WIC costs for formula and foods for
infants and mothers as well as reduced administrative expenses and lower
Medicaid health care costs including costs for pharmacy reimbursement for the
breastfed infants.11
Preventive Intervention Information
The purpose of counseling is to educate women on the benefits of breastfeeding
and to provide support and skills-training for women who choose to breastfeed,
thereby increasing the number of women who initiate and maintain breastfeeding
for the minimum recommended period of 12 months.
Breastfeeding has important short- and long-term health outcomes for children.
Research shows that children who were breastfed are at significantly lower risk for
childhood obesity as well as type 1 and type 2 diabetes than their non-breastfed
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peers. Breastfed infants and children also have lower rates of otitis media (ear
infections), respiratory infections, gastroenteritis, and eczema (a skin disorder).12
Breastfeeding also has important short- and long-term health benefits for the
mother. A woman’s risk of breast cancer is decreased 4.3% for every 12-month
increment of breastfeeding over her lifetime.12 Her risk of ovarian and
endometrial cancer is decreased by breastfeeding as well. Breastfeeding improves
uterine tone, helps to stop post-birth bleeding, assists postpartum weight loss,
and temporarily suppresses ovulation to aid in child-spacing.2
Educational programs have been shown to increase the proportion of women
who initiate breastfeeding immediately after birth by 23% and the number of
women who continue to breastfeed for 1 to 3 months by 39%. The efficacy of
education programs is enhanced by ongoing support for breastfeeding initiation
and continuation.13
There are no known risks of counseling to promote breastfeeding. In the United
States, only women with the following conditions should be advised to avoid
breastfeeding: women who are HIV positive; are taking antiretroviral
medications; have untreated, active tuberculosis; are infected with human T-cell
lymphotropic virus type I or type II; are using illicit drugs; are taking prescribed
cancer chemotherapy agents that interfere with DNA replication; and whose
infants who are diagnosed with galactosemia. Women undergoing radiation
therapies need to temporarily interrupt breastfeeding but do not need to
discontinue breastfeeding permanently.14
Counseling to promote breastfeeding should be offered to all women of
childbearing age. It should begin during prenatal care and continue throughout
the intrapartum hospital stay and into the postpartum period. Counseling should
be given, according to need, throughout the course of lactation.
Counseling should include breastfeeding initiation advice as well as skills and
referrals to support breastfeeding continuation. The most effective breastfeeding
education and counseling interventions last approximately 30 to 90 minutes and
feature directive health education combined with behaviorally-oriented skills
training and problem-solving.1
Effective breastfeeding education and behavioral counseling programs1: 
• Begin during the prenatal period.
• Use face-to-face individual or group sessions. 
• Are led by specially trained nurses, midwives, or lactation specialists.
• Sessions last 30 to 90 minutes.
• Include education on the benefits of breastfeeding for mother and infant, basic
physiology, technical training on positioning and latch-on techniques, skills on
how to overcome common barriers, skills to garner social support, how to use
basic lactation support equipment such as breast pumps, etc.
Not Applicable
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found at least fair evidence to support the provision of
structured breastfeeding education and behavioral counseling to all pregnant
and postpartum women to promote the initiation and continuation of
breastfeeding.1
• The USPSTF also found at least fair evidence to suggest that continued
support via in-person visits or telephone contact with a clinician or counselor
increases the proportion of women who continue breastfeeding their infants
for 6 months.1
The American Academy of Family Physicians (AAFP)
Strength of Evidence: R (Recommended)
• AAPF recommends structured breastfeeding education and behavioral
counseling programs to promote breastfeeding. Although evidence exists which
demonstrates the net benefit of counseling to promote breastfeeding, either the
benefit is only moderate in magnitude or the evidence supporting a substantial
benefit is only fair. The intervention is perceived to be cost-effective and
acceptable to most patients.3
Authored by: 
Campbell KP, Chattopadhyay S. Breastfeeding evidence-statement: counseling. In: Campbell KP, Lanza A,
Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical Preventive
Services: Moving Science into Coverage. Washington, DC: National Business Group on Health; 2006.
257
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 

























Folic Acid Supplementation (Counseling 
and Preventive Medication)
Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that
all women of childbearing age who are capable of becoming pregnant (even those
currently using contraception) consume 0.4 micrograms of folic acid per day to
reduce the risk of a pregnancy affected by either spina bifida, anencephaly, or
another neural tube defect. 
This recommendation is archived and considered out of date. 
The CDC concurs with the U.S. Public Health Service (see description below). 
The American Academy of Family Physicians (AAFP) recommends that clinicians
prescribe 0.4-0.8 mg/day of folic acid supplementation from at least 1 month
prior to conception through the first trimester of the pregnancy to women who
have not had a previous pregnancy affected by a neural tube defect.1
Good quality evidence exists which demonstrates the substantial net benefit of
folic acid supplementation over harm; the intervention is perceived to be cost-
effective and acceptable to nearly all patients.1
The American Academy of Family Physicians (AAFP) recommends that clinicians
prescribe 0.4 mg folic acid supplementation to women not planning a pregnancy
but of childbearing potential who have not had a previous pregnancy affected by
a neural tube defect.1
Although evidence exists which demonstrates the net benefit of folic acid
supplementation, either the benefit is only moderate in magnitude or the
evidence supporting a substantial benefit is only fair. The intervention is
perceived to be cost-effective and acceptable to most patients.1
The American Academy of Family Physicians (AAFP) recommends that clinicians
prescribe 4 mg/day of folic acid supplementation from 1 to 3 months prior to
conception through the first trimester of pregnancy to women who are planning
a pregnancy and have had a previous pregnancy affected by a neural tube defect.1
Good quality evidence exists which demonstrates the substantial net benefit 
of folic acid supplementation over harm; the intervention is perceived to be 
cost-effective and acceptable to nearly all patients.1
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The U.S. Public Health Service recommends that2-3:
• All women of childbearing age in the United States who are capable of
becoming pregnant should consume 0.4 mg of folic acid per day for the
purpose of reducing their risk of having a pregnancy affected with spina bifida
or other neural tube defects.
• Women who have had a prior NTD-affected pregnancy are at high risk of
having a subsequent affected pregnancy and should consult their physicians
when planning to become pregnant again. 
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American College of Obstetricians and Gynecologists (ACOG)
• Centers for Disease Control and Prevention (CDC)
• National March of Dimes Birth Defects Foundation
• Peer-reviewed research
• U.S. Public Health Service (USPHS)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Spina bifida and anencephaly are severe, potentially fatal birth defects. Both are
neural tube defects (NTD) resulting in failure of the neural tube to fuse correctly.
Approximately 3,000 pregnancies are affected by NTDs, and approximately
2,200 infants are born with neural tube defects each year.4 Many NTD-affected
pregnancies do not result in a live birth because they are electively or
spontaneously aborted (commonly referred to as a miscarriage) or result in fetal
death or stillbirth.4
Anencephaly is always fatal and affected infants die shortly after birth. The
majority of infants born with spina bifida grow into adulthood, but have severe
medical complications such as paralysis and varying degrees of bowel and bladder
incontinence.2
Folic acid, a B vitamin, prevents NTDs. Evidence (from populations not
consuming foods fortified with folic acid) shows that consuming the
recommended daily amount of synthetic folic acid (0.4 mg) through folic acid
supplements can reduce a woman’s chance of having a NTD-affected pregnancy
by 40% to 80%.5 
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Synthetic folic acid can be consumed via folic acid supplements, folic acid-
containing multivitamins, cereals that have been fortified with folic acid, and
fortified grains. The natural form of this vitamin, folate, can be found in foods
such as green leafy vegetables, orange juice, and beans. Synthetic folic acid
vitamin supplementation is recommended because it is easier for the body to
absorb than folate found in food and because up to 50% of naturally occurring
folate is lost during cooking.6
Despite the known benefit of folic acid, only 33% of women of childbearing age
report taking vitamins that contain folic acid and certain subpopulations have
even lower rates of vitamin supplementation.7
NTD rates are highest among the Hispanic population. Efforts to ensure
supplementation among this population are important for eliminating health
disparities.8
Value of Prevention
The economic burden of NTDs is substantial. The total lifetime cost for a child
born with spina bifida is estimated to be $636,000 (in year 2002 dollars).9
Applying the prevalence rate for spina bifida from the National Birth Defect
Prevention Network data10 to the 4 million live births each year, that amounts to
$814 million in lifetime costs for each one-year cohort of births (all children
born in one year).9 Costs associated with NTDs are shared by parents, employers,
and communities.
Apart from the excess medical costs for affected children, employers face
productivity loss costs associated with employees’ absences to care for children
with spina bifida. The present value of the cost of such caregiver time was
estimated to be $252,000 per child (in year 1993 dollars).11
The economic benefit of folic acid supplementation is based on the cost savings
that result from averted direct and indirect costs of each NTD that is prevented
with supplementation. 
In 2004, the private-sector cost of counseling to promote folic acid
supplementation averaged $23 per session; approximately 95% of all paid claims
fell within the range of $0 to $81 per session.12
The cost of supplementation is highly variable, depending on the type of vitamin
supplement that is taken and for how long. The cost of over-the-counter vitamins
is relatively cheap and is an out-of-pocket cost for beneficiaries. Prescription
strength folic acid (recommended for women who have had a previous pregnancy
affected by a NTD) costs approximately $100 per year.13
Not Provided
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At present there is no evidence on the incremental cost-effectiveness of folic acid
supplementation. A study undertaken before the implementation of the folic acid
fortification program, examined a public and provider education program as a
possible strategy to increase folic acid consumption through consumption of
vitamin supplements and estimated that, compared to no program, the cost-
effectiveness of supplementation was approximately $5,000 per quality-adjusted
life year (QALY).11 
Preventive Intervention Information
Encouraging a woman to increase her folic acid intake prior to pregnancy via
support, counseling, and/or prescription vitamins can lead to improved nutrition,
thereby improving her chance of a healthy pregnancy and reducing her risk of an
NTD-affected pregnancy. 
A double-blind, placebo-controlled, randomized trial showed that folic acid
supplementation before and during pregnancy decreased the risk of a first
occurrence of a neural tube defect.14-15 The efficacy of such folic acid
supplementation has since been confirmed by many other studies. 
The South Carolina NTD prevention program has reported great success in
preventing the recurrence of isolated NTDs by providing counseling and
vitamins to women who have had a previous NTD-affected pregnancy.16
Folic acid supplementation is believed to have minimal risks. Folic acid is
considered nontoxic even at very high doses and is rapidly excreted in the urine.
Folic acid supplementation information should be provided during routine
healthcare visits and throughout the first trimester of pregnancy. Folic acid
supplements should be prescribed/recommended, as medically indicated.
Clinicians should 1) advise all women of child-bearing age who are capable of
becoming pregnant about the importance of folic acid supplementation and 2)
provide them with guidance on folic acid supplementation and, if needed, a
prescription for folic acid supplements.
Not Applicable
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
The American Academy of Family Physicians (AAFP) 
Strength of Evidence: SR (Strongly Recommended ), R (Recommended)
SR (Strongly Recommended)
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Authored by: 
Campbell KP, Grosse S, Chattopadhyay S. Folic acid supplementation evidence-statement: counseling and
preventive medication. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors.
A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington, DC:
National Business Group on Health; 2006.
• AAFP recommends that clinicians prescribe 0.4-0.8 mg/day of folic acid
supplementation from at least 1 month prior to conception through the first
trimester of the pregnancy to women planning to become pregnant who have
not had a previous pregnancy affected by a neural tube defect. Good quality
evidence exists which demonstrates the substantial net benefit of folic acid
supplementation over harm; the intervention is perceived to be cost-effective
and acceptable to nearly all patients.1
R (Recommended)
• AAFP recommends that clinicians prescribe 0.4 mg folic acid supplementation
to women not planning a pregnancy but of childbearing potential who have
not previously had a baby with a neural tube defect. Although evidence exists
which demonstrates the net benefit of folic acid supplementation, either the
benefit is only moderate in magnitude or the evidence supporting a substantial
benefit is only fair. The intervention is perceived to be cost-effective and
acceptable to most patients.1
• AAFP recommends that clinicians prescribe 4 mg/day of folic acid
supplementation from 1-3 months prior to conception through the first
trimester of pregnancy to women who are planning a pregnancy and had a
previous pregnancy affected by a neural tube defect.1 Good quality evidence
exists which demonstrates the substantial net benefit of folic acid
supplementation over harm; the intervention is perceived to be cost-effective
and acceptable to nearly all patients.1
Recommended Guidance:
U.S. Public Health Service (USPHS)
Strength of Evidence: Not Specified
• The U.S. Public Health Services recommends that all women of childbearing
age in the United States who are capable of becoming pregnant should
consume 0.4 mg of folic acid per day for the purpose of reducing their risk of
having a pregnancy affected with spina bifida or other neural tube defects.
Women who have had a prior NTD-affected pregnancy are at high risk of
having a subsequent affected pregnancy, and should consult their physicians
when planning to become pregnant again.2-3
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Group B Streptococcal Disease (GBS)
(Screening and Preventive Medication)
Clinical Preventive Service Recommendations
Not Applicable
The Centers for Disease Control and Prevention (CDC) recommends that
clinicians screen all pregnant women for vaginal and rectal group B streptococcal
(GBS) colonization at 35 to 37 weeks’ gestation.1
• Women should be tested for GBS at each pregnancy as colonization at a prior
pregnancy is not an indication for antibiotic prophylaxis in subsequent
pregnancies. 
• Women who are identified through screening as GBS carriers should be given
intrapartum antibiotic prophylaxis. 
• Women whose screening status is unknown at the time of labor should receive
intrapartum antibiotic prophylaxis if they present with any of the following
risk factors: delivery at less than 37 weeks’ gestation, membrane rupture >18
hours, or intrapartum fever 38C.
• Women with GBS isolated from the urine at any time in the current
pregnancy should also be given intrapartum antibiotic prophylaxis.
• Women who have previously given birth to an infant with invasive GBS
disease should receive intrapartum antibiotic prophylaxis. 
• Women who are expected to deliver preterm (less than 37 weeks’ gestation)
should be assessed for their need for intrapartum antibiotic prophylaxis to
prevent perinatal GBS disease. 
• GBS colonized women who have a planned cesarean before rupture of the
membranes are at a low risk for delivering an infant with early-onset GBS
disease and should thus not routinely receive intrapartum antibiotic
prophylaxis.
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Royal College of Obstetricians and Gynecologists 
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
263
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 
















Group B streptococcus (GBS), a bacterium, has been a leading cause of infection-
related infant death in the United States since the 1970s.1 GBS disease is a
serious infection that causes sepsis (blood poisoning), pneumonia, and meningitis
in newborns. GBS can be lethal: 1 in every 20 babies born with GBS dies. Each
year in the United States between 1,300 and 1,600 infants contract early-onset
GBS and 65 to 80 infants die from it.1 Those who survive are often left with
lifelong disabilities such as hearing loss, vision impairments, and/or learning
disabilities.1
In the 1980s, scientists discovered that administering antibiotics during labor to
women who carry GBS could prevent early-onset GBS disease from developing
in newborns. One in every 4 to 5 pregnant women carries GBS in her vagina or
rectum.1 While most women colonized with GBS are asymptomatic (meaning
that they can pass the disease to their child, but are not affected by it themselves),
some women become infected with GBS and are at risk of womb infections,
bladder infections, and stillbirth.1
Pregnant women are at a higher risk of delivering an infant with GBS disease if
they have GBS in their urine, are colonized with GBS at the time of labor, have a
fever during labor, rupture their membranes 18 hours or more before delivery, or
if they have previously had a baby with GBS disease.1
Value of Prevention
While the rate of neonatal GBS infections has declined since the 1990s due to
widespread screening and treatment, GBS continues to have an economic toll in
the United States.2 The average neonatal intensive care cost of a GBS-infected
infant was estimated to be $30,100 in 2001.3 The excess average discounted
lifetime healthcare cost for an infant disabled by an early-onset GBS (over that
for a healthy infant) was estimated to equal $261,000 (in year 2001 dollars).4
Productivity losses associated with absenteeism and presenteeism for parents of
GBS-affected children have not been quantified. 
Preventing a case of infant disability due to GBS can reduce the discounted
lifetime healthcare costs for an infant by $261,000, on average (year 2001
dollars).4 In 1993, researchers estimated that treating high-risk women identified
through screening with intrapartum antibiotic prophylaxis could prevent 3,300
cases of GBS annually; saving approximately $16 million in direct medical costs.2
In 2004, the private-sector cost of screening for GBS averaged $13 per screen;
approximately 95% of all paid claims fell within the range of $4 to $33 per
screen.6 When women with a positive test result are treated with antibiotic
therapy during labor (an initial dose of 2g of ampicillin intravenously, followed
by 1g every 4 hours) the preventive mediation costs are estimated to equal $63
per course of therapy.4
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The cost of treating an infant with early-onset group B streptococcal sepsis (a
severe form of the disease) was estimated to exceed $123,000 (in year 1993
dollars).4
Screening to prevent early-onset GBS is estimated to cost less than $12,000 (in
year 1997 dollars) per prevented case. Preventive intervention may also generate
net cost-savings if the high cost of managing a case of early-onset GBS is
considered.3
In comparison to other preventive interventions and to commonly accepted cost-
effectiveness benchmarks, screening for GBS is cost-effective. 
Preventive Intervention Information
Identifying women who carry group B streptococcal bacteria allows clinicians to
administer antibiotic prophylaxis during labor, thus preventing transmission of
the bacteria to the infant. Vaccines to prevent GBS disease are under
development but are not currently available. Thus, universal prenatal GBS
culture-based screening is the best available prevention strategy.1
The risks of screening for GBS colonization are minimal. However, there are risks
associated with intrapartum antibiotic prophylaxis. Severe anaphylaxis is
associated with the use of penicillin in some women. Anaphylaxis occurs in 1 out
of every 10,000 treatments and can be fatal. Also, the widespread use of
antibiotics, particularly broad-spectrum antibiotics such as ampicillin, contributes
to the development of resistant organisms.1
Despite the risks associated with prevention, screening for group B streptococcal
colonization and intrapartum antibiotic prophylaxis can reduce the rate of
neonatal infection death and prevent infants from significant disability. These
significant benefits outweigh the risks and costs associated with screening. 
All pregnant women should be screened for vaginal and rectal group B
streptococcal (GBS) colonization between 35 and 37 weeks’ gestation. Preventive
medication should be given to colonized women, as medically indicated. 
All women should be screened for vaginal and rectal group B streptococcal
colonization using recommended laboratory methods for GBS isolation and
identification. Women should be screened for GBS with each pregnancy as
colonization at a prior pregnancy is not an indication for antibiotic prophylaxis
in subsequent pregnancies.
Intrapartum antibiotic prophylaxis should be given, as medically indicated, to: 
• Women who are identified as GBS carriers. 
• Women whose screening status is unknown at the time of labor if they present
with any of the following risk factors: delivery at less than 37 weeks’ gestation,
membrane rupture 18 hours, or intrapartum fever  38C. 
265
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 




• Women with GBS isolated from the urine at any time in the current
pregnancy. 
• Women who have previously given birth to an infant with invasive GBS
disease.
Women who are expected to deliver preterm (less than 37 weeks gestation)
should be assessed for their need for intrapartum antibiotic prophylaxis to
prevent perinatal GBS disease. 
GBS colonized women who have a planned cesarean before rupture of the
membranes are at a low risk for delivering an infant with early-onset GBS disease
and should thus not routinely receive intrapartum antibiotic prophylaxis.1
Health benefits should include provisions for treatment services for affected
women and infants. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
The Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Not Specified
• The CDC recommends screening all pregnant women for vaginal and rectal
group B streptococcal (GBS) colonization between 35 and 37 weeks’
gestation.1
Authored by: 
Campbell KP, Chattopadhyay S. Group B streptococcal disease evidence-statement: screening and 
preventive medication. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA,
editors. A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington,
DC: National Business Group on Health; 2006.
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Hepatitis B Virus (HBV) (Screening,
Immunization, and Treatment)
Clinical Preventive Service Recommendations
Screening
The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening
for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.1
The USPSTF found good evidence that universal prenatal screening for HBV
infection using HBsAg substantially reduces prenatal transmission of HBV and
the subsequent development of chronic HBV infection. The current practice of
vaccinating all infants against HBV infection and post-exposure prophylaxis with
hepatitis B immune globulin administered at birth to infants of HBV-infected
women substantially reduces the risk for acquiring HBV infection.1
Immunization
The U.S. Preventive Services Task Force (USPSTF) defers to the Advisory
Committee on Immunization Practices (ACIP) and the Centers for Disease
Control and Prevention (CDC) on recommendations surrounding immunization.
Screening
The Advisory Committee on Immunization Practices (ACIP) recommends that all
pregnant women be tested routinely for hepatitis B surface antigen (HBsAg) during
an early prenatal visit (i.e., first trimester) in each pregnancy, even if they have been
previously vaccinated or tested. Women who were not screened prenatally, those
who engage in behaviors that put them at high risk for infection (e.g., injection-
drug use, having had more than one sex partner in the previous 6 months or an
HBsAg-positive sex partner, evaluation or treatment for a sexually transmitted
infection [STI], or recent or current injection-drug use) and those with clinical
hepatitis should be tested at the time of admission to the hospital for delivery.2,3
Immunization
The ACIP further recommends the hepatitis B vaccine for pregnant women at risk
for hepatitis B virus infection. Pregnant women who are identified as being at risk
for HBV infection during pregnancy (see list of risk factors in preceding paragraph)
should be vaccinated. Pregnant women at risk for HBV infection during pregnancy
should be counseled concerning other methods to prevent HBV infection.2,3
Management of Exposed or Potentially Exposed Infants/Treatment
The ACIP recommends that all infants born to HBsAg-positive women should
receive single-antigen hepatitis B vaccine and hepatitis B immune globulin
prophylaxis (HBIG) (0.5 mL) within the first 12 hours following the birth,
administered at different injection sites.2,3
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Women admitted for delivery without documentation of HBsAg test results
should have blood drawn and tested as soon as possible after admission. While
test results are pending, all infants born to women without documentation of
HBsAg test results should receive the first dose of single-antigen hepatitis B
vaccine (without HBIG) within 12 hours following the birth.2-3
A summary of guidelines for the immunization of pregnant women can be found
online (www.cdc.gov/nip/publications/preg_guide.htm).
Expert Consensus
The American Academy of Family Physicians (AAFP) strongly recommends
screening for hepatitis B virus (HBV) infection in pregnant women at their first
prenatal visit.5
Good quality evidence exists which demonstrates the substantial net benefit of
screening for HBV over harm; the intervention is perceived to be cost-effective
and acceptable to nearly all patients.5
The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Immunization Practices (ACIP)
• American Academy of Family Physicians (AAFP)
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Over 1 million people in the United States are chronic carriers of HBV.4 In 2003,
an estimated 73,000 new HBV infections were reported in the United States.4
Hepatitis infection can lead to liver disease, including liver cancer, which without
treatment can result in death. Between 4,000 and 5,000 chronic carriers of HBV
die each year in the United States.4 Hepatitis B can be treated with medications if
diagnosed early, but some individuals do not respond to treatment and require
liver transplants to survive. 
The severity of hepatitis B infection depends on the age at which an individual
becomes infected and the presence of other comorbid conditions such as alcohol
abuse, HIV/AIDS, or other types of liver disease.6 Most adolescents and adults
with acute HBV infections recover fully, but 30% of children aged 1 to 5 years
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and 2% to 6% of adults become chronically infected with hepatitis B.7
Immunization against HBV is the single most effective way of preventing
hepatitis B infection and its consequences.2
The risk factors for hepatitis B include intravenous drug use, concurrent
infection with a sexually transmitted infection (STI), multiple sexual partners,
household contact with an infected person, and being a healthcare worker with
exposure to bodily fluids. However, 30% to 40% of infected individuals have no
identified risk factors.6
Infants can contract hepatitis B from an infected woman during labor and
delivery and as many as 90% of infants infected through perinatal transmission
become chronic carriers of HBV.2
Value of Prevention
The economic burden of hepatitis B infection depends on whether the infection
is acute or chronic and what treatment is required. The direct medical cost of
outpatient treatment for symptomatic acute hepatitis B has been estimated at
$272 per occurrence, while the cost of hospitalization for symptomatic hepatitis
B infection is $8,080 per occurrence (both in year 2000 dollars).8 If a patient
develops liver disease as a result of chronic HBV infection, the direct medical cost
of treatment is estimated to be $59,308 (before discounting)8 and patients who
require a liver transplant can have first-year billed charges of up to $244,600 (in
year 1999 dollars).9
HBV is also responsible for disability costs, costs associated with work-loss and
absenteeism, and other indirect costs.
Screening pregnant women for HBV, and treating the infants of HBV-positive
women with post-exposure hepatitis B immune globulin prophylaxis and HBV
vaccination can dramatically reduce the incidence of perinatal HBV transmission
and thus the number of infants who become chronically infected with hepatitis
B.2 The additional recommended step of vaccinating all infants with HBV at
birth also serves as a safety net to prevent perinatal hepatitis B transmission.2 The
averted direct and indirect costs of illness from each case of HBV prevented
constitute the predominant economic benefit of the preventive intervention.
From a societal perspective, prevention of perinatal HBV infection was estimated
to save $41.8 million (in year 1993 dollars) in medical and work-loss costs.10
In 2004, the private-sector cost of11:
• Screening for HBV via the hepatitis B surface antigen test averaged $22;
approximately 95% of all paid claims fell within the range of $0 to $64 per
test.
• An adult HBV vaccine averaged $35; approximately 95% of all paid claims fell
within the range of $0 to $77.
• Vaccine administration averaged $10; approximately 95% of all paid claims fell
within the range of $0 to $20 (3 doses are usually needed for full protection).
269
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 



















In 2004, the private-sector cost of post-exposure hepatitis B immune globulin
prophylaxis (for infants born to HBV-positive women) averaged $178 and
approximately 95% of all paid claims fell within the range of $0 to $514.11
The cost of therapeutic treatment of chronic hepatitis B varies according to the
medication required; a single course of interferon therapy costs $5,570 including
provider visits and laboratory costs (in year 1995 dollars).12
The estimated cost of preventing a perinatal HBV infection is $164 per year of
life saved, (in year 1993 dollars).10 In comparison to other preventive
interventions and to commonly accepted cost-effectiveness benchmarks, hepatitis
B screening is highly cost-effective. 
Preventive Intervention Information
Screening pregnant women for HBV, immunizing women at high-risk of HBV,
and treating the infants of HBV-positive women with post-exposure hepatitis B
immune globulin prophylaxis and HBV vaccination, can dramatically reduce
perinatal HBV transmission and, thus, the number of infants who become
chronically infected with hepatitis B.2
The benefits of screening, immunization, and treatment are substantial; an
untreated maternal hepatitis B viral infection may result in severe disease for the
woman and chronic infection for the newborn.2
There is no apparent risk of adverse effects for developing fetuses when a
hepatitis B vaccine is administered to a pregnant woman.3
Screening for hepatitis B should be conducted at the first prenatal visit in each
pregnancy. Women at increased risk of acquiring HBV may be screened again
during the third trimester and/or during labor and delivery and should be offered
the hepatitis B vaccine. Household contacts of women with a positive HBsAg test
should also be screened for HBV infection. Women admitted for delivery
without documentation of HBsAg test results should have blood drawn and
tested as soon as possible after admission.2
HBV immunization should be given to high-risk pregnant women as deemed
appropriate by the clinician.2 
All infants should receive their first hepatitis B immunizations at the time of
birth. Infants born to HBV-infected women should be immunized and given
immune globulin within 12 hours of birth. Infants born to women with
unknown HBsAg status should receive one dose of single-antigen hepatitis B
vaccine (without HBIG) within 12 hours of birth, while awaiting the woman’s
test results.2
Post-exposure hepatitis B immune globulin prophylaxis should be given, as
medically indicated.2
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The principal screening test for detecting an HBV infection (acute or chronic) is
the identification of HBsAg in the blood. Testing methods include the HBsAg
Immunoassay and the “rapid test,” an assay that detects HBsAg and the hepatitis
B e-antigen HBeAg simultaneously.
HBV immunizations are administered via injection. 
Post-exposure hepatitis B immune globulin prophylaxis.
Please refer to the “Intervention Process” section for information on preventive
treatment. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
The U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence that universal prenatal screening for HBV
infection using HBsAg substantially reduces prenatal transmission of HBV and
the subsequent development of chronic HBV infection. The current practice of
vaccinating all infants against HBV infection and post-exposure prophylaxis
with hepatitis B immune globulin administered at birth to infants of HBV-
infected women substantially reduces the risk for acquiring HBV infection.1
The American Academy of Family Physicians (AAFP) 
Strength of Evidence: SR (Strongly Recommended)
• AAFP strongly recommends screening for hepatitis B virus (HBV) infection in
pregnant women at their first prenatal visit.5 Good quality evidence exists
which demonstrates the substantial net benefit of screening for HBV over
harm; the intervention is perceived to be cost-effective and acceptable to nearly
all patients.5
Recommended Guidance:
The Advisory Committee on Immunization Practices (ACIP)
Strength of Evidence: Expert Consensus
Screening
The ACIP recommends that all pregnant women be tested routinely for HBsAg
during an early prenatal visit (e.g., first trimester) in each pregnancy, even if they
have been previously vaccinated or tested. Women who were not screened
prenatally, those who engage in behaviors that put them at high risk for infection
(e.g., injection-drug use, having had more than one sex partner in the previous 6
months or an HBsAg-positive sex partner, evaluation or treatment for a sexually
transmitted infection [STI], or recent or current injection-drug use) and those
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with clinical hepatitis should be tested at the time of admission to the hospital
for delivery.2,3 
Immunization
The ACIP recommends the hepatitis B vaccine for pregnant women at risk for
hepatitis B virus infection. 
This recommendation is supported by:
The U.S. Preventive Services Task Force (USPSTF) 
Management of Exposed Infants/Treatment
The ACIP recommends that all infants born to HBsAg-positive women should
receive single-antigen hepatitis B vaccine and HBIG (0.5 mL) within 12 hours of
birth, administered at different injection sites.2
The ACIP recommends that all infants born to women without documentation
of HBsAg test results should receive the first dose of single-antigen hepatitis B
vaccine (without HBIG) within 12 hours of birth, while the woman’s test results
are pending.2
Authored by: 
Campbell KP, Lindley MC, Lentine D, Bhatt A. Hepatitis B virus evidence-statement: screening,
immunization, and treatment. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA,
editors. A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington,
DC: National Business Group on Health; 2006.
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Human Immunodeficiency Virus (HIV) 
(Screening, Counseling, and Preventive
Medication)
Clinical Preventive Service Recommendations (Screening)
The U.S. Preventive Services Task Force recommends that clinicians screen all
pregnant women for HIV.1
The USPSTF found good evidence that both standard and FDA-approved rapid
screening tests accurately detect HIV infection in pregnant women and fair
evidence that introduction of universal prenatal counseling and voluntary testing
increases the proportion of HIV-infected women who are diagnosed and are
treated before delivery. There is good evidence that recommended regimens of
highly active antiretroviral therapy (HAART) are acceptable to pregnant women
and lead to significantly reduced rates of mother-to-child transmission. Early
detection of maternal HIV infection also allows for discussion of elective cesarean
section and avoidance of breastfeeding, both of which are associated with lower
HIV transmission rates. There is no evidence of an increase in fetal anomalies or
other fetal harm associated with currently recommended antiretroviral regimens
(with the exception of efavirenz). Serious or fatal maternal events are rare using
currently recommended combination therapies. The USPSTF concluded that the
benefits of screening all pregnant women substantially outweigh potential harms.1
The Centers for Disease Control and Prevention (CDC) recommends that
clinicians screen all pregnant women for HIV.2
• HIV screening should be a routine part of prenatal care for all women.
Providers should inform all of their obstetric patients of the substantial benefit
that knowledge of HIV status has for the health of a woman and her infant. 
• HIV screening should occur as early as possible during pregnancy so that
informed therapeutic decisions can be made and treatment can begin early. For
women at high-risk of HIV infection (e.g., women who have a history of
sexually transmitted infections [STIs], women who exchange sex for money or
drugs, women who have multiple sex partners during pregnancy, and women
who use illicit drugs during pregnancy) should be re-tested during the third
trimester (at or before 36 weeks’ gestation). 
• Women who are admitted for labor and delivery who have not been screened
for HIV or whose HIV status is unknown should be tested immediately so
that timely prophylactic treatment can be initiated if appropriate. In such
cases, rapid testing or the expedited return of standard testing results is
recommended. After delivery, the standard confirmatory testing should be
completed. 
• HIV screening should be voluntary and free of coercion. Women should not
be tested without their knowledge, and a woman’s decision to decline testing
must not have detrimental consequences for the quality of prenatal care or
labor and delivery care she receives.
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CDC recommends that all pregnant women receive counseling and educational
information on HIV and HIV screening before they are screened/tested.2
• Information regarding HIV and the risks of HIV infection should be given to
all pregnant women as a part of routine prenatal care health education. 
• Pregnant women who have behaviors that place them at high risk for acquiring
HIV infection (e.g., multiple sex partners, history of STIs, substance abuse,
etc) should be referred to an HIV risk-reduction service (e.g., HIV centers
with personnel trained in HIV counseling, drug treatment centers, etc).
The U.S. Public Health Service concurs with the CDC recommendations
regarding screening and counseling. 
Regulations, laws, and policies regarding HIV screening of pregnant women and
infants differ throughout the United States and its territories. Healthcare providers
should adhere to local laws and regulations concerning maternal HIV screening.3
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Public Health Service (USPHS)
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Approximately 120,000 to 160,000 HIV infected women live in the Unites States,
80% of whom are of childbearing age.3 Each year between 1985 and 1995,
approximately 6,000 to 7,000 HIV infected women gave birth. Infected women
can pass on HIV to their infants (called perinatal HIV transmission) during
pregnancy, during labor and delivery, or after delivery through breastfeeding.3
During the early 1990s, before preventive medication was available to prevent
HIV transmission from an infected pregnant woman to her infant, an estimated
1,000 to 2,000 infants were born with HIV infection each year and the risk for
mother-to-child transmission ranged from 16% to 25%.3 Widespread universal
screening and perinatal use of combination antenatal antiretroviral drugs and/or
zidovudine combined with cesarean section sharply reduced transmission risk and
thus the number of perinatally acquired HIV infections.3 By 2001, the perinatal
transmission rate was reduced to less than 2%.3
However, despite important screening and treatment advances, perinatal HIV
transmission continues to occur; the CDC estimates that each year in the United
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States 280 to 370 infants are born with HIV.3 Most exposed infants are born to
women who were not tested for HIV prenatally or whose test results were
unknown at the time of delivery.3
Risk factors for perinatal HIV transmission include immunologically or clinically
advanced HIV disease in the woman, a high plasma viral load, preterm delivery,
injection drug use during pregnancy, and breastfeeding. The risk of perinatal
transmission also increases with protracted labor after the rupture of membranes,
maternal infection with a secondary STI, and the use of certain obstetrical
procedures.3
Value of Prevention
Analysis of the KIDS Inpatient Database of the Healthcare Cost and Utilization
Project (HCUP) estimated that there were 4,107 hospitalizations among HIV-
infected children in the United States in 2000, which accounted for approximately
$100 million in hospital charges and more than 30,000 hospital days.4
The estimated lifetime health care related cost of a pediatric HIV infection is
estimated to range between $100,000 and $117,000 (in year 1994 dollars). The
total costs depends on how rapidly an infant’s HIV progresses to AIDS and the
length of his or her life.5
Not Provided
The economic benefit of the preventive intervention includes the value of life
years saved plus savings that accrue by avoiding the lifetime cost of managing an
HIV infection. 
The cost of screening, testing, and treating HIV varies significantly, depending
on where the test is administered, whether counseling is also provided, and what
treatment protocol is followed. In 2004, the private-sector cost of HIV screening
averaged $29 (range $4 to $90); the cost of counseling averaged $39 (range $0-to
$129).6
The average wholesale price (AWP) for a 1-month supply of oral zidovudine
(ZDV) tablets is $219.02 (generic) or $410.54 (brand – Retrovir®).7 The AWP
for 6 weeks worth of zidovudine syrup — the recommended treatment for
exposed infants — is $48.13 (generic) or $54.73 (brand – Retrovir®). Retrovir®
treatment for HIV-positive women during labor/delivery is $246.71 (cost varies
depending on dose, which is based on the woman’s weight).7
Researchers studied the costs associated with screening and treating HIV/AIDS
in pregnant women and found that universal screening can be cost-saving in this
population. For example, compared to no screening, a universal screening
program targeting pregnant women would save an estimated $3.69 million
dollars and prevent 64.6 cases of pediatric HIV infection for every 100,000
pregnant women screened.8
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The purpose of screening is to identify infected women early in the course of
pregnancy. Early identification and the administration of preventive medication
can reduce perinatal transmission rates to less than 2%.3 Counseling services are
required to educate women on the benefits and risks of screening, risk reduction
strategies, and, for those who screen positive, treatment options.
The risks associated with screening for HIV include the potential negative
consequences of HIV infection such as discrimination and stigmatization, loss of
relationships, domestic violence, and adverse psychological reactions such as
depression or anxiety. The benefit of identification and early treatment — both
necessary to prevent perinatal HIV transmission — outweigh the risks and costs
associated with screening. Further, many of the aforementioned risks can be
reduced through appropriate education and counseling.3
HIV screening should occur as early as possible during pregnancy so that
informed therapeutic decisions can be made and treatment can begin early. For
women at high risk of HIV infection (e.g., women who have a history of STIs,
women who exchange sex for money or drugs, women who have multiple sex
partners during pregnancy, and women who use illicit drugs during pregnancy)
should be re-tested during the third trimester (at or before 36 weeks’ gestation). 
Women who are admitted for labor and delivery who have not been screened for
HIV or whose HIV status is unknown should be tested immediately so that
timely prophylactic treatment can be initiated if appropriate. In such cases, rapid
testing or the expedited return of standard testing results is recommended. After
delivery, the standard confirmatory testing should be completed.2
Counseling should be provided before and after screening, as medically indicated.
Preventive medication should be provided, as medically indicated, to prevent
perinatal transmission.
Screening for HIV should be conducted with an Food and Drug Administration
(FDA)-licensed enzyme immunoassay (EIA). If positive, the EIA should be
followed by a confirmatory test with an FDA-licensed supplemental test such as
the Western blot test. If a woman is being screened for the first-time during labor
and delivery, a rapid assay test should be used in place of the EIA. A rapid test
can provide a definitive negative result and a preliminary positive result, thus
identifying women who could benefit from antiretroviral treatment and a
cesarean delivery, and identifying infants who could benefit from antiretroviral
prophylactic treatment. Rapid tests should be confirmed by a supplemental test,
but, due to time constraints, suspected HIV positive women may be offered
treatment before the results of the supplemental test are received. Only one FDA-
approved rapid HIV test is currently available in the United States, the Abbott
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Murex Single Use Diagnostic System HIV-1 test. Other tests are pending
approval.2
All pregnant women should receive counseling and educational information on
HIV and HIV screening before they are screened.2 Pregnant women who have
behaviors that place them at high risk for acquiring HIV infection (e.g., multiple
sex partners, history of STIs, substance abuse, etc) should be referred to an HIV
risk-reduction service (e.g., HIV centers with personnel trained in HIV
counseling, drug treatment centers, etc).1 HIV-infected pregnant women should
receive HIV prevention counseling. This counseling should include discussion of
the risk for perinatal HIV transmission, ways to reduce this risk, and the
prognosis for infants who become infected. HIV-infected pregnant women
should be counseled regarding antiretroviral therapy during pregnancy to
improve their health and prevent perinatal transmission.3
The primary strategy to prevent perinatal transmission (in addition to avoidance
of breastfeeding) is antiretroviral chemoprophylaxis using zidovudine (ZDV),
now often part of a combined antiretroviral therapy regimen that reduces viral
load as low as possible near the time of delivery. ZDV should be administered
orally to the mother during the second and third trimesters of pregnancy;
intravenous administration of ZDV should be given to the woman during labor
and delivery. Infants born to HIV-positive women should be given ZDV during
the first 6 weeks of life.3
Health benefits should include provisions for ongoing treatment for HIV-positive
women and their infants.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence) 
• The USPSTF found good evidence to recommend that clinicians screen all
pregnant women for HIV.1
Recommended Guidance:
The Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Not Specified
• The CDC recommends that clinicians screen all pregnant women for HIV.2
• The CDC recommends that all pregnant women receive counseling and
educational information on HIV and HIV screening before they are
screened/tested.2
• The CDC recommends that zidovudine be administered orally to HIV-positive
pregnant women during the second and third trimesters of pregnancy and
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intravenously during labor and delivery. The CDC also recommends that oral
ZDV be administered to exposed infant during the first 6 weeks of life.2
These recommendations are supported by the:
• U.S. Public Health Service
Influenza (Immunization)
Clinical Preventive Service Recommendations
Not Applicable – The U.S. Preventive Services Task Force defers to the Advisory
Committee on Immunization Practices and the CDC on recommendations
surrounding immunization.
The Advisory Committee on Immunization Practices (ACIP) recommends that
all women who are pregnant during the influenza season (October to mid-May)
be vaccinated with trivalent inactivated influenza vaccine.1 Because this
population is considered at risk for influenza-related complications, it should be
given priority access to the vaccine in case of shortage.2
Note: Live attenuated influenza vaccine (LAIV) is contraindicated during
pregnancy. Because the intranasal vaccine spray contains live virus, it should not
be administered to pregnant women.1
A summary of guidelines for the immunization of pregnant women can be found
online (www.cdc.gov/nip/publications/preg_guide.htm).
Expert Consensus
The American Academy of Family Physicians (AAFP) and the American College
of Obstetricians and Gynecologists (ACOG) concur with the ACIP
recommendations. 
Authored by: 
Lentine D, Campbell KP. Human immunodeficiency virus evidence-statement: screening, counseling, and
preventive medication. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors.
A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington, DC:
National Business Group on Health; 2006.
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Economic Burden of 
Condition/Disease
The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Immunization Practices (ACIP)
• American Academy of Family Physicians (AAFP)
• American College of Obstetricians and Gynecologists (ACOG)
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research 
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Influenza is a viral respiratory tract infection that occurs during the winter
months in temperate climates. Uncomplicated cases of the illness usually resolve
within several days to weeks and include fever, cough, sore throat, headache,
muscle aches, and tiredness. 
Influenza infection can exacerbate other underlying medical conditions and can
lead to hospitalization or even death.1 Throughout the 1990s in the United
States, influenza infection was associated with an average of 36,000 deaths and
over 200,000 hospitalizations per year.3-4
Pregnant women are considered to be at increased risk for complications from
influenza infection. Healthy pregnant women in their third trimester are
hospitalized for influenza at rates as high as 250 per 100,000 reported cases.1
Rates are higher among pregnant women with other underlying medical
conditions. Researchers estimate that an average of 1 to 2 hospitalizations can be
prevented for every 1,000 pregnant women vaccinated.5
Despite the seriousness of influenza infection and the fact that the inactivated
influenza vaccine is safe and effective, only 12% to 13% of pregnant woman are
inoculated against influenza.1,6
All pregnant women who are not immunized against influenza are at risk of
infection.
Value of Prevention
The overall national economic burden of influenza-attributable illness for adults
aged 18 to 64 years is $4.6 billion in direct medical costs and an additional $5.6
billion in lost productivity resulting from 17 million missed workdays.7
Furthermore, adult hospitalizations from influenza-attributable illness result in
3.1 billion dollars per year in direct hospitalization costs (in year 2003 dollars).7
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Benefits and Risks 
of Intervention
Influenza-related complications during pregnancy increase medical care costs and
productivity losses triggered by lost work days. An infected employee may also
spread infection to other employees or family members.
Although no study specifically examined the case for pregnant women, studies of
the economic benefit of immunization in working adults commonly include
reduced hospitalizations, physician visits, and lost workdays; and an increase in
quality-adjusted days due to symptom relief from influenza-like illness.8-9
In 2004, the private-sector cost of an adult influenza vaccine averaged $13 and
approximately 95% of all paid claims fell within the range of $3 to $24 per
vaccine.10 Vaccine administration averaged $10 per dose and approximately 95%
of all paid claims fell within range of $0 to $20 per dose.10
Zanamivir and oseltamivir, the antiviral medications recommended for treatment
of influenza, have not been studied in pregnant women. Because of the unknown
effects of these drugs, they should only be used during pregnancy if the potential
benefit justifies the potential risk to the embryo or fetus.1
A review of several economic studies shows that vaccination of healthy working
adults is cost-effective and may result in cost-savings in some years.11 Though no
specific study was conducted with reference to pregnant women, economic
results are likely to be at least as favorable for this group since pregnant women
are at high risk for influenza-related complications.
Preventive Intervention Information
Immunization against influenza reduces the chance that a pregnant woman will
contract influenza thereby reducing her chance of experiencing influenza-related
illness, hospitalization, and associated costs.
There are many benefits to influenza vaccination. First, when a pregnant woman
is immunized during pregnancy, antibodies can be passed to her fetus and can
also be passed in breast milk.6 Because children under 6 months are at high risk
of complications from influenza, but cannot be vaccinated themselves, the
vaccination of persons who may transmit influenza to infants is recommended.1
That includes parents, siblings, and other caregivers. Second, healthy, working
adults who receive influenza shots (in a year when the vaccine is well matched to
the circulating influenza viruses) experience significantly fewer days of influenza-
like illness (ILI), make fewer doctor visits for such illnesses, and take fewer days
off from work due to ILIs, compared to unvaccinated workers.8-9
Influenza vaccination with inactivated virus is considered to be safe for both
pregnant women and their fetuses. Two studies with a total of over 2,250
pregnant women found no adverse events after vaccination, regardless of when
during pregnancy the vaccine is given.6,12
No studies have been conducted on the safety of LAIV in pregnant women.
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All women who will be pregnant during the influenza season (October to mid-
May) should be given the inactivated influenza vaccine at some point during
pregnancy. This single-dose vaccine may be administered during any trimester.1
The ideal time to vaccinate is October and November, although vaccination in
December or even later can still be beneficial since influenza activity peaks in
February or later in most years.1
It is important to note that a woman should receive an influenza vaccination with
each pregnancy to protect herself and her fetus. Immunity gained from the influenza
vaccine does not carry from year to year. Influenza vaccination is also recommended
for all household contacts of children less than 5 years of age and particularly for
households with children less than 6 months of age since infants are at very high risk
of influenza complications but are too young to receive the influenza vaccine.1
Inactivated influenza vaccine is administered via intra-muscular injection.
Injections can be administered in various settings including doctor office visits or
at the worksite. 
Influenza-specific antiviral medications are available, but no safety studies have
been conducted in pregnant women. Because of the unknown effects of these
drugs on fetuses, they should be used during pregnancy only if the potential
benefit justifies the potential risk to the embryo or fetus.1
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
Advisory Committee on Immunization Practices (ACIP)
Strength of Evidence: Expert Consensus
• The ACIP recommends vaccinating all women who are/will be pregnant
during the influenza season (October to mid-May) with trivalent inactivated
influenza vaccine.1
This recommendation is supported by the:
• American Academy of Family Physicians (AAFP) 
• American College of Obstetricians and Gynecologists (ACOG) 
• U.S. Preventive Services Task Force (USPSTF)
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Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that
clinicians screen all pregnant women for preeclampsia by taking a blood pressure
measurement at the first prenatal visit and periodically throughout the
pregnancy.1
Given the availability of new evidence, the USPSTF decided to update its 1996
recommendation. This work is in a queue to be scheduled for review. 
The American College of Obstetricians and Gynecologists (ACOG) recommends
that clinicians monitor blood pressure at the first prenatal visit, every 4 weeks
until 28 weeks’ gestation, every 2 to 3 weeks until 36 weeks’ gestation, and
weekly thereafter.2
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Pediatrics (AAP)
• American College of Obstetricians and Gynecologists (ACOG) 
• Agency for Healthcare Quality and Research (AHRQ)
• National Vital Statistics
• Peer-reviewed research
• Preeclampsia Foundation
• World Health Organization (WHO)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Preeclampsia occurs when a woman with normal blood pressure experiences acute
hypertension (140 mm Hg or higher systolic or 90 mm Hg or higher diastolic)
or an increase blood pressure (an increase of  30 mm Hg in systolic blood
pressure or  15 mm Hg in diastolic blood pressure) after 20 weeks’ of
gestation.3 While more common towards the end of pregnancy, preeclampsia can
appear as early as 20 weeks’ gestation. Symptoms of the condition include the
presence of protein in the urine, swollen extremities, sudden weight gain,
headaches, and changes in vision. However, many women report no symptoms.4
Preeclampsia affects 5% to 7% of all pregnancies.5 Women with preeclampsia are
at an increased risk for placental abruption, acute renal failure, cerebral
hemorrhage, disseminated intravascular coagulation, pulmonary edema,
282
EVIDENCE-STATEMENT: Healthy Pregnancy (Screening, Testing, Counseling, 
Immunization, and Preventive Medication)
circulatory collapse, and progression to full-blown eclampsia, an extremely
serious condition characterized by maternal seizure activity, coma, and death.
Preeclampsia can also cause severe problems for the fetus such as delayed growth,
low birth weight, and the risk of premature birth.6
Preeclampsia/eclampsia is the third leading cause of maternal death worldwide1
and is responsible for 18% of all maternal deaths in the United States.7 In the
United States during 2002, preeclampsia/eclampsia caused:
• Maternal death in 56 out of every 100,000 live birth.8
• Neonatal death in 71 out of every 100,000 live births.9
Research indicates that women that are pregnant for the first time, women with
multiple gestations, molar pregnancy or fetal hydrops, chronic hypertension or
diabetes, and those with a personal or family history of eclampsia or preeclampsia
are at increased risk for preeclampsia and eclampsia. Overweight and obese
women are also at increased risk of preeclampsia.10
Value of Prevention
According to the Hospital Cost Utilization Project (HCUP) Nationwide Inpatient
Survey (NIS), spending on hypertension during pregnancy totaled nearly $2.3
billion in the United States in 2003.11 During that year, approximately 204,868
pregnant women were admitted to the hospital for hypertension, staying an
average of 3.5 days. The average per-person charge for such hospital admissions
totaled $11,208.11 Few data are available about the incremental costs for infants
because of preeclampsia or the value of years of life lost due to preeclampsia and
its complications, including maternal or neonatal deaths. 
The medical care costs of maternal and neonatal complications due to
preeclampsia impose an additional financial burden on employer-sponsored
health insurance plans. 
Pregnancy-related complications affecting their own health or the health of their
children may also require working mothers to take significant time off from
work, resulting in additional productivity losses at the workplace.
Screening, which involves minimal cost, and early treatment can minimize and
prevent otherwise costly medical conditions. For example, although there is a lack
of recent research, there is acceptance of the finding that women with
preeclampsia or eclampsia stay in the hospital substantially longer than do
normotensive women (i.e., women having blood pressure typical of the group to
which they belong), regardless of their method of delivery. The longer hospital
stays and higher rates of cesarean section delivery among women with
preeclampsia and eclampsia lead to more costly obstetric medical claims. For
example, 217,700 excess hospital days for delivery admissions were attributable to
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Blood pressure screening is a standard procedure at each office visit and involves
minimal cost. Screening for preeclampsia is conducted as a part of routine
prenatal care and does not require a separate visit. 
Not Provided
Complete cost-effectiveness analyses are not available. 
Preventive Intervention Information
Screening allows clinicians to identify affected women early in the course of their
pregnancies and begin treatment, thereby reducing the risk of complications for
affected women and their infants. 
Regular blood pressure screening during pregnancy is used to detect
preeclampsia. Early detection of hypertension permits continuous monitoring
and early intervention (e.g., bed rest, medications, early delivery). Although
studies have not shown that early identification of hypertension and preeclampsia
is associated with better outcomes, clinical experience suggests that to be the case.
As such, the medical community considers regular blood pressure screening to be
in the best interest of both mother and fetus. At the same time, blood pressure
screening is simple, inexpensive, and acceptable to patients.
ACOG recommends that clinicians monitor blood pressure at the first prenatal
visit, every 4 weeks until 28 weeks’ gestation, every 2 to 3 weeks until 36 weeks’
gestation, and weekly thereafter.
Screening for preeclampsia can be conducted via conventional measures (arm 
cuff and a mercury calibrated aneroid or digital sphygmomanometer) or
ambulatory blood pressure monitoring. Before a diagnosis of preeclampsia can 
be made, the patient must have two elevated blood pressure readings (defined 
as  140/90 mmHg) taken at least 6 hours apart. Preeclampsia may also be
diagnosed if a woman has undergone an increase of 30 mmHg or more in
systolic pressure or 15 mmHg or more in diastolic pressure since becoming
pregnant. Clinicians should be aware that overweight and obese patients may
need to be monitored more closely, especially if they have preexisting
hypertension, due to their increased risk of preeclampsia.2
Treatment methods for preeclampsia include bed rest, medication, and delivery.
Health benefits should include provisions for follow-up and treatment services.
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance: 
The American College of Obstetricians and Gynecologists (ACOG)
Strength of Evidence: Not Specified
• The American College of Obstetricians and Gynecologists recommends
screening pregnant women for preeclampsia by monitoring blood pressure at
the first prenatal visit, every 4 weeks until 28 weeks’ gestation, every 2 to 3
weeks until 36 weeks’ gestation, and weekly thereafter.2
Prenatal Diagnosis of Chromosomal
Abnormalities and Neural Tube Defects
(Screening and Testing)
Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that
clinicians offer serum multiple marker screening to all pregnant women at low
risk for Down syndrome and amniocentesis or chorionic villus sampling (CVS)
testing to all pregnant women at high risk for Down syndrome. 
This recommendation is considered out of date and has been archived. 
In 1996, the U.S. Preventive Services Task Force recommended that clinicians
offer neural tube defect screening to all pregnant women who have access to
adequate prenatal care, counseling, and follow-up services. 
Screening for neural tube defects during pregnancy is currently considered part of
standard prenatal care. The USPSTF knows of no reason at the present time to
update its 1996 recommendation.
Offering pregnant women screening and testing (prenatal diagnosis) to detect
chromosomal abnormalities is standard clinical practice. All pregnant women are
candidates for screening services. Most clinical guidelines recommend that
women age 35 and older (and those who have equivalent risk) be offered testing
in place of, or in addition to, screening.1
Authored by: 
Campbell KP, Chattopadhyay S. Preeclampsia evidence-statement: screening. In: Campbell KP, Lanza A,
Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical Preventive
Services: Moving Science into Coverage. Washington, DC: National Business Group on Health; 2006.
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Offering all pregnant women (irrespective of age) screening services to detect
neural tube defects (NTDs) and offering testing services (prenatal diagnosis) to
women at elevated risk is standard clinical practice.2
There are several screening and prenatal diagnosis methods available. There is no
single current authoritative source on which of the various methods provides the
best outcome. Therefore, it is recommended that employers provide healthcare
coverage for all screening and testing methods, including — but not limited to
— the following:
• All types of maternal serum screening tests
• Amniocentesis 
• Chorionic villus sampling (CVS) 
• Ultrasound
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Obstetricians and Gynecologists (ACOG)
• Centers for Disease Control and Prevention (CDC)
• March of Dimes
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
• U.S. Public Health Service
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Chromosomal Abnormalities
Down syndrome (trisomy 21) is the most common chromosomal abnormality in
the United States, affecting 1 in every 800 to 1,000 live-born babies.3 Children
with Down syndrome have physical abnormalities including heart defects, short
stature, characteristic facial abnormalities, and varying degrees of mental
retardation. Although Down syndrome and its complications cannot be cured,
early intervention programs that begin in infancy may help those living with
Down syndrome achieve certain developmental milestones in a more timely
fashion.
Life expectancy among individuals with Down syndrome has increased
substantially over the past three decades. In 1983, the average life expectancy for
an individual with Down syndrome was 25 years; by 1997, life expectancy had
risen to 49 years.4 However, life expectancy gains have not been equal among
individuals with Down syndrome, and large survival disparities have been noted
between white and black infants.4
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Other chromosomal abnormalities include trisomy 13, trisomy 18, and sex-
chromosome abnormalities. Trisomy 13 and 18 are very severe and usually cause
fetal or infant death.5 Sex-chromosome abnormalities are the most mild form or
chromosomal abnormality and occur in approximately 1 in every 2,000 to 2,500
female infants and 1 in every 600 to 800 male infants.5 These abnormalities lead
to sexual development problems (including infertility) and, sometimes,
behavioral or learning problems.5
Neural Tube Defects (NTDs)
Spina bifida and anencephaly are common and permanent neural tube defects
(NTDs) which result from the failure of the neural cord to properly fuse. Each
year in the United States, approximately 3,000 pregnancies are affected by NTDs
and approximately 2,200 infants are born with neural tube defects.6 Many 
NTD-affected pregnancies do not result in a live birth since they are electively or
spontaneously aborted (commonly referred to as a miscarriage) or result in fetal
death or stillbirth.
Anencephaly is fatal; all affected infants die shortly after birth. Approximately
92% of infants born with spina bifida survive with varying degrees of disability.
Debilitating medical complications associated with spina bifida include paralysis
and bowel and bladder incontinence.7
Chromosomal Abnormalities
The risk of Down syndrome increases dramatically with advancing maternal age.
For example, the risk of delivering a baby with Down syndrome is about 1 in
1,250 for a 25-year-old woman, 1 in 1,000 for a 30-year-old woman, 1 in 400
for a 35-year-old woman, and 1 in 100 for a 40-year-old woman.8 Risk factors
other than age are poorly understood, and 97% of Down syndrome pregnancies
occur in families with no previous history of the syndrome.1
As with Down syndrome, the risk of trisomy 13 and trisomy 18 increases with
advancing maternal age; women age 35 or older are most at risk for these
conditions.5
Neural Tube Defects (NTDs)
Inadequate folic acid consumption is the major risk factor for NTDs.
Consuming the recommended daily amount of folic acid (0.4-0.8mg) can reduce
a woman’s chance of having a NTD-affected pregnancy by 40% to 80%.9
However, only 33% of childbearing-age women report taking vitamins that
contain folic acid.9
Spina bifida, the most common type of NTD, occurs most frequently among
Hispanics and European whites and least frequently among African-Americans
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The economic impact of chromosomal abnormalities and NTDs is substantial. 
The lifetime cost of live-born infants with Down syndrome includes the
incremental medical, developmental, and special education costs as well as lost
productivity and earnings due to death and disability. The total lifetime cost for
all cases of Down syndrome (based on 1988 cross-sectional data) was estimated
to exceed $1.8 billion in year 1992 dollars.11
The total lifetime cost for a child born with spina bifida is estimated at $636,000
(in year 2002 dollars).12 Applying that cost to the prevalence rate for spina bifida
from National Birth Defect Prevention Network data13 (4 million live births each
year) yields an estimated $814 million in lifetime costs for each cohort.12 Costs
associated with NTDs are shared by parents, employers, and communities.
Lost productivity attributable to premature morbidity and mortality due to
Down syndrome was estimated to total $1.18 billion in 1992 dollars, comprising
nearly 64% of total lifetime cost for all cases of Down syndrome.11
Apart from the incremental excess cost of medical care for affected children,
employers face productivity losses of employees who must care for affected
children. The present value of lost workdays for a typical caregiver was estimated
to be $252,000 in year 1993 dollars.14
The economic benefit of prenatal screening is defined as the averted cost from
preventing the birth of a child with a chromosomal abnormality or NTD. These
averted costs include savings from the direct costs of medical, developmental, and
special education services as well as the indirect costs associated with lost
productivity due to morbidity and mortality.12
In 2004, the private-sector cost of15:
• Screening for NTDs via ultrasound averaged $155; approximately 95% of all
paid claims fell within the range of $41 to $352 per ultrasound.
• Screening for chromosomal abnormalities averaged $56; approximately 95% of
all paid claims fell within the range of $0 to $158 per test. The full range of
tests totaled, on average, $8,255.
• Genetic testing (including complete gene sequence analysis) averaged $408 per
test; approximately 95% of all paid claims fell within the range of $0 to
$1,852. The full range of tests totaled, on average, $5,013. 
• Genetic counseling averaged $39; approximately 95% of all paid claims fell
within the range of $1 to $129.
• An amniocentesis averaged $296.
• Chorionic villus sampling averaged $355. 
When birth defects are detected, the cost of treatment may include costs
associated with genetic counseling and termination.
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Benefits and Risks 
of Intervention
California is one of two states with a public prenatal screening program, which is
supported by fees paid by prenatal care providers and insurers. In 1998, the fee
paid by payers was $105, which covered the cost of the State’s expanded
screening program for chromosomal abnormalities and NTDs. The fee covered
both the initial screening and reimbursements for genetic counseling, ultrasound,
amniocentesis, and genetic testing.16 The California prenatal screening program
estimated a benefit-to-cost ratio of 2.7, meaning that, on average, each $1 spent
on the program would be offset by $2.70 in economic benefits calculated using a
discount rate of 5% per year.16
Preventive Intervention Information
The major benefit of screening for and diagnosing chromosomal abnormalities
and NTDs is the opportunity to inform women and their partners of the
likelihood that they are carrying an affected fetus. The usefulness of this
information depends on the values and preferences of the parents. With
appropriate information and counseling, parents can decide whether to terminate
or continue a pregnancy. Parents who decide to continue the pregnancy have an
opportunity to prepare emotionally and financially for the birth of their child. 
The knowledge gained by screening can help women and their families make an
informed decision as to whether or not to undergo prenatal diagnosis (testing). In
turn, prenatal diagnosis can help women and their families make an informed
decision about whether to continue or terminate the pregnancy. Prenatal
diagnosis of a chromosomal abnormality or NTD may preclude trauma
associated with the unexpected delivery of an affected infant.1 Furthermore,
information gained from prenatal diagnosis may help providers better prepare for
the delivery of an affected infant.1,17 For example, some studies show reduced
severity of paralysis in infants with spina bifida delivered by cesarean section
compared with those having vaginal delivery.17
The risks of screening and prenatal diagnosis depend on the method used. The
major risk associated with screening is the chance of a false-positive result, which
can lead to unnecessary anxiety.16 Thus, confirmatory testing (prenatal diagnosis)
is considered to be essential. Risks of prenatal diagnosis include the risks
associated with amniocentesis or CVS (in very rare cases the fetus can be injured,
suffer an infection, or miscarry), the psychological effects for the woman and her
partner of a positive result, and the risks associated with abortion.
Many women who test positive for an NTD-affected pregnancy choose to
terminate their pregnancy. Screening thus leads to the prevention of the births of
affected infants. In fact, some studies have shown that the availability of
screening, testing, and the opportunity for termination reduces the number of
infants born with NTDs by up to 70%.16 However, termination rates vary
depending on the ethnic and religious backgrounds of the families and many
other factors. In one study of an ethnically diverse population in California,
termination rates for spina bifida averaged 67%.16 It is important to remember
that many women who choose to carry the pregnancy to term will have either a
stillborn fetus or an infant who will die in the first few hours or days after birth.
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The screening and testing process is defined by several factors: the type of test
utilized, whether there is need for follow-up testing, and the risk-status of the
pregnant woman. Timing is left to the discretion of the physician and should be
determined by the pregnant woman’s needs and the stage of pregnancy when she
began prenatal care. 
Several screening methods are used to determine risk for chromosomal
abnormalities and NTDs. Most methods examine biological markers in maternal
blood samples. 
Down syndrome can be diagnosed prenatally by identifying an extra
chromosome 21 through a cell sample. Fetal cell samples can be obtained
through an amniocentesis, chorionic villus sampling (CVS), or cordocentesis.1
Health benefits should include provisions for follow-up services such as:
• Genetic counseling
• Termination or continuing prenatal care and labor and delivery. 
Cures for chromosomal abnormalities and NTDs are not available, but various
interventions can be used to improve the functioning or quality of life of those
who are affected. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance: 
Offering pregnant women screening and testing (prenatal diagnosis) to detect
chromosomal abnormalities is standard clinical practice. All pregnant women are
candidates for screening services. Most clinical guidelines recommend that
women age 35 and older, (and those who have equivalent risk) be offered testing
in place of, or in addition to, screening.2-3 
Offering all pregnant women (irrespective of age) screening to detect neural tube
defects (NTDs) and offering testing (prenatal diagnosis) to women at elevated
risk is standard clinical practice.2-3 
There are several screening and prenatal diagnosis methods available. There is no
single current authoritative source on which of the various methods provides the
best outcome. Therefore, it is recommended that employers provide healthcare
coverage for all screening and testing methods, including — but not limited to
— the following:
• All types of maternal serum screening tests
• Amniocentesis 
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Rh (D) (Screening and Preventive
Medication)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends Rh (D)
blood typing and antibody testing for all pregnant women during their first visit
for pregnancy-related care.1
The USPSTF also recommends repeated Rh (D) antibody testing for all
unsensitized Rh (D)-negative women between 24 and 28 weeks’ gestation, unless
the biological father is known to be Rh (D)-negative.1
The USPSTF found good evidence that Rh (D) blood typing, anti-Rh (D)
antibody testing, and intervention with Rh (D) immunoglobulin, as appropriate,
prevents maternal sensitization and improves outcomes for newborns. The
benefits substantially outweigh any potential harms.1
The USPSTF found fair evidence that repeated antibody testing for unsensitized
Rh (D)-negative women (unless the father is also known to be Rh [D]-negative)
and intervention with Rh (D) immunoglobulin, as appropriate, provides
additional benefit over a single test at the first prenatal visit in preventing
maternal sensitization and improving outcomes for newborns. The benefits of
repeated testing substantially outweigh any potential harms.1
The American Academy of Family Physicians (AAFP) concurs with the USPSTF.
The American College of Obstetricians and Gynecologists (ACOG) concurs with
the U.S. Preventive Service Task Force (USPSTF) recommendations, with the
exception that ACOG strongly recommends that clinicians administer
immunoglobulin to Rh (D)-negative pregnant women after undergoing invasive
procedures such as chronic villus sampling or fetal blood sampling.2
ACOG further recommends that immunoglobulin be administered following a
possible spontaneous or elective abortion, second or third trimester bleeding,
external cephalic version, or abdominal trauma.2
Expert Consensus
Authored by: 
Campbell KP, Grosse S, Chattopadhyay S. Prenatal diagnosis of chromosomal abnormalities and neural
tube defects evidence-statement: screening and testing. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay
S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical Preventive Services: Moving Science into
Coverage. Washington, DC: National Business Group on Health; 2006.
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The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatricians (AAP)
• The American College of Obstetricians and Gynecologists (ACOG)
• National Institutes of Health (NIH)
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Rh (D) incompatibility refers to a condition that develops when a pregnant
women with Rh-negative blood type carries a fetus with an Rh-positive blood
type. In reaction to what is perceived to be a foreign substance, the woman’s body
makes antibodies that attack fetal red blood cells (isoimmunization). Since it
takes time to build up antibodies, first pregnancies are typically not affected by
Rh incompatibility. However, in subsequent pregnancies, Rh incompatibility may
cause destruction of fetal red blood cells (hemolysis), which leads to anemia and
an accumulation of bilirubin in the fetus’s bloodstream (hyperbilirubinemia) that
produces jaundice. Extreme jaundice leads to kernicterus, a form of brain damage
associated with cerebral palsy and mental retardation. The hemolytic destruction
of red blood cells can also lead to hydrops fetalis, a severe anemia resulting in
fetal heart failure, total body swelling, respiratory distress or total circulatory
collapse, and often death.3
Rh incompatibility occurs in approximately 10% of all pregnancies, depending
on the race of the pregnant woman and her fetus. Without treatment, 25% to
30% of these fetuses will show various degrees of hemolytic anemia and
hyperbilirubinemia. An additional 20% to 25% will be hydropic and will either
die in utero (resulting in a stillbirth) or shortly after birth. Hemolytic disease of
the fetus accounts for 4 to 5 deaths per 100,000 births in the United States.3
Only Rh-negative women are at risk of having a baby with Rh disease. If an Rh-
negative woman and Rh-positive man conceive an Rh-positive fetus, there is a
chance that some of the fetus’s Rh-positive red blood cells may enter the woman’s
blood stream, which stimulates the woman’s immune system to produce
antibodies against the fetus’s Rh-positive cells. The risk of Rh disease becomes
greater with each subsequent pregnancy.4
Value of Prevention
No data exist that estimate the total direct or indirect costs of Rh (D)
incompatibility in the United States.
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The value of life years lost due to fetal loss, stillbirth, neonatal and post-neonatal
deaths, and productivity loss associated with disability constitute the major
components of the economic burden of Rh (D) incompatibility. Costs would be
even higher if the additional medical care costs and productivity losses of
working pregnant women are considered. 
In addition to the incremental medical care utilization costs due to complications
from Rh (D) incompatibility, there can be significant productivity losses at the
workplace when working parents need to take time off from work to care for
short- or long-term health problems of their children. 
Early identification of Rh (D) incompatibility allows clinicians to begin
treatment before damage is done to the fetus. This prevents otherwise expensive
medical treatment, lifelong disability, and even death.
In 2004, the private-sector cost of screening for Rh (D) incompatibility averaged
$15 per screen; approximately 95% of all paid claims fell within the range of $0
to $38. The cost of immune globulin averaged $111 and approximately 95% of
all paid claims fell within the range of $0 to $178.5
Not Provided
A review undertaken on behalf of the National Institute of Clinical Excellence in
the United Kingdom, the governmental unit responsible for producing evidence-
based recommendations for the UK, found that routine antenatal anti-D
preventive medication (immunoglobulin) provides a cost-effective intervention
for preventing the incidence of hemolytic disease of the newborn in pregnancies
of Rh (D)-negative women.6
Preventive Intervention Information
Early identification of Rh (D) incompatibility allows clinicians to begin
treatment before damage is done to the fetus. This prevents otherwise expensive
medical treatment, lifelong disability, and even death.
Early detection of Rh (D)-negative blood type in a pregnant woman is of
substantial benefit (when the woman is not yet isoimmunized and the father of
the fetus is not known to be Rh (D)-negative) because it makes prevention of
isoimmunization possible. Clinicians can administer anti-D immune globulin to
Rh (D)-negative pregnant women, thereby preventing the maternal
isoimmunization that would adversely affect subsequent pregnancies. This course
of treatment prevents isoimmunization in 96% of women at risk.4 Screening and
treatment with immunoglobulins have few adverse affects.4
The USPSTF strongly recommends that all pregnant women undergo Rh (D)
blood typing and antibody testing at their first prenatal visit. Furthermore, the
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USPSTF recommends that women known to be Rh (D)-negative and
unsensitized undergo a repeat Rh (D) antibody test between 24 and 28 weeks’
gestation to determine their degree of sensitivity. This second step is unnecessary
if the fetus’s father is known to be Rh (D)-negative. 
A full dose (300mg) of immunoglobulin should be administered to1-2:
• All unsensitized Rh (D)-negative women after their repeated antibody screen
between 24 and 28 weeks’ gestation.
• D-negative women within 72 hours of delivering a Rh (D)-positive infant.
• D-negative women following amniocentesis or either induced or spontaneous
abortion (a 50 mg dose should be administered when abortion occurs prior to
13 weeks).
Clinicians have discretion regarding the provision of immunoglobulin to 
Rh (D)-negative pregnant women after undergoing invasive procedures such as
chorionic villus sampling or fetal blood sampling and/or following a possible
spontaneous or elective abortion, second or third trimester bleeding, external
cephalic version, or abdominal trauma.2
Rh (D) blood typing and antibody testing is conducted via an analysis of the
blood. Immunoglobulin is administered to those at risk of Rh disease through an
injection.
Health benefit coverage should include provisions for follow-up and treatment
services. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
The U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence), 
B (Recommended/At Least Fair Evidence)
A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to support Rh (D) blood typing and
antibody testing for all pregnant women during their first visit for pregnancy-
related care.1
B (Recommended/At Least Fair Evidence)
• The USPSTF found fair evidence to support Rh (D) antibody testing for all
unsensitized Rh (D)-negative women between 24 and 28 weeks’ gestation,
unless the biological father is known to be Rh (D)-negative.1
This recommendation is supported by the:









The American College of Obstetricians and Gynecologists (ACOG)
Strength of Evidence: Expert Consensus 
• The ACOG concurs with the USPSTF recommendations, with the exception
that ACOG strongly recommends that clinicians 1) administer
immunoglobulin to Rh (D)-negative pregnant women after undergoing
invasive procedures such as chorionic villus sampling or fetal blood sampling,
and 2) administer immunoglobulin following a possible spontaneous or
elective abortion, second or third trimester bleeding, external cephalic version,
or abdominal trauma.2
Rubella (Screening)
Clinical Preventive Service Recommendations
Not Applicable – The U.S. Preventive Services Task Force defers to the Advisory
Committee on Immunization Practices and the CDC on recommendations
surrounding immunization. 
Rubella vaccine is contraindicated during pregnancy. Because the vaccine
contains live virus, it should not be administered to pregnant women.1
The Advisory Committee on Immunization Practices (ACIP) recommends that
clinicians screen all women of childbearing age, including pregnant women, for
rubella susceptibility during their first clinical encounter. A history of vaccination
(proved by written documentation of receipt of  1 dose of a rubella-containing
vaccine after the age of 1 year) or a serologic test for antibodies (offering
laboratory evidence of immunity) can be used to document immunity against
rubella. Susceptible, nonpregnant women should be vaccinated, and susceptible
pregnant women should be vaccinated immediately after delivery or at the end of
their pregnancies (such as following miscarriage). Nonpregnant women may be
offered vaccination without serologic screening.1
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medication. In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors.
A Purchaser’s Guide to Clinical Preventive Services: Moving Science into Coverage. Washington, DC:
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The American Academy of Family Physicians (AAFP) concurs with the ACIP
recommendations.
The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Immunization Practices (ACIP)
• American Academy of Family Physicians (AAFP)
• Centers of Disease Control and Prevention (CDC)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
For most people, rubella is a mild illness. However, when contracted during early
pregnancy, particularly during the first trimester, rubella can cause serious
complications including miscarriage, stillbirth, and congenital rubella syndrome
(CRS) – a constellation of birth defects that include hearing impairment, growth
retardation, developmental delays, and heart and eye defects.2 Because rubella
infection can affect all the organs of a developing fetus, the earlier a woman is
infected with rubella during her pregnancy, the more severe the complications are
for the developing fetus. Approximately 90% of infants born to women who
contracted rubella during the first 11 weeks of pregnancy develop CRS and about
20% of infants born to women who contracted rubella during the first 20 weeks
of pregnancy develop CRS.2
In 1964-1965, an epidemic of rubella hit the United States: over 12 million
individuals were infected resulting in 11,000 fetal losses (as a result of miscarriage
or abortion) and 20,000 cases of CRS.3
In 1969, rubella vaccines were licensed in the United States to protect individuals
from rubella. Widespread vaccine use led to a 99% reduction in the number of
rubella cases over 3 decades; this reduced the rubella caseload from a high of
57,686 cases in 1969 to only 271 cases in 1999.2
Since universal childhood immunization was initiated in 1969, there has not
been another rubella epidemic, although isolated outbreaks do occur. The United
States experienced a resurgence of rubella in the early 1990s with 1,124 cases
reported in 1990 and 1,412 in 1991. During this time period 66 infants were
born with CRS.4
In 2004, an expert panel convened by CDC concluded that rubella and CRS
have been eliminated from the United States; however, continued vaccination of
susceptible women and children is necessary to maintain this success.3
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Because pregnant women are most susceptible to the complications of rubella,
experts recommend the targeted screening and vaccination of childbearing-aged
women. Such a practice would reach those individuals who were not vaccinated
in childhood. The rubella vaccine is contraindicated for use during pregnancy
due to the theoretical possibility that the live virus rubella vaccine could cause
fetal infection and CRS; however, there have been no documented cases of CRS
related to use of the rubella vaccine.1
Since the mid-1990s, rubella and CRS has disproportionately affected foreign-
born ethnic minorities. In 1999, 73% of all rubella cases in the United States
occurred among Hispanics, most of whom were from Mexico and Central
America (CDC, unpublished data). Between 1998 and 2000, over 90% of all
CRS cases occurred among infants of Hispanic women 96% of whom were
foreign-born.3
Value of Prevention
CRS and its complications have substantial health consequences and economic
costs. A large rubella outbreak in 1964-1965 cost an estimated $840 million.5 In
2006, the estimated lifetime cost of treating a child born with CRS exceeded
$200,000.5
Rubella and CRS result in excess direct medical costs. Indirect costs constitute
the major workplace burden of rubella, however. Indirect costs include
permanent disability caused by CRS as well as productivity losses associated with
the missed work time of employed caregivers attending to their sick children. 
The economic benefits of immunization result from reducing hospitalizations
and outpatient visits and by avoiding productivity losses caused by rubella or
CRS-related disabilities.
In 2004, the private-sector cost of screening for rubella antibodies averaged $21;
approximately 95% of paid claims fell within the range of $0 to $50.6 The cost of
the rubella vaccine averaged $20 and approximately 95% of all paid claims fell
within the range of $0 to $40 per dose (1 to 2 doses are required for protection
against rubella).6
In 2006, the lifetime cost of treating a child born with CRS exceeded $200,000.5
Although there is a lack of economic evidence about the cost-effectiveness of
screening pregnant women, one study that investigated the current 2-dose MMR
vaccination program for children through a decision-tree-based analysis
demonstrated that the program resulted in substantial cost-savings and high
benefit-to-cost ratios. The estimated total cost savings to society of $7.6 billion
(in year 2001 dollars) included a savings of $549 million from rubella and CRS
prevention.7
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Screening allows clinicians to identify childbearing-age women who are at risk for
rubella and to immunize them before they become pregnant. Screening pregnant
women allows clinicians to identify at-risk women and to encourage them to be
immunized immediately after delivery, thereby offering protection during
subsequent pregnancies. 
Screening for rubella susceptibility involves minimal risk, although false-positive
test results may lead to unnecessary treatment. The rubella vaccine is very
effective; more than 90% of individuals vaccinated show long-term protection
from the illness.1 Adverse reactions to the rubella vaccine may include pain at the
injection site or temporary rash, which are usually mild in both children and
adults, although adults — particularly women — commonly complain of
temporary joint pain after vaccination.
All women of childbearing age, including pregnant women, should be screened
for rubella susceptibility during their first clinical encounter. All women of
childbearing age who are not pregnant should be vaccinated at their first clinical
encounter if not immune to rubella. A susceptible pregnant woman should be
vaccinated immediately after delivery or at the end of her pregnancy (e.g.,
miscarriage).
Screening is conducted by ascertaining an individual’s risk for rubella. Immunity
to rubella can be documented by 1) a history of immunization (proved by
written documentation of receipt of 1 dose of a rubella-containing
immunization after the age of 1 year), or 2) a serologic test for antibodies
(offering laboratory evidence of immunity). Individuals who cannot document
immunity are considered at risk for rubella. 
Rubella immunization is administered via an injection. 
Health benefits should include provisions for treatment services.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
Advisory Committee on Immunization Practices (ACIP)
Strength of Evidence: Expert Consensus
The ACIP recommends that clinicians screen all women of childbearing age,
including pregnant women, for rubella susceptibility during their first clinical
encounter. Susceptible non-pregnant women should be vaccinated and
susceptible pregnant women should be vaccinated immediately after delivery or
at the end of their pregnancy (e.g., miscarriage).1
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This recommendation is supported by the:
• U.S. Preventive Services Task Force (USPSTF) 
Syphilis (Screening)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that
clinicians screen all pregnant women for syphilis infection.1
The USPSTF found good evidence that screening pregnant women decreases the
proportion of infants with clinical manifestations of syphilis infection and those
with positive serologies. The USPSTF concludes that the benefits of screening
substantially outweigh the potential harms.1
The Centers for Disease Control and Prevention (CDC) recommends a serologic
test for syphilis for all pregnant women at the first prenatal visit. Women who are
at high risk for syphilis morbidity, are previously untested, or have a positive
serology in the first trimester should be screened again early in the third trimester
(28 weeks gestation) and at delivery. Infants should not be discharged from the
hospital unless the syphilis serologic status of the mother has been determined at
least one time during pregnancy and preferably again at delivery.2
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Authored by: 
Campbell KP, Lindley MC, Bhatt A, Chattopadhyay S. Rubella evidence-statement: screening. In: Campbell
KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical
Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group on Health;
2006.
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Syphilis is a serious sexually transmitted infection (STI) that, if left untreated,
may result in cardiovascular and neurological complications leading to disability
and ultimately death.1
In addition to sexual transmission, syphilis can be passed from an infected
mother to her infant during pregnancy and delivery. Congenital syphilis is
particularly severe and results in fetal or infant death in 40% of cases.1 In 2002,
451 cases of congenital syphilis were reported in the United States.3 Of these
cases, 333 (73.8%) occurred because the mother had no documented treatment
or received inadequate treatment of syphilis before or during pregnancy.3 Infected
infants who survive may suffer serious central nervous system abnormalities,
deafness, bone and joint deformities, skin abnormalities, blood disorders, and
other problems.3
Populations at increased risk for syphilis infection (as determined by incidence
rates) include commercial sex workers, persons who exchange sex for drugs, and
those in adult correctional facilities. 
The prevalence of syphilis infection varies widely among communities and
patient populations.1 Some populations have a particularly high risk of infection,
specifically African-Americans and people living in the Southeastern United States.4
Value of Prevention
The average annual national cost of treating infants with congenital syphilis is
approximately $18.4 million (in year 1995 dollars).5
The health, disability, and life insurance costs of syphilis-infected employees
impose a significant economic burden on employers. Affected women may also
lose work time in order to seek treatment for themselves or for their affected
infants. 
Screening and early detection are key to averting costs associated with disease
progression, long-term complications, and neonatal transmission. For example,
treatment for early stage syphilis ($41.26) is much less expensive than treatment
for later stage disease ($2,062) (both figures in year 2001 dollars).6
In 2004, the private-sector cost of screening for syphilis averaged $12;
approximately 95% of all paid claims fell within the range of $0 to $32.7
The cost of treating syphilis will vary depending on the medication used and
other factors. For azithromycin therapy, the 2001 public-sector price of the 1-g
sachet formulation was $11.50 and the wholesale price for a 1-g dose ranged
from $17.32 for the sachet formulation to $27.89 for tablets. The public sector
cost of standard IM benzathine penicillin therapy ranged from $18.64 to $22.22
(in year 2001 dollars).6
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Serological screening of pregnant women is cost-effective even when there is a
very low prevalence of maternal infection because screening is inexpensive but
treating congenital syphilis is costly.8
Preventive Intervention Information
Screening for syphilis allows clinicians to identify affected patients and begin
treatment early in the course of disease. Early intervention improves outcomes
and avoids the health and economic consequences of latent disease in the mother
and the occurrence of congenital syphilis.2 Treatment also reduces the risk of
transmission between the affected woman and her sexual partner(s). 
No studies have documented harms associated with screening for syphilis.
Theoretical harms include partner discord, stigma, unnecessary anxiety, treatment
in the case of a false-positive result, and opportunity costs (in terms of time and
resources) to both the clinician and patient. Harms of treatment include allergic
reactions to penicillin and other side effects of treatment medications such as the
Jarisch-Herxheimer reaction (fever, headache, and pain that occurs during the 24
hours after initiating antibiotic treatment for syphilis and is caused by the release
of fragments of the dead, infective microorganism into the bloodstream).1
The benefits associated with screening are substantial. Screening allows for early
detection and treatment, prevention of complications that may occur in later
stages of the disease, and prevention of neonatal transmission. Antibiotic
treatment for syphilis is effective, and inexpensive. Therefore, the USPSTF
concluded that the benefits of screening pregnant women for syphilis infection
substantially outweigh the potential harms.1
All pregnant women should be screened for syphilis at their first prenatal care
visit. For women in high-risk groups, repeat serologic testing may be necessary in
the third trimester (28 weeks) and again at delivery.1-2 Follow-up serologic tests
should be obtained to document successful treatment.1
A variety of syphilis tests are available and in development. Screening for syphilis
typically involves the use of 2 different tests, a nontreponemal test and a
treponemal-specific test, for screening and confirmation. For example, a
nontreponemal blood test such as the venereal disease research laboratory
(VDRL) or the rapid plasma reagin (RPR) may be performed. A second,
different kind of test, such as the fluorescent treponemal antibody absorbed
(FTA-ABS) or the T. palladium particle agglutination (TP-PA) may then be used
to confirm the results of the nontreponemal test.1,4 
Syphilis screening tests that are approved by the Food and Drug Administration
(FDA) or are pending FDA approval include1,4:
• Nontreponemal test such as the venereal disease research laboratory (VDRL) or
the rapid plasma regain (RPR) on serum specimens followed by a fluorescent
treponemal antibody absorbed (FTA-ABS) or T. palladium particle
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Information
agglutination (TP-PA) for confirmation.
• Immunochromatographic Strip (ICS) point-of-care test on blood specimen,
when FDA approved.
• Line Immunoassay (LIA) point-of-care test on blood specimen, when FDA
approved.
• Enzyme-linked Immunosorbent Assay (ELISA) for treponemal antibody in
serum specimens. 
• RPR point-of-care test for nontreponemal antibody in serum specimens. 
• Dark field microscope examination of lesion specimens.
Follow-up tests should be performed using the same nontreponemal test initially
used to document infection (e.g., VDRL or RPR) to ensure comparability.1
Syphilis should be treated with an antibiotic regimen appropriate for the woman’s
stage of disease. Some experts recommend additional therapy (e.g., a second dose
of benzathine penicillin 2.4 million units IM) one week after the initial dose,
particularly for those women in the third trimester of pregnancy and for women
who have secondary syphilis during pregnancy.9
Infants should be treated for presumed congenital syphilis if they were born to
mothers who, at delivery:
• Had untreated syphilis; 
• Were treated with a non-recommended antibiotic regimen; 
• Were treated less than one month prior to delivery; or 
• Had evidence of relapse or reinfection after treatment. 
Recommended treatment regimens for infants include aqueous crystalline
penicillin G (administered every 12 hours during the first 7 days of life and every
8 hours thereafter) for 10 to14 days or procaine penicillin G (administered daily
in a single dose for 10 to 14 days). If more than one day of therapy is missed, the
entire course should be restarted.10
Health benefits should include provisions for treatment services.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence) 
• The USPSTF found good evidence that screening pregnant women decreases
the proportion of infants with clinical manifestations of syphilis infection and
those with positive serologies. The USPSTF concludes that the benefits of
screening substantially outweigh the potential harms.1
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Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Not Specified
• The CDC recommends a serologic test for syphilis on all pregnant women at
the first prenatal visit. Women who are at high risk for syphilis morbidity, are
previously untested, or have a positive serology in the first trimester should be
screened again early in the third trimester (28 weeks gestation) and at delivery.
Infants should not be discharged from the hospital unless the syphilis serologic
status of the mother has been determined at least one time during pregnancy
and preferably again at delivery.2
Tetanus (Immunization)
Clinical Preventive Service Recommendations
Not Applicable – The U.S. Preventive Services Task Force defers to the Advisory
Committee on Immunization Practices and the CDC on recommendations
surrounding immunization.
The Advisory Committee on Immunization Practices (ACIP) recommends that
all previously vaccinated pregnant women who have not been vaccinated against
tetanus in the past 10 years receive a booster vaccination against tetanus.1-2
Pregnant women who have not completed a three-dose primary vaccination series
against tetanus should complete the series.1-2 Pending guidance from ACIP,
pregnant women should receive the Td vaccine in preference to the Tdap
vaccine.3
A summary of guidelines for the immunization of pregnant women can be found
online (www.cdc.gov/nip/publications/preg_guide.htm). 
Expert Consensus
The American Academy of Family Physicians (AAFP) supports the ACIP
recommendation.1
Authored by: 
Choucair J, Lentine D, Campbell KP, Chattopadhyay S. Syphilis evidence-statement: screening.
In: Campbell KP, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide 
to Clinical Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group 
on Health; 2006.
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The recommendations and supporting information contained in this document
came from several sources, including the:
• Advisory Committee on Immunizations (ACIP)
• American Academy of Family Physicians (AAFP)
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Tetanus is generally characterized by painful muscle rigidity and uncontrollable
spasms. Between 1998 and 2000, 18% of persons in the United States who
contracted tetanus died as a result of the disease.4 Neonatal tetanus is a severe and
often fatal disease; it accounted for an estimated 200,000 deaths worldwide in
2000 but is extremely rare in the United States.5 Because nearly all neonatal
tetanus occurs in infants born to mothers who are not adequately immunized
against tetanus, it is important that all pregnant women be vaccinated against tetanus.4
All pregnant women who are not fully immunized are at risk of infection.
Value of Prevention
There are few economic data on the burden of tetanus disease and no data about the
costs of neonatal tetanus in the United States. A recent economic evaluation of the
7-vaccine routine childhood immunization schedule in the United States estimated
that, if there had not been a tetanus vaccination program in the United States, 153
cases of tetanus and 23 deaths from tetanus would have occurred at a total cost of
$29 million (direct and indirect costs in year 2001 dollars) based on a hypothetical
2001 birth cohort of 3.8 million infants that was followed from birth to death.6
Not Provided
The averted mortality and morbidity costs due to prevented tetanus cases
constitute the major economic benefit of immunization. 
In 2004, the private-sector cost of an adult tetanus vaccine (usually given as Td)
averaged $15; approximately 95% of all paid claims fell within the range of $0 to
$28.7 The additional cost of vaccine administration averaged $10 and 95% of
paid claims fell within the range of $0 to $20.7
Not Provided
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In one analysis, it was estimated that administering tetanus booster
immunizations every 10 years (‘decennial’ boosters) is associated with a cost of
$143,138 per year of life saved. Although decennial boosters are more
expensive than once-in-a-lifetime booster immunizations, they also prevent
more than twice the number of tetanus cases that would be prevented by a
single lifetime booster.8
Preventive Intervention Information
Tetanus immunization offers long-term protection against tetanus for the
vaccinated woman, and maternal vaccination confers significant protection to the
fetus. In fact, field assessments have reported 70% to 100% effectiveness of the
vaccine in preventing neonatal tetanus among the children of women receiving at
least two doses of tetanus vaccine.9 Notably, in all three cases of neonatal tetanus
that have occurred in the United States since 1989, the infant’s mother was not
fully immunized against tetanus.4
The benefits of tetanus immunization are substantial. Adverse reactions to
tetanus vaccination can include local swelling or pain; extensive swelling and
systemic reactions are rare, however.10 Although no evidence exists that tetanus
immunization during pregnancy causes harm to the fetus, delaying needed
tetanus immunizations to the second or third trimester is a reasonable precaution
to minimize any concerns about the theoretical possibility of such adverse
effects.11
Women should be assessed for risk of tetanus at their first prenatal care visit.
Pregnant women without adequate documentation of a completed primary
tetanus series and a tetanus vaccination within the past ten years should be
immunized against tetanus in the second or third trimester.
Clinicians should assess all pregnant women for susceptibility to tetanus.
Pregnant women are considered susceptible to tetanus if they have an uncertain
immunization history (i.e., they cannot provide written proof of immunization)
or if they have not had a tetanus booster in the previous 10 years. 
Susceptible women who have not completed a primary series of immunizations
against tetanus should complete a three-dose series; women who have completed
the primary series but have not been vaccinated against tetanus in the past ten
years should receive a booster dose.1-2
In 2005, two new tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) vaccines were licensed for use in the United States. Pending
guidance from ACIP on the use of Tdap during pregnancy, pregnant women
should receive Td vaccine in preference to the Tdap vaccine.3
Tetanus vaccinations are given via injection.
Health benefits should include provisions for treatment services.
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Recommended Guidance:
Advisory Council on Immunization Practices (ACIP)
Strength of Evidence: Expert Consensus
• The ACIP recommends that all adults with an uncertain history of a complete
tetanus vaccination series receive a three-dose primary tetanus series, and that
all adults receive periodic tetanus boosters every 10 years.1-2
This recommendation is supported by the:
• American Academy of Family Physicians (AAFP)
• U.S. Preventive Services Task Force (USPSTF)
Tobacco Use Treatment (Screening and
Counseling)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
screen all pregnant women for tobacco use and provide augmented pregnancy-
tailored counseling to those who smoke.1
The USPSTF found good evidence that extended or augmented smoking
cessation counseling (5 to15 minutes) using messages and self-help materials
tailored for pregnant smokers, compared with brief generic counseling
interventions alone, substantially increases abstinence rates during pregnancy, and
leads to increased birth weights. Although relapse rates are high in the
postpartum period, the USPSTF concluded that reducing smoking during
pregnancy is likely to have substantial health benefits for both the baby and the
expectant mother. The USPSTF concluded that the benefits of smoking cessation
counseling outweigh any potential harms.1
The American Academy of Family Physicians (AAFP)2, the American College of
Preventive Medicine (ACPM)3, and the U.S. Surgeon General concur with the
USPSTF recommendations.4
Authored by: 
Lindley MC, Bhatt A, Campbell KP, Chattopadhyay S. Tetanus immunization evidence-statement. In: Campbell KP,
Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical Preventive
Services: Moving Science into Coverage. Washington, DC: National Business Group on Health; 2006.
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The American Academy of Family Physicians (AAFP) strongly recommends that
clinicians counsel smoking parents with children in the house regarding the
harmful effect of smoking and children’s health.2
Good quality evidence exists which demonstrates the substantial net benefit
(compared with harm) of counseling to prevent exposure to secondhand smoke; the
intervention is perceived to be cost-effective and acceptable to nearly all patients.2
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American College of Preventive Medicine (ACPM)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)
• Peer-reviewed research
• Smoke Free Families
• U.S. Public Health Service (USPHS)
• U.S. Surgeon General
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Twenty-one percent (21%) of all childbearing-aged women in the United States
smoke.4 Depending on demographic factors, between 11% and 20% of all
pregnant women in the United States smoke.4
Tobacco use during pregnancy causes significant damage to the developing fetus,
putting the future infant at risk for an array of severe short- and long-term health
problems. Compared to non-smokers, women who smoke during their
pregnancy are 83% more likely to deliver a low-birth-weight infant, 129% more
likely to deliver an infant that will die of SIDS, 30% more likely to deliver an
infant with respiratory distress syndrome, and 41% more likely to deliver an
infant with a perinatal respiratory condition.5 And children whose mothers
smoked during pregnancy and/or smoke in the home shortly after birth are at
increased risk of asthma, impaired lung function, stunted growth, ear infections,
and upper respiratory problems.6-7
Prenatal tobacco use is a known risk factor for low birth weight, which itself is a
significant risk factor for neonatal morbidity and mortality. In 2003, 12.4% of all
women, 13% of Hispanic women, and 20.2% of black women who smoked
during pregnancy delivered a low-birth-weight infant.8
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Table 1.0 Infant Deaths Resulting from Tobacco Use 
Source: Centers for Disease Control and Prevention. National Center for Chronic Disease
Prevention and Health Promotion: Division of Reproductive Health. MCH health outcomes
report. Maternal and Child Health Smoking-Attributable Mortality, Morbidity, and Economic
Costs. Atlanta, GA: Centers for Disease Control and Prevention; 2005.
* March of Dimes. Perinatal statistics. [cited 2005 Jul 8]. Available from:
http://www.marchofdimes.com/aboutus/680_2203.asp. 
**Discovery labs (distributors of surfactant, a medicine used to treat RDS in infants. [cited 2005
Jul 8]. Available from: http://www.discoverylabs.com/2002pr/071802-PR.pdf. 
Women who smoke during pregnancy are likely to be young (18 to 24 years of
age), have low levels of education, and be from racial or ethnic minorities. Level
of education is highly correlated with prenatal smoking. For example, while only
2% of college-educated non-Hispanic white women smoke during pregnancy,
42.7% of non-Hispanic white women with only 9 to 11 years of education
smoke during one or more of their pregnancies.9
Value of Prevention
The economic burden of prenatal tobacco use is substantial. In 1996, maternal
smoking accounted for 2.3% of all neonatal medical expenditures.10 Each
pregnant smoker incurs an additional $704 in healthcare costs (in year 1996
dollars)5 and, annually, smoking-attributable neonatal costs (defined as all costs
related to labor /delivery and the care of infants within the first few months of
life) are estimated to meet or exceed $367 million in the United States.10-11
The direct costs of care for mothers and their children exposed to environmental
tobacco smoke (ETS) (also known as secondhand smoke) also add to the overall
cost of smoking, although exact cost figures are not known. 
Smoking-attributable neonatal costs impose a heavy burden on employer-
sponsored health insurance spending. Moreover, working parents are required to
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Benefits and Risks 
of Intervention
take additional time off from work to attend to the health care needs of children
affected by neonatal smoke exposure. This results in productivity losses in the
workplace. 
A smoking cessation program that could achieve an annual drop of 1 percentage
point in smoking prevalence has been estimated to produce an economic benefit
of $21 million in (in year 1995 dollars) direct medical costs solely by reducing
the number of low-birth-weight live births. In 7 years, the cumulative
undiscounted saving in direct medical costs would become $572 million through
the prevention of 57,200 low-birth-weight infants.12
In 2004, the private-sector cost of tobacco risk assessment and prevention
counseling averaged $62; approximately 95% of all paid claims fell within the
range of $0 to $139.13 In 2004, the private-sector cost (per pregnant smoker) for
tobacco use treatment averaged $39 and approximately 95% of all paid claims
fell within the range of $0 to $134.13
Tobacco cessation treatment for pregnant women is considered one of the most
cost-saving preventive services.4,14 Clinical trials have shown that $6 are saved in
healthcare costs for every $1 invested in smoking cessation programs for pregnant
women.15
Preventive Intervention Information
Screening allows clinicians to identify smokers and offer them cessation services
in order to improve their chances of quitting. Quitting smoking reduces the risk
of serious smoking-related health problems for the individual and — with regards
to pregnant smokers — reduces the fetus’s risk of smoking-related health
problems such as pre-term birth, low birth weight, and SIDS. 
The benefits of tobacco use screening and counseling are substantial. Tailored
tobacco cessation programs that feature patient education and support have been
proven to be effective in reducing the number of women who smoke during
pregnancy. For example, one health plan’s tobacco cessation program saw a
massive reduction in smoking among participants; 81% of participants reported
that they stopped smoking altogether or cut the number of cigarettes they
smoked each day in half. Women in the program who stopped smoking
completely had fewer preterm deliveries and fewer low-birth-weight babies
compared to the pregnant smokers who did not participate in the program.16
Counseling interventions (as compared to printed self-help materials) are
especially effective for smokers at high risk of complications from smoking, such
as pregnant women. Notably, 21% of pregnant women who receive physician
counseling successfully quit, which is double the quit rate of their nonpregnant
counterparts.3
There are no documented risks to screening pregnant women for tobacco use.
Risks of tobacco cessation counseling are few but include the possibility of a
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negative self-perception and perceived feelings of discrimination. 
The benefits of screening and counseling, including early identification and early
treatment, far outweigh the risks associated with screening and counseling. 
All adults, including pregnant women, should be screened for tobacco use at
every preventive care visit or as deemed appropriate by the clinician.1,3 Pregnant
women who screen positive for tobacco use should be advised to quit at every
medical encounter and referred to 1-800-Quit-Now, the national portal number
that refers callers to their state’s quitline service. All pregnant women who screen
positive for tobacco use should be counseled.
The USPSTF recommends the use of the “5-A” behavioral counseling framework
for tobacco screening and counseling. This framework is composed of 5 steps
aimed at engaging the patient in a discussion about their tobacco use and their
intention to quit:
• Ask about tobacco use
• Advise to quit through clear and personalized messages
• Assess the patient’s willingness to quit
• Assist to quit
• Arrange for follow-up and support services
The USPSTF further recommends that clinicians provide problem-solving
guidance for smokers to develop a quit plan and to overcome common barriers to
quitting. Practices that complement the “5-A” framework include motivational
interviewing or other methods of intensive counseling, referral for quitters that
may need extra help, and referral to quitlines for adjunct counseling.1,5
Effective counseling interventions for pregnant smokers include individual face-
to-face, group, and telephone counseling.17 The most effective type of smoking
cessation interventions for pregnant women are multi-component programs that
feature: 1) healthcare provider reinforcement, 2) printed self-help materials, and
3) follow-up in-person or telephone counseling.11 Physician counseling has been
shown to increase quit rates among patients in primary care. The more intensive
the counseling is (as measured by length of counseling session) the higher the
quit rate. For example, 10.5% of patients who receive less than 3 minutes of
physician counseling quit smoking, 12.1% of patients who receive 3 to 10
minutes quit, and 18.7% of patients who receive over 10 minutes of counseling
quit.3
Pharmacologic therapy can enhance the effectiveness of tobacco-cessation
interventions and can be used when the physician and patient concur that
medication use would be beneficial. Because there have not been adequate studies
to ensure the safety of tobacco cessation medications among pregnant women,
patient education and provider counseling remain the primary methods of
tobacco use treatment. Postpartum women who are not breastfeeding may want
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Information
Please refer to the “Intervention Process” section.
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this 
section is described below.
Evidence-Based Research:
The U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence that extended or augmented smoking
cessation counseling (5 to 15 minutes) using messages and self-help materials
tailored for pregnant smokers, compared with brief generic counseling
interventions alone, substantially increases abstinence rates during pregnancy,
and leads to increased birth weights.1
This recommendation is supported by the:
• American Academy of Family Physicians (AAFP)
• American College of Preventive Medicine (ACPM)
• U.S. Public Health Service (USPHS)
The American Academy of Family Physicians (AAFP) 
Strength of Evidence: SR (Strongly Recommended)
• AAFP strongly recommends that clinicians counsel smoking parents with
children in the house regarding the harmful effect of smoking and children’s
health.2 Good quality evidence exists which demonstrates the substantial net
benefit of counseling to prevent exposure to secondhand smoke; the
intervention is perceived to be cost-effective and acceptable to nearly all
patients.2
Authored by: 
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• Hypertension (high blood pressure) is the most common primary diagnosis in
the United States and is responsible for 35 million office visits each year.1
• Nearly 1 in 3 U.S. adults has high blood pressure.2-3
• Adults with untreated or poorly controlled hypertension are at increased risk of
heart disease and stroke, peripheral artery disease, end-stage renal disease,
retinopathy, and aortic aneurysm.3
• The diagnosis and management of hypertension cost $63.5 billion in 2006,
including $47.5 billion in direct medical expenses and $16 billion in lost
productivity.3
• Hypertension is one of the 10 most expensive health conditions for U.S.
employers. Its complications are a major cause of preventable absenteeism,
reduced productivity, and disability.4
• Screening for hypertension allows clinicians to identify affected patients and
begin treatment early. 
• Controlling blood pressure with medications is one of the most cost-effective
methods of reducing premature cardiovascular morbidity and mortality.1,5 A 12
to 13-point reduction in blood pressure can reduce the number of heart attacks
by 21%, strokes by 37%, and all deaths from cardiovascular disease by 25%.1
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force recommends that clinicians screen all
adults aged 18 years and older for hypertension.6
The U.S. Preventive Services Task Force found good evidence that (1) screening
for high blood pressure can identify adults at increased risk for cardiovascular
disease, (2) treating high blood pressure can significantly decrease the prevalence
of cardiovascular disease, and (3) the benefits of screening outweigh the harms.6
The Centers for Disease Control and Prevention (CDC) supports the Seventh
Report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure1 recommendations for blood pressure
screening, prevention, and control (described in the next section).7 More
information on the CDC’s hypertension-related guidance is available online
(www.cdc.gov/dhdsp/library/fs_bloodpressure.htm).
Like the U.S. Preventive Services Task Force, the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
recommends that clinicians screen all adults aged 18 years and older for
hypertension.1
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Guidance for the prevention and management of hypertension is provided in the
Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure.1 In this report, the
Committee recommends that clinicians incorporate its recommendations into the
management plans of their patient groups by (1) ensuring that screening and
detection of hypertension is provided in the medical practice and community; (2)
evaluating all patients with hypertension for accompanying risk factors and target
organ damage; (3) promoting lifestyle management to prevent hypertension; (4)
setting a target blood pressure for each patient with hypertension and monitoring
progress toward that goal; (5) recognizing that a blood pressure goal of less than
130/85 mm Hg is appropriate for many patients; (6) monitoring special diseases
and conditions, such as diabetes, congestive heart failure, and renal dysfunction;
(7) considering combination therapy for patients with hypertension; (8)
maximizing staff efforts to enhance patient adherence to hypertension therapy;
and (9) encouraging patient, family, and community activities to promote
healthy lifestyles and blood pressure control.  In addition, clinicians should
encourage persons with pre-hypertension, defined as systolic pressure of 120–139
or diastolic pressure of 80–89 mm Hg, to adopt lifestyle modifications to prevent
the development of hypertension.1
The Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure is based on peer-reviewed
scientific literature, including observational studies and clinical trials (from
January 1997 through April 2003), and on expert opinions from 33 national
hypertension leaders.1
The authors of the Fourth Report from the National High Blood Pressure
Education Program Working Group on Children and Adolescents recommend
that children older than 3 years have their blood pressure measured at least once
during every healthcare visit.8 Although the U.S. Preventive Services Task Force
did not find evidence to support screening children, many professional
organizations such as the American Academy of Pediatrics, the American Heart
Association, and the American Medical Association (AMA) recommend that
children aged 3 years and older who are seen in medical care settings should have
their blood pressure measured at least once during every healthcare episode.9
Not Specified
The recommendations and supporting information in this document came from
several sources, including the:
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP)
• American Dietetic Association
• American Heart Association 
• American Medical Association (AMA)
• Centers for Disease Control and Prevention (CDC)
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Explanation of
Condition
• Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure
• National Heart, Lung, and Blood Institute (NHLBI)
• Peer-reviewed research 
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information in this document is based on a
compilation of research findings. All information presented in this document
should be attributed to its referenced sources and should not be considered a
reflection of the opinions of other organizations cited in the text. 
Condition/Disease-Specific Information
Blood pressure is often expressed as two numbers — the top (systolic) number
represents the pressure while the heart is beating, while the bottom (diastolic)
number represents the pressure when the heart is resting between beats. Normal
blood pressure is a systolic blood pressure less than 120 mm Hg and a diastolic
blood pressure less than 80 mm Hg.
A person is considered to have high blood pressure (also called hypertension)
when he or she has a systolic pressure of 140 mm Hg or above, a diastolic blood
pressure of 90 mm Hg or above, or both.3 Once hypertension occurs, it generally
remains a life-long, chronic condition. A person who is being treated for high
blood pressure, even though repeated blood pressure readings are recorded in the
normal range, still has high blood pressure.3 If treatment stops, the hypertension
will almost invariably recur.
Pre-hypertension is defined as systolic pressure of 120–139 mm Hg or diastolic
pressure of 80–89 mm Hg.3 Persons with pre-hypertension are at increased risk of
progressing to hypertension. About 28% of American adults aged 18 and older
have pre-hypertension.3
Information on the classification and management of blood pressure for adults
aged 18 years and older is provided in Table 1. The table lists lifestyle
modification and drug therapy recommendations for adults by risk category.  
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Table 1: Classification and Management of Blood Pressure for Adults 
Aged 18 Years and Older 
Note: Initial treatment should be determined by the patient’s highest blood pressure category
(e.g., a patient with a systolic blood pressure of 110 mm Hg and a diastolic blood pressure of
90 mm Hg should be treated for stage 1 hypertension).
Source: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
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Nearly 1 in 3, or 65 million, adults in the United States has high blood pressure.2
High blood pressure affects about 2 in 5 African-Americans, 1 in 5 Hispanics and
Native Americans, and 1 in 6 Asians.3 High blood pressure was the primary or a
contributing cause of  death for 277,000 people in the United States in 2002.3
Hypertension is the most common ambulatory care primary diagnosis in the
United States and is responsible for 35 million office visits each year.1 Although
hypertension is the most common chronic medical condition to be treated in
primary care settings, only about 34% of people with hypertension have their
blood pressure controlled to a level of less than 140/90 mm Hg, and another
30% are unaware of their condition.1 As a result, about two-thirds of Americans
with hypertension are at increased risk of heart disease and stroke, which are both
leading causes of death in the United States. They also have an increased risk of
developing peripheral artery disease, end-stage renal disease, retinopathy, and
aortic aneurysm.3
Risk factors for hypertension include increased age, smoking, heavy alcohol use,
family history, obesity, physical inactivity, and moderate salt intake.1,3 The
prevalence of hypertension in African-Americans in the United States, in people
with low levels of education or low socioeconomic status, and in those who live
in the southeastern United States is among the highest in the world.3 The rate of
fatal strokes is 1.8 times higher in blacks than whites, while their rates of death
from heart disease are 1.5 times higher and of kidney disease are 4.2 times
greater. These disparities are caused, in part, by their higher prevalence of
hypertension.10
Value of Prevention
The costs associated with hypertension accounted for $63.5 billion of the total
costs associated with cardiovascular diseases in 2006.3 This figure includes $47.5
billion in direct medical expenses and $16 billion in lost productivity.3 When the
costs of other conditions and diagnoses attributable to hypertension were
included, the direct healthcare expenses associated with  hypertension were
$108.8 billion in 1998.11
Hypertension is one of the 10 most expensive health conditions for U.S.
employers. Its complications are a major cause of preventable absenteeism,
reduced productivity, and disability.4
A recent study found that the overall economic burden of illness to employers
was higher for hypertension than for nine other conditions — $392 per eligible
employee per year (based on average impairment and prevalence estimates using
2001 average hourly wages and benefits). On-the-job productivity losses
(employees with uncontrolled hypertension who were less productive at work
than healthy employees) accounted for 63% of this total.12
Screening, detection, and early treatment can significantly reduce the medical
care costs associated with hypertension and the other diseases for which people
with hypertension are at increased risk. Estimates of full economic benefits
should also take into account productivity gains due to better on-the-job
performance and added years of life, as well as to declines in disability,
absenteeism, and employee turnover.
A meta-analysis of four trials involving more than 20,000 patients with hypertension
showed that reducing their blood pressure led to a 15% reduction in major
cardiovascular events, a 20% reduction in strokes, and a 10% reduction in coronary
heart disease events.4 According to another study, reducing blood pressure from less
than 140/90 mm Hg to less than 130/85 mm Hg in high-risk individuals would
increase life expectancy by 16.5–17.4 years and decrease total lifetime medical costs
by $1,450.13 A third study found that total life expectancy was about 5 years longer
for adults with normal blood pressure than those with hypertension.14
These studies suggest that reducing blood pressure in patients with hypertension
saves money and extends life expectancy. They also suggest that the medical,
economic, and human costs of untreated and inadequately controlled high blood
pressure are enormous.13,15-16
The cost of screening for blood pressure in a clinician’s office as part of a routine
physical examination is minimal.  
Lifestyle counseling to promote a healthy diet and physical activity is usually the
first step in preventing or treating hypertension and remains important
throughout all stages of treatment. The cost for these services varies.1 In 2004,
the private-sector cost of preventive medicine counseling averaged $39;
approximately 95% of all paid claims fell within the range of $0 to $129.17
If lifestyle changes do not achieve blood pressure control, antihypertensive
medications are typically used. Many types of antihypertensive medications are
currently available. The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure states that
thiazide diuretics are among the most effective drugs for hypertension, are available
in generic form, and are also among the least expensive.1,16 The JNC-7 further
states that more than one antihypertensive medication may be needed in order to
achieve hypertension control, the combination of which should be based on the
physician’s treatment decisions in order to achieve the most optimal results.
The cost of follow-up or treatment-related appointments varies by type of
provider, location, and practice setting.
Disease management programs and centralized blood pressure control clinics
have been judged to be useful to encourage compliance with treatment and to
meet treatment goals. The costs of these services also vary considerably.
328








EVIDENCE-STATEMENT: Hypertension (Screening, Counseling and Treatment)
Controlling blood pressure with medications is one of the most cost-effective
methods of reducing premature cardiovascular morbidity and mortality.1,5 This is
particularly true for older men and women and those with high pretreatment
blood pressure levels.13,18 The ALLHAT Study concluded that thiazide-type
diuretics are at least as effective as newer drugs in preventing one or more forms
of cardiovascular disease and are less expensive.19
Preventive Intervention Information
Screening for hypertension allows clinicians to identify affected patients and
begin treatment early in the disease course to prevent the serious consequences of
high blood pressure, including stroke, coronary artery disease, heart attack, and
heart and kidney failure.1
High blood pressure is easily detectable and can be controlled by lifestyle
modifications, such as increasing physical activity or reducing dietary salt intake,
and a variety of medications. 
The benefits of screening and detecting high blood pressure are substantial.
Screening identifies patients with hypertension and allows them to begin
treatment for their condition early in the course of the disease. 
Some studies have suggested that screening for hypertension and labeling
individuals as having hypertension could result in adverse psychological effects
and transient increases in absenteeism.20 However, these studies had inconsistent
results and the causes of absenteeism related to screening and diagnosis were not
well established.20 The risk of false-positive classification can be reduced by
multiple measurements.1
The benefit-to-harm ratio of treating hypertension overwhelmingly argues for
treatment. A 12 to 13-point reduction in blood pressure can reduce the number
of heart attacks by 21%, strokes by 37%, and all deaths from cardiovascular
disease by 25%.1 In clinical trials, antihypertensive therapy has been associated
with a 35% to 40% mean reduction in stroke incidence, a 20% to 25%
reduction in myocardial infarction incidence, and a decrease of more than 50%
in heart failure incidence.1,21-22 Providing antihypertensive medications to adults
with severe hypertension reduces their odds of developing congestive heart failure
by 86% and active treatment of isolated systolic hypertension in elderly patients
reduces the incidence of both stroke and coronary heart disease events by 30%,
coronary vascular disease by 18%, and total mortality by 13%.9,23
The side effects of antihypertensive medications (such as dizziness,
lightheadedness, or fainting) can interfere with patient adherence, but side effects
can usually be minimized by patient education and by modifying medications or
their dosages. Serious side effects (such as fever or chills, joint or stomach pain)
are rare and can be reduced or eliminated by switching medications or reducing
drug dosage.20 Clinicians should also discuss with their patients the benefits of
adopting a healthy lifestyle (such as increasing physical activity and reducing














Blood pressure screening should be conducted routinely among all patients aged
18 or older, or as deemed necessary by a physician. Children older than 3 years
who are seen in medical care settings should have their blood pressure measured
at least once during every health care epidsode.8-9 Evidence is insufficient to
determine the optimal interval for screening. Expert opinion captured in the
Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure indicates that people with a
systolic blood pressure of under 130 mm Hg and a diastolic blood pressure of
under 85 mm Hg should be screened every 2 years, while people with elevated
blood pressure (130/85 mm Hg or above) should be screened more frequently.1
All patients with diagnosed hypertension should be counseled and encouraged to
make therapeutic lifestyle changes in order to lower their blood pressure. Many
patients will also require antihypertensive drug therapy. Once this is initiated,
most patients should return for follow-up and adjustment of medications at
monthly intervals or less until the blood pressure goal is reached. More frequent
visits are necessary for patients with stage 2 hypertension or with complicating
comorbid conditions. Comorbidities such as heart failure, diabetes, and the need
for laboratory tests influence the frequency of visits.  Other cardiovascular risk
factors should be monitored and treated to their respective goals.  After blood
pressure is at goal and stable, follow-up visits can usually be at 3- to 6-month
intervals, or more often if necessary.1
Blood pressure screening is usually conducted in a clinician’s office using an arm
cuff and a calibrated sphygmomanometer (blood pressure meter).  Ambulatory
blood pressure measurement techniques, conducted outside of the clinical setting,
can be particularly helpful in identifying patients who have elevated blood
pressures only in the clinic environment, known as “white-coat hypertension.”24
However, due to its high costs, ambulatory blood pressure monitoring is rarely
used to screen for high blood pressure.24 Due to natural variability in blood
pressure in humans and the possibility of equipment or observer error, the U.S.
Preventive Services Task Force recommends that a diagnosis of high blood
pressure be made only after two or more elevated readings are obtained on two or
more occasions over a period of several weeks.9
Beginning at the initial visit with a patient who has hypertension, the clinician
should counsel and encourage the patient to make therapeutic lifestyle changes
— such as dietary changes, increased physical activity, tobacco avoidance, and
weight control — and monitor the patient’s progress. Therapy begins with
lifestyle modification.  If the blood pressure goal is not achieved thiazide-type
diuretics should be used as initial therapy for most patients, either alone or in
combination with one of the other class of medications that have also been
shown in clinical trials to reduce one or more hypertensive complications.1
Persons who are diagnosed with hypertension should start a treatment plan to
lower their blood pressure. Treatment plans usually include non-pharmacological
therapies, pharmacological therapies, or a combination of the two.1
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Lifestyle Interventions (Initial Treatment/“First-Line” Therapy): Healthy
lifestyles are critical in preventing and managing hypertension.1 Lifestyle
interventions decrease blood pressure, enhance antihypertensive drug efficacy,
and decrease cardiovascular risk. The major lifestyle modifications that have been
shown to reduce blood pressure are listed in Table 2. They include weight
reduction in obese or overweight individuals,5 programs to assure adequate
physical activity, and adoption of the “Dietary Approaches to Stop Hypertension
Eating Plan,” which calls for reduced consumption of saturated fat, cholesterol,
and total fat and increased consumption of potassium and calcium,25 reduced
intake of dietary sodium,26 increased physical activity,27 and moderation of
alcohol consumption.28 The Plan has been clinically proven to enhance blood
pressure reduction.1 Information about the “Dietary Approaches to Stop
Hypertension Eating Plan” is available online (www.nhlbi.nih.gov/health/
public/heart/hbp/dash/).
• Lifestyle modification is encouraged for those with a systolic blood
pressure greater than 120 mm Hg or a diastolic blood pressure greater
than 80 mm Hg.
• People with multiple coronary heart disease risk factors that place them at
high risk for coronary heart disease (10-year cardiovascular event risk of
10% to 20%) should be encouraged to change their lifestyles to achieve
their blood pressure goals. If lifestyle changes are unsuccessful, drug
therapy should be considered. 
• People with coronary heart disease (10-year cardiovascular event risk
greater than 20%) need to reduce their blood pressure to the target level
and should consider drug therapy in addition to lifestyle interventions if
their systolic blood pressure exceeds 140 mm Hg or their diastolic blood
pressure is higher than 90 mm Hg.
A risk assessment tool is available online
(http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof ).
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Table 2:  Lifestyle Modifications to Prevent and Manage Hypertension*
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Maintain normal body weight (body-mass
index of 18.5 to 24.9)
Consume a diet is rich in fruits, vegetables,
and low-fat dairy products, with little
saturated and total fat
Reduce dietary sodium intake to no more than
2.4 grams of sodium or 6 grams of sodium
chloride. (6 grams of sodium equals about 1
teaspoon of table salt (sodium chloride)
Engage in regular aerobic physical activity,
such as brisk walking, at least 30 minutes
per day on most days of the week
Limit consumption to no more than two
drinks per day (1 ounce or 30 ml ethanol
[e.g., 24 ounces of beer, 10 ounces of wine, or
3 ounces of 80-proof whiskey]) for most men
and no more than one drink per day for
women and lighter-weight persons.






RecommendationModification Approximate Systolic Blood
Pressure Reduction Range
*Note: For overall cardiovascular risk reduction, individuals should stop smoking. The effects of
implementing these modifications depend on dose and duration.
Source: Dietary Approaches to Stop Hypertension. JAMA 2003;289:2560-72.
Pharmacologic Treatment:  Lifestyle interventions may not be sufficient to
reduce blood pressure in many patients. In those cases, the addition of
pharmacological therapy to a treatment plan is often beneficial. In fact, most
people with hypertension require two or more antihypertensive medications to
achieve their target blood pressure.29-30 Clinical trial outcome data indicate that
several classes of drugs — including angiotensin-converting enzyme inhibitors,
angiotensin-receptor blockers, -blockers, calcium channel blockers, and
thiazide-type diuretics — can reduce the complications of hypertension. A
detailed list of antihypertensive drugs and recommended dose ranges is provided
in Table 6 of the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Express (www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm). The Joint
National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure recommends that patients with pre-hypertension or stage 1
hypertension return for follow-up and adjustment of medications approximately
once a month until they reach their blood pressure goal. More frequent visits are
necessary for patients with stage 2 hypertension (160/90 mm Hg or higher) or
who have complicating comorbid conditions.
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Other Important Information
The most effective therapy prescribed by clinicians will control hypertension only if
the patient takes the prescribed medication as instructed and establishes and
maintains a health-promoting lifestyle. Electronic and paper clinician decision
support systems, flow sheets, feedback reminders, and involvement of nurse
clinicians and pharmacists are important program components aimed at controlling
hypertension.31 Furthermore, cost-effective healthcare interventions to prevent and
control hypertension can only be implemented if the capacity of primary health
care system, policy environment, and financing enable delivery of services.32
For more information on medication adherence, please refer to Part VI of the
Purchaser’s Guide, “Leveraging Benefits: Promoting the Delivery and Use of
Preventive Services.”
For more information on healthy diets, refer to the National Heart, Lung, and
Blood Institute (NHLBI) tipsheets which are available online (www.nhlbi.nih.
gov/chd/Tipsheets/daily.htm).
Strength of Evidence for the Clinical Preventive Service
The levels of evidence supporting the recommendations in this chapter is
described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to support the routine screening of all
adults, aged 18 and above, for hypertension.6
Recommended Guidance:
Seventh report of Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure 
Strength of Evidence: The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure is
based on peer-reviewed scientific literature on observational studies and clinical
trials (conducted in January 1997 through April 2003) and on expert opinion
from 33 national hypertension leaders.
Screening
• The Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure recommends that all adults aged 18 and
above be routinely screened for hypertension.1
Treatment
• The Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure recommends that clinicians provide primary
and secondary prevention services to reduce elevated blood pressure, including
lifestyle consultations and medications.1
National High Blood Pressure Education Program Working Group on Children
and Adolescents 
Strength of Evidence: Not Specified
Screening
• The National High Blood Pressure Education Program Working Group found
evidence to support routine screening for hypertension in children aged 3 and
older and adolescents during routine preventive care visits and at every
episodic healthcare visit in medical care settings.8
This recommendation of the National High Blood Pressure Education Program
Working Group is supported by the:
• American Academy of Pediatrics (AAP)
• American Heart Association (AHA)
• American Medical Association (AMA)
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• Prevention of vaccine-preventable diseases is one of 10 great public health
achievements of the 20th century.1
• Approximately 11,000 babies born each day in the United States will need
vaccination against fourteen diseases before age two.
• An average of 36,000 deaths and over 200,000 hospitalizations associated with
influenza occur each year in the United States, the majority among adults aged
65 years and older.2 Influenza vaccination of healthy working adults younger
than 65 years can reduce the rates of influenza-like illness, lost workdays, and
physician visits.3
• Vaccines are cost-effective, and most child and adolescent vaccines are cost-
saving. The routine childhood vaccination program saves nearly $10 billion in
direct medical costs and $43 billion in societal costs for every birth cohort (all
children born in one year).4
• Among adults, influenza in particular results in extensive direct and indirect
costs. The overall national economic burden of influenza-attributable illness for
adults 18 to 64 years old is $10.2 billion. Each year, 17 million workdays are
lost to influenza-related illness at a cost of $5.6 billion.5
• Approximately 24% of toddlers may be vulnerable to serious illnesses,
including polio, measles, mumps, rubella, diphtheria, tetanus, pertussis,
invasive Haemophilus influenzae type b infection, hepatitis B, and varicella
because they have not completed the recommended vaccination series.6
Clinical Preventive Service Recommendations
Not Applicable — The U.S. Preventive Services Task Force (USPSTF) defers to
the Advisory Committee on Immunization Practices (ACIP) and the Centers for
Disease Control and Prevention (CDC) on recommendations for immunizations.
ACIP and CDC recommend that all children and adolescents with no
contraindications receive all routinely recommended childhood vaccinations.
Children and adolescents who fall into high-risk groups because of health
conditions, behaviors, or membership in certain communities should receive
additional vaccines.
ACIP and CDC recommend that all adults with no contraindications receive
three routinely recommended vaccines (age-dependent). Adults who fall into
high-risk groups because of health conditions, behaviors or exposures, as well as
those without a history of immunization for certain diseases, should receive
additional vaccines.
Please refer to Appendix 1 for specific information on child, adolescent, and
adult immunizations and schedules for their administration. Please note these
schedules are abbreviated and may not reflect the most current ACIP
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The recommendations and supporting information contained in this chapter
came from several sources, including the:
• Advisory Committee on Immunization Practices (ACIP)
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP)
• American College of Obstetricians and Gynecologists (ACOG)
• Centers for Disease Control and Prevention (CDC)
• Partnership for Prevention
• Peer-reviewed research
The background and supporting information contained in this chapter is a
compilation of research findings. All information presented in this chapter should
be attributed to its referenced source and should not be considered a reflection of
other organizations cited in the text. 
Condition/Disease Specific Information
Prevention of vaccine-preventable diseases is one of 10 great public health
achievements of the 20th century.1 In 2006, Partnership for Prevention evaluated
25 clinical preventive services based on the clinical burden that could be prevented
by the intervention and the cost-effectiveness of the intervention. Childhood
immunization was one of three services to receive a perfect score, and adult
influenza and pneumococcal vaccinations were also highly ranked.7 Today, most
vaccine-preventable diseases (VPD) occur at record or near-record low levels.
However, high rates of vaccination must be constantly maintained: countries that
have reduced or discontinued use of certain vaccines have experienced large, costly
outbreaks of VPD as a result of waning vaccination coverage.8
Children
Approximately 11,000 babies born each day in the United States will need
vaccination against fourteen diseases before age two. Approximately 24% of
toddlers may be vulnerable to serious illnesses, including polio, measles, mumps,
rubella, diphtheria, tetanus (lockjaw), pertussis (whooping cough), invasive
Haemophilus influenzae type b infection, hepatitis B, and varicella (chickenpox)
because they have not completed the recommended vaccination series.6
Adolescents
Traditionally, vaccines have been associated with protecting young children, but
recently many vaccines targeted toward adolescents have been recommended. In
2005, the meningococcal conjugate vaccine (MCV4) was recommended for 11 to
12 year-olds at the pre-adolescent visit, and for older adolescents and college
freshman in dormitories, as these groups experience higher rates of
meningococcal disease than the general population.9 Invasive meningococcal
disease has a 10% death rate, and up to 19% of survivors can suffer serious
aftereffects like deafness or loss of limbs.10 Also recommended in June 2005 was a
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new tetanus-diphtheria-acellular pertussis vaccine meant to combat waning
immunity to pertussis in adolescents. It is also important for adolescents to receive
certain “catch-up” immunizations if they were not fully vaccinated in childhood
(please refer to www.cdc.gov/nip/recs/child-schedule.htm#catchup for more
information). In June 2006, a vaccine against the human papillomavirus (HPV),
which causes cervical cancer, was recommended by the ACIP for use among
adolescent girls and young women (ages 9 to 26). Clinical trials including
approximately 20,000 adolescent girls and women showed that among those not
previously infected, the vaccine prevented 100% of pre-cancerous lesions from the
two types of HPV that cause the majority of cervical cancer in the United States.11-12 
Adult
The burden of vaccine-preventable disease in adults in the United States is
substantial. Recent estimates indicate that an average of 36,000 deaths and over
200,000 hospitalizations associated with influenza occur each year in the United
States, the majority among adults aged 65 years and older.2 When combined,
pneumonia and influenza were the fifth leading cause of death in 2002 among all
persons aged 65 years and older (estimate based on national mortality data).13
Among all age groups, influenza and pneumonia were the seventh leading cause
of death in the United States in 2002, accounting for over 65,000 deaths (2.7%
of all deaths).13
Risk factors vary for each vaccine-preventable disease.
Value of Prevention
Childhood vaccine-preventable diseases were once extremely costly. For example, a
large outbreak of rubella in 1964-1965 cost an estimated $840 million.14 Today, the
lifetime cost to treat a single case of congenital rubella syndrome (CRS) is
estimated to exceed $200,000.14 Using published studies and hospital discharge
data, an economic analysis of the DTaP (diphtheria, tetanus, and acellular pertussis)
vaccine showed that in the absence of immunizations, over $23 million dollars
would be spent to treat disease among all the children born in a single year.15
Among adults, influenza in particular results in extensive direct and indirect costs.
The overall national economic burden of influenza-attributable illness for adults is
$10.2 billion.5 Direct medical costs for influenza total $4.6 billion including $3.1
billion for adult hospitalizations resulting from influenza-attributable illness.5
Influenza is also responsible for substantial indirect costs, which mainly result
from lost productivity. Each year, among adults age 18 to 64 years, 17 million
workdays are lost to influenza-related illness at a cost of $5.6 billion.5
Children/Adolescents
Vaccines are cost-effective, and most child and adolescent vaccines are cost-
saving. The routine childhood vaccination program saves nearly $10 billion in
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direct medical costs and $43 billion in societal costs for every birth cohort (all
children born in one year).4 This cost-savings estimate includes reduced costs from
lost productivity. The introduction of new vaccines has led to a substantial decline
in medical spending for some conditions. For example, in 1995, a vaccine to
protect against varicella (chickenpox) was added to the childhood schedule. In
1994-1995, the total estimated direct medical cost of varicella hospitalizations and
ambulatory visits was almost $85 million; in 2002, after the vaccine was
introduced, the cost declined to $22.1 million.16
Although not cost-saving, the 2005 recommendation for routine adolescent
meningococcal vaccination is expected to prevent an estimated $18 million in direct
costs and $50 million in lost productivity caused by meningococcal disease.17 
Adults
A randomized controlled trial showed that healthy, working adults who received
influenza shots (in a year when the vaccine was well matched to circulating
influenza viruses) experienced significantly fewer days of influenza-like illness
(ILI), made fewer doctor visits for such illnesses, and took fewer days off from
work due to ILIs, compared with workers who were not vaccinated.3 Furthermore,
among persons aged 65 to 79 years who were members of a Medicare managed
care plan, influenza immunization was estimated to save about $80 per year, per
person vaccinated by preventing hospitalizations from influenza-related illnesses.18
This is consistent with other studies showing economic benefits from vaccinating
persons 65 and older against influenza.
Table 1 details the direct and indirect savings (per dollar spent) of many vaccines
routinely administered to children and adolescents. 
Table 1: Direct and Indirect Savings per Dollar Spent on Select Vaccines
* Indirect savings include prevention of work loss, death, and disability
+ Includes second dose of MMR





Diphtheria-Tetanus-Pertussis (DTaP) $9.00 $27.00
Measles-Mumps-Rubella+(MMR) $14.20 $26.00






Inactivated Polio Virus (IPV) $3.03 $5.45
All Routine# $5.30 $16.50
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Sources: Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR. Economic
evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and
whole-cell pertussis vaccine in the United States, 1997. Arch Pediatr Adolesc Med 2000;154:797-
803. (DTaP); Zhou F, Reef S, Massoudi M, Papania MJ, Yusuf HR, Bardenheier B, et al. An
economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in
the United States. J Infect Dis 2004; 189(Suppl 1):S131-45. (MMR); Zhou F, Bisgard KM, Yusuf
HR, Deuson RR, Bath SK, Murphy TV. Impact of universal Haemophilus influenzae type b
vaccination starting at 2 months of age in the United States: an economic analysis.Pediatrics
2002; 110(4):653-61. (Hib); Zhou F, Santoli J, Messonnier ML, Yusuf HR, Shefer A, Chu SY, et
al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United
States, 2001. Arch Pediatr Adolesc Med 2005; 159:1136-44. (all routine); CDC unpublished
data. (hepatitis B, varicella, IPV)
Based on catalog prices current as of 7/10/2006, the average private-sector cost to
vaccinate a healthy child through adolescence with universally recommended
vaccines is approximately $1,600 to $1,700, depending on the brand of vaccine
given.19
Based on catalog prices current as of 7/10/2006, the average private-sector cost to
vaccinate a healthy adult through age 74 with universally recommended vaccines
is approximately $380 to $480, depending on the brand of vaccine given.20
In 2004, the private-sector cost per vaccination averaged $36 per dose and
ranged from $20 for the oral polio vaccine to $270 for the hepatitis B vaccine for
immunocompromised patients. Vaccine administration averaged $10;
approximately 95% of paid claims fell within the range of $0 to $20.21
Not Provided
Please refer to “Economic Benefit of Preventive Intervention” for information on
the cost-effectiveness of immunizations. 
Preventive Intervention Information
The purpose of immunizing children, adolescents, and adults, is to prevent
vaccine-preventable diseases.
All routinely recommended childhood vaccines have been demonstrated to be
efficacious, and noticeable reductions in rates of disease have occurred following
consistent, widespread use of vaccines.22 In each birth cohort (all children born in
one year), the routine childhood immunization program prevents at least 13.6
million cases and 33,000 deaths from vaccine-preventable diseases.4 Influenza
vaccination of healthy working adults younger than 65 years can reduce the rates
of influenza-like illness, lost workdays and physician visits.3
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The benefits of vaccination include partial or complete protection against the
consequences of infection for the vaccinated person, as well as overall benefits to
society as a whole through reduced transmission of disease. Individual benefits
include protection from symptomatic illness, improved quality of life and
productivity (fewer lost workdays), and prevention of death. Societal benefits
include creation and maintenance of herd immunity against communicable
diseases (which protects people who themselves are not able to be immunized),
prevention of disease outbreaks, and reduction in healthcare-related costs.22
No vaccine is 100% effective or completely without risk. The risks of screening
for susceptibility to vaccine-preventable diseases are minimal for both
examination of vaccination history and serologic testing, although false-positive
or false-negative results are possible. Immunization risks range from common,
minor, and local adverse effects to rare, severe, and life-threatening conditions.
Thus, recommendations for immunization practices balance scientific evidence of
benefits for each person and to society against the potential costs and risks of
vaccination programs.22
The potential for significant adverse reactions to immunization can be minimized
by adherence to the recommendations and contraindications for immunizations
stipulated by ACIP. Information on vaccine contraindications is available online
(www.cdc.gov/nip/recs/contraindications_guide.pdf ). 
Patients of all ages, beginning at birth and throughout the lifespan, can benefit
from screening and appropriate immunization. Screening for susceptibility to
rubella should occur at the first clinical encounter with any woman of
childbearing age.
All indicated vaccines should be offered at every visit. It is important for persons
of all age groups who have not received all recommended vaccines to receive
“catch-up” vaccinations. 
One or more vaccinations may be deferred when medically contraindicated or
when a parent, guardian, or patient refuses on religious, philosophical, or other
grounds. Providers should document deferrals and exemptions in accordance
with state and local requirements.
Most vaccines are administered via injection. There are several approved vaccine
types and brands. Please refer to the accompanying SPD for more information.
Health benefits should include provisions for treatment services.
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Other Important Information
For children, CDC’s National Center for Immunization and Respiratory Diseases
(NCIRD) provides an automatic scheduler that uses a child’s birth date to
calculate the appropriate dates of administration for each routinely recommended
childhood vaccination. The scheduler is available online
(www.cdc.gov/nip/scheduler_online_child.htm). 
The NCIRD website provides a self-administered questionnaire for adults to
determine which immunizations they may need. It asks questions about age,
work environment and travel plans, and information about certain health
conditions and risk factors (“Do you have asthma?” “Has your spleen been
damaged or removed?”) that may affect which immunizations are indicated. The
quiz is available online (www2.cdc.gov/nip/adultImmSched/). 
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Recommended Guidance:
Advisory Committee on Immunization Practices (ACIP) 
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Expert Consensus
• The ACIP and CDC recommend that all children and adolescents with no
contraindications receive all routinely recommended childhood vaccinations.
Children and adolescents who fall into high-risk groups because of health
conditions, behaviors, or membership in certain communities should receive
additional immunizations.
• The ACIP and CDC recommend that all adults with no contraindications
receive three routinely recommended vaccines (age-dependent). Adults who fall
into high-risk groups because of health conditions, behaviors or exposures, as
well as those without a history of immunization for certain diseases, should
receive additional immunizations.
Authored by: 
Lindley MC, Bhatt A. Child, adolescent, and adult immunizations evidence-statement. In: Campbell KP,
Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch RA, editors. A Purchaser’s Guide to Clinical
Preventive Services: Moving Science into Coverage. Washington, DC: National Business Group on 
Health; 2006.
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Appendix 1: Abbreviated Child/Adolescent and Adult Schedules
Note: The Recommended Childhood and Adolescent Immunization Schedule below does not include existing ACIP
recommendations for routine immunization with rotavirus and human papillomavirus vaccines, and for a routine second dose of
varicella vaccine. Current ACIP recommendations may be obtained from: www.cdc.gov/nip/publications/acip-list.htm.
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• Lipid disorders result from abnormal levels of cholesterol in the blood.
• Cardiovascular disease is caused by atherosclerosis, a thickening or hardening
of the arteries, and is particularly sensitive to lipid (including cholesterol)
levels. Coronary heart disease, a type of cardiovascular disease, can lead to
angina pectoris (heart pain), heart attack, or both.1
• The American Heart Association estimates that more than 70 million women
and men in the United States have some form of cardiovascular disease and
927,000 die of the disease every year. Heart disease and stroke, the major
forms of cardiovascular disease, account for nearly 38% of all reported deaths
nationally in the United States.1
• Several large studies have found that patients who take cholesterol-lowering
drugs for 5 to 7 years can decrease their risk of heart disease by about 30%.2
• The estimated direct and indirect costs of all types of cardiovascular disease in
2006 totaled $403.1 billion; this included the costs associated with coronary
heart disease, which exceed $142 billion.1
• Screening for lipid disorder allows patients and clinicians to begin lipid-
lowering treatment. Reducing low-density lipoprotein cholesterol levels to a
normal level reduces the risk of coronary heart disease and thereby reduces a
person’s risk of cardiovascular disease events, such as heart attacks and strokes.
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force strongly recommends that clinicians
screen men aged 35 and older and women aged 45 and older for lipid disorders
and that they treat abnormal lipid levels in persons who are at increased risk of
coronary heart disease (based on such factors as age, total or low-density
lipoprotein cholesterol level, high-density lipoprotein cholesterol level, smoking
status, and systolic blood pressure).3
The USPSTF found good evidence that lipid measurement can identify
asymptomatic middle-aged people at increased risk of coronary heart disease and
good evidence that lipid-lowering drug therapy substantially decreases the incidence
of coronary heart disease in such people with abnormal lipids and causes few major
harms. The USPSTF concluded that the benefits of screening for and treating lipid
disorders in middle-aged and older people substantially outweigh harms.3
The USPSTF recommends that clinicians routinely screen younger adults (men
aged 20 to 35 and women aged 20 to 45) for lipid disorders if they have other
risk factors for coronary heart disease.3
The USPSTF found good evidence that lipid measurement can identify younger
people at increased risk for coronary heart disease, that risk is highest in those
with other risk factors, and that the absolute benefits of lipid-lowering treatment
depend on a person’s underlying risk of coronary heart disease. The USPSTF
concluded that benefits of screening for and treating high-risk young adults
outweigh harms.3
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Note: The National Cholesterol Education Program’s Adult Treatment Expert
Panel-III is the most recent national guideline for lipid screening and treatment.4
Please refer to the “Other Recommendations” section.
The Centers for Disease Control and Prevention (CDC) supports the National
Cholesterol Education Program’s Adult Treatment Expert Panel-III
recommendations.  More information is available on the CDC website
(www.cdc.gov/dhdsp/library/fs_cholesterol.htm). 
Since the release of the U.S. Preventive Services Task Force recommendation in
2001, the National Heart, Lung, and Blood Institute’s (NHLBI) National
Cholesterol Education Program (NCEP) has updated its guidelines for lipid
screening and treatment. The NCEP’s Adult Treatment Expert Panel-III
recommends that clinicians routinely screen all adults aged 20 and older for elevated
blood cholesterol levels every 5 years.4 Screening should involve a complete
lipoprotein profile that includes low-density lipoprotein cholesterol levels.4
The Adult Treatment Expert Panel-III also recommends that clinicians counsel all
patients at risk for cardiovascular disease about healthy lifestyles, including
methods for lowering saturated fat intake, losing weight, and increasing exercise
levels. Persons considered at high risk include those with elevated low-density
lipoprotein or diminished high-density lipoprotein cholesterol levels.4
The Adult Treatment Expert Panel-III contains both evidence statements and
recommendations based on those statements. The panel’s recommendations are
based on large randomized controlled clinical trials, prospective epidemiological
studies, and smaller clinical trials. An expert panel assigned each statement to a
category of type of evidence (based on the source of the evidence) and strength of
evidence as follows4:
Category of Type of Evidence:
A Large randomized controlled clinical trials.
B Smaller clinical trials and meta-analyses of clinical trials.
C Observational and metabolic studies.
D Clinical experience.
Strength of Evidence:
1 Very strong evidence.
2 Moderately strong evidence.
3 Strong trend.
The Adult Treatment Expert Panel-III states that the benefits of screening for lipid
disorders outweigh the risks and costs1 for the reasons listed below. The codes for
type of evidence and strength of evidence are provided for each statement.
1. Elevated low-density lipoprotein cholesterol levels increase a person’s risk of
coronary heart disease, coronary artery disease, and other forms of
cardiovascular disease {A1, B1, C1}.
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2. Total cholesterol levels in young adults correlate with coronary heart disease
rates in later life {C1}.
3. Screening for lipid disorders can identify persons at increased risk of coronary
heart disease {A1, B1, C1}.
4. Treating abnormal lipids in persons at increased risk of coronary heart disease
can substantially decrease their risk of cardiovascular disease events, such as
heart attacks, and their risk of coronary heart disease mortality {A1, B1}.
The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Health Care Research and Quality (AHRQ)
• American Heart Association 
• Centers for Disease Control and Prevention (CDC)
• National Center for Health Statistics (NCHS)
• National Cholesterol Education Program Adult Treatment Expert Panel-III 
• National Heart, Lung, and Blood Institute (NHLBI)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information in this document is based on a
compilation of research findings. All information presented in this document
should be attributed to its referenced sources and should not be considered a
reflection of the opinions of other organizations cited in the text. 
Condition/Disease-Specific Information
Lipid disorders, which result from abnormal levels of cholesterol in the blood,
increase the risk of cardiovascular diseases, including coronary heart disease.
Some amount of cholesterol in the blood is normal and, in fact, necessary.
However, high levels of low-density lipoprotein cholesterol increase the risk 
of — and can even cause — coronary heart disease. In contrast, low levels of
high-density lipoprotein cholesterol are strongly associated with increased risks 
of coronary heart disease and high levels of high-density lipoprotein are
associated with protection. Elevated serum triglycerides are associated with
increased risk of coronary heart disease.4
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Table 1: Classification of Low-Density Lipoprotein Cholesterol, High-Density
Lipoprotein Cholesterol, Total Cholesterol, and Triglyceride Levels
Low-Density Lipoprotein (bad) Classification by Association with 
Cholesterol Levels (mg/dL) Cardiovascular Disease Risk
Less than 100 Optimal
100-129 Near or above optimal
130-159 Borderline high
160-189 High
190 and above Very high
High-Density Lipoprotein (good) Classification by Association with 
Cholesterol Levels (mg/dL) Cardiovascular Disease Risk
Less than 40 Low (major risk factor for coronary heart disease)
60 and above High (protective against heart disease)
Total cholesterol levels (mg/dL)
Less than 200 Desirable
200-239 Borderline high





500 and above Very high
Adapted from: National Heart, Lung, and Blood Institute’s Third Report of the National Cholesterol
Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III); May 2001, p. 3.
Reducing low-density lipoprotein cholesterol levels to normal reduces the risk of
coronary heart disease and cardiovascular events such as heart attacks and strokes.
Because low-density lipoprotein cholesterol levels are so strongly correlated with
coronary heart disease and reducing low-density lipoprotein cholesterol has been
shown to reduce coronary heart disease risk, goals and thresholds for low-density
lipoprotein cholesterol have been established.4 Please refer to Table 2 for
information about recommended target low-density lipoprotein cholesterol levels.
Between 1999 and 2002, about 17% of adults aged 20 years and over in the
United States had high cholesterol levels (total cholesterol 240 mg/dL or higher).5
Clinical studies have repeatedly shown a strong and graded relationship between
increasing levels of low-density lipoprotein cholesterol (“bad” cholesterol) and
increasing risk of coronary heart disease events.  Low levels of high-density
lipoprotein cholesterol levels are strongly associated with increased risks of
coronary heart disease. Evidence from clinical trials suggests that increasing high-
density lipoprotein cholesterol (“good” cholesterol) levels reduces the risk of
coronary heart disease.1
Elevated lipid levels contribute to the development of cardiovascular diseases,
including coronary heart disease, stroke, and coronary atherosclerosis.6 Coronary
heart disease, which kills more Americans than any other single disease, can lead
to angina pectoris (heart pain), heart attack, or both.1 One American has a heart
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attack about every 26 seconds, and about 40% will die from the heart attack in
any given year.1 At age 40, a man in the United States has a 49% chance and a
woman has a 32% chance of having a coronary heart disease event (such as a
heart attack) in his or her lifetime.7
About 65 million adults require therapeutic lifestyle changes (such as dietary
changes, increased physical activity, and weight control) to reduce their low-
density lipoprotein cholesterol levels. Of these people, about 36 million also
require both drug therapy and therapeutic lifestyle changes to reduce their low-
density lipoprotein cholesterol levels to safe amounts. 
Risk factors that are associated with high cholesterol levels include a family
history of cardiovascular disease (including familial hypercholesterolemia, an
inherited genetic condition), older age, male sex, a diet high in fats, overweight,
and lack of exercise. 
Many of these risk factors including diet, overweight, and lack of exercise are
modifiable4:
• Diets high in saturated fat increases low-density lipoprotein (low-density
lipoprotein) cholesterol levels more than any other factor in the human
diet. Trans-fatty acids, formed when vegetable oil is hydrogenated to
harden it, also increase cholesterol levels. These fatty acids are found in
such foods as stick margarine, crackers, and French fries. Cholesterol is
found in foods from animal sources, such as egg yolks, meat, and cheese. 
• Being overweight tends to increase low-density lipoprotein levels, decrease
high-density lipoprotein levels, and increase total cholesterol levels.
• Lack of regular exercise can lead to weight gain, which can increase low-
density lipoprotein cholesterol levels. Poor physical fitness appears to be
associated with cardiovascular disease, even if it has not produced
overweight or obesity.
Value of Prevention
The economic burden of lipid disorders is substantial due to the impact of lipid
levels on the risk of cardiovascular disease and coronary heart disease events. The
direct and indirect costs of all types of cardiovascular disease in 2006 were
estimated to be $403.1 billion, including costs associated with coronary heart
disease (estimated to exceed $142 billion annually).1 The cost of cardiovascular
disease exceeds that of many other high-cost medical conditions. For example, in
2004, the estimated total cost of all cancers was $190 billion and in 1999, the
estimated total cost of HIV infections was $28.9 billion.1
Heart disease and stroke are not only a major cause of premature death in
persons younger than 65 years but are also major causes of serious disability in
the United States.1 The indirect costs of cardiovascular disease, including those
related to lost productivity, are enormous; it is estimated that the indirect cost of
cardiovascular disease will total over $145 billion in 2006.1
Cost-effectiveness analyses show that reducing low-density lipoprotein cholesterol
levels can reduce costs in three ways4:
1)Direct economic savings from decreased hospital and ambulatory services
from angina, myocardial infarction, revascularization procedures, stroke,
and heart failure.
2)Prevention of coronary heart disease mortality, which increases rates of
gainful employment and productivity.
3)Prevention of the disability, distress, and pain associated with coronary
heart disease, which increases quality-adjusted life expectancy as well as
rates of gainful employment and productivity.  
The cost of implementing a lipid screening program varies by location, provider
base, method of screening, which cholesterol measurements are taken, and other
factors. The average cost of a single cholesterol or lipid profile test is relatively
low but the cumulative costs of screening can be substantial, especially if all
recommended screening and follow-up procedures are followed.8 In 2004, the
private-sector cost of cholesterol and lipids screening averaged $13;
approximately 95% of all paid claims fell within the range of $0 to $32.9
Preventive medicine counseling averaged $39 and approximately 95% of all paid
claims fell within the range of $0 to $129.9
The total cost of reducing low-density lipoprotein includes the costs of physician
services, lifestyle counseling, screening, case finding and monitoring, dietary and
exercise modifications, medications, and treatment of side effects.  The annual
cost of statin drugs to reduce low-density lipoprotein cholesterol levels can range
from $100 to $1,500 per year.4 The cost of follow-up or treatment-related
appointments varies by type of provider, location, and practice setting. Although
the cost of reducing low-density lipoprotein cholesterol levels can be high, it is
much lower than the direct and indirect costs of cardiovascular disease.
In 2002, the National Cholesterol Education Program (NCEP) panel found that,
based on current retail prices for lipid-lowering drugs, low-density lipoprotein-
lowering drug therapy is highly cost-effective for persons with established coronary
heart disease (including a prior coronary heart disease event); cost-effective for the
primary prevention of coronary heart disease in persons with a coronary heart
disease risk equivalent (the person does not have coronary heart disease but does
have an absolute 10-year risk of developing major coronary events, such as
myocardial infarction and coronary death, equal to that of persons with coronary
heart disease), and those at high risk for coronary heart disease; and acceptable for
the primary prevention of coronary heart disease in persons whose 10-year risk of
“hard coronary heart disease” (heart attack and death from coronary heart
disease) is between 10% and 20%.4,10
The National Cholesterol Education Program recommends using dietary therapy,
which is more cost-effective than low-density lipoprotein-lowering drugs, as the
first-line therapy in persons with a 10-year risk of coronary heart disease that is
less than 10% per year.  (Information about dietary therapy is found in the
Other Important Information section of this document).
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Screening for lipid disorders allows patients and clinicians to begin 
lipid-lowering treatment before cardiovascular disease develops or progresses.
Most patients agree to be screened for lipid disorders, even when the screening
involves fasting.7
Clinical trials have shown that reducing low-density lipoprotein levels reduces
coronary heart disease risk, but the benefits of increasing high-density lipoprotein
levels have not yet been fully demonstrated.  In short-term clinical trials, a 1%
reduction in low-density lipoprotein cholesterol levels, on average, reduced the
risk of hard coronary heart disease events by about 1%. Persons who take low-
density lipoprotein cholesterol-lowering drugs for about 5 years reduce their low-
density lipoprotein levels by approximately 30% and decrease their risk of
cardiovascular disease, including heart attacks, by about 30%.2 However, only
about half of those who would benefit from lipid treatment receive it.11
In persons with established coronary heart disease, low-density lipoprotein-
lowering therapy reduces risk of stroke by about 30%.7 Statin therapy for the
primary and secondary prevention of cardiovascular disease can reduce adverse
cardiovascular events (including heart attacks and stokes) by 32% among patients
aged 65 and older.12 Primary prevention trials using statins have shown a
significant reduction in coronary heart disease mortality, no increase in non-
coronary heart disease mortality, and a strong trend toward lower overall mortality.
All adults aged 20 and older should be screened for abnormal lipid and elevated
blood cholesterol levels every 5 years.  Evidence is insufficient to determine the
age at which screening is no longer necessary; therefore decisions regarding when
to stop screening are left to the discretion of the clinician.4
Beginning at the initial visit with a patient who has a high level of cholesterol,
the clinician should counsel and encourage the patient to make therapeutic
lifestyle changes — such as dietary changes, increased physical activity, and
weight control — and monitor the patient’s progress.4,11 The clinician should
evaluate the patient’s low-density lipoprotein cholesterol level at the 6-week, 12-
week, and 4 to 6-month follow-up visits, or more often if necessary.4
Low-density lipoprotein cholesterol levels should be the primary target of
cholesterol-lowering therapy.4 The first step in selecting a low-density lipoprotein-
lowering therapy is assessing the patient’s coronary heart disease risk status, which
requires measuring low-density lipoprotein cholesterol levels as part of
lipoprotein analysis; identifying risk factors, such as family history; and
determining whether the patient has coronary heart disease, other clinical forms
of atherosclerotic disease, or the major risk factors for coronary heart disease
other than low-density lipoprotein cholesterol.4
Patients are considered to be at high risk of coronary heart disease if they have
coronary heart disease or coronary heart disease risk equivalents (the person does
not have coronary heart disease but does have an absolute 10-year risk of
developing major coronary events, such as myocardial infarction and coronary
death, equal to that of persons with coronary heart disease), including:  
• Other clinical forms of atherosclerotic disease (such as peripheral arterial
disease, abdominal aortic aneurysm, or symptomatic carotid artery disease).
• Diabetes.
• Multiple risk factors that confer a 10-year risk of coronary heart disease of at
least 20%.
Risk status in persons without coronary heart disease or other forms of
atherosclerotic disease is determined by a two-step procedure. 
First, the clinician counts the number of risk factors for coronary heart disease,
including: 
• Cigarette smoking.
• Hypertension (blood pressure of 140/90 mmHg or higher, or the patient is
taking antihypertensive medication).
• Diminished high-density lipoprotein cholesterol level (less than 40 mg/dL).
• Family history of premature coronary heart disease (in male first degree relative
younger than 55 or a female first degree relative younger than 65).
• Age (men aged 45 years or older; women aged 55 years or older).
If the clinician determines that the patient has at least two of these risk factors,
the Framingham scoring is used to determine the patient’s 10-year risk of
coronary heart disease.4 Risk factors used in Framingham scoring include age,
total or low-density lipoprotein cholesterol level, high-density lipoprotein
cholesterol level, smoking status, systolic blood pressure, and whether the
individual is taking antihypertensive therapy. Persons with several of these risk
factors are assigned to one of three categories of 10-year risk of coronary heart
disease: higher than 20%, 10% to 20%, or less than 10%. A person with 
10-year risk that is higher than 20% is categorized as “coronary heart disease 
risk equivalent,” meaning that the person does not have coronary heart disease
but does have an absolute 10-year risk of developing major coronary events, 
such as myocardial infarction and coronary death, equal to that of persons 
with coronary heart disease, or the person has diabetes. Framingham scoring is
the most reliable method available for identifying high-risk persons to 
determine the appropriate low-density lipoprotein level goal and treatment
intensity.4 A Framingham-based risk assessment tool is available online
(http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof ).
Lipid measurement should include a comprehensive lipoprotein profile in
addition to assessing other risk factors such as family history, smoking status,
weight, blood pressure, and age. 
The National Cholesterol Education Program (NCEP) recommends a 9 to 12-hour
fasting lipoprotein profile of total cholesterol, low-density lipoprotein, high-density
lipoprotein cholesterol, and triglycerides every 5 years for adults aged 20 and over,
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although total cholesterol and high-density lipoprotein cholesterol can be measured
on either fasting or non-fasting samples (venous or capillary blood samples).  The
results of the lipoprotein profile should be used to assess coronary heart disease risk
as recommended in the Adult Treatment Expert Panel-III guidance.
Beginning at the initial visit with a patient who has a high level of cholesterol,
the clinician should counsel and encourage the patient to make therapeutic
lifestyle changes — such as dietary changes, increased physical activity, and
weight control — and monitor the patient’s progress.4,11 The clinician should
evaluate the patient’s low-density lipoprotein cholesterol level at the 6-week, 12-
week, and 4 to 6-month follow-up visits, or more often if necessary.4
Target goals for low-density lipoprotein levels and treatment are based on the
person’s 10-year risk of coronary heart disease, as described in the “Risk
Assessment” section. 
The first line of therapy for elevated low-density lipoprotein cholesterol levels is
therapeutic lifestyle changes; drug therapy can be combined with therapeutic
lifestyle changes if additional low-density lipoprotein reduction is required. 
Therapeutic Lifestyle Interventions (Initial Treatment/“First-Line” Therapy):
On the therapeutic lifestyle change diet, saturated fat should account for no more
than 7% of calories, no more than 200 mg of cholesterol should be consumed
per day, and total fat intake may range from 25% to 35% of all calories.4,11
Trans-fat intake should be as low as possible. The person’s diet should also
include 2–3 g/day of plant stanol esters (sitostanol and sitostanol esters, found in
soft margarine), 10–25 g/day of soluble fiber (fruits, vegetables, and whole
grains), and 400 mg/day of folate consumed largely from dietary sources.
Carbohydrates should be limited to 60% of total calories. Therapeutic lifestyle
interventions also include smoking cessation, weight management, regular
physical exercise, and moderation of alcohol intake — no more than two drinks
per day for men and one drink per day for women (one alcoholic drink is
defined as 5 ounces of wine, 12 ounce of beer, or 1.5 ounces of hard liquor). If,
after 3 months, therapeutic lifestyle interventions in a patient who is not at high
risk have not reduced low-density lipoprotein cholesterol levels sufficiently, the
addition of drug therapy to the treatment plan should be considered. In high-risk
patients, drug therapy should be considered together with therapeutic lifestyle
changes at the initiation of treatment if the low-density lipoprotein level is at
least 100 mg/dL. The intensity of risk-reduction therapy should be adjusted to an
individual’s absolute 10-year risk of coronary heart disease, which is based on age,
lipoprotein profile, previous history of coronary heart disease events, and other
risk factors. 
A combination of sustained changes in diet, weight loss, and exercise can lower
low-density lipoprotein cholesterol levels by as much as 20% to 30%.4
If the patient’s target low-density lipoprotein cholesterol level has not been
achieved by the 6-week visit, the clinician should intensify the low-density
lipoprotein-lowering therapy by adding plant stanol/sterol esters and viscous
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(soluble) fiber to the diet (refer to “Treatment Information and Therapeutic
Lifestyle Interventions” for more information). If the low-density lipoprotein goal
is not achieved by the 12-week follow-up visit, the therapeutic lifestyle changes
should be intensified by increasing the emphasis on physical activity and weight
control. Drug treatment, such as statins, should also be considered. After the 12-
week visit, adherence to therapeutic lifestyle changes and drug treatment should
be monitored every 4 to 6 months, or more often if necessary.4
The recommended first-line therapy for elevated serum triglycerides is
therapeutic lifestyle changes, including reduced intake of fat, avoidance of very
high carbohydrate intake (no more than 60% of calories), increased physical
activity, weight control, and restriction of alcohol intake.
Therapeutic lifestyle changes and drug therapy by risk category are summarized
in Table 2.
Table 2: Target Low-Density Lipoprotein Cholesterol Levels and Treatment
Recommendations
Risk Category Target Low-Density Low-Density Lipoprotein Low-Density Lipoprotein
Lipoprotein Level Levels (mg/dL) at Which  Levels (mg/dL) at Which 
(mg/dL) to Initiate Therapeutic to Consider Drug Therapy
Lifestyle Changes 
High Risk: <100 100 100
Coronary heart disease (<70 optional goal for (if lipoprotein levels are
or a 10-year coronary patients with coronary  <100, a lipid-lowering 
heart disease risk heart disease) drug is a therapeutic 
equivalent (including option, based on 
diabetes or two or clinical trials)
more risk factors 
and a 10-year risk 
of at least 20%)
Moderately High Risk: <130 130 130 (after 3 months
Two or more risk factors of therapeutic 
(10-year risk 10% lifestyle changes)
to 20%)
Moderate Risk: <130 130 160 (after 3 months
Two or more risk factors of therapeutic
(10-year risk <10%) lifestyle changes)
Lower Risk: <160 160 190 (after 3 months
No risk factors or one of therapeutic lifestyle 
risk factor changes) 
(at 160-189 mg/dL, 
low-density lipoprotein-
lowering drugs are optional)
Table adapted from: Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake
DB, Implications of recent clinical trials for the National Cholesterol Education Adult Treatment
Panel III (ATP III) guidelines.  Circulation 2004; 110:227-39.
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Other Important Information
Physicians should have primary responsibility for implementing the Adult
Treatment Expert Panel-III treatment guidelines. In addition, a multidisciplinary
team, potentially including nurses, dieticians, nurse practitioners, pharmacists,
and health educators, should be involved in and reimbursed whenever possible
for these services. The model of a multidisciplinary case management approach
for patients with lipid disorders encompasses primary and secondary prevention
across the lifespan and nutritional and exercise management, defines the
indications for pharmacological therapy, and emphasizes the importance of
treatment adherence.13 Use of this collaborative approach for the treatment of
lipid disorders will ultimately reduce cardiovascular and cerebrovascular (stroke)
morbidity and mortality. 
More information on adherence methods that payers can use to improve
beneficiary adherence to lipid-lowering treatments is available in Part VI of the
Purchaser’s Guide, Leveraging Benefits.
More information on the therapeutic lifestyle intervention diet is available in the
National Heart, Lung, and Blood Institute tipsheets
(www.nhlbi.nih.gov/chd/Tipsheets/daily.htm).
Information on ways to reduce low-density lipoprotein cholesterol levels is
available in Your Guide to Lowering your Cholesterol Level with Therapeutic
Lifestyle Changes (www.nhlbi.nih.gov/health/public/heart/chol/_tlc.pdf ).
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained in this chapter
is described below.
Evidence-Based Research:
The U.S. Preventive Services Task (USPSTF)
Strength of Evidence: A (Strongly Recommended / Good Evidence)
• The USPSTF force strongly recommends that clinicians screen men aged
35 and older and women aged 45 and older for lipid disorders and that
they treat abnormal lipid levels in persons who are at increased risk of
coronary heart disease (based on such factors as age, total or low-density
lipoprotein cholesterol level, high-density lipoprotein cholesterol level,
smoking status, and systolic blood pressure).3
Recommended Guidance:
Adult Treatment Expert Panel-III, National Cholesterol Education Program
(NCEP)  Strength of Evidence: The Adult Treatment Expert Panel-III
recommendations are based on large randomized controlled clinical trials,
prospective epidemiological studies, and smaller clinical trials. An expert panel
assigned each recommendation to a category of type of evidence (based on the
source of the evidence) and strength of evidence as follows4: 
Category of Type of Evidence:
A Major randomized controlled clinical trials.
B Smaller randomized controlled clinical trials and 
meta-analyses of clinical trials.
C Observational and metabolic studies.
D Clinical experience.
Strength of Evidence:
1 Very strong evidence.
2 Moderately strong evidence.
3 Strong trend.
The Adult Treatment Expert Panel-III recommended that:
• Clinicians screen all adults aged 20 and older for elevated blood
cholesterol levels every 5 years {A1, B1, C1}.4 Screening should involve a
complete lipoprotein profile, including an evaluation of low-density
lipoprotein cholesterol level.4
• Clinicians treat all patients with abnormal lipid levels to decrease their
risk of cardiovascular disease events, such as heart attacks. The first line of
treatment should be counseling about healthy therapeutic lifestyle
changes.4
• Reducing low-density lipoprotein cholesterol levels should be the primary
target of cholesterol-lowering therapy {A1, B1, C1}.4
These recommendations are supported by the:
• Centers for Disease Control and Prevention (CDC)
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• Motor vehicle-related injuries kill more children and young adults than any
other single cause in the United States.1 In 2004, 1,638 children ages 14 years
and younger died as occupants in motor vehicle-related crashes, and
approximately 214,000 were injured resulting in an average of 6 deaths and
673 injuries each day.2
• In a given year, 41,000 Americans will die in motor vehicle crashes, 500,000
will have crash injuries requiring hospitalization, and 4 million will have crash
injuries requiring a visit to an emergency department.1
• Motor vehicle-related deaths and injuries cost the United States a total of $230
billion dollars per year (in year 2000 dollars).3 Costs due to motor vehicle-
related injuries in children are estimated to approach $20 billion annually. The
average cost, per child, for a motor-vehicle related injury is estimated to be
$10,600 (updated to year 2000 dollars).4
• The workplace burden of motor vehicle-related crashes is also substantial: each
year, motor vehicle-related crashes result in $61 billion in lost productivity and
$5 billion in workplace administrative costs (in year 2000 dollars).3
• Motor vehicle-related fatal and nonfatal injuries are highly preventable.
Seatbelts, child safety seats, safety helmets (for motorcycles), and not driving
while impaired by alcohol or drugs, are proven to reduce the risk of motor
vehicle-related injuries.5-11
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) issued a recommendation on
counseling to prevent motor vehicle crash injuries in 1996. Given the availability
of new evidence, the USPSTF decided to update its 1996 recommendation. This
work is currently in progress. Please refer to the USPSTF website for updates
(www.ahrq.gov/clinic/prevenix.htm).
The American Academy of Family Physicians (AAFP) recommends that
physicians counsel all parents and patients over the age of 2 years regarding
accidental injury prevention including, as appropriate: child safety seats, lap and
shoulder belt use, bicycle safety, motorcycle helmet use, and driving while
intoxicated.12
Although evidence exists which demonstrates net benefit, either the benefit is
only moderate in magnitude or the evidence supporting a substantial benefit is
only fair. The intervention is perceived to be cost effective and acceptable to most
patients. The AAFP Summary of Recommendations for Clinical Preventive
Services (RCPS) originated in the Commission on Clinical Policies and Research
and was approved by the AAFP Board of Directors in August 2005.
The starting point for the recommendations is the rigorous analysis of scientific
knowledge available as presented by the U.S. Preventive Services Task Force
(USPSTF) in their Guide to Clinical Preventive Services, 2nd Edition and ongoing
releases of evidence reports and recommendations from the 3rd Edition. 
EVIDENCE-STATEMENT:
MOTOR VEHICLE-RELATED INJURY PREVENTION
(Counseling)
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The AMA urges physicians to educate their patients about the dangers of alcohol
abuse and operating a motor vehicle while under the influence of alcohol.13
The AMA recommends that all adolescents receive health guidance annually to
promote the reduction of injuries.14 Health guidance for injury prevention
includes the following:
• Counseling to avoid the use of alcohol or other substances while using motor
or recreational vehicles, or where impaired judgment may lead to injury;
• Counseling to use safety devices, including seat belts, and motorcycle and
bicycle helmets.
Expert Opinion. The AMA developed its recommendations with contributions
from a Scientific Advisory Panel, comprised of national experts, as well as
representatives of primary care medical organizations and the health insurance
industry. The body of scientific evidence indicated that the periodicity and
content of preventive services can be important in promoting the health and
well-being of adolescents.
The American Academy of Pediatrics (AAP) recommends that pediatricians
counsel parents of most children (those who weigh more than 12 lbs at 4 months
of age) to encourage use of a convertible car safety seat that will accommodate
them rear facing at higher weights.15 Further, the AAP encourages pediatricians to
emphasize to parents and teenagers repeatedly the paramount importance of safe
driving behavior. During office visits, pediatricians can address risk factors,
especially driving while impaired by alcohol or other drugs and nighttime
driving. Pediatricians are encouraged to counsel parents that adolescents, despite
their physical maturity, are still developing their driving skills and need time to
master this complex task by practicing while supervised in a low-risk
environment. The pediatrician should address the tendency of some parents to
deny that their teenagers might be unsafe drivers. Pediatricians should advise
parents that their parenting responsibilities include the following15: 
• Setting a good driving example (e.g., no drinking and driving, no speeding,
and requiring all occupants to use safety belts);
• Establishing driving behavior limits on their teenagers, such as limiting the
number and age of passengers, restricting nighttime driving for novice drivers,
and delaying the onset of unsupervised driving as they see fit; 
• Showing that they expect responsible driving behavior from their teenagers and
imposing penalties for irresponsible actions; Supervising novice drivers in a
vehicle; 
• Ensuring the mechanical safety of any car used by a teenager.
Not Specified
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The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP)
• American Medical Association (AMA)
• Centers for Disease Control and Prevention (CDC), National Center for
Injury Prevention and Control
• National Highway Traffic Safety Administration (NHTSA)
• Peer-reviewed research
• U.S. Department of Transportation (DOT)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Motor vehicle-related injuries kill more children and young adults (18 to 34 years
of age) than any other single cause in the United States.1 In a given year, 41,000
Americans will die in motor vehicle crashes, 500,000 will have crash injuries
requiring hospitalization, and 4 million will have crash injuries requiring a visit
to an emergency department.1
In the United States during 2004, 1,638 children ages 14 years and younger died
as occupants in motor vehicle-related crashes, and approximately 214,000 were
injured resulting in an average of 6 deaths and 673 injuries each day.2
During 2004, 16,694 people in the United States died in alcohol-related motor
vehicle crashes, representing 39% of all traffic-related deaths.16 Drugs other than
alcohol (e.g., marijuana and cocaine) are involved in about 18% of motor vehicle
deaths. These drugs are usually used in combination with alcohol.17 Nearly three
quarters of those convicted of driving while impaired are either frequent heavy
drinkers (alcohol abusers) or alcoholics (alcohol dependent).17
Risk factors for motor vehicle-related injuries among children include failing to
use occupant protection, improper use of occupant protection, and being a
passenger in a vehicle driven by a person under the influence of alcohol or other
drugs. Restraint use among young children often depends upon the driver’s
restraint use. Almost 40% of children riding with unbelted drivers were
themselves unrestrained.18 Even children who do use child restraints are at risk if
they are improperly secured. A survey of more than 17,500 children found that
only 15% of children in safety seats were correctly harnessed into correctly
installed seats.18
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The economic burden of motor vehicle-related deaths and injuries is enormous,
costing the United States more than $230 billion each year (year 2000 dollars).3
Of the estimated $230 billion, $61 billion is due to lost workplace productivity,
$59 billion due to property damages, $34 billion due to medical expenses, $25
billion due to delayed transit, $20 billion due to lost household productivity, $15
billion due to insurance administration, $11 billion due to legal fees, and $5
billion due to workplace administration.3
Costs due to motor vehicle injuries in children are estimated to approach $20
billion annually. Costs per child injured (when a child occupies a vehicle involved
in a crash) are estimated at $10,600 per injury (updated to year 2000 dollars).4
Alcohol-involved crashes pose a great economic burden in the United States. The
economic costs for motor vehicle injuries involving alcohol are estimated at $50.9
billion annually (year 2000 dollars).3
As stated above, the workplace burden of motor vehicle-related crashes is
substantial. Each year, motor vehicle-related crashes result in $61 billion in lost
productivity and $5 billion in workplace administrative costs (year 2000 dollars).3
The savings associated with preventable medical-care costs, lost productivity, and
other injury-related expenditures constitute the major economic benefit of
counseling to prevent motor vehicle-related injuries. Including intangible
consequences such as pain and suffering, the total value of preventing a motor
vehicle-related death was estimated to be $3.4 million (in year 2000 dollars) per
life saved.19
In 2004, the private-sector cost of injury prevention counseling averaged $38 per
session; approximately 95% of paid claims fell within the range of $0 to $129
per session.19
The cost of motor-vehicle injuries varies tremendously depending on the type
and severity of the injury. 
Injury prevention counseling by pediatricians has been shown to be cost-saving in
some studies. The studied intervention included 11 brief sessions of
approximately 1.5 minutes each, one of which was related to the use of child
safety seats. Cost savings from the child safety seat counseling session ranged
from $24 to $69 per child counseled. These counseling costs are comparable with
the costs of counseling for other prevention messages.20-22
Counseling trauma patients (an injured patient treated in an emergency
department or admitted to a hospital) on the dangers of alcohol was estimated to
have a net cost-savings of $330 per patient intervention due to reduced future
alcohol related trauma. The counseling included a brief screening and
intervention session by a healthcare professional.23
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Motor vehicle-related fatal and nonfatal injuries are highly preventable. Seatbelts,
child safety seats, safety helmets (for motorcycles), and not driving while
impaired by alcohol or drugs, are proven to reduce the risk of motor vehicle-
related injuries.5-11 The rates of fatal and non-fatal motor vehicle-related injuries
have declined in recent years, partially due to program and policy interventions
designed to prevent these injuries.5-11 For example, over 80% of all adults use seat
belts. However, children remain at high risk for motor-vehicle related injuries
because only 15% of children are correctly harnessed into correctly installed
safety seats.18
Several studies have evaluated counseling parents to increase seat belt usage
among their children24-29 and to use safety seats for infants and newborns.30-40
Other studies have shown that counseling adolescents and adults can increase seat
belt usage.26,41-44 In general, most of the evidence suggests that there is a relatively
short-term effect of clinician counseling on the use of occupant restraints,
indicating the need for periodic reinforcement of this message.
While little is known about how effectively clinicians can influence patients to
refrain from driving while impaired by alcohol or other drugs, there is good
evidence that brief clinician counseling can reduce alcohol consumption in
problem drinkers, which may, in turn, result in reduced drinking and driving.45-47
Studies also find that counseling provided as a component of trauma care (care
delivered to an injured patient in an emergency department of through
hospitalization) significantly reduces injuries and the rate of trauma recidivism
(re-injury).48-50 Further, despite the fact that there are over 159 million episodes of
alcohol-impaired driving each year, only 1.5 million persons are arrested annually
for driving under the influence of alcohol.51 Thus, it is likely that many patients
would benefit from clinician counseling to modify their behaviors as drivers and
passengers in motor vehicles. Since motor vehicle crashes represent a leading
cause of death and nonfatal injury in the United States, even modest successes
through clinical interventions could have major public health benefits. 
Although the harms associated with counseling are not well-studied, they may
include stigma, psychological stress, and anxiety. It is likely that these risks are
minimal, and the harms associated with counseling are far outweighed by the
benefits. 
There is insufficient evidence to determine the optimal ages at which to begin
and cease counseling to prevent motor vehicle-related injuries. Experts agree that
counseling for motor vehicle-related injuries should be initiated and stopped
when deemed appropriate by the clinician. 
Likely initiation periods might be: 1) when patients first begin to drive (age 15,
16 or older depending on state law), 2) when patients first become parents, 3)
when patients seek other preventive services for young children, 4) when patients
present with alcohol or other drug dependencies, and 5) when patients receive
trauma care for alcohol-related injuries. 
Evidence is insufficient to determine the optimal interval to counsel patients
about motor vehicle-related injuries. Thus, clinicians are encouraged to use their
judgment in deciding how frequently to counsel patients for motor vehicle-
related injuries. Clinicians should be encouraged to periodically reinforce
prevention messages with all patients (at least once per year), particularly with
those patients at high-risk of motor vehicle-related injuries (patients aged 18 to
33 years, parents of small children or adolescents, and substance and alcohol
abusers).
The specific method of counseling is left to the discretion of the clinician.
Common methods of counseling include brief clinician counseling (3 minutes or
less) and intensive counseling.
The provider of any patient who has suffered an alcohol-related motor vehicle
crash should screen the individual for alcohol misuse. For more information on
alcohol misuse screening and counseling please refer to the Alcohol Misuse
Screening and Counseling Evidence-Statement. 
Not Applicable
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
American Academy of Family Physicians (AAFP)
Strength of Evidence: R (Recommended)
• The AAFP recommends that physicians counsel all parents and patients over
the age of 2 years regarding accidental injury prevention including, as
appropriate: child safety seats, lap and shoulder belt use, and driving while
intoxicated.12
Recommended Guidance:
American Medical Association (AMA)
Strength of Evidence: Not Specified
• The AMA urges physicians to educate their patients about the dangers of
alcohol abuse and operating a motor vehicle while under the influence of
alcohol.2
• The AMA recommends that all adolescents receive health guidance annually to
promote the reduction of injuries.14 Health guidance for injury prevention
includes the following:
> Counseling to avoid the use of alcohol or other substances while using
motor or recreational vehicles, or where impaired judgment may lead to
injury;
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> Counseling to use safety devices, including seat belts, and motorcycle and
bicycle helmets.
American Academy of Pediatrics (AAP)
Strength of Evidence: Not Specified
• The AAP recommends that pediatricians counsel parents of most children
(those who weigh more than 12 lb at 4 months of age) to encourage use of a
convertible car safety seat that will accommodate them rear facing at higher
weights.5
• The AAP encourages pediatricians to emphasize to parents and teenagers
repeatedly the paramount importance of safe driving behavior. During office
visits, pediatricians can address risk factors, especially driving while impaired
by alcohol or other drugs and nighttime driving. Pediatricians are encouraged
to counsel parents that adolescents, despite their physical maturity, are still
developing their driving skills and need time to master this complex task by
practicing while supervised in a low-risk environment. The pediatrician should
address the tendency of some parents deny that their teenagers might be unsafe
drivers.5
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• Obesity is epidemic in the United States. Between 1976 to 1980 and 1999 to
2002, the proportion of adults classified as obese doubled. During that period,
the proportion of children (aged 6 to 11 years) classified as overweight doubled
and the proportion of overweight adolescents (aged 12 to 19 years) tripled.1
• Nearly 80% of obese adults suffer from diabetes, high blood pressure, coronary
artery disease, high cholesterol, osteoarthritis, or a combination of these
conditions.2
• Because it contributes to so many other serious conditions, obesity is
considered to be one of the most important, underlying, and preventable
causes of poor health and premature death.3
• Obesity contributes significantly to medical costs in the United States.4
• The cost to employers of obesity-related health problems in 1994 was
estimated to be $13 billion per year, including $8 billion in medical claims,
$2.4 billion in paid sick leave, $1.8 billion in life insurance, and almost $1
billion in disability insurance.5
• Each year, an estimated 39 million work days are lost to obesity-related
illnesses.6
• For adults, losing excess weight has positive effects on overall health status. A
5% to 7% reduction in body weight decreases the risk of type 2 diabetes,
reduces blood pressures, and improves lipid profiles.7 Among patients with
existing glucose intolerance, weight loss through lifestyle change is associated
with as much as a 58% reduction in incidence of diabetes.8
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
screen all adult patients for obesity and offer intensive counseling and behavioral
interventions to promote sustained weight loss for obese adults.9
The USPSTF found good evidence that body mass index (BMI), calculated as
weight in kilograms divided by height in meters squared, is reliable and valid for
identifying adults at increased risk for mortality and morbidity due to overweight
and obesity. There is fair to good evidence that high-intensity counseling —
about diet, exercise, or both — together with behavioral interventions aimed at
skill development, motivation, and support strategies produces modest, sustained
weight loss (typically 3 to 5 kg for 1 year or more) in adults who are obese (as
defined by BMI  30 kg/m2). Although the USPSTF did not find direct
evidence that behavioral interventions lower mortality or morbidity from obesity,
the USPSTF concluded that changes in intermediate outcomes, such as improved
glucose metabolism, lipid levels, and blood pressure, from modest weight loss
provide indirect evidence of health benefits.9
EVIDENCE-STATEMENT:
OBESITY (Screening and Counseling)
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The FDA has approved two medications for the treatment of obesity that can
reduce patient weight by an average of 2.6 to 4.8 kg (5.7 to 10.6 lbs) for at least
2 years: orlistat (Xenical®) and sibutramine (Meridia®).10-11
Clinical Trials
The NHLBI recommends that surgical procedures for obese patients be reserved
for patients with class III obesity (BMI  40) and patients with class II obesity
(BMI of 35 to 39.9) who also have at least one obesity-related illness.12
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
• American Academy of Bariatric Surgery
• American Academy of Family Physicians (AAFP)
• American Academy of Pediatrics (AAP)
• American Medical Association (AMA)
• Food and Drug Administration (FDA)
• National Academy of Sciences, Institute of Medicine (IOM)
• National Center for Education in Maternal and Child Health
• National Heart, Lung, Blood Institute (NHLBI)
• Peer-reviewed research
• U.S. Department of Health and Human Services
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information in this document is based on a
compilation of research findings. All of the information presented in this
document should be attributed to its referenced source and should not be
considered a reflection of the opinions of other organizations cited in the text. 
Condition/Disease-Specific Information
The Body Mass Index (BMI) is widely used as an index of body composition and
weight. BMI’s in the range of 18.5 to 24.9 are generally considered to be optimal
for adults. “Underweight” is generally defined as a BMI less than 18.5,
“overweight” as BMI between 25 to 29.9, and “obesity” as a BMI greater than
30. Age- and gender-specific standards also exist for children and adolescents that
take into account the changes in body composition that occur as children grow
(See “Other Important Information,” below).
Obesity is epidemic in the United States. Between 1976 to 1980 and 1999 to
2002, the proportion of adults classified as obese doubled.1 Nearly 80% of obese
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adults suffer from diabetes, high blood pressure, coronary artery disease, high
cholesterol, osteoarthritis, or a combination of these conditions.2 Research has
also documented that obesity is associated with decreased quality of life.13
During this period, the proportion of children (aged 6 to 11 years) classified as
overweight doubled and the proportion of overweight adolescents (aged 12 to 
19 years) tripled.1 The complications of being overweight are particularly severe
for children due to the years of life they are at risking of losing as a result of
early-onset chronic diseases, such as diabetes14 and cardiovascular disease.15
For adults, losing excess weight has positive effects on overall health status. A 5%
to 7% reduction in body weight decreases the risk of type 2 diabetes, reduces
blood pressures, and improves lipid profiles.7 Among patients with existing
glucose intolerance, weight loss through lifestyle change is associated with as
much as a 58% reduction in incidence of diabetes.8 The USPSTF found limited
data on the positive effect that weight loss may have on overall mortality, mental
health, and daily functioning.9
Obesity is more common among adult women, Native Americans, African-
Americans, Native Hawaiians, and Hispanics than other populations.7
Value of Prevention
Obesity contributes significantly to medical costs in the United States. In 1998,
9.1% of total annual medical expenditures could be attributed to obesity.4
Between 1987 and 2001, 27% of the growth in inflation-adjusted per-capita
healthcare spending was associated with obesity.6 The annual cost of obesity is
estimated to range from $69 billion to $117 billion (including $61 billion for
direct medical expenses and $56 billion for indirect expenses such as lost
productivity [in year 2000 dollars]).16
The expected lifetime costs of cardiovascular disease (including coronary heart
disease, heart attack, and stroke) increase by 20% with mild obesity (class I: BMI
of 30 to 34.9), 50% with moderate obesity (class II: BMI of 35 to 39.9), and
nearly 200% with severe obesity (class III: BMI of 40 or higher).5 One large
health plan found that its yearly total medical claims were 18% higher for
overweight individuals and 32% higher for obese than for healthy-weight
individuals.17
A 2001 study found obese adults had, on average, about 37% higher healthcare
expenses per person than normal-weight adults. This excess expense increased
private healthcare spending by nearly 12% (more than $36 billion).6
The cost to employers of obesity-related health problems in 1994 was estimated
to be $13 billion per year, including $8 billion in medical claims, $2.4 billion in
paid sick leave, $1.8 billion in life insurance, and almost $1 billion in disability
insurance.5
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Obesity and related illnesses are also a major cause of disability.  Each year, an
estimated 39 million work days are lost to obesity-related illnesses.6
Nutrition education, diet, and exercise counseling are effective interventions for
obesity prevention and have the potential to significantly reduce the direct and
indirect costs of obesity-related illnesses. Researchers have estimated that even a
modest reduction of 10% in body weight in an obese individual might reduce
the expected lifetime healthcare costs of major obesity-related diseases for the
individual by $2,200 to $5,300, depending on age, sex, and initial BMI.18
The cost of BMI screening is negligible when height and weight measurements
are already recorded as part of a routine physical exam. In 2004, the private-
sector cost of obesity counseling averaged $39 per session; approximately 95% of
all paid claims fell within the range of $0 to $129 per session.19
In the United States, the costs associated with treating obesity vary by location,
provider type, and treatment modality.  For example, in 2006 the average wholesale
price of a 1-month supply of pharmacological therapy for obesity was $207.04 for
orlistat (Xenical“) (120 mg three times daily) and $423.60 for a 3-month supply of
sibutramine (Meridia“) (15 mg daily).28 In contrast, the average price of a surgical
procedure for obesity in 2004 ranged from $20,000 to $35,000.21
The cost-effectiveness of screening for and treating obesity is unclear. Because
obese individuals are at risk for serious and costly complications, such as diabetes
and cardiovascular disease, screening for obesity and early intervention to reduce
excess weight could improve lives and increase the cost-effectiveness of healthcare
dollars. However, few studies have tested the cost-effectiveness of screening for
and treating obesity in the United States, although several cost-effectiveness
studies have been conducted in England, Australia, and Northern Europe. The
studies conducted abroad applied their-effectiveness analyses to morbidly obese
patients (i.e., persons with BMIs  40, which is approximately 100 pounds over
normal weight for a typical person). The studies found that a range of
interventions (such as pharmacotherapy, surgery, and intensive diet and
behavioral therapy) can be inexpensive or even cost-saving, depending on the
population’s risk and the interventions used.22 These results cannot be generalized
to patients who are not morbidly obese. Further, the results may not be
generalizable to the U.S. population because of differences between the
populations studied and the U.S. population and differences in healthcare system
funding and delivery mechanisms in the countries studied.
Preventive Intervention Information
Because obesity is a modifiable major risk factor for several serious conditions,
screening for obesity and treating it successfully can be expected to produce
significant health benefits. Screening for obesity allows clinicians to identify
patients at risk and begin treatment before serious weight-related complications
occur. Unfortunately, weight is frequently overlooked in primary care practice;
only 42% of obese patients report receiving advice to lose weight during a
routine check-up in the previous year.23
Although the USPSTF did not find direct evidence that behavioral interventions
lower mortality or morbidity from obesity, the USPSTF concluded that changes
in intermediate outcomes, such as improved glucose metabolism, lipid levels, and
blood pressure, from modest weight loss provide indirect evidence of health
benefits.9
The USPSTF was unable to find studies that suggested harms associated with
screening or counseling obese patients.24 However, the USPSTF notes that
because obesity carries a stigma, there is a potential risk in labeling patients as
obese. The USPSTF found evidence that dieting among overweight and obese
adults does not lead to problems in psychological functioning or eating disorders.
However, the USPSTF notes that the evidence is limited and conflicting on the
harms of weight cycling (losing and then regaining a large amount of weight). In
addition, the USPSTF notes that some forms of treatment, specifically
pharmacological therapy and surgical intervention, carry potential harm.24
The USPSTF concluded that the benefits of screening and behavioral
interventions outweigh potential harms.
The USPSTF did not find evidence to determine the optimal times for the
initiation, cessation, or interval of obesity screening. Several health organizations,
including the American Academy of Family Physicians (AAFP),25 the American
Heart Association (AHA),26 and the American College of Preventive Medicine
(ACPM),27 agree on the importance of screening for obesity and recommend
periodically measuring the height and weight of all patients. Some authorities
have recommended that height and weight be recorded and BMIs calculated at
every healthcare visit. 
High-intensity counseling is defined by the USPSTF as 2 or more person-to-
person sessions per month for at least the first 3 months of treatment for a total
of 6 counseling sessions per calendar year.
The USPSTF notes that the most effective interventions for obesity combine
nutrition education, diet and exercise counseling, and behavioral strategies to
help obese patients acquire the skills they need to successfully change their eating
habits and to become more physically active.9
The preferred method of screening an adult patient for obesity is to measure their
body-mass index (BMI). This is a reliable and valid measurement of adult weight
status. BMI is defined as weight in pounds divided by height in inches squared
and multiplied by 703, or as weight in kilograms divided by height in meters
squared. BMI charts provide completed calculations and can be used to
determine BMI by simply entering weight and height. The following definitions
from the Clinical Guidelines on the Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults12 should be used to classify weight status:
Screening for obesity may also include measurement of waist circumference
because central adiposity (excess fat around the middle) can also increase an
individual’s risk of developing cardiovascular disease. A waist circumference
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greater than 102 centimeters for men and 88 centimeters for women is associated
with an increased risk of cardiovascular disease. However, waist measurements are
not reliable indicators of cardiovascular disease risk in obese patients with a BMI
of 35 or above.24
The most effective behavioral interventions for obesity combine nutrition
education, diet and exercise counseling, and behavioral strategies to help obese
patients acquire the skills they need to change their eating habits and become
more physically active.28
Clinicians should offer a treatment plan of intensive counseling and behavioral
interventions to obese patients. Intensive counseling is defined as 2 or more
person-to-person individual or group sessions per month for at least 3 months.24
If clinicians are unable to offer obese patients intensive counseling and behavioral
interventions, they should refer patients to a program or provider that can offer
these services. However, this should not undermine the existing patient-physician
relationship because research has shown that clinicians’ advice plays a role in
many health outcomes.29-30
No evidence exists to show that one counseling method is better than another for
obese patients. Clinicians must therefore use their own judgment to select an
appropriate counseling method for a given patient. The “5-A” framework31 that is
used for smoking cessation counseling might be useful for the initial evaluation
and counseling of an obese patient and might be helpful in broaching the subject
of weight loss with patients:
• Assess the patient’s weight by measuring his or her BMI and waist and evaluate
the patient’s factors that affect choice of behavior change goals/methods.
• Advise the patient to lose weight through physical activity and a healthy diet
using clear, specific, and personalized messages.
• Agree with the patient on specific changes he or she can make to reach his or
her target weight.
• Assist the patient in making changes by offering support services, education,
and resources.
• Arrange for follow-up and support services.
Experts recommend that pharmacological therapy for obesity, such as
medications that induce weight loss or suppress appetite, only be used as part of a
BMI Chart for Adults
Classification BMI
Underweight Less than 18.5
Healthy 18.5 to 24.9
Overweight 25 to 29.9
Obese (class I) 30 to 34.9
Obese (class II) 35 to 39.9
Obese (class III) 40 and above
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treatment plan that also includes lifestyle modifications such as intensive diet,
exercise, and behavioral counseling.9 The Food and Drug Administration (FDA)
has approved two medications for the treatment of obesity that can reduce
patient weight by an average of 2.6 to 4.8 kg (5.7 to 10.6 lbs) for at least 2 years:
orlistat (Xenical®) and sibutramine (Meridia®).10-11 While these drugs are effective,
they may produce unwanted side effects and few data are available on the safety
of their long-term use. 
The National Heart, Lung, and Blood Institute (NHLBI) recommends that
surgical procedures be reserved for obese patients with class III obesity (BMI
greater than 40) and patients with class II obesity (BMI of 35 to 39.9) who have
at least one obesity-related illness. Surgical procedures, such as bariatric surgery,
are effective for treating obesity in the short-term (on average, extremely obese
patients lose 10 to 159 kg [22 to 349.8 lbs] in 1 to 5 years).12
Bariatric surgery produces improvements in health for most of the patients. For
example, a meta-analysis of bariatric surgery studies found that 60% to 70% of
patients lost all of their excess weight and that diabetes was brought under
control in almost 77% of patients who had had diabetes prior to the surgery.32
Although the long-term health effects of surgery for obesity are not well
characterized, surgical cohort studies suggest that large amounts of weight loss
may be linked to dramatic improvements in glucose metabolism. In addition,
some evidence indicates that surgically treated patients are more likely to have
resolution of diabetes, hypertension, and certain lipid disorders than patients who
do not undergo surgery.28
However, bariatric surgery is associated with serious risks, including the risk of
death, and 25% of patients may need a second operation within 5 years.28
Other Important Information
The USPSTF concluded that the evidence was insufficient to recommend for or
against routine screening for overweight in children and adolescents as a means to
prevent adverse health outcomes.33
The USPSTF found 1) fair evidence that BMI is a reasonable measure for
identifying children and adolescents who are overweight or are at risk for
becoming overweight, 2) fair evidence that overweight adolescents and children
( 8 years old)are at increased risk for becoming obese adults, 3) insufficient
evidence for the effectiveness of behavioral counseling or other preventive
interventions with overweight children and adolescents that can be conducted in
primary care settings or to which primary care clinicians can make referrals, and
4) insufficient evidence to ascertain the magnitude of the potential harms of
screening or prevention and treatment interventions. The USPSTF was unable to
determine the balance between potential benefits and harms of routine screening
of children and adolescents for overweight.
Although the USPSTF found insufficient evidence to recommend for or against
screening children and adolescents for overweight, many health organizations
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have created guidelines for this type of screening. For example, the American
Academy of Family Physicians (AAFP),34 American Academy of Pediatrics
(AAP),35 National Center for Education in Maternal and Child Health,36 and
American Medical Association (AMA) have developed guidelines that include
recommendations for measuring height and weight as part of periodic health
examinations for children and adolescents. 
In 2003, the AAP published a policy statement on the prevention of pediatric
overweight and obesity. In this report, the AAP stated that a BMI between the
85th and 95th percentiles for age and sex indicates that the child or adolescent is
at risk for overweight and a BMI at or above the 95th percentile indicates that
the child or adolescent is overweight or obese.35 Because obesity is associated with
significant health problems in children, the AAP proposed strategies to foster
prevention and early detection of overweight and obesity. In addition to the
healthy nutrition recommendations, the AAP developed a policy statement on
active healthy living for the prevention of childhood obesity.37 According to this
policy, physicians and other healthcare professionals should advocate for policy
changes at the community, state, and national levels to support healthy nutrition,
reduce sedentary time, and increase physical activity levels in children and
adolescents while providing education and supervision of the child’s health on the
importance of regular physical activity and reduced sedentary time to families.   
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found fair to good evidence to support screening all adult
patients for obesity and offering intensive counseling and behavioral
interventions to promote sustained weight loss for obese adults.9
Food and Drug Administration (FDA)
Strength of Evidence: Clinical Trials
The FDA has approved two medications for the treatment of obesity that can
reduce patient weight by an average of 2.6 to 4.8 kg (5.7 to 10.6 lbs) for at least
2 years: orlistat (Xenical®) and sibutramine (Meridia®).10-11
Recommended Guidance::
The National Heart, Lung, and Blood Institute (NHLBI)
Strength of evidence: Not Specified
• The NHLBI recommends that surgical procedures for obese patients be
reserved for patients with class III obesity (BMI 40) and patients with class
II obesity (BMI of 35 to 39.9) who also have at least one obesity-related
illness.12
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• Approximately 44 million Americans — 55% of the adult population over the
age 50 — have either osteoporosis or osteopenia. Many of the 10 million
Americans who have osteoporosis are undiagnosed.1
• Approximately 50% of postmenopausal women will suffer a fracture as a result
of osteoporosis at some point during their lifetime.2 Twenty-five percent
(25%) of these women will suffer a deformity in their spines and 15% will
fracture their hips.3
• Fractures are a costly and common events associated with osteoporosis.
Approximately 1.5 million osteoporotic fractures occur in the United States
each year, which result in more than 500,000 hospitalizations, over 800,000
emergency room visits, more than 2,600,000 physician office visits, and nearly
180,000 nursing home admissions.4
• The estimated annual direct-care expenditure for osteoporotic fractures ranges
from $12 billion to $18 billion (in year 2002 dollars).4 In 2001, the cost of
osteoporotic care delivered in hospitals and nursing homes totaled $17 billion.5
• Osteoporosis will continue to grow as a major public health problem for both
women and men as the population ages.1 By the year 2020 experts predict
that, combined, osteoporosis and osteopenia will affect 61 million Americans
over the age of 50 and by the year 2040 the number of hip fractures is
estimated to triple or quadruple.4
• Screening offers the opportunity to intervene early in the course of disease and
prevent further weakening of the bones, thus reducing an individual’s risk of
fracture. 
• Osteoporosis can be effectively treated with medication to improve bone
density and reduce the risk of fractures.  
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
screen all women over the age of 65 for osteoporosis. The USPSTF also
recommends that clinicians screen women at high risk of osteoporosis beginning
at age 60. Age and lower body weight (less than 70 kg) are the best predictors of
low bone density. There is some evidence to support other risk factors, such as
white race, smoking, weight loss, family history, decreased physical activity,
alcohol or caffeine use, or low calcium and vitamin D intake.6
The USPSTF found good evidence that the risk for osteoporosis and fracture
increases with age and other factors, that bone density measurements accurately
predict the risk for fractures in the short-term, and that treating asymptomatic
women with osteoporosis reduces their risk for fracture. The USPSTF concluded
that the benefits of screening and treatment are of at least moderate magnitude
for women at increased risk by virtue of age or presence of other risk factors.6
The Food and Drug Administration (FDA) has approved the following classes of
medications for the treatment of osteoporosis4,7: 
• Bisphosphonates such as alendronate (Fosomax®), risedronate (Actonel®), and
ibandronate (Boniva®).
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• Selective Estrogen Receptor Modulators (SERMs) such as raloxifene (Evista®).
• Calcitonin (Miacalcin®)
• Parathyroid hormone (Forteo®)
FDA-approved drug therapies have been shown through clinical trials to
effectively reduce osteoporotic or fragility fractures at various sites in the body.
The recommendations and supporting information contained in this document
came from several sources, including the:
• Agency for Healthcare Research and Quality (AHRQ)
• Food and Drug Administration (FDA)
• National Osteoporosis Foundation (NOF)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
• U.S. Surgeon General
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Osteoporosis is a common and serious disease associated with aging; it is a
skeletal disorder characterized by compromised bone strength.4 Osteoporosis
weakens the bones though a thinning of the bone mass, thereby increasing an
individual’s chance of experiencing a fracture.2 Fractures occur at different and
often multiple sites including the hip, vertebrae, wrist, and forearm.
Osteoporosis can also cause chronic pain and loss of height due to compression
of the spine. Osteoporosis is defined as a bone mineral density (BMD) 2.5
standard deviations or more below the mean BMD of healthy adult women.
Authoritative diagnostic criteria for men are not established, but a BMD value
2.0 to 2.5 below normal for men with an appropriate clinical history has been
proposed as a threshold for intervention.8 Osteopenia is a milder reduction in
bone mass (BMD 1- 2.5 SD’s below mean of healthy persons), which results in
some increased risk of fracture, but not as great as the increased risk associated
with osteoporosis. Because osteopenia covers a wide range of BMD values, not
everyone with osteopenia is at the same risk of fracture, and therefore the best
approach to minimize fracture risk in this group will vary.
Approximately 44 million Americans — 55% of the adult population over the
age 50 — have either osteoporosis or osteopenia. Many of the 10 million
Americans who have osteoporosis are undiagnosed.1 Although women have a
higher risk of developing osteoporosis than do men, osteoporosis is not only a
disease of women and many men experience osteoporotic fractures. 
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Condition/Disease
Risk Factors
Osteoporosis will continue to grow as a major public health problem for both
women and men as the population ages.1 By the year 2020 experts predict that,
combined, osteoporosis and osteopenia will affect 61 million Americans over the
age of 50.4 With such a rise in prevalence, the number of osteoporotic fractures
— particularly hip fractures — is likely to increase. In fact, by the year 2040 the
number of hip fractures is estimated to triple or quadruple.4
There is a strong and direct relationship between declining bone density and
increasing risk of fracture. According to a recent research study, women diagnosed
with osteoporosis are 4 times as likely to suffer a fracture in the year after they are
diagnosed with osteoporosis compared to their peers without osteoporosis.3
Approximately 50% of postmenopausal women will suffer a fracture as a result of
osteoporosis at some point during their lifetime.2 Twenty-five percent (25%) of these
women will suffer a deformity in their spines and 15% will fracture their hips.3
Each year, 1.5 million Americans suffer a fracture as a result of bone diseases such
as osteoporosis and osteopenia including1,4:  
• 700,000 vertebral fractures
• 300,000 hip fractures
• 250,000 wrist fractures
• 300,000 fractures at other sites
Vertebral fractures range in severity and can cause severe pain and disfigurement.
Vertebral fractures cause 150,000 hospitalizations each year for adults over the
age of 65, require approximately 161,000 physician office visits, and lead to over
5 million days of restricted activity.9
Hip fractures are one of the most serious complications of osteoporosis.
Approximately 10 million men and women over the age of 50 suffer from
osteoporosis of the hip, and an additional 33.6 million Americans suffer from
osteopenia of the hip.4 Hip fractures are associated with high mortality rates and
are a major cause of disability. Individuals who suffer hip fractures have a 2.8 to 4
greater risk of dying during the first 3 months after the fracture than do fracture-
free individuals of similar age, gender, and health status. Individuals who survive
a hip fracture often suffer pain, loss of independence, and a reduced quality of
life. For example, only 15% of patients are able to walk across a room without
assistance six months after a hip fracture.1 It is estimated that 1 in 5 individuals
who suffer a hip fracture is forced to enter a nursing home.4 Further, hip fractures
often initiate a downward spiral in health; 24% of individuals who suffer a hip
fracture die within a year of the fracture.1
Two major risk factors for the presence and severity of osteoporosis are gender
and increasing age. Eighty-percent (80%) of those affected by osteoporosis are
women.1 Osteoporosis strikes mainly postmenopausal women in their 60s, 70s,
and 80s and the percentage of women with osteoporosis increases markedly with
age. Nearly 70% of white women age 80 and older have osteoporosis.1
Another major risk factor for osteoporosis is personal history. Individuals who
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experienced a fracture in adulthood are at high risk of experiencing a subsequent
fracture. Because of this relationship, it is recommended that any individual with
a history of a low-trauma fracture should be assessed for osteoporosis if they have
not been previously evaluated.4 Unfortunately, many of those at risk for
subsequent fractures fail to be evaluated and treated for osteoporosis.
Other major risk factors for osteoporosis include low body weight, no current use
of estrogen, and Caucasian descent. Physical inactivity, tobacco use, weight loss, a
family history of osteoporosis and osteoporotic fractures, alcohol and caffeine use,
and insufficient calcium or vitamin D intake are also risk factors.4
Certain medications, particularly glucocorticoids and other steroids, can induce
osteoporosis. Other medications such as those used to treat rheumatoid arthritis,
endocrine disorders, and seizure disorders may also increase an individual’s risk of
osteoporosis.
Rates of osteoporosis vary by ethnicity. The prevalence of osteoporosis is highest
in elderly white women. African-American women experience osteoporosis at half
the rate of white women, but other ethnic minorities such as Mexican-Americans
experience rates similar to whites.3
Value of Prevention
The economic burden of fractures resulting from osteoporosis is substantial. Each
year there are approximately 1.5 million osteoporotic fractures in the United
States, which result in more than 500,000 hospitalizations, over 800,000
emergency room visits, more than 2,600,000 physician office visits and nearly
180,000 nursing home admissions. Hip fractures are the most severe osteoporotic
fracture, accounting for 60% of all osteoporotic hospitalizations each year.4 A
recent study that analyzed a private insurance claims database and the Medicare
Supplemental and Coordination of Benefits (COB) database, found that
osteoporosis patients with concurrent fractures represent just 7% of all
osteoporosis patients but are responsible for 61% of the costs attributable to the
disease.10 The estimated annual direct-care expenditure for osteoporotic fractures
ranges from $12 billion to $18 billion (in year 2002 dollars).4 In 2001, the cost
of osteoporotic care delivered in hospitals and nursing homes totaled $17 billion.5
The indirect costs associated with osteoporosis have not been well-studied but
would likely raise the direct cost estimates by several billion dollars.1
Osteoporosis dramatically reduces an individual’s functional status. Many
individuals who suffer fractures are unable to care for themselves during their
recuperation, and some are unable to care for themselves ever again. The burden
of care often falls on family members who must take time off work to care for
affected parents or spouses. Osteoporosis can thus be a direct or indirect cause of
lost productivity and absenteeism. While it is rare for working-age adults to suffer
severe fractures as a result of osteoporosis, it can — and does — happen,
resulting in lost work time and possibly long-term disability. As the workforce
ages, the workplace burden of osteoporosis is certain to increase unless preventive
measures are implemented.
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Benefits and Risks 
of Intervention
The economic benefits of screening for osteoporosis mainly result from decreases
in treatment and rehabilitation costs associated with a reduction in osteoporotic
fractures. A full analysis of the economic benefits of screening and early
treatment should also include averted mortality and morbidity costs.
The cost of screening for osteoporosis varies depending on locality, provider type,
and measurement tool used. In 2004, the private-sector cost of the initial health
risk assessment averaged $23 and approximately 95% of all paid claims fell
within the range of $0 to $81.11 In 2004, the private-sector cost of osteoporosis
screening, bone density scans, and ultrasonography averaged $55 and
approximately 95% of all paid claims fell within the range of $0 to $132.11
The cost of treatment varies substantially depending on the type of medication
used and its dosage. Average wholesale price (AWP) figures are noted below for a
1-month supply of FDA-approved medications for the treatment of osteoporosis.12




parathyroid hormone (Forteo®) $608.72
raloxifene (Evista®) $80.64
risedronate (Actonel®)  $64.28 (dose pack)
risedronate (Actonel®)  $68.86 (daily)
A recent study found that, compared to no intervention, universal screening with
bone densitometry combined with alendronate therapy for those diagnosed with
osteoporosis is highly cost-effective for women aged 65 years and older and may
be cost-saving for ambulatory women age 85 and older.5
Preventive Intervention Information
Screening for osteoporosis allows clinicians to identify affected patients and begin
treatment early in the course of disease. Established treatments can reduce bone
loss and improve bone density, thereby reducing the risk of fractures and their
associated complications. 
While no controlled studies have specifically evaluated the effect of screening for
osteoporosis on fracture-related mortality, screening does offer the opportunity to
intervene early in the course of disease and prevent further weakening of the
bones, thus reducing an individual’s risk of fracture.
Screening for and treating osteoporosis does carry risks. Women who are
diagnosed with osteoporosis report increased fear and anxiety in their daily lives.
As with all screening tests, false-positive results can precipitate unnecessary
treatment.7 In the past, women who were screened for osteoporosis were more
likely to begin hormone replacement therapy than women who were not screened.
Hormone replacement therapy (HT) carries additional risks. Some of the
medications used to treat osteoporosis increase the risk of other serious medical
complications such as gastrointestinal disorders, ulcer disease, thromboembolic
events, endometrial cancer, and cholecystis.3 Despite these risks, experts agree that
the benefits of screening for osteoporosis and treating osteoporosis in its earliest
stages have substantial benefits that outweigh the risks involved. 
Screening for osteoporosis should begin for normal-risk women at age 65 and for
high-risk women at age 60. The benefits of screening increase with age because
osteoporosis affects older women more frequently than younger women and because
osteoporosis is more likely to result in fractures in older women.3 The age at which
screening no longer offers substantial benefit is not known and there is little
information on screening or treating women over the age of 85 for osteoporosis.
Clinicians should cease screening for osteoporosis when a woman and her physician
agree that the risks of screening outweigh the benefits of screening. Although there is
not yet wide consensus regarding screening in men, some groups have recommended
screening healthy men starting at age 70, with earlier testing of men with risk factors
such as fracture, primary hyperparathyroidism, or use of GNRH agonists or
glucocorticoids.4
The optimal interval for screening has not been established. Evidence suggests
that screening intervals of no less than 2 years is reasonable because the bone
density tests are not precise enough to measure a change in bone density reliably
in a shorter period of time. Evidence suggests that less frequent screening may be
reasonable in younger women.7
Medications used to treat osteoporosis should be used — and covered — as
prescribed by a clinician. 
Several methods of screening for osteoporosis are currently used. The best
predictor of hip fracture is the dual-energy x-ray absorptiometry of the hip
(DXA). Other bone density tests include DXA of the spine, whole body or
forearm, ultrasound, radiographic absorptiometry, single-energy absorptiometry,
peripheral dual-energy x-ray absorptiometry, and peripheral quantitative
computed tomography.3 The likelihood of a diagnosis of osteoporosis depends on
the type of measurement tool used, the site of the measurement, the number of
sites tested, the brand of the measurement tool, and the relevance of the reference
range.3
Physician- or self-administered verbal or written screening instruments used to
detect and assess the risk of low bone density generally have high sensitivity but
low specificity; therefore false-positive results are a greater problem than false-
negative results. One validated instrument is the Osteoporosis Risk Assessment
Instrument (ORAI), a 3-item tool that uses an individual’s age, weight, and
hormone replacement therapy history to quantify the risk of osteoporosis.
Another instrument is the Simple Calculated Osteoporosis Risk Estimation tool
(SCORE), a similar 6-item measure of risk based on age, weight, ethnicity,
estrogen use, presence of rheumatoid arthritis, and history of fractures.3
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Health benefits should include provisions for treatment services. 
Osteoporosis can be effectively treated with medication to improve bone density
and reduce the risk of fractures. The Food and Drug Administration (FDA) has
approved the following classes of medications for the treatment of osteoporosis4,7: 
• Bisphosphonates such as alendronate (Fosomax®), risedronate (Actonel®),
and ibandronate (Boniva®)
• Selective estrogen receptor modulators (SERMs) such as raloxifene
(Evista®)
• Calcitonin (Miacalcin®)
• Parathyroid hormone (Forteo®)
Any decision to use hormone therapy (HT) must take into consideration its
impact on overall health outcomes, including its potential to reduce the risk of
fractures and its potential to increase the risk of other health problems. The FDA
has advised that postmenopausal women who use, or are considering using,
estrogen or estrogen with progestin discuss the therapy’s benefits and risks with
their physicians. These products are approved therapies for relief from moderate
to severe hot flashes and symptoms of vulvar and vaginal atrophy. Although HT
is effective for the prevention of postmenopausal osteoporosis, it should only be
considered for women at significant risk of osteoporosis who cannot take non-
estrogen medications. The FDA recommends that estrogens and progestins
should be used at the lowest possible doses for the shortest amount of time
needed to achieve treatment goals. It is not yet clear whether following this
advice will lead to long-term benefits for bone health.4
Note: The USPSTF recommends against (“D” rating) routine use of HT to
prevent chronic diseases in postmenopausal women because the harmful effects of
unopposed estrogen are likely to exceed the chronic disease prevention benefits in
most women.13
Because the purpose of treating osteoporosis it to prevent the poor health outcomes
associated with fractures, treatment is considered a preventive intervention. Please
refer to “Intervention Process” for information on treatment services. 
In addition to medications, physical activity, in general, and resistance-weight-
training, in particular, is very helpful in preventing fractures. Resistance training
helps retard bone loss. Moreover, physical activity reduces the risks of falls by a
variety of mechanisms (e.g., increased agility, increased strength, etc), thereby
indirectly influencing fracture rates. While there is no direct mechanism for
purchasers to cover the promotion of physical activity through health plan
benefits, purchasers should encourage their at-risk beneficiaries to partake in
physical activity.
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendations contained 
in this chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The USPSTF found good evidence to support screening all women over the
age of 65 for osteoporosis. The Task Force also recommends that clinicians
screen women at high-risk of osteoporosis beginning at age 60. Age and lower
body weight (less than 70 kg) are the best predictors of low bone density.
There is some evidence to support other risk factors, such as: white race,
smoking, weight loss, family history, decreased physical activity, alcohol or
caffeine use, or low calcium and vitamin D intake.6
Food and Drug Administration (FDA)
Strength of Evidence: FDA approved drug therapies have been shown through
clinical trials to effectively reduce osteoporotic or fragility fractures at various sites
in the body.
• The Food and Drug Administration (FDA) has approved the following classes
of medications for the treatment of osteoporosis4,7: 
• Bisphosphonates such as alendronate (Fosomax®), risedronate (Actonel®),
and ibandronate (Boniva®)
• Selective estrogen receptor modulators (SERMs) such as raloxifene
(Evista®)
• Calcitonin (Miacalcin®)
• Parathyroid hormone (Forteo®)
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This chapter covers screening and counseling interventions for the following
sexually transmitted infections: chlamydia, gonorrhea, human immunodeficiency
virus (HIV), and syphilis.
• Sexually transmitted infections (STIs) are among the most common infections
that occur in the United States today, and they affect men and women of all
backgrounds and economic levels. 
• Untreated STIs can result in significant complications including major
infections, infertility, and death. 
• Screening allows for early identification and treatment, which improves
outcomes and can prevent transmission of infections to others. Generally, early
treatment is also less expensive. For example, the baseline cost of treating early-
stage syphilis was estimated to be $41.26 (in year 2001 dollars) compared to
$2,061.70 for late-stage syphilis.1
• Sexually transmitted infections are a substantial economic burden to the U.S.
healthcare system and to employers.
• The most recent estimate of the annual cost of chlamydial infection and its
sequelae is $460 million.2
• In women, some STIs can progress to pelvic inflammatory disease (PID). A
conservative estimate of $1,334, based on a national insurance claims dataset,
was reported as the cost per case of PID in year 2000 dollars.2 The average
lifetime cost for women who develop major complications of PID is $6,350 for
chronic pelvic pain, $6,840 for an ectopic pregnancy, and $1,270 for
infertility. Approximately 79% of these costs occur within 5 years of the
precipitating infection.3
• HIV/AIDS often affects people during their prime working years and
HIV/AIDS-induced morbidity and mortality can result in significant
economic losses to businesses. Considering only the changes in insurance
premiums, disability payments, unemployment benefits, retirement and
pension benefits, and lost productivity, a recent study found that, in 2002, an
asymptomatic HIV-infected employee would cost an employer in the United
States an estimated $37,320 and a symptomatic HIV-infected employee would
cost $50,347 per person-year.4
• Screening for sexually transmitted infections is especially important because
many people with STIs do not experience symptoms in the early phases of
disease. For example, it is estimated that 70% to 90% of women and a
substantial percentage of men with chlamydia do not have symptoms.5
Counseling to Prevent Sexually Transmitted
Infections(STIs) (Counseling)
Physicians and other healthcare providers play a critical role in preventing and
treating sexually transmitted infections (STIs).1 Clinicians have the opportunity
to provide client education and counseling and to participate in identifying and
treating persons with STIs as well as their infected sex partners.
EVIDENCE-STATEMENT:
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The USPSTF recommends that clinicians educate all adolescents and adults on
the risk factors for HIV and other sexually transmitted infections (STIs) and
counsel patients on effective measures to reduce their risk of infection.
Counseling should be tailored to the needs of the individual and should take into
consideration the abilities of each patient.2
Interactive counseling approaches directed at a patient’s personal risk, the
situations in which risk occurs, and use of goal-setting strategies are effective in
STI prevention.3 Results from randomized controlled trials demonstrate that,
compared with traditional approaches to providing information, certain brief
risk-reduction counseling approaches can reduce the occurrence of new sexually
transmitted infections by 25% to 40% among STI clinic patients.4
Physicians and other providers should counsel their sexually active patients on
the following STIs: chlamydia, gonorrhea, hepatitis B, HIV, and syphilis.
Chlamydia (Screening)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that
clinicians routinely screen all sexually active women aged 25 years and younger
for chlamydia.1 Other asymptomatic women at increased risk (e.g., prior history
of a sexually transmitted disease, having cervical ectopy, having multiple or new
sex partners, using barrier contraceptives inconsistently) should also be screened
for chlamydial infection. However, the USPSTF suggests clinicians consider the
characteristics of the communities they serve, particularly prevalence information,
in determining appropriate screening strategies.
The USPSTF found good evidence that screening women at risk for chlamydial
infection reduces the incidence of pelvic inflammatory disease (PID) and fair
evidence that community-based screening reduces prevalence of chlamydial
infection. The USPSTF concluded that the benefits of screening substantially
outweigh the potential harms, such as adverse effects of a false-positive or false-
negative diagnoses on patients and their partners, and adverse reactions to
antibotic treatment.1
CDC also recommends screening all sexually active women aged 25 years and
younger and older women with risk factors (e.g., those who have a new sex
partner or multiple sex partners).2 All pregnant women should be routinely tested
at the first prenatal visit. Pregnant women aged 25 years and younger and those
at increased risk should be re-tested during the third trimester to prevent
maternal postnatal complications and chlamydial infection in the infant.2
Not Specified
The recommendations and supporting information contained in this document
came from several sources, including the:
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• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Chlamydia is the most commonly reported bacterial STI in the United States. In
2004, 930,000 cases of chlamydia were reported by state health departments in
the United States; a 5% increase compared to 2003.3 If untreated, chlamydia can
result in significant complications in both men and women.
Among women, 20% to 40% of cases of untreated chlamydia infection may
progress to pelvic inflammatory disease (PID), a serious condition resulting in
chronic pelvic pain, an increased risk of ectopic pregnancy due to scaring of the
fallopian tubes, and infertility.4 Approximately 8% of U.S. women are diagnosed
with PID in their lifetime, and over 1 million women are treated for PID each
year.5 Among pregnant women, there is some evidence that chlamydial infection
increases the risk of pregnancy complications including premature rupture of the
membranes, pre-term delivery, low-birth-weight infants, and postpartum
endometritis. A chlamydial infection can be transmitted to an infant by an
infected mother during labor and delivery and may cause neonatal conjunctivitis
(a severe eye infection) and/or pneumonia. 
In men, untreated chlamydia infection can lead to urethritis or acute
epididymitis, which can result in infertility, chronic prostatitis, reactive arthritis,
and problems with the urethra.6
Infection with chlamydia increases both men and women’s susceptibility to HIV.
Adolescents (of both sexes) and women under the age of 20 are at the highest risk
for chlamydial infection; the highest reported rates occur in girls aged 15 to19
years.7 Chlamydial infections are also prevalent among women aged 20 to 25
years.6 The prevalence of chlamydia is also higher among African-American
populations and among individuals who are unmarried, have a prior history of
STIs, have multiple sexual partners, suffer from cervical ectopy, and/or who use
barrier contraceptives incorrectly or inconsistently.6
Value of Prevention
The most recent estimate of the annual cost of chlamydial infection and its
sequelae is $460 million.8 The lifetime medical cost of chlamydia has been
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Up to 40% of untreated and 6% of treated cases of acute chlamydia may progress
to pelvic inflammatory disease (PID), a serious condition that is expensive to
treat. It is estimated that treatment for a single case of PID costs between $1,060
and $3,626.9 A conservative estimate of $1,334, based on a national insurance
claims dataset, was reported as the cost per case of PID in year 2000 dollars.9
The reproductive and other health problems of chlamydia impose a significant
cost to employers by way of health and disability insurance costs. The lifetime
productivity losses for young working-age adults suffering from the long-term
health effects of chlamydial infection are high. An untreated case of chlamydia is
estimated to result in $130 in lost productivity costs and an acute case of PID is
estimated to result in $632 in lost productivity costs (in year 2001 dollars).10
Because screening allows for the early recognition of disease and subsequently an
earlier initiation of treatment, it can prevent the costly complications of late-stage
disease such as PID and infertility. 
In 2004, the private-sector cost of chlamydia screening averaged $42;
approximately 95% of all paid claims fell within the range of $0 to $87.11
The estimated direct cost (including office visits, diagnostic testing, and
medication) of acute care ranges from $23 to $109 per case.8
Annual screening among women 15 to 29 years of age followed by semiannual
screening for those with a history of infection was estimated to cost less than
$25,000 per quality-adjusted life year (QALY) compared with the annual
screening only.12
A review of 10 cost-effectiveness studies found that screening was more cost-
effective than simply testing symptomatic women. The models showed that in
some instances, screening was cost-saving (compared to testing symptomatic
women) even at prevalence rates as low 1.1%.10
Preventive Intervention Information
Screening for chlamydia allows clinicians to identify affected patients and begin
treatment earlier in the course of disease, thereby improving outcomes and
avoiding the health and economic consequences of latent disease such as PID and
infertility. In fact, a recent well-designed randomized trial demonstrated that
screening women at risk for chlamydia reduces the incidence of PID by 50%.13
Routine screening for chlamydia is especially important because of its
asymptomatic nature. It is estimated that 70% to 90% of women (and a
substantial percentage of men) with chlamydia do not have symptoms.6 
Few studies have documented the risks associated with screening for chlamydia.
Potential risks include partner discord, stigma, and side effects of treatment. As
with all types of screening, the risk of false-positive results may cause undue
anxiety or unnecessary treatment. The benefits of screening for chlamydia
substantially outweigh the harms. Screening allows for early recognition and
treatment, reducing complications and long-term effects. Screening programs can
lead to reduced person-to-person transmission of infection and can substantially
lower infection rates at the population level; states implementing new screening
programs have reported up to a 67% decrease in new chlamydial infection rates.7
Reducing the rate of chlamydia within a population has substantial positive
health effects including lower rates of PID.
Average-risk women should be screened annually from the onset of sexual activity
through age 25. Women with known risk factors and women who have
experienced a previous infection should continue screening beyond the age of 25,
as medically indicated. Re-screening at 6 to 12 months may be appropriate for
previously infected women because of high rates of reinfection.6
Asymptomatic sex partners of individuals infected with chlamydia should also be
screened.
The optimal time for screening during pregnancy is unknown. Screening for
chlamydia early in pregnancy offers greater opportunities in reducing the risk of
low birth weight and premature delivery. However, screening during the third
trimester is thought to be more effective in preventing transmission to the infant
during labor and delivery. 
Several effective methods of screening for chlamydia are currently available6: 
• Nucleic acid amplification tests (NAAT) such as polymerase chain reaction
(PCR), strand displacement assay (SDA), and transcription-mediated
amplification (TMA) on endocervical/urethral or urine specimens. 
• Non-amplified nucleic acid hybridization tests on endocervical specimens.
• Culture analysis of an endocervical or urethral swab.
• Antigen detection tests such as direct fluorescent antibody (DFA) assay and
enzyme immunoassay (EIA) on endocervical specimens.
• Point-of-care antigen detection tests on endocervical specimens and leukocyte
esterase on urine.
• Culture of swab specimens from exposed sites urethra (male), endocervix,
throat, or rectum (male).
Health benefits should include provisions for diagnostic and treatment services.
Treatment, usually a 7-day course of oral antibiotics or a single dose of
azithromycin, is easy, inexpensive, and noninvasive. Side effects of treatment
(gastrointestinal distress, nausea) occur infrequently. Moreover, treatment is
highly effective (97% of nonpregnant women and men treated for chlamydia are
cured).6
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Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendation in this section is 
described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to support routine screening of all sexually
active women age 25 years and younger and other asymptomatic women at
increased risk for infection.1
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Not Specified
• CDC recommends screening all sexually active women aged 25 years and
younger and older women with risk factors (e.g., those who have a new sex
partner or multiple sex partners).2 All pregnant women should be routinely
tested at the first prenatal visit. Pregnant women aged 25 years and younger
and those at increased risk should be re-tested during the third trimester to
prevent maternal postnatal complications and chlamydial infection in the
infant.2
Gonorrhea (Screening)
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
screen all sexually active women, including those who are pregnant, for
gonorrhea infection if they are at increased risk for infection (that is, if they are
young or have other individual or population risk factors).1
The U.S. Preventive Services Task Force found at least fair evidence that
screening tests can accurately detect gonorrhea infection and good evience that
antibiotics can cure gonorrhea infection. There is at least fair evidence that
screening pregnant women at high risk for gonorrhea, including women at high
risk because of younger age, may prevent other complications associated with
gonococcal infection during pregnancy, such as preterm delivery and
chorioamnionitis.1
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive services Task Force (USPSTF)
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The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Approximately 335,000 cases of gonorrhea were reported by state health
departments in the United States in 2004, a slight decrease when compared to
2003 data.2
Complications of gonorrhea for women include pelvic pain, pelvic inflammatory
disease (PID), ectopic pregnancy, and infertility. Pregnant women infected with
gonorrhea are at an increased risk for pregnancy complications such as
chorioamnionitis, premature rupture of membranes, preterm labor, and
stillbirth.3 Infected women may also pass the disease to their infants during
pregnancy, labor, and delivery. Gonococcal opthalmia can cause conjunctivitis
leading to corneal scarring and blindness. 
In men, gonorrhea can cause urethritis or epididymitis, but few serious or long-
term complications. 
Gonorrhea also increases both men and women’s susceptibility to other STIs,
including HIV. 
Risky sexual behavior is the major risk factor for gonorrhea. As with most STIs,
younger populations are at highest risk. The highest reported rates of gonorrhea
are among female adolescents 15 to 19 years of age and adult males and females
20 to 24 years of age.1 The rate of gonorrhea among African-Americans is 20
times higher than the rate among whites.1 Persons with other types of STIs (e.g.,
chlamydia) may be more susceptible to contracting gonorrhea. 
Value of Prevention
The lifetime medical care cost of gonorrhea has been estimated at $53 per case for
men and $266 per case for women (in year 2000 dollars).4
In addition medical and disability-related costs, the workplace burden of the
disease includes:
• Productivity losses among gonorrhea-infected employees; 
• Direct medical costs for infected adolescents who are covered by their parent’s
insurance plan; and
• Productivity losses associated with the time employee caregivers dedicate to
attending to sick dependents (i.e., children or spouses). 
Because screening for gonorrhea allows for the early recognition of disease and
leads to earlier treatment, it may prevent the costly complications of late-stage
disease such as PID. The average lifetime cost of PID has been estimated to range
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from $1,060 to $3,626 in year 2000 dollars.4 The average lifetime cost for
women who develop major complications of PID is $6,350 for chronic pelvic
pain, $6,840 for an ectopic pregnancy, and $1,270 for infertility; 79% of these
costs have been found to occur within 5 years of the precipitating infection.5
In 2004, the private-sector cost of screening for gonorrhea screening averaged
$17; approximately 95% of paid claims fell within the range of $0 to $63.6
The cost of treatment for gonorrhea will vary depending on the type of antibiotic
chosen. 
A recent study that focused on gonorrhea screening in urban emergency
departments found that screening women between 15 and 29 years of age using
urine-based nucleic acid amplification tests (NAAT) saved $177 (in year 2002
dollars) per patient compared to no screening.7
Preventive Intervention Information
Screening for gonorrhea allows clinicians to identify affected patients and begin
treatment earlier in the course of disease, thus potentially improving outcomes
and avoiding the health and economic consequences of latent disease. Screening
is particularly important for women because many women who are infected with
gonorrhea have no symptoms and are thus unaware of their condition.8
The benefits of screening for gonorrhea are substantial. Screening allows for early
recognition and treatment, dramatically reducing complications, other long-term
effects, and the transmission of the infection to others. Few studies have
documented the risks associated with screening for gonorrhea. Possible risks
include partner discord, stigma, opportunity costs (in terms of time and
resources) for both the clinician and the patient, and side effects of treatment. As
with all types of screening, the risk of false-positive results may cause undue
anxiety or unnecessary treatment. The USPSTF found that the benefits of
screening outweigh the risks associated with screening.1
Routine screening for gonorrhea is recommended for all women under the age of
25 and women over the age of 25 who are at risk of infection, especially women
who are in one or more of the following established high-risk groups: commercial
sex workers, women with a prior history of gonorrhea, and women who live in
regions where infection rates are high. 
The frequency of screening is left to the discretion of the provider and should be
based on the individuals’ risk factors and previous history of STIs. 
All pregnant women at risk for gonorrhea should be screened during the first
trimester, ideally during the first prenatal care visit. Pregnant women at
continued risk of infection should be re-screened again during the third
trimester.1
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Several effective methods of screening for gonorrhea are currently available1:
• Culture of swab specimens from exposed sites (urethra [male], endocervix,
throat or rectum [male]).
• Nucleic acid amplification assays such as polymerase chain reaction (PCR),
strand displacement assay (SDA), and transcription-mediated amplification
(TMA) on genital swab or urine specimens. 
• Microscopic examination of Gram-stained urethral or cervical specimen.
• Non-amplified nucleic acid hybridization tests on genital swab specimens. 
• Point-of-care antigen detection tests on genital swab specimens and urine
dipstick for leukocyte esterase (LE).
Gonorrhea can be effectively treated with antibiotics. Health benefits should
include provisions for diagnostic, follow-up, and treatment services. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendation in this section is 
described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: B (Recommended/At Least Fair Evidence)
• The U.S. Preventive Services Task Force found at least fair evidence that
screening tests can accurately detect gonorrhea infection and good evidence
that antibiotics can cure gonorrhea infection. There is at least fair evidence that
screening pregnant women at high risk for gonorrhea, including women at
high risk because of younger age, may prevent other complications associated
with gonococcal infection during pregnancy, such as preterm delivery and
chorioamnionitis.1
Human Immunodeficiency Virus (HIV)
(Screening and Counseling)
Clinical Preventive Service Recommendations
This special notice is included to alert readers about differences between Centers
for Disease Control and Prevention (CDC) and U.S. Preventive Services Task
Force (USPSTF) HIV screening recommendations for individuals who are not at
increased risk for HIV infection. 
In 2006, the CDC issued new HIV testing guidance for healthcare settings that
recommends screening all patients aged 13 to 64 years for HIV. In 2005, the
USPSTF considered HIV screening and issued a “C”-rating, thereby making no
recommendation for or against routinely screening adults and adolescents who
are not considered to be at increased risk for HIV infection. 
The Purchaser’s Guide recommendation reflects the broader CDC
recommendation. The CDC recommendation is preferred because clinicians are
not consistently able to distinguish between high- and no-risk testing candidates1-2
and because spread often occurs between individuals who do not know that they
are infected.3
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians
screen all adolescents and adults with an increased risk of infection for human
immunodeficiency virus (HIV). Increased risk is defined by the USPSTF as
having one or more individual risk factor STIs or receiving healthcare in a high-
prevalence or high-risk clinical setting. Please refer to the “Condition/Disease
Risk Factors” section for additional information.4
The USPSTF recommends that clinicians screen all pregnant women for HIV.4
The USPSTF found good evidence that both standard and U.S. Food and Drug
Administration (FDA)-approved rapid screening tests accurately detect HIV
infection. The USPSTF also found good evidence that appropriately timed
clinical intervention, particularly highly active antiretroviral therapy (HAART),
lead to improved health outcomes for many of those screened, including reduced
risk for clinical progression and reduced mortality.4
The USPSTF found good evidence that both standard and FDA-approved rapid
screening tests accurately detect HIV infection in pregnant women and fair
evidence that the introduction of universal prenatal counseling and voluntary
testing increases the proportion of HIV-infected women who are diagnosed and
are treated before delivery. There is good evidence that recommended regimens of
HAART are acceptable to pregnant women and lead to significantly reduced
rates of mother-to-child transmission.4
The Centers for Disease Control and Prevention (CDC) recommends that
providers screen all patients aged 13 to 64 years for HIV unless prevalence of
undiagnosed HIV infection among the provider’s patient population has been
documented to be less than 0.1%.5
Subsequent HIV tests should be provided to all persons likely to be at high risk
(i.e., sex partners of HIV infected persons, men who have sex with men,
heterosexuals who themselves or whose sex partners have had a new sex partner
or more than one sex partner since their most recent HIV test, injection drug
users, and persons who exchange sex for money or drugs) all patients seeking
treatment for an STI, and those who are initiating a new sexual relationship.5
The Centers for Disease Control and Prevention (CDC) also recommends that
clinicians screen all pregnant women for HIV.6 
CDC recommendations were developed with guidance from the scientific
literature and expert technical opinion. Information was also drawn from a
survey CDC conducted with HIV CTR practitioners. Internal CDC edits and
public comments were obtained.5 
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The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Human immunodeficiency virus (HIV), the virus that causes acquired immune
deficiency syndrome (AIDS), is a retrovirus that attacks helper T cells of the
immune system. It causes immune deficiency because it reduces the number and
functionality of CD4 lymphocytes. HIV is transmitted when the infected blood,
semen, or vaginal secretions of an infected person comes into contact with the
broken skin or mucous membranes of an uninfected person. Infected pregnant
women can pass HIV to their babies during pregnancy or delivery, or when
breastfeeding. 
HIV is known to affect between 1,039,000 and 1,185,000 persons in the United
States; a quarter of those infected with the virus are unaware of their status.7
There are approximately 40,000 new HIV infections diagnosed each year in the
United States.8 Untreated HIV infection eventually develops into AIDS and
ultimately leads to death.9 More than 500,000 people in the United States have
died from AIDS; 18,000 in 2003 alone.8
While antiretroviral therapies can slow the damage that HIV does to the body’s
immune system by decreasing the amount of virus is the body, HIV infection is
not curable. An HIV-positive person will develop AIDS when CD4 lymphocyte
levels have dropped so low as to allow opportunistic infections and/or cancers. 
HIV infection is more common in certain segments of the U.S. population.
There is some evidence that about half of all HIV infections are acquired by
those under the age of 25.6 Of newly diagnosed HIV infections in 2003, CDC
estimates that 63% were among men who have sex with men (MSM), 50% were
among blacks, 32% were among whites, and 16% were among Hispanics.10
Individual risk factors include: 
• Men who have had sex with men (MSM) after 1975.
• Men and women who have unprotected sex with multiple partners.
• Past or present injection drug users.
• Men and women who exchange sex for money or drugs or have sex partners
who do.
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• Persons whose past or present sex partners were HIV-infected, bisexual, or
injection drug users.
• Persons being treated for sexually transmitted infections (STIs).
• Persons with a history of blood transfusion between 1978 and 1985. 
Persons who request an HIV test despite reporting no individual risk factors may
also be considered at increased risk. High-risk settings include STI clinics,
correctional facilities, homeless shelters, tuberculosis clinics, clinics serving men
who have sex with men, and adolescent health clinics with a high prevalence of
STIs. High-prevalence settings are defined by the CDC as those known to have a
1% or greater prevalence of infection among the patient population being served.
Value of Prevention
The economic burden of HIV in the United States is substantial. The average
lifetime cost per case (in year 2000 dollars) is estimated at $199,800.11
Accounting for the 15,000 new cases reported annually among 15 to 24-year-
olds, the total direct cost of HIV in the United States was approximately $3.0
billion in 2000.11
HIV/AIDS often affects people during their prime working years and
HIV/AIDS-induced morbidity and mortality can result in significant economic
losses to businesses. Considering only the changes in insurance premiums,
disability payments, unemployment benefits, retirement and pension benefits,
and lost productivity, a recent study found that, in 2002, an asymptomatic HIV-
infected employee would cost an employer in the United States an estimated
$37,320 and a symptomatic HIV-infected employee would cost $50,347 per
person-year.12
Earlier diagnosis of HIV infection is associated with less expensive treatment. For
those with CD4 counts greater than 500, monthly expenditures for treatment
total approximately $500. This figure increases to $2,300 per month for those
with CD4 counts less than 50. Generally, the earlier HIV infection is detected,
the higher the CD4 count.13
In 2004, the private-sector cost of HIV screening averaged $23; approximately
95% of all paid claims fell within the range of $4 to $75.14 In 2004, the private-
sector cost of HIV counseling averaged $39 and approximately 95% of all paid
claims fell within the range of $0 to $129.14
The average annual cost of treating an HIV-infected patient is estimated to range
between $18,000 and $20,000.15
Researchers studied the costs associated with screening and treating HIV/AIDS
in pregnant women and found that universal screening can be cost-saving in this
population. For example, compared to no screening, a universal screening
program targeting pregnant women would save an estimated $3.69 million
dollars and prevent 64.6 cases of pediatric HIV infection for every 100,000
pregnant women screened.16404


































Screening allows for the earlier diagnosis of HIV infection, which is associated
with less expensive treatment, better health outcomes, and reduced risk of spread
of infection to other persons.
Counseling services are required to educate screening candidates on 1) the
benefits and risks of screening, 2) risk reduction strategies, and, for those who
screen positive, 3) treatment options.
The benefit of screening and counseling includes early diagnosis of HIV
infection, the potential for a longer life (due to earlier initiation of treatment),
and the opportunity to prevent disease transmission. Counseling also allows
prevention and risk-reduction messages to be conveyed. The benefits associated
with screening pregnant women are also substantial. Screening allows for early
detection and treatment and can prevent mother-to-child transmission. There is
no evidence of an increase in fetal anomalies or other fetal harm associated with
recommended antiretroviral regimens.4
Risks associated with screening for HIV include false-positive test results and
partner discord. Information about the effects of false-positive test results (e.g.,
anxiety, labeling) is predominately anecdotal. The standard method of diagnosing
HIV infection (a repeatedly-reactive enzyme immunoassay followed by
confirmation Western blot of immunoflourescent assay) has a 1 in 250,000 test
chance of false-positive identification in a low prevalence setting.8 Newer HIV
detection technologies, specifically the rapid HIV tests, are similar to traditional
tests with extremely low false-positive rates. False- and true-negative test results
may give false reassurance to those engaging in high-risk behavior, leading to its
continuation. Finally, notification of a positive HIV test can cause emotional or
psychological distress. 
Although no studies have evaluated the optimal frequency of screening for
HIV/AIDS, it is recommended that screening be conducted at the discretion of a
clinician with frequency determined by an individual’s risk factors and the
characteristics of the region in which the clinician practices.
All pregnant women should be screened as early as possible, ideally at the first
prenatal care visit.17 Pregnant women at high risk for infection or all women
living in an area with high HIV prevalence among women of childbearing age
should be re-tested during the third trimester.17
Counseling should be provided before and after screening, as medically indicated.
The standard method of screening for HIV/AIDS uses an enzyme immunoassay
on serum or plasma; if the enzyme immunoassay is repeatedly reactive, a
confirmatory Western blot or immunoflourescent assay is then performed.
Several HIV tests that provide results within 10 to 30 minutes are available. The
Food and Drug Administration (FDA) has also approved a home collection kit,
which uses a blood sample from a finger prick for testing purposes. 
There are three approved methods of screening for HIV, including:
• Repeatedly-reactive enzyme immunoassay followed by confirmatory Western
blot or immunoflourescent assay on serum or plasma.
• Rapid HIV tests with result in 10-30 minutes; two point-of-care rapid tests are
available (Uni-Gold Recombigen & Oraquick Advance) and one rapid test is
intended for laboratory use. 
• A home collection kit (Home Access) that uses a dried blood spot.
All patients should receive counseling and educational information on HIV and
HIV screening before they are screened. Patients that have behaviors that place
them at high risk for acquiring HIV infection (e.g., multiple sex partners, history
of STIs, substance abuse, etc) should be referred to an HIV risk-reduction service
(e.g., HIV centers with personnel trained in HIV counseling, drug treatment
centers, etc).18
Health benefits should include provisions for follow-up and treatment services. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendation in this section is 
described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to support routine screening for HIV
among all adolescents and adults with an increased risk of infection for human
immunodeficiency virus (HIV).4
• The USPSTF found good evidence to support routine screening for HIV
among all pregnant women.4 
Recommended Guidance:
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: CDC recommendations were developed with guidance
from the scientific literature and expert technical opinion. Information was also
drawn from a survey CDC conducted with HIV CTR practitioners. Internal
CDC edits and public comments were obtained.
• The CDC found good evidence to support routine screening for HIV among
all pregnant women.5
• The CDC found good evidence to support the provision of HIV-related
counseling, testing, and referral (CTR) to all patients on a routine basis to
ensure that those clients that may benefit from the service have the
opportunity to do so.5406






















Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that
clinicians screen all persons at increased risk for syphilis infection. Increased risk
includes men who have sex with men (MSM) and engage in high-risk sexual
behavior, commercial sex workers, persons who exchange sex for drugs, and those
in adult correctional facilities. Clinicians should consider the characteristics of the
communities they serve in determining appropriate screening strategies.1
The USPSTF strongly recommends that clinicians screen all pregnant women for
syphilis infection.1
Although the USPSTF found no new direct evidence that screening for syphilis
infection leads to improved health outcomes in persons at increased risk, there is
adequate evidence that screening tests can accurately detect syphilis infection and
that antibiotics can cure syphilis.1
The USPSTF found observational evidence that the universal screening of
pregnant women decreases the proportion of infants with clinical manifestations
of syphilis infection and those with positive serologies.1
CDC also recommends screening of all pregnant women, and all persons at
increased risk for syphilis infection, per the USPSTF definition.
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
Condition/Disease Specific Information
Approximately 33,289 cases of syphilis were reported by state health departments
in the United States in 2004, a slight decrease when compared to 2003 data.2
Syphilis rates vary dramatically by region and are highest in the Southeastern
United States and in concentrated pockets of metropolitan areas such as Atlanta,
Baltimore, Chicago, Detroit, Indianapolis, Memphis, New Orleans, Newark,
Richmond, St. Louis, and Washington, D.C.3 Surveillance data from the Centers
for Disease Control and Prevention (CDC) indicate that the rate of syphilis
increased nationwide by 19% between 2000 and 2003.4
Syphilis is a serious condition that, if left untreated, may result in cardiovascular
and neurological complications leading to disability and ultimately death.1
Syphilis can be transmitted from an infected mother to her infant during labor
and delivery. Congenital syphilis can be particularly severe and results in fetal or
infant death in 40% of cases.1 Infants who survive may suffer serious central
nervous system abnormalities, deafness, bone and joint deformities, skin
abnormalities, blood disorders, and other problems.
Populations at increased risk for syphilis infection (as determined by incident
rates) include men who have sex with men and engage in high-risk sexual
behavior, commercial sex workers, persons who exchange sex for drugs, and those
in adult correctional facilities.1
The prevalence of syphilis infection varies widely among communities and
patient populations.1 Some populations have a particularly high risk of infection,
specifically African-Americans and people living in the Southeastern United
States.5 In 2004, the incidence of P&S syphilis was highest among women aged
20 to 24 years (3.0 cases per 100,000 population) and among men aged 35 to 39
years (12.4 cases per 100,000 population).6
Value of Prevention
The lifetime cost per case of syphilis has been estimated at $444 (in year 2000
dollars).7 The economic burden of syphilis would be much higher if the costs of
congenital syphilis and HIV infections occurring from the facilitating effect of
syphilis were included in cost analyses.
The health, disability, and life insurance costs of syphilis-infected employees
impose a significant economic burden on employers. Lost productivity may also
accrue when infected employees seek medical attention for their condition. 
Screening and early detection are key to averting costs associated with disease
progression and long-term complications. The avertable syphilis-attributable HIV
cost was estimated to be $4,653 (in year 1996 dollars) for each new syphilis case.8
Treatment for early stage syphilis is also much less expensive than treatment for
later stage disease: the baseline cost of treating early syphilis was estimated to be
$41.26 (in year 2001 dollars) compared to $2,061.70 for late syphilis.9
In 2004, the private-sector cost of screening for syphilis averaged $12;
approximately 95% of all paid claims fell within the range of $0 to $32.10
The cost of treating syphilis will vary depending on the treatment medication
and other factors. The public-sector cost of standard IM benzathine penicillin
therapy (first-line treatment) ranged from $18.64 to $22.22 (in year 2001
dollars).9 Treatment for late-stage syphilis can cost upwards of $2,000 (in year
2001 dollars).9
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One study compared the per-case cost and cost-effectiveness of two alternative
strategies – selective screening and partner notification — from the perspective of
a health department. When prophylactic treatment of sexual contacts was not
considered, selective screening proved to be more cost-effective. Cost, in general,
was low for both strategies for all cases of infectious syphilis considered.11 
Serological screening of pregnant women can be cost-effective even when there is
a very low prevalence of maternal infection because screening is inexpensive while
treating congenital syphilis is costly.12
Preventive Intervention Information
Screening for syphilis allows clinicians to identify affected patients and begin
treatment earlier in the course of disease, potentially improving outcomes and
avoiding the health and economic consequences of latent disease. Treatment also
reduces the likelihood of spread to others.
No studies have documented the harms associated with screening for syphilis.
Potential harms include partner discord, stigma, unnecessary anxiety or treatment
in the case of a false-positive result, and opportunity costs (in terms of time and
resources) to both the clinician and the patient. Harms of treatment include
allergic reaction to penicillin, and side effects of the medication including the
Jarisch-Herxheimer reaction (fever, headache, and pain that occurs during the 24
hours after initiating antibiotic treatment for syphilis due to the release of
treponema antigens).1
The benefits associated with screening are great. Screening allows for early
detection and treatment, preventing complications that may occur in later stages
of disease, and it reduces the risk that syphilis will be spread to others. Antibiotic
treatment for syphilis is effective and inexpensive. The USPSTF concluded that
the benefits of screening persons at increased risk for syphilis infection
substantially outweigh the potential harms.1
The optimal screening interval for syphilis is unknown. Experts recommend that
clinicians base the frequency at which they screen patients for syphilis on the
patient’s risk factors and the characteristics of the community in which they
practice. Pregnant women at risk of syphilis should be screened at the first visit of
every pregnancy and, if at high risk, again during the third trimester (28 weeks)
and at delivery.5
A variety of syphilis tests are available and in development. Screening for syphilis
typically involves the use of 2 different tests, a nontreponemal test and a
treponemal-specific test, for screening and confirmation. For example, a
nontreponemal blood test such as the venereal disease research laboratory
(VDRL) or the rapid plasma reagin (RPR) may be performed, a second, different
kind of test, such as the fluorescent treponemal antibody absorbed (FTA-ABS) or
the T. palladium particle agglutination (TP-PA) may then be used to confirm the
results of the nontreponemal test.1 
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The tests for syphilis screening that are approved or pending FDA approval
include:
• Nontreponemal test such as the venereal disease research laboratory (VDRL) or
the rapid plasma regain (RPR) on serum specimens followed by a fluorescent
treponemal antibody absorbed (FTA-ABS) or T. palladium particle
agglutination (TP-PA) for confirmation.
• Immunochromatographic strip (ICS) point-of-care test on blood specimen,
when FDA approved.
• Line Immunoassay (LIA) point-of-care test on blood specimen, when FDA
approved.
• Enzyme-linked immunosorbent assay (ELISA) for treponemal antibody in
serum specimens. 
• RPR point-of-care test for nontreponemal antibody in serum specimens. 
• Dark field microscope examination of lesion specimens.
Follow-up tests should be performed using the same nontreponemal test initially
used to document infection (e.g., VDRL or RPR) to ensure comparability.
Syphilis is treated with penicillin. Health benefits should include provisions for
treatment. 
Strength of Evidence for the Clinical Preventive Service
The level of evidence supporting the recommendation in this section is 
described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to support screening for syphilis among all
persons at increased risk for syphilis infection.1
• The USPSTF found good evidence to support screening for syphilis among all
pregnant women.1
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• Tobacco use is the leading cause of preventable death in the United States.
Each year, approximately 440,000 individuals die as a result of smoking1,
accounting for 20% of all deaths in the United States annually.2
• In the United States the direct medical costs associated with smoking total
$75.5 billion per year.2 Smoking also costs an estimated $92 billion per year in
lost productivity due to sickness and premature death.3
• Smokers who successfully stop smoking reduce their potential medical costs
associated with cardiovascular disease by an average of $47 during the first year
and approximately $853 during the following 7 years (in year 1995 dollars).4
• Cost analyses have shown that tobacco-cessation benefits, from an employer’s
perspective, are cost-saving.5 An employer’s cost to implement a tobacco-
cessation program becomes cost-neutral at 3 years and begins to save
healthcare dollars at 5 years.6
• Screening for tobacco use allows clinicians to identify tobacco users and offer
them effective cessation treatments such as counseling and pharmacotherapy
(nicotine replacement products or cessation medications). Counseling and
pharmacotherapy have each been proven to double quit rates.7
Clinical Preventive Service Recommendations
The U.S. Preventive Services Task Force (USPSTF) strongly recommends that
clinicians screen all adults for tobacco use and provide tobacco cessation
interventions for those who use tobacco products.8
The USPSTF found good evidence that brief smoking cessation interventions,
including screening, brief behavioral counseling (less than 3 minutes), and
pharmacotherapy delivered in primary care settings, are effective in increasing the
proportion of smokers who successfully quit smoking and remain abstinent after
1 year. The USPSTF and the Surgeon General’s Report on the Health
Consequences of Smoking found good evidence that smoking cessation lowers
the risk for heart disease, stroke, cancer, and lung disease.9-10 The USPSTF
concluded that there is good evidence that even small increases in the quit rates
from tobacco cessation counseling and/or medication would produce important
health benefits.8
The USPSTF strongly recommends that clinicians screen all pregnant women for
tobacco use and provide augmented pregnancy-tailored counseling to those who
smoke.8
The USPSTF found good evidence that extended or augmented smoking
cessation counseling (5 to 15 minutes) using messages and self-help materials
tailored for pregnant smokers, compared with brief generic counseling
interventions alone, substantially increases abstinence rates during pregnancy and
leads to increased birth weights. Although relapse rates are high in the post-
partum period, the USPSTF concluded that reducing smoking during pregnancy
is likely to have substantial health benefits for both the baby and the expectant
mother. 
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The Community Guide to Preventive Services strongly recommends providing
coverage for tobacco dependence treatment and initiating provider reminder
systems to enhance treatment.11
Recommendations are based on the strength of the evidence of effectiveness
found through a systematic review of published studies conducted by a team of
experts on behalf of the Task Force. Strong evidence indicates that there are a
number of supportive studies that recommend the action.12
The U.S. Public Health Service Clinical Practice Guideline, Treating Tobacco Use
and Dependence (PHS Guideline) strongly recommends screening for tobacco use
and providing tobacco cessation treatment (including counseling and/or
medication).13 The U.S. Public Health Service found good evidence that benefits
covering screening for tobacco use and providing cessation treatment (counseling
and pharmacotherapy) to those who use tobacco are effective in increasing the
proportion of smokers who successfully quit and remain abstinent at one year.7
Recommendations are based on research from multiple, well-designed
randomized clinical trials, directly relevant to the recommendation that yielded a
consistent pattern of findings.
The Centers for Medicare and Medicaid Services (CMS) recommends that
physicians provide tobacco screening, counseling, and treatment services. Medicare
provides coverage for 2 cessation attempts per year. Each attempt includes a
maximum of 4 intermediate or intensive counseling cessations for a total
maximum benefit of 8 counseling sessions in a 12-month period. Medicare Part D
covers all smoking cessation medications that are prescribed by a physician.13
CMS Mandate
The recommendations and supporting information contained in this document
came from several sources, including the:
• Center for Medicaid and Medicare Services (CMS)
• Centers for Disease Control and Prevention (CDC)
• Community Guide to Preventive Services
• George Washington University, Center for Health Services Research and Policy
• Partnership for Prevention
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
• U.S. Public Health Service (PHS)
• U.S. Surgeon General
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text. 
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Tobacco use contributes to many diseases and is the primary underlying cause of
death in the United States. Each year, approximately 440,000 individuals die as a
result of smoking1, accounting for 20% of all deaths in the United States
annually.2 Approximately 155,000 of these deaths result from cancer, 80,000
result from ischemic heart disease, and 17,000 result from cerebrovascular
disease. 
Among the estimated 43.4% (91.5 million) of persons alive in 2003 who had
ever smoked, 50.3% (45.9 million) were former smokers and 49.7% (45.4
million) were current smokers. Current smokers make up 20.9% of the adult
population in the United States. If these current smokers continue smoking, half
will die due to their tobacco use.2
Tobacco use also affects the health of non-smokers. Second-hand smoke exposure
at work or at home (also called environmental tobacco smoke) increases non-
smokers’ risk of developing heart disease by 25% to 30% and increases their risk
of lung cancer by 20% to 30%.14 Second-hand smoke exposure contributes to the
deaths of 38,000 people each year; 3,000 die as a result of lung cancer and
35,000 die as a result of cardiovascular disease.2 In addition, each year in the
United States 300,000 children suffer from respiratory tract infections and
asthma as a result of being exposed to secondhand smoke.15 Smoking during
pregnancy is particularly dangerous because it increases the risks of premature
birth, miscarriage, stillbirth, and low birth weight.10 Prenatal tobacco use resulted
in an estimated 1,007 infant deaths annually between 1995 and 1999.16
There is substantial evidence that smoking cessation improves health by lowering
an individual’s risk for diseases caused by smoking such as heart disease, stroke,
and cancer.1 Yet despite the documented risks of smoking, 20.8% of the United
States population continues to smoke.2 Seventy percent (70%) of smokers say
they want to quit and each year 41% of smokers make a quit attempt of at least
24 hours.6 Without assistance, only 7% are abstinent at 1 year.17
There are numerous risk factors for cigarette smoking, including: younger age,
male sex, race, a lower level of education, and low socioeconomic status.18
Young adults (18 to 24-year-olds and 25 to 44-year-olds) are more likely to
smoke than older adults (45 to 64-year-olds and persons above the age of 65).18
Nearly 80% of all adult smokers began smoking before they were 18 years old,
and it is estimated that more than 2,000 adolescents become daily smokers each
day.19 During 2005, 23% of high school students smoked cigarettes daily.20
Men are also at increased risk of tobacco use; while 23.4% of men smoke
cigarettes, only 18.5% of women smoke.18 
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The prevalence of cigarette smoking by race is highest among American
Indians/Alaska Natives (33.%), followed by whites (22.2 %), African-
Americans (20.2%), Hispanics (15%), and Asians [excluding Native
Hawaiians and other Pacific Islanders] (11.3%).18 
Approximately 39.6% of adults with a General Education Development
(GED) diploma and 34% of adults with 9 to 11 years of education smoke,
while only 11.7% of adults who complete an undergraduate degree and 8%
of adults who complete a graduate college degree smoke.18 Cigarette smoking
is also more common among adults who live below the poverty level (29.1%)
than among those living at or above the poverty level (20.6%).18
Value of Prevention
The cost of smoking-related illnesses and the loss of productivity
associated with smoking are considerable. In the United States, the direct
medical costs associated with smoking are $75.5 billion per year.3 During
1997 to 2001, these expenditures plus productivity losses exceeded $167
billion per year.3
Individuals who smoke have higher total medical expenses than do
nonsmokers due to their higher burden of illness. Men who smoke incur
$15,800 and women who smoke incur $17,500 more in lifetime medical
expenses than do nonsmokers (in year 2002 dollars).3
In addition to direct medical costs, smokers incur higher costs related to
disability, lost productivity, and absenteeism than do nonsmokers. For
example, men who smoke use 4 more sick days per year than do
nonsmoking males, and women who smoke use 2 more sick days per year
than do nonsmoking females.6 In 1999, lost productivity due to smoking
and smoking-related illnesses cost employers $1,897 per smoking
employee. Excess medical expenses due to smoking and smoking-related
illnesses cost employers $1,850 per smoking employee (both figures are
adjusted to year 2002 dollars).3
Smokers who successfully stop smoking reduce potential medical costs
associated with cardiovascular disease by about $47 during the first year
and by about $853 during the following 7 years (in year 1995 dollars).4,21
An annual drop of 1 percentage point in smoking prevalence among
pregnant women would prevent 1,300 low birth weight live births and
save 21 million in direct medical costs in the first year of a smoking
cessation program.22 Besides the savings in healthcare costs, economic
benefits of preventive intervention include reductions in absenteeism
costs, on-the-job productivity loss, life-insurance costs, and costs
associated with fire and property damage due to smoking.6,23
The cost of implementing a comprehensive tobacco cessation program
including screening, counseling, and treatment, will vary by location and
provider base, but is generally considered to be low. Research has shown
that the average cost of providing a comprehensive tobacco cessation program for
all employees ranges from 10 cents to 40 cents per member, per month.24
In 2004, the private-sector cost of screening for tobacco use averaged $39;
approximately 95% of all paid claims fell within the range of $0 to $129.25 In
2004, the private-sector cost of counseling averaged $39 per session;
approximately 95% of all paid claims fell within the range of $0 to $134 per
session.25
The cost of pharmacological interventions vary depending on type and dosage.
The average wholesale price (AWP) of a 1-month supply of bupropion ranges
from $86.54 to $196.07 depending on the brand and type chosen; a 1-month
supply of varenicline (ChantixTM) is $89.60.26
Research has shown that tobacco screening and cessation-treatment efforts are
cost-effective from a societal perspective. Cost analyses have shown that the
provision of tobacco-cessation benefits are cost-saving from an employer’s
perspective.12 The cost to employers of implementing a tobacco cessation
program equalizes at 3 years and begins to save healthcare dollars at 5 years.6
Smokers who successfully stop smoking reduce potential medical costs associated
with cardiovascular disease (including heart attack and stroke) by about $47
during the first year and by about $853 during the following 7 years.4 In fact,
treating tobacco use ranked the highest among adult preventive services in terms
of health impact, cost-effectiveness and cost, yet, according to a recent study by
the Partnership for Prevention, the service is provided to less than 35% of
tobacco users.12
The most cost-effective population to target for smoking cessation programs is
pregnant women.4 Pregnant women incur an additional $704 in neonatal
healthcare costs compared to nonsmokers. Clinical trials have shown that, for
every $1 invested in smoking cessation programs for pregnant women, $7.75 are
saved in short-term medical costs and an additional $7.63 (in year 2002 dollars)
are saved in long-term costs by preventing disability among low birth weight
infants who survive.5
The manner in which tobacco cessation programs are crafted influences their
cost-effectiveness. For example, reducing the patient out-of-pocket costs for
effective cessation therapies provides a net benefit of $362 to $1,449 per
enrollee.27 In fact, subsidizing the out-of-pocket expense for patients who wish 
to quit smoking increases the use of effective cessation therapies, increases the
number of people who attempt to quit, and — most importantly — increases 
the number of people who quit successfully.28
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Screening for tobacco use allows clinicians to identify tobacco users and offer
them effective cessation treatments such as counseling and pharmacotherapy
(nicotine replacement products or cessation medications). Counseling and
pharmacotherapy have each been proven to double quit rates.7
Despite the strong evidence supporting tobacco use screening, cessation
counseling, and medication use, and the fact that 70% of smokers report they
want to quit smoking, few adults receive recommended care for tobacco use
treatment. For example, only 71.2% of smokers are advised to quit by their
providers and only 39% of smokers are offered prescription medication or
counseling to support the quitting process.29-30
The benefit of screening for tobacco use and cessation counseling and treatment
is substantial. Smoking cessation is proven to lower an individual’s risk for
diseases caused by smoking such as heart disease, stroke, and cancer.1 There are
no documented risks to screening for tobacco use.
The benefit of providing smoking-cessation coverage is considerable. As
mentioned above, subsidizing the out-of-pocket expense for patients who wish to
quit smoking increases the use of effective cessation therapies, increases the
number of people who attempt to quit, and — most importantly — increases the
number of people who quit successfully.28 Additional workplace interventions,
such as establishing smoke-free workplaces, add even more benefit. Smoke-free
workplaces and the provision of comprehensive coverage presumably act together
to reduce smoking, and they have been demonstrated to increase quit attempts.11 
All adults should be screened for tobacco use at every provider visit. Adults who
screen positive for tobacco use should be advised to quit and offered counseling
and medication at every medical encounter.10 There is limited evidence on the
efficacy of screening and counseling children and adolescents for tobacco use.
However, because most adult smokers began smoking during their teenage years,
the USPSTF recommends that clinicians screen and counsel this population at
their discretion.10
At least two courses of 4 to 6 counseling sessions of at least 30 minutes each
should be provided annually, for a total of 12 sessions per calendar year until the
patient successfully quits smoking. Some patients may require additional sessions. 
Guidelines for the duration of medication treatment are specified in the PHS
Guideline and differ depending on the medication type.10
Patients identified as recently quit should be eligible for up to 4 additional
counseling sessions and/or 4 to 8 weeks of medication to maintain tobacco
abstinence (depending on the medication).10
The USPSTF10 and the PHS Guideline7 recommend the use of the “5-A’s”
behavioral counseling framework for tobacco screening and counseling.  This
framework is composed of 5 steps aimed at engaging the patient in a discussion
about their tobacco use and their intention to quit:
• Ask about tobacco use.
• Advise the patient to quit through clear and personalized messages.
• Assess the patient’s willingness to quit.
• Assist to quit, develop a quit plan, and set a quit date.
• Arrange for medications and support services.
The PHS Guideline recommends several effective methods of tobacco cessation
counseling including brief counseling (3 minutes or under), intensive counseling
(5 to 15 minutes), telephone based counseling (4 to 6 sessions), and tailored
counseling (with information and support specific to the population, e.g.,
pregnant women).7 The USPSTF further recommends that clinicians provide
problem-solving guidance for smokers to develop a quit plan and to overcome
common barriers to quitting. Practices that complement the 5-A framework
include provision of medications, motivational interviewing or other methods of
intensive counseling, referral for those who may need extra help, and referral to
telephone quitlines.10 
The USPSTF and the PHS Guideline note that there is a dose-response
relationship between the intensity and frequency of counseling and tobacco
abstinence rates.7,10 For example, brief counseling interventions (under 3 minutes)
are more effective than no counseling, but intensive counseling sessions (5 to 15
minutes) are more effective than brief counseling sessions. The more time a
patient is exposed to counseling, the more likely it is that the patient will be
successful in quitting.7 Although there is limited evidence on the optimal amount
of counseling, there is evidence that counseling up to 300 minutes per course of
treatment has the most effectiveness.7
Counseling and pharmacotherapy have each been proven to double quit rates7:
therefore, a tobacco use treatment benefit should include brief counseling (in-
person) and intensive counseling (in-person or telephonic) as described above,
and:
• All first-line FDA-approved over-the-counter (OTC) and prescription nicotine
replacement products such as nicotine replacement gum, patches, lozenges,
inhalers, and nasal sprays.
• All FDA-approved tobacco cessation prescription medications such as
bupropion (e.g., Wellbutrin® and Zyban®)7 and varenicline (ChantixTM). 
Because reducing out-of-pocket costs for tobacco use treatment medications and
nicotine replacement products has proven to further reduce quit rates27, FDA-
approved medications/products should not be subject to the deductible and
copayments should be reduced or eliminated.
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EVIDENCE-STATEMENT: Tobacco Use Treatment (Screening, Counseling, and Treatment)
Prescription and Over-the-Counter Tobacco Cessation Medications Approved by 
the Food and Drug Administration (FDA) 
**Received FDA approval in October 2002; therefore not addressed in the 2000 PHS Guidelines.
*** Received FDA Approval in May 2006; therefore not addressed in the 2000 PHS Guidelines.
Some populations of smokers require specialized and tailored interventions.  For
example, pregnant women who smoke should be offered tailored and intensive
counseling (5 to 15 minutes) and self-help materials as brief counseling has been
found to be less effective in this population.7 The PHS Guideline recommends 
that pharmacotherapy be considered on a case-by-case basis for tobacco cessation
during pregnancy.7
Strength of Evidence for the Clinical Preventive Service 
The level of evidence supporting the recommendations contained in this 
chapter is described below.
Evidence-Based Research:
U.S. Preventive Services Task Force (USPSTF)
Strength of Evidence: A (Strongly Recommended/Good Evidence)
• The USPSTF found good evidence to recommend that clinicians screen all 
adults for tobacco use and provide tobacco cessation interventions 
(counseling, medication, and follow-up) for those who use tobacco products.8
• The USPSTF found good evidence to recommend that clinicians screen all
pregnant women for tobacco use and provide augmented pregnancy-tailored
counseling to those who smoke.8
The Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Strong Evidence (Systematic review of published studies
conducted by a team of experts).
• The Community Guide to Preventive Services11 strongly recommends 
establishment of provider reminder systems within health care systems, 











Nasal Spray Nicotrol® Prescription
Lozenge Commit®** OTC
Buproprion SR Pill Zyban® Wellbutrin® Prescription
Varenicline Pill ChantixTM*** Prescription
provision of telephone counseling services and establishment of effective media
campaigns. 
U.S. Public Health Service (USPHS)
Strength of Evidence: Strong Evidence (Research from multiple, well designed
randomized clinical trials, directly relevant to the recommendation that yielded a
consistent pattern of findings).
• The Public Health Service Clinical Practice Guideline, Treating Tobacco Use
and Dependence (PHS Guideline)3 strongly recommends screening for tobacco
use and providing tobacco cessation treatment (counseling and medication).
Recommended Guidance:
The Centers for Medicare and Medicaid Services (CMS) 
Strength of Evidence: CMS Mandated
• CMS recommends that physicians provide tobacco screening, counseling, and
treatment services. Medicare provides coverage for two cessation attempts per
year. Each attempt includes a maximum of 4 intermediate or intensive
counseling cessations for a total maximum benefit of 8 counseling sessions in a
12-month period. Medicare Part D covers all smoking cessation medications
that are prescribed by a physician.13
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• An estimated 3% to 5% of persons (or 9.8 to 15.1 million persons) residing in
the United States have latent tuberculosis infection (LTBI),1 a condition in
which an individual is infected with Mycobacterium tuberculosis but does not
currently have tuberculosis (TB) disease. Individuals who have LTBI have no
signs or symptoms and cannot spread TB. Approximately 5% to 10% of
persons with LTBI will develop clinical TB disease at some point in their
lifetime.2-3 When active TB disease occurs, these persons may become
infectious and then transmit the infection to others. 
• The global TB burden is substantial and increasing. Immigration to the United
States from areas of the world where TB is common is continually
supplementing the pool of persons in the United States with TB and LTBI. 
• Preventing TB involves preventing those with LTBI from progressing to TB
disease. Therefore, testing and treatment for LTBI is recommended for those at
high risk for TB disease, especially those from regions with high TB rates. 
• Identifying and properly treating persons with TB disease early can prevent
extensive transmission and costly contact investigations.
• Businesses that employ workers from countries or regions where TB is
common or that are based in those countries may face a heightened risk of a
TB outbreak. In addition, businesses that employ workers at high risk for TB
(such as HIV-infected or other immunosuppressed persons or low-income
minorities) or have clients who are at high risk for TB need to be aware and
knowledgeable about TB and include prevention activities in their plans.
Clinical Preventive Service Recommendations
In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended
screening for LTBI with tuberculin skin testing (TST) for asymptomatic high risk
persons.4
The USPSTF recognizes the importance of targeted screening for tuberculosis.
However, the USPSTF has decided not to update its 1996 recommendation and
rather defers to the guidelines of the Centers for Disease Control and Prevention
(CDC) referenced below.
CDC has published guidelines on screening for LTBI,2 preventing transmission
in health-care settings,5 investigating contacts of infectious TB patients,6 treating
TB disease,7 and controlling TB in the United States.8
The CDC recommends conducting targeted testing of persons at high risk for
TB (see below) to identify LTBI and TB disease early and treating those who
have TB and LTBI to prevent transmission and prevent progression of LTBI to
disease.2 Targeted testing programs should be conducted among groups at risk for
recent infection with M. tuberculosis and those who, regardless of duration of







The CDC does not recommend targeted testing of persons at low risk for TB,
with the exception of initial (baseline) testing of persons whose future activity
will place them at increased risk of exposure, such as some healthcare workers
who may require serial screening.
Not Specified. Each of the referenced CDC guidelines describes the evidence
basis for the recommendations, but not all provide ratings.
The recommendations and supporting information contained in this document
came from several sources, including the:
• Centers for Disease Control and Prevention (CDC)
• Peer-reviewed research
• U.S. Preventive Services Task Force (USPSTF)
The background and supporting information contained in this document is a
compilation of research findings. All information presented in this document
should be attributed to its referenced source and should not be considered a
reflection of other organizations cited in the text.
Condition/Disease Specific Information
Tuberculosis is a bacterial disease caused by Mycobacterium tuberculosis, which
usually attacks the lungs (pulmonary TB) but can attack any part of the body,
including the kidney, spine, and brain. Symptoms of TB disease include a
productive cough lasting more than 2 to 3 weeks, chest pain, coughing up blood,
fever, chills, night sweats, appetite loss, weight loss, and easy fatigue. A person
who has developed infectious pulmonary or laryngeal TB disease can spread
infection to others through coughing, sneezing, speaking, or singing. 
When exposure to infectious TB occurs, the health department conducts a
contact investigation.6 Studies of contact investigations in the United States reveal
that 30% to 40% of close contacts of persons having infectious TB disease
become infected with LTBI (as evidenced by a positive tuberculin skin test or
“TST”) and identify an additional two percent with active TB disease.9-10
Approximately 5% to 10% of persons with LTBI will progress to clinically active
TB disease at some point in their lives.2-3 About half of those who progress will
do so in the first 2 years after initial infection (i.e., recent infection). Treatment
of LTBI reduces the risk of developing TB disease by 70% to 90%.2
Populations at high risk for TB include persons who had recent close contact
with an infectious TB patient, foreign-born persons from areas where TB is
common, HIV-infected and other immunosuppressed persons, homeless persons,
substance users (e.g., injection drug users, crack cocaine users, alcoholics), low-
income minorities, young children exposed to high-risk adults, health care
workers who serve high-risk clients, residents and employees of high-risk
congregate settings such as homeless shelters, correctional institutions, nursing







The proportion of TB cases in the United States occurring among foreign-born
persons increased progressively during the 1990s; in 2004, persons born outside
the United States accounted for 54% of reported cases.11 Although foreign-born
persons who received a diagnosis of TB in 2004 were born in approximately 150
countries worldwide, 5 countries of origin accounted for over half of foreign-
born persons with TB: Mexico (25%), the Philippines (11%), Vietnam (8%),
India (7%), and China (5%). The number of states in which greater than 50% of
the total reported cases occurred among foreign-born persons increased from 5
(10%) in 1992 to 22 (44%) in 2004.11 Among U.S. states and cities, this profile
can change rapidly, reflecting changes in patterns of immigration and refugee
settlement.12 Globally, half of new TB cases each year occur in India, China,
Indonesia, Bangladesh, and Pakistan.13
In the United States, the majority of healthcare workers do not have a high risk
for TB, but some, such as respiratory therapists, appear to be at greater risk.5,14
Persons who work in, or are served by, clinics or community health organizations
providing care to HIV-infected persons are considered a priority population for
targeted testing and treatment of TB and LTBI because of the risk of
transmission to this highly vulnerable population.8
An individual at high risk for TB has one or more of the following characteristics:
recent exposure to a person having infectious TB; history of previous TB disease
or positive tuberculin skin test or QuantiFERON-TB Gold result; HIV infection
or other immunosuppressive medical condition; being a young child with contact
to a high-risk adult; history of injection or non-injection drug use; birth outside
the United States in a region where TB is common; being a resident or employee
of a high-risk congregate setting; being a member of a low-income minority
population; or being a health care worker who serves high-risk persons. However,
TB should be suspected in any patient who has had a persistent cough for more
than 2 to 3 weeks, with at least one additional symptom, including fever, night
sweats (sufficient to require changing of bed clothes or sheets), weight loss, or
hemoptysis (coughing up blood). 
Value of Prevention
From the late 1980s through the early 1990s, outbreaks of TB among HIV-
infected persons in the United States contributed to a surge in TB, reversing a
steadily declining trend. Billings or charges for inpatient TB care increased 3.2-
fold from 1985 through 1990.15 During that period, an estimated 77,700 TB
hospitalizations resulted in about 1.1 million days of care. The total direct
medical expenditures for TB in a 1991 study of TB outpatient treatment,
screening, and treatment for LTBI, contact investigation, and surveillance were
estimated at $703 million and TB costs were estimated at $574 million (in year
1991 dollars.) In addition, 20,803 TB hospitalizations resulting in 413,980 days
of inpatient care occurred.16 Extrapolating from a 1996 study at 10 mostly urban
sites, an estimated 12,631 TB hospitalizations and approximately 270,650 days
of inpatient care occurred in the United States in 1996.17 A study in 2000
estimated that there were over 11,000 TB hospitalizations resulting in more than





which adds approximately $19,000 to the cost of treatment.17 While it
appears that there might be a slight downward trend in TB
hospitalizations as management practices have improved and the total
number of TB patients declines each year, TB still places a substantial
burden on the U.S. economy.
More recently, direct medical TB costs have been estimated (and updated
to 2004 dollars) from several studies17-21 with the costs varying according
to the kinds of treatment needed. Direct medical costs of LTBI screening
and treatment caused by exposure to strains susceptible to normally-used
drugs were approximately $208 to $311 per person without directly
observed treatment (DOT).19 DOT improves the likelihood of completion
of a full course of treatment. If drug susceptible TB disease is diagnosed,
outpatient treatment costs are approximately $4,000 under daily DOT.20
Costs associated with MDR TB are likely to be much higher than for
drug-susceptible tuberculosis due to longer hospitalization, longer and
more complex treatment with more expensive and toxic medications, and
higher mortality. Direct medical costs associated with MDR TB
hospitalization range from $15,000 to $137,000 per case.21 In-patient
MDR TB costs average $30,740 per person and $1,232 per person-day of
hospitalization. Outpatient costs average $22,625, or $52 a day per
person. Direct medical costs for both inpatient and outpatient MDR TB
care average approximately $53,000 per person. For each infected contact
of a patient with multidrug-resistant (MDR) TB in California, the cost of
two years of follow-up and treatment to prevent the development of
MDR TB was estimated to be $11,125.22
These direct medical costs are underestimates because they exclude the
additional public health program costs of providing culturally appropriate
outreach, interpreters, and transportation services. Also, in areas where
the cost-of-living is much higher, such as San Francisco and New York
City, medical costs may be 80% to 95% higher.23 Additional costs to
society include the productivity losses associated with TB deaths and
productivity losses for the 6 months of treatment when patients are
unable to work. 
The workplace burden of TB includes lost productivity, absenteeism, high
hospitalization costs, and disease transmission to other employees.
Hospitalization burdens include not only direct medical costs, but also
the lost productivity of workers during hospitalization days. Outpatient
care involves workers’ lost productivity due to clinic visits or fatigue and
other effects of the illness. In fact, productivity losses may last for months
or longer if permanent physical effects are experienced.24 Disease
transmission may result in a costly contact investigation as well as
stigmatization and disruption of business. However, the risk of TB
transmission in the workplace is highly variable, depending on factors
such as the TB risk of clients served, the activities conducted by the


















Benefits and Risks 
of Intervention
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Successfully completing a treatment regimen for LTBI and thereby eliminating
the preventable direct medical cost of illness due to TB disease saves $4,000 per
case.20 Benefits rise if the case of disease that is prevented would have required
hospitalization ($19,000 benefit) and even more if that case would have required
treatment of a multi-drug-resistant strain ($15,000 to $137,000 benefit).17, 21
Additional benefits include the reduction of worker productivity losses due to
illness and the avoidance of stigmatization or work disruption that often follows a
TB outbreak in a worksite.
Early identification of TB disease can also be expected to substantially reduce the
costs of contact investigations, which would be less extensive than if the patient
were undiagnosed for a long period, and costs of secondary TB cases among
contacts, which would be fewer than for contacts of later diagnosed cases.
In 2004, the private-sector cost of tuberculosis screening averaged $22;
approximately 95% of all paid claims fell within the range of $0 to $49 per
screen.25
Direct medical costs of LTBI screening and treatment (without DOT) for
infection by presumed M. tuberculosis strains that can be treated by first-line
drugs are approximately $208 to $311 per person.19 If employees miss work for
the screening and treatment, productivity losses for the standard 9 months of
treatment might also occur. The direct medical cost of illness due to TB disease is
approximately $4,000 per case of drug susceptible TB disease treated by DOT.20
Costs rise if the case of disease requires hospitalization ($19,000) and even more
for treatment of a multi-drug-resistant strain ($15,000 to $137,000).17, 21
For individuals at high risk for TB, the benefits of screening for LTBI and
completion of treatment outweigh the costs if treatment reduces the risk of —
and costs associated with — TB disease and hospitalization.26 Reducing the risk
of medication-induced adverse events and any potential productivity losses
associated with LTBI treatment would add to the benefit. 
Preventive Intervention Information
Screening/testing individuals at high risk for TB allows clinicians to identify
affected persons and begin treatment. Early identification and treatment of TB
disease improves outcomes and reduces the risk of transmission. Identification of
LTBI and completion of LTBI treatment reduces an individual’s risk of
developing TB disease by 70% to 90%.2
Clinicians should individualize their decision to conduct targeted testing and
treatment for TB and LTBI to the specific patient’s risks and environment.
Routine testing for TB or LTBI is not recommended for persons who are not at
high risk for TB. The TST is subject to variability like all medical tests, but many
of the inherent variations in administering and reading tests can be avoided by
careful attention to details and the clinical provider should be aware of these
details. Interferon gamma release assays (IGRA), such as the QuantiFERON-TB®
(QFT) Gold blood test can be used instead of the TST for LTBI screening. CDC
has published guidelines for the use of approved IGRAs,27 and will do so for
additional tests as they become available. For individuals at high risk for TB, the
benefits of LTBI screening and completion of treatment outweigh the costs.26
Screening high-risk populations for TB disease by asking about the major TB
symptom, a cough of 2 to 3 weeks duration, has been shown to be effective,28
and is likely to be cost-effective over routine screening using chest radiographs.
This intervention is simple, inexpensive, and is potentially cost-effective in many
settings.
TB and LTBI testing programs should be conducted among groups at high risk
for recent infection with M. tuberculosis and those who, regardless of duration of
infection, are at increased risk for progressing to TB disease (e.g., HIV-infected or
other immunosuppressed persons with certain medical conditions, injection drug
users, those with a history of inadequately treated TB disease). 
Workers in health-care settings who have face-to-face contact with patients with
suspected or confirmed TB disease or clinical TB specimens should be included
in a screening program.5 In settings where routine screening is mandated but
classified as low risk for TB exposure (where persons with TB disease are not
expected to be encountered), workers should receive baseline testing using a two-
step TST or an IGRA upon hiring (with appropriate follow-up evaluation for
those found to have positive TST or IGRA results); additional screening is not
necessary unless TB exposure occurs. In settings classified as medium risk (where
workers will or will possibly be exposed to persons with TB disease or TB clinical
specimens), workers should receive baseline two-step TST and annual screening
for TB symptoms; workers who are TST-negative at baseline should also receive
annual TST. If the setting has potential ongoing TB transmission, more frequent
TST may be needed until infection control lapses have been corrected.5
For the majority of infected persons, the only evidence of LTBI is an immune
response to mycobacterial antigens, demonstrated by a positive TST or IGRA
result. In the United States, the preferred skin test for LTBI is the intradermal, or
Mantoux method, injection of 0.1 ml (5 TU) of purified protein derivative
(PPD). Tests should be read by a trained professional 48 to 72 hours after the
skin test has been applied. Multiple puncture tests (e.g., Tine and Heaf ) and
PPD strengths of 1 TU and 250 TU should not be used.2
IGRAs have been shown to have a lower likelihood of giving false-positive
readings.27 IGRAs provide significant advantages in delivery (e.g., no patient
return for test reading) that may actually make them more cost-effective than the
TST in populations that are likely to have high rates of false-positive TST results
because of prior vaccination with the Bacille Calmette-Gerin (BCG). However,
data on IGRA performance in high-risk populations are being evaluated.
Screening high-risk populations for TB disease by asking about the major TB
symptom, a cough of 2 to 3 weeks duration, is simple, inexpensive, and is











Health benefits should include provisions for follow-up and treatment services. 
A daily 9-month regimen of isoniazid (300 mg for adults, 10 to 15 mg/kg up to
300 mg for children) is recommended for treatment of LTBI caused by isoniazid-
susceptible strains of M. tuberculosis. Completion of 270 doses within a 12-
month period is optimal.2 Twice-weekly dosing is an acceptable alternative (76
doses within 12 months).2 A daily regimen of rifampin (10 to 20 mg/kg, 600 mg
maximum) for 4 months is also an acceptable alternative and is the
recommended choice for contacts to isoniazid-resistant TB patients; completion
is considered optimal with 120 doses taken within 6 months.2 Directly-observed
treatment (DOT) improves the outcome of TB disease treatment and is therefore
recommended over self-administered therapy (SAT), and has been shown to be
cost-effective to prevent the development of drug resistant TB disease.29 DOT is
also recommended for LTBI treatment of vulnerable populations, such as HIV-
infected persons or young children.
Strength of Evidence for the Clinical Preventive Service
The strength of evidence for the recommendations contained in this chapter is
described below.
Recommended Guidance:
Centers for Disease Control and Prevention (CDC)
Strength of Evidence: Not Specified. Each of the referenced CDC guidelines
describes the evidence basis for the recommendations, but not all provide ratings.
• The CDC recommends conducting targeted testing of persons at high risk for
TB and treating those who have TB and LTBI to identify TB disease early,
prevent transmission, and prevent progression of LTBI to disease.2
• The CDC recommends, if routine TB screening is mandated in low-risk
settings, the provision of baseline LTBI testing upon hiring, with the addition
of annual screening for TB symptoms in medium-risk settings.5
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Practical advice about the 
prioritization and strategic 
implementation of clinical 
preventive service benefits.
Sections include:
• The Purpose and Process of
Prioritizing Recommended
Clinical Preventive Services in
order to:
- Provide Economic and 
Health Value
- Address Demographic Needs
- Address Beneficiary Risk and 
Reduce Specific Healthcare 
Costs
• Employer Scenarios




The Purpose and Process of Prioritizing Recommended
Clinical Preventive Services
Employers with limited resources, or those facing competing demands, may not be able to
add all of the 46 recommended clinical preventive service benefits in a single benefit revision
cycle. These employers should consider a strategic implementation approach and prioritize
benefit expansion. 
There are multiple ways to prioritize the clinical
preventive services recommended in the Purchaser’s Guide.
Several methods of prioritization are listed below.
Prioritization methods are not listed in preferential
order; nor are they mutually exclusive. Each method has
its own strengths and weaknesses and employers may
want to consider combining multiple approaches.
Employers should evaluate their current clinical
preventive service benefits and the needs of their own




in a Strategic 
Implementation Plan
4
Health outcomes in the United
States could be improved at less
expense if the healthcare system,
clinicians, and patients gave priority 
to services that were most beneficial
and offered the greatest value.1
Partnership for Prevention 
Priorities for America’s Health, 2006
Value – An Important Variable
Like any investment aimed at keeping a workforce healthy and productive, clinical preventive
services offer value. The “value” of an individual preventive service is determined by its ability
to prevent a significant amount of morbidity and mortality in relation to the cost of offering the
service. Because offering a clinical preventive service has a real (monetary) cost and an
opportunity cost (there is a finite amount of services that can be delivered/received in a given
period of time), it is important for purchasers to quantify the value of clinical preventive 
services in relation to one another when making coverage decisions.
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4 Prioritization of Clinical Preventive Services in a Strategic Implementation Plan
Employer Guidance
Strength of evidence for a given clinical preventive service should be the first filter used in
prioritization and strategic implementation efforts. The U.S. Preventive Services Task Force
(USPSTF) uses a lettered grading system:
A-B: Employers should implement coverage for all services recommended in the
Purchaser’s Guide, (particularly the USPSTF “A” and “B” recommendations and all
ACIP recommended services immediately.)
I: Employers have discretion as to whether to provide coverage for services with limited
or conflicting evidence (services that received an “I” rating). The provision of coverage
for “I”-rated services should be secondary to the provision of coverage for all
recommended services featured in the Purchaser’s Guide (“A” and “B”-rated services and
equivalencies*).
C: Employers should provide coverage for USPSTF “C”-rated services only if there is a
population-specific and compelling reason to do so as there appears to little or no
health value derived from these interventions. The provision of coverage for “C”-rated
services should be secondary to the provision of coverage for all recommended services
featured in the Purchaser’s Guide (“A” and “B”-rated services and equivalencies*).  
D: Employers should not provide coverage for “D”-rated clinical preventive services for
their asymptomatic beneficiary population. However, employers may choose to cover
these services on a case-by-case basis as determined by beneficiary risk or medical
necessity criteria. Further, these services should be covered when part of a medical
treatment plan for an existing condition/disease or when an individual is determined to
be at high risk for the respective condition/disease. 
*Other organizations have comparable rating systems. For example, the American
Academy of Family Physicians (AAFP) uses a SR (Strongly Recommended), R
(Recommended), NR (No Recommendation), RA (Recommend Against), I
(Insufficient Evidence to Recommend Either For or Against) rating system. For more
information on AAFP’s grading system please refer to the Introduction of the
Purchaser’s Guide.
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Methods of Prioritization: An Overview 
Rank order clinical preventive services by their economic and health value. The National
Commission on Prevention Priorities has rank-ordered clinical preventive services according
to their cost-effectiveness and ability to prevent disease, injury, or premature death. “High-
value” services are those services that, when delivered
appropriately, are both cost-effective and reduce the burden of
disease within a population. Employers interested in providing
coverage for the clinical preventive services that provide a good
value for their money should consider this method.
Rank order clinical preventive services by their ability to meet the needs of a defined
population based on age and gender. Many employers have beneficiary populations that are
demographically homogeneous (i.e., their beneficiary population is mostly male or mostly
female, mostly young adults [20s, 30s, 40s], mostly older adults [50s, 60s, 70s]). Similarly,
many clinical preventive services are relevant only for one age or
gender group (e.g., cervical cancer screening is only recommended
for women). Employers who have a relatively homogenous
beneficiary population and who want to provide coverage for
the clinical preventive services that are most likely to meet the
needs of that population should consider this method. 
Rank order clinical preventive services by their ability to address the risk profile of a
population based on results from a population risk assessment such as an health risk
appraisal (HRA) or conditions and diseases frequently seen in healthcare cost data.
Employers who sponsor HRAs can use the results of the assessment to establish a beneficiary
risk profile. This group risk profile can then inform the selection of clinical preventive
service benefits. Similarly, analyzing healthcare cost data (e.g., medical claims data, disability
claims data) can alert employers to high-frequency and/or high-cost claims that are a result
of a preventable disease (e.g., hospitalization for chickenpox) or modifiable behavior (e.g.,
tobacco use). Clinical preventive service benefits can then be
prioritized for implementation based on their ability to address
the preventable conditions reflected in the employer’s healthcare
cost data. Employers interested in providing coverage for
clinical preventive services that 1) address the specific health
risks of their beneficiary population and/or 2) address their
beneficiaries’ preventable healthcare costs should consider 
this method.
440




























Figure 4.1: Top 25 High-Value Preventive Services (evaluated in terms of the preventable
burden of disease and cost-effectiveness)2
Aspirin
Chemoprophylaxis
































Continued on next page
Provide Economic and Health Value
Rank order clinical preventive services by their economic and health value. 
The National Commission on Prevention Priorities (NCPP), a blue-ribbon panel of
thought-leaders on prevention chaired by former Surgeon General Dr. David Satcher and
staffed by Partnership for Prevention, recently ranked the 25 preventive services
recommended by the U.S. Preventive Services Task Force (USPSTF) and the Advisory
Committee on Immunization Practices (ACIP) according to health impact and cost-
effectiveness. 
NCPP used a rigorous methodology to rank the selected clinical preventive services. A
clinical preventive services was deemed “high-value” when it was determined to be both
cost-effective (it cost a “reasonable” amount of money for the added quality of life or life-
years gained) and impacts the clinical preventable burden of a disease (the service prevented
a substantial proportion of disease, injury, or
premature death when delivered appropriately).
Employers interested in maximizing the value of their
investment in preventive services, within a large
population and over a sustained period of time, may
want to consider using this approach to prioritization.
Additional information on the
National Commission on Prevention
Priorities is available online at:
www.prevent.org/content/view/46/96/
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4 Prioritization of Clinical Preventive Services in a Strategic Implementation Plan
High-Value Clinical
Preventive Service
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Figure 4.1: Top 25 High-Value Preventive Services (evaluated in terms of the preventable




































Breast Cancer, Screening 4 2 6
Calcium
Chemoprophylaxis
Not included in the
Purchaser’s Guide
3 3 6
Obesity Screening Obesity, Screening,
counseling, and treatment
3 2 5
Chlamydia Screening Chlamydia, Screening 2 4 6
Depression Screening Depression, Screening 3 1 4
Vision Screening
(Children)
Vision, Screening 2 4 6
Hearing Screening Newborn Hearing, Screening 2 2 4
Diabetes Screening Diabetes (type 2), Screening 1 1 2

















Method suggested for: Employers with large and diverse populations (in terms of age and
gender) and who want to provide services with the greatest value to their employees. 
Employer Scenario: Employer A has 100,000 employees, 60,000 dependents, and 10,000
retirees. Employer A provides health insurance coverage for all beneficiaries, including
Medicare Part B coverage for retirees. The beneficiary population is very diverse: 49% of
beneficiaries are female and the average age of a beneficiary is 35 (but ranges from 0 to 81
years). After reviewing HRA information and medical claims data, no single preventable
condition emerges as a major health or cost problem. Rather, many preventable conditions
affect the population. Employer A is facing cost cutbacks relative to medical spending and
wants to ensure it receives a good value for any new benefit it implements. In order to
receive the most value from its clinical preventive service benefit expansion, employer A
decides to implement “high-value” clinical preventive services that received a score of > 8
immediately, and then implement the remaining services over the next two benefit revision
cycles.


















Tobacco Use Screening and
Brief Intervention





Alcohol Misuse, Screening and
counseling
8








Vision screening (Adults) Not included in the Purchaser’s Guide 8
Colorectal Cancer Screening Colorectal Cancer, Screening 8




Subsequent Implementation – Benefit Revision Cycle 2
Subsequent Implementation – Benefit Revision Cycle 3
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4 Prioritization of Clinical Preventive Services in a Strategic Implementation Plan
High-Value Clinical
Preventive Service





Cholesterol Screening Lipid Disorders, Screening, counseling,
and treatment
7
Cervical Cancer Screening Cervical Cancer, Screening 7
Breast Cancer Screening Breast Cancer, Screening 6
Calcium Chemoprophylaxis Not included in the Purchaser’s Guide 6
Chlamydia Screening Chlamydia, Screening 6
Vision Screening (Children) Vision, Screening 6
High-Value Clinical
Preventive Service








Counseling and preventive medication
5













Depression Screening Depression, Screening 4
Depression Screening Depression, Screening 2
Diabetes Screening Diabetes (type 2), Screening 2






Osteoporosis Screening Osteoporosis, Screening and treatment 4
Hearing Screening Newborn Hearing, Screening 4
Address Demographic Needs
Rank order clinical preventive services by their ability to meet the needs of
a defined population based on age and gender. 
Many clinical preventive services are specifically intended for a particular group of people
based on their age, gender, or other risk factor. For example, newborn hearing screening is
only relevant for beneficiaries who have (or who are) infants that will need this age-
dependent service. When an employer’s beneficiary population is relatively homogenous
(e.g., mostly male, mostly old) it may be wise to first implement the specific clinical
preventive services that are most relevant for the majority population.
Method suggested for: Employers with a homogenous beneficiary population that is heavily
weighted towards one gender or age group. 
Employer Scenario: Employer B has 7,000 employees and provides health insurance for an
additional 2,000 dependents, and 4,000 retirees. The beneficiary population is homogenous;
the average age of a beneficiary is 53 and 73% of the beneficiary population is male. In
order to best address the needs of the majority population, employer B decides to implement
clinical preventive services recommended for normal risk males in their 40s, 50s, and 60s in
the first year of the implementation program and then add benefits for clinical preventive
services that address the needs of other populations over the subsequent 5 years.
In the abovementioned scenario, employer B would implement benefits for the following
services immediately. Examples are listed in alphabetical order, but could be implemented
according to health impact and economic value.
• Abdominal Aortic Aneurysm, Screening
• Alcohol Misuse, Screening and counseling
• Aspirin Therapy for the Prevention of Cardiovascular Disease, Counseling
• Colorectal Cancer, Screening
• Depression, Screening
• Diabetes (type 2), Screening
• Healthy Diet, Counseling
• Hypertension, Screening, counseling, and treatment
• Influenza, Immunization
• Lipid Disorders, Screening, counseling, and treatment
• Obesity, Screening, counseling, and treatment
• Pneumococcal disease, Immunization
• Tobacco Use Treatment, Screening, counseling, and treatment
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Address Beneficiary Risk and Reduce Specific 
Healthcare Costs
Rank order clinical preventive services by their ability to address:
1. The risk profile of a population based on results from a population risk assessment 
such as an health risk appraisal (HRA); and/or 
2. Conditions, diseases, or behaviors frequently seen in healthcare cost data.
Analyzing healthcare cost data can help employers identify the specific health problems that
are afflicting their beneficiaries. Targeting these behaviors, conditions, or diseases may
provide the “biggest bang for the buck” by reducing beneficiaries’ burden of disease and
overall healthcare costs simultaneously.
Method suggested for: Employers who currently have a HRA (or other population risk
assessment tool) in place and the ability to analyze those data to determine a beneficiary
population risk profile and employers who are able to analyze their healthcare cost data and
determine which preventable behaviors, conditions or disease account for a substantial
proportion of medical, disability, or other health-related claims costs.
Employer Scenario 1: Employer C has 15,000 employees and provides health insurance for
an additional 13,000 dependents. For the past three years, employer C has required all
beneficiaries to complete an HRA. Employer C carefully analyzed the group data from the
past year’s HRA and determined the following,
1. Beneficiaries are significantly overweight; the average BMI of a beneficiary is 
30 kg/m2.
2. Beneficiaries do not get an adequate amount of physical activity; the average
beneficiary reports only 15 minutes of physical activity per week. 
3. Beneficiaries report unhealthy diets; they consume excess amounts of total fat,
saturated-fat, and cholesterol, and inadequate amounts of fruits, vegetables, and
whole grains. 
4. Forty-five percent (45%) of employees use tobacco products, far above the national
average. 
5. Thirty-seven percent (37%) of adult beneficiaries consume more than 7 alcoholic
beverages per week. 
Based on this data, employer C knows that its beneficiary population is at high risk for
alcohol misuse, cancer, obesity, type 2 diabetes, heart disease, hypertension, and smoking-
related illnesses. To best address the risks of its beneficiary population, employer C decides
to immediately implement benefits for the clinical preventive services that address these
behaviors and diseases, including (examples are listed in alphabetical order, but could be
implemented according to health impact and economic value):
• Alcohol Misuse, Screening and counseling
• Breast Cancer, Counseling and preventive medication
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• Breast Cancer, Screening
• Cervical Cancer, Screening
• Colorectal Cancer, Screening
• Diabetes (type 2), Screening
• Healthy Diet, Counseling
• Hypertension, Screening, counseling, and treatment
• Lipid Disorders, Screening, counseling, and treatment
• Motor Vehicle Related Injury Prevention, Counseling
• Obesity, Screening, counseling, and treatment
• Tobacco Use Treatment, Screening, counseling, and treatment
Employer Scenario 2: Employer D provides health benefits for 36,000 employees and
40,000 dependents. Over three-quarters of the employee population is female and most are
relatively young. Further, employee demographic data show that 45% of beneficiaries are
African-American. A large portion of employer D’s medical claims are for labor and delivery
charges and a large proportion of employer D’s disability claims are paid for short- and long-
term disabilities related to complications of pregnancy. Employer D’s beneficiaries have a
higher than normal rate of preterm births and neonatal intensive care (NICU) admissions.
Employer D knows that African-Americans are at increased risk for poor birth outcomes
including preterm birth, low birth weight, and infant mortality.3 Employer D would like to
reduce its medical claims related to pregnancy complications and reduce racial and ethnic
disparities in healthcare by ensuring that all its beneficiaries have access to high-quality
preconception, prenatal, and postpartum care. 
To promote access, employer D decides to immediately implement benefits for all clinical
preventive services related to pregnancy, infant care, and childhood health promotion.
Further, employer D decides to provide “safe-harbor” coverage for preventive services in
HDHP and HSA-qualified plans and to eliminate copays for preventive care in HMO,
PPO, and POS plans.
Clinical preventive services aimed at promoting healthy pregnancies include:
• Alcohol Misuse, Screening and counseling
• Asymptomatic Bacteriuria, Screening
• Breastfeeding, Counseling
• Prenatal Diagnosis of Chromosomal Abnormalities and Neural Tube Defects (NTDs),
Screening and testing
• Folic Acid Supplementation, Counseling and preventive medication
• Group B Streptococcal Disease (GBS), Screening and preventive medication
• Hepatitis B Virus (HBV), Screening, immunization, and treatment








• Tobacco Use Treatment, Screening and counseling
Clinical preventive services specific to infants and children include: 
• Child Development, Screening
• Child Immunizations, Immunization
• Dental Caries Prevention through Oral Fluoride Supplementation, Preventive
medication
• Lead, Elevated Blood Level, Screening
• Newborn Screening for Genetic and Endocrine Disorders, Screening, medical foods,
and treatment
• Newborn Hearing, Screening
• Vision, Screening
References:
1. Partnership for Prevention. Priorities for America’s Health: Capitalizing on Life-Saving, Cost-Effective 
Preventive Services. Washington, DC: Partnership for Prevention. [Cited 2006 Jun 29]. Available from: 
http://www.prevent.org/images/stories/clinicalprevention/executive%20summary.pdf. 
2. Maciosek MV, Coffield AB, Edwards NM, Goodman MJ, Flottemesch TJ, Solberg LI. Priorities among 
effective clinical preventive services: results of a systematic review and analysis. Am J Prev Med 2006; 
31(1):52-61. Table reprinted from Am J Prev Med 2006; 31(1):52-61 with permission from the American 
Journal of Preventive Medicine.
3. Alexander GR, Kogan M, Bader D, Carlol W, Allen M, Mor J. U.S. birth weight/gestational age-specific 
neonatal mortality: 1995–1997 rates for whites, Hispanics, and blacks. Pediatrics 2003; 111(1): e61-e66. 
448
4 Prioritization of Clinical Preventive Services in a Strategic Implementation Plan
The United States spends billions on healthcare services of questionable value
while basic, evidence-based preventive services are not getting done as often as they
should. Yet the time available to deliver healthcare services is limited. Brief clinician 
office visits must address chronic conditions, acute illness, and preventive are. In this
environment, prioritization of healthcare services is occurring, but it is rarely systematic
or rational. And the consequences of misplaced priorities are high: people die and 
illnesses worsen because the most important preventive services do not get done.1
Partnership for Prevention
Priorities for America’s Health: Capitalizing on Life-Saving, Cost-Effective
Preventive Services, 2006
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Information on clinical preventive
services that were reviewed by
the USPSTF, but not included in
the Purchaser’s Guide. This 
information may assist benefits
staff in determining which clinical
preventive services currently
offered in their health plan(s)
should be re-evaluated.
I Statem
ents and C and D
Recom
m
endations of the USPSTF
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The vast majority of recommendations featured in the
Purchaser’s Guide to Clinical Preventive Services are
recommended by the U.S. Preventive Services Task
Force (USPSTF). 
The USPSTF grades clinical preventive services based
on the strength of evidence available to support a
particular clinical preventive service and the magnitude of net benefit for that service. 
The net benefit of a clinical preventive service is defined as the benefits of the service 
(e.g., years of life saved through early cancer detection) minus the harms of the service 
(e.g., risks associated with false-positives). The USPSTF
assigns each clinical preventive service it reviews a
grade. The Purchaser’s Guide includes all USPSTF “A”
(Strongly Recommended) and “B” (Recommended)
rated recommendations (as of March 2006).
The USPSTF also identifies other services that, for one
reason or another, are not recommended: 
• “I”-rated (Insufficient Evidence to Recommend 
For or Against)
• “C”-rated (No Recommendation Either For 
or Against)
• “D”-rated (Recommend Against)
I Statements and C and D




In a resource-constrained 
environment, employers must 
carefully consider which preventive
services to offer. Many preventive
services are available. Some are
known to be effective; others are
known to be relatively ineffective or
even harmful; others may be effective
but the proof of effectiveness is weak.
In addition to adding coverage for
services recommended in the
Purchaser’s Guide, employers should
evaluate their current preventive service
benefits and consider removing benefits
for services that are ineffective or
harmful (“D”-rated services).
Important Note: 
Several services recommended in the Purchaser’s Guide received an “I” rating from the
U.S. Preventive Services Task Force (USPSTF). These services are recommended for 
inclusion in benefit plans by the National Business Group on Health because they are 
recommended by other respected organizations, but they are not endorsed by the USPSTF.
For more information on the U.S.
Preventative Services Task Force 
(USPSTF) please refer to the 
Introduction of the Purchaser’s Guide.
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Employer Action
Employers have discretion as to whether to provide coverage for services with
limited or conflicting evidence (services that received an “I” rating). The
provision of coverage for “I” rated services should be secondary to the provision of
coverage for all recommended services featured in the Purchaser’s Guide. 
It is important to remember that “insufficient evidence” means just that: the evidence is not
now adequate for evidence-based decisions. On occasion, employers may need to resort to
the informed opinions of unbiased experts about such interventions. There are several
reasons why an intervention may have insufficient evidence. It may be a new intervention
for which there has been insufficient time to conduct and publish the large, rigorous studies
needed to assess it. In other instances, such as with vaccines that have been widely used for
decades, it is generally agreed that it would be unethical to conduct controlled studies,
where a vaccine would be tested against a placebo. Similarly, if a preventive intervention has
made a condition so rare that it almost never occurs, but experience suggests that removing
the preventive intervention from use would threaten the health of people, the preventive
service would be imprudent to test in the United States. It is also possible that an
intervention has minimal effectiveness and that, despite considerable study, its small effects
have been insufficient to allow a decision about its value. 
Employers should provide coverage for “C”-rated services only if there is a
population-specific and compelling reason to do so. The USPSTF issues a “C”
rating to services in which the balance of benefits and harms is too close to justify a
general recommendation. Therefore, the provision of coverage for “C”-rated services should
be secondary to the provision of coverage for all recommended services featured in the
Purchaser’s Guide. 
Employers are discouraged from providing coverage for clinical preventive
services that received a “D” rating from the USPSTF, as these services have been
found to be ineffective or to have more harms than benefits. 
Important Note: 
“D”-rated services are not recommended for the general asymptomatic population and
therefore should not be covered as preventive services within a medical benefit plan.
However, these services may play an important role in the treatment or management of






The USPSTF strongly recommends that clinicians provide the service to
eligible patients. The USPSTF found good evidence that the service improves
important health outcomes and concludes that the benefits substantially
outweigh harms.1
B Recommended
The USPSTF recommends that clinicians provide the service to eligible
patients. The USPSTF found at least fair evidence that the service improves
important health outcomes and concludes that the benefits outweigh harms.1
C No Recommendation Either For or Against
The USPSTF makes no recommendation either for or against routine provision
of the service. The USPSTF found at least fair evidence that the service can
improve health outcomes but concludes that the balance of benefits and harms
is too close to justify a general recommendation.1
D Recommend Against
The USPSTF recommends against routinely providing the service to
asymptomatic patients. The USPSTF found at least fair evidence that the
service is ineffective or that the harms associated with the service outweigh
benefits.1
I Insufficient Evidence in Order to Make a Recommendation
The USPSTF concludes that the evidence is insufficient to recommend for or
against routinely providing the service. Evidence that the service is effective is
lacking, of poor quality, or conflicting, and the balance of benefits and harms
cannot be determined.1
Figure 5.0: U.S. Preventive Services Task Force (USPSTF) Ratings
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I Statements of the USPSTF
Explanation: The USPSTF concludes that the evidence is insufficient to recommend for or
against routinely providing [the service]. Evidence that [the service] is effective is lacking, of
poor quality, or conflicting, and the balance of benefits and harms cannot be determined.1
Employers have discretion to cover these services if they choose. However, the provision of
coverage for “I”-rated services should be secondary to the provision of coverage for all
recommended services featured in the Purchaser’s Guide (“A” and “B”-rated services and
equivalencies).
Clinical Preventive Services with
Insufficient Evidence Available to
Make a Recommendation Explanation
*Alcohol Misuse, Screening and
behavioral counseling interventions
The USPSTF concludes that the evidence is insufficient
to recommend for or against screening and behavioral
counseling interventions to prevent or reduce alcohol
misuse by adolescents in primary care settings.
Bacterial Vaginosis in
Pregnancy, Screening
The USPSTF concludes that the evidence is
insufficient to recommend for or against routinely
screening high-risk pregnant women for bacterial
vaginosis.
Breast Cancer, Screening The USPSTF concludes that evident is insufficient to
recommend for or against routine clinical breast exam
(CBE) alone to screen for breast cancer. 
Breast Cancer, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against teaching or
performing routine breast self-examination.
Breastfeeding, Behavioral
interventions to promote 
The USPSTF found insufficient evidence to
recommend for or against the following interventions to
promote breastfeeding: brief education and counseling
by primary care providers; peer counseling used alone
and initiated in the clinical setting; and written
materials, used alone or in combination with other
interventions.
Important Note: Several services recommended in the Purchaser’s Guide received an “I”
rating from the U.S. Preventive Services Task Force (USPSTF). These services are recommended for
inclusion in benefit plans by the National Business Group on Health because they are recommended
by other respected organizations, but they are not endorsed by the USPSTF.
*Recommended for coverage in the Purchaser’s Guide
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Cervical Cancer, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against the routine
use of new technologies to screen for cervical cancer.
Depression, Screening The USPSTF concludes the evidence is insufficient to
recommend for or against routine screening of children
or adolescents for depression.
Developmental Dysplasia of
the Hip, Screening
The USPSTF concludes that evidence is insufficient to
recommend for or against routine screening for
developmental dysplasia of the hip in infants as a
means to prevent adverse outcomes.
Diabetes Mellitus Type 2,
Screening
The USPSTF concludes that the evidence is
insufficient to recommend for or against routinely
screening asymptomatic adults for type 2 diabetes,
impaired glucose tolerance, or impaired fasting glucose. 
Dental Caries (in preschool
children), Preventive medication
The USPSTF concludes that the evidence is
insufficient to recommend for or against routine risk
assessment of preschool children by primary care
clinicians for the prevention of dental disease.
Cervical Cancer, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against the routine
use of human papillomavirus (HPV) testing as a
primary screening test for cervical cancer. 
Chlamydial Infection, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against routinely
screening asymptomatic men for chlamydial infection.
Coronary Heart Disease,
Screening
The USPSTF found insufficient evidence to recommend
for or against routine screening with electrocardiography
(ECG), exercise treadmill test (ETT), or electron-beam
computerized tomography (EBCT) scanning for
coronary calcium for either the presence of severe
Coronary Artery Stenosis (CAS) or the prediction of
Coronary Heart Disease (CHD) events in adults at
increased risk for CHD events.
I Statements of the USPSTF (continued)
Diet, Behavioral counseling The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
behavioral counseling to promote a healthy diet in
unselected patients in primary care settings.
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Gonorrhea, Screening The USPSTF found insufficient evidence to
recommend for or against routine screening for
gonorrhea infection in pregnant women who are not
at increased risk for infection.
*High Blood Pressure, Screening The USPSTF concludes that evidence is insufficient
to recommend for or against routine screening for
high blood pressure in children and adolescents to
reduce the risk of cardiovascular disease.
Iron Deficiency Anemia,
Screening children and pregnant
women
The U.S. Preventive Services Task Force (USPSTF)
concludes that evidence is insufficient to recommend
for or against routine screening for iron deficiency
anemia in asymptomatic children aged 6 to 12 months.
Hepatitis C, Screening The USPSTF found insufficient evidence to
recommend for or against routine screening for
hepatitis C virus (HCV) infection in adults at high
risk for infection.
Family and Intimate Partner
Violence, Screening
The USPSTF found insufficient evidence to
recommend for or against routine screening of parents
or guardians.
Dementia, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening for dementia in older adults.
Gonorrhea, Screening The USPSTF found insufficient evidence to
recommend for or against routine screening for




The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening for gestational diabetes. 
Iron Supplementation for
Children and Pregnant Women,
Preventive medication 
The USPSTF concludes that evidence is insufficient to
recommend for or against routine iron supplementation
for asymptomatic children aged 6 to 12 months who
are at average risk for iron deficiency anemia. The
USPSTF concludes that evidence is insufficient to
recommend for or against routine iron supplementation
for non-anemic pregnant women.
I Statements of the USPSTF (continued)
*Recommended for coverage in the Purchaser’s Guide
*Newborn Hearing, Screening
Oral Cancer, Screening The USPSTF concludes that the evidence is insufficient




The USPSTF concludes that the evidence is insufficient
to recommend for or against behavioral counseling in
primary care settings to promote physical activity.
Prostate Cancer, Screening The USPSTF concludes that the evidence is insufficient
to recommend for or against routine screening for
prostate cancer using prostate specific antigen (PSA)
testing or digital rectal examination (DRE).
*Overweight in Children and
Adolescents, Screening
The USPSTF concludes that the evidence is insufficient
to recommend for or against routine screening for
overweight in children and adolescents as a means to
prevent adverse health outcomes.
Obesity, Counseling
Obesity, Counseling The USPSTF concludes that the evidence is insufficient
to recommend for or against the use of counseling of
any intensity and behavioral interventions to promote
sustained weight loss in overweight adults. 
The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening of newborns for hearing loss during the
postpartum hospitalization.
The USPSTF concludes that the evidence is insufficient
to recommend for or against the use of moderate- or
low-intensity counseling together with behavioral
interventions to promote sustained weight loss in obese
adults. 
I Statements of the USPSTF (continued)
Skin Cancer, Counseling The USPSTF concludes that the evidence is
insufficient to recommend for or against
routine counseling by primary care clinicians
to prevent skin cancer.
*Recommended for coverage in the Purchaser’s Guide
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Speech and Language Delay in
Preschool Children, Screening
The USPSTF concludes that the evidence is
insufficient to recommend for or against routine use
of brief, formal screening instruments in primary care
to detect speech and language delay in children up to





The USPSTF concludes that the evidence is
insufficient to recommend for or against the use of
supplements of vitamins A, C, or E; multivitamins
with folic acid; or antioxidant combinations for the
prevention of cancer or cardiovascular disease.
Thyroid Disease, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening for thyroid disease in adults.
Suicide Risk, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening by primary care clinicians to detect suicide




The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening for tobacco use or interventions to prevent
and treat tobacco use and dependence among children
and adolescents. 
Skin Cancer, Screening The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
screening for skin cancer using a total-body skin
examination for the early detection of cutaneous
melanoma, basal cell cancer, or squamous cell skin
cancer. 
Skin Cancer, Counseling The USPSTF concludes that the evidence is
insufficient to recommend for or against routine
counseling by primary care clinicians to prevent skin
cancer.
I Statements of the USPSTF (continued)
*Recommended for coverage in the Purchaser’s Guide
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C Recommendations of the USPSTF
Explanation: The USPSTF makes no recommendation for or against routine provision of [the
service]. The USPSTF found at least fair evidence that [the service] can improve health
outcomes but concludes that the balance of benefits and harms is too close to justify a general
recommendation.1
Employers have discretion to cover “C”-services if they choose. However, the provision of
coverage for “C”-rated services should be secondary to the provision of coverage for all
recommended services featured in the Purchaser’s Guide (“A” and “B”-rated services and
equivalencies




The USPSTF makes no recommendation for or
against screening for AAA in men aged 65 to 75 who
have never smoked.
Chlamydial Infection, Screening The USPSTF makes no recommendation for or
against routinely screening asymptomatic low-risk
women in the general population for chlamydial
infection.
Chlamydial Infection, Screening The USPSTF makes no recommendation for or
against routine screening for asymptomatic, low-risk





The USPSTF makes no recommendation for or
against routinely screening for HIV adolescents and
adults who are not at increased risk for HIV infection. 
*Lipid Disorders in Adults,
Screening
The USPSTF makes no recommendation for or
against screening for lipid disorders in younger adults
(men aged 20 to 35 years or women aged 20 to 45
years) in the absence of known risk factors for




The USPSTF makes no recommendation for or against
routine osteoporosis screening in postmenopausal
women who are younger than 60 or in women aged 60
to 64 who are not at increased risk for osteoporotic
fractures. 
*Recommended for coverage in the Purchaser’s Guide
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D Recommendations of the USPSTF
Explanation: The USPSTF recommends against routinely providing [the service] to
asymptomatic patients. The USPSTF found at least fair evidence that [the service] is
ineffective or that harms outweigh benefits.1
Employers should not provide coverage for these clinical preventive services for their general
asymptomatic beneficiary population. However, employers may choose to cover these
services on a case-by-case basis as determined by beneficiary risk or medical necessity
criteria. Further, these services should be covered when part of a medical treatment plan for






The USPSTF recommends against routine screening
for AAA in women.
Asymptomatic Bacteriuria,
Screening
The USPSTF recommends against the routine




The USPSTF recommends against routinely screening
average-risk asymptomatic pregnant women for
bacterial vaginosis.
Bladder Cancer, Screening The USPSTF recommends against routine screening
for bladder cancer in adults.
Breast Cancer, Preventive
medication
The USPSTF recommends against routine use of
tamoxifen or raloxifene for primary prevention of
breast cancer for women at low or average risk for
breast cancer. 
Cervical Cancer, Screening The USPSTF recommends against routinely screening
women older than age 65 for cervical cancer if they
have had adequate recent screening with normal Pap
smears and are not otherwise at high risk.
Cervical Cancer, Screening The USPSTF recommends against routine Pap smear
screening in women who have had a total




The USPSTF recommends against screening with
resting electrocardiography (ECG), exercise treadmill
test (ETT), or electron-beam computerized tomography
(EBCT) scanning for coronary calcium for either the
presence of severe coronary artery stenosis (CAS) or the
prediction of coronary heart disease (CHD) in adults at
low risk for CHD events.
Hepatitis B Virus Infection,
Screening
The USPSTF recommends against routinely screening
the general asymptomatic population for chronic
hepatitis B virus infection. 
Hormone Therapy, Prevention of
chronic conditions in
postmenopausal women
The USPSTF recommends against the routine use of
combined estrogen and progestin for the prevention of
chronic conditions in postmenopausal women. The
USPSTF recommends against the routine use of
unopposed estrogen for the prevention of chronic
conditions in postmenopausal women who have had a
hysterectomy.
Idiopathic Scoliosis, Screening The USPSTF recommends against the routine
screening of asymptomatic adolescents for idiopathic
scoliosis. 
Hepatitis C, Screening The USPSTF recommends against routine screening
for hepatitis C virus (HCV) infection in asymptomatic
adults who are not at increased risk (general
population) for infection.
Genetic Risk Assessment and
BRCA Mutation Testing for
Breast and Ovarian Cancer
Susceptibility
USPSTF recommends against routine referral for
genetic counseling or routine breast cancer
susceptibility gene (BRCA) testing for women whose
family history is not associated with an increased risk
for deleterious mutations in breast cancer susceptibility
gene 1 (BRCA1) or breast cancer susceptibility gene 2
(BRCA2).
Gonorrhea, Screening The USPSTF recommends against routine screening for
gonorrhea infection in men and women who are at low
risk for infection.
D Recommendations of the USPSTF (continued)
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Pancreatic Cancer, Screening The USPSTF recommends against routine screening
for pancreatic cancer in asymptomatic adults using
abdominal palpation, ultrasonography, or serologic
markers.
Testicular Cancer, Screening The USPSTF recommends against routine screening
for testicular cancer in asymptomatic adolescent and
adult males.
Syphilis Infection, Screening The USPSTF recommends against routine screening




The USPSTF recommends against routine screening
for peripheral arterial disease (PAD).
Source: Agency for Healthcare Research and Quality. The Guide to Clinical Preventive Services: Recommendations of
the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2005. 
D Recommendations of the USPSTF (continued)
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Actions employers can take to
strengthen prevention efforts.
Sections include:
• The Importance of Supporting
Community-Level Interventions
• The Guide to Community
Preventive Services
• Employer Action in the
Absence of Evidence-Based
Guidelines 
• General Advice to Employers
about Health Improvement 




• Employer Case Examples,
Success Stories, and 
Action Examples
Opportunities to Prom
ote the Delivery 
and Use of Preventive Services
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The previous sections of the Purchaser’s Guide
include the scientific evidence and detailed
benefit language employers need to implement
comprehensive and structured clinical preventive
service benefits within their medical benefit
plan(s). They provide actionable strategies for
improving health and reducing healthcare costs, and information on 46 conditions, 
diseases and injuries, that can be prevented through appropriate screening, testing,
counseling, immunizations, preventive medication, and preventive treatment.
Providing coverage for clinical preventive services is an essential step to improving overall
employee health. But, while coverage is necessary to promote the delivery and use of
preventive services, it is not sufficient to optimize the health of employees. Employers are in
a position to affect health behavior and lifestyle choices in multiple ways. 
The Importance of Supporting Community-Level
Interventions
Community-level preventive services include a diverse array of activities that:
• Educate people about the availability or use of preventive services.
• Encourage people to seek preventive services.
• Encourage providers, health plans, and health systems to offer preventive services. 
Employers are in a unique position to assure the use of clinical preventive services and
promote the use of community- or population-level preventive services. By supporting
community-level interventions employers can improve the overall health and safety of the
communities in which they reside, thereby improving the health and quality of life of
current and future employees. Supporting community-level interventions may also benefit
employers. Employers may develop important relationships with potential business partners
in the area, they may increase the positive image of their companies, and they may develop a
new set of knowledge, skills, and abilities that further
enhances or improves their business strategies.
Leveraging Benefits:
Opportunities to Promote 
the Delivery and Use of
Preventive Services
6
Employers have opportunities to 
promote the delivery and use of 
preventive services beyond the 
provision of medical benefits.
Employers can — and should —
enhance the health of the 
communities in which they operate
by supporting population-level
health interventions. Improving 
community health will protect and 
promote the health of present and
future employees.
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The Guide to Community Preventive Services
The Guide to Community Preventive Services (Community
Guide), published by the Centers for Disease Control
and Prevention (CDC), is an important resource for all
stakeholders about population health issues. It addresses
ways to increase the use of clinical and community
preventive services and complements the work of the
Guide to Clinical Preventive Services (Clinical Guide), a
publication of the U.S. Preventive Services Task Force
(USPSTF), and the Purchaser's Guide. 
The Community Guide is developed by the independent
and nonfederal Task Force on Community Preventive
Services, which is composed of experts from a range of
health promotion and related fields. Recommendations
contained in the Community Guide are based on
rigorous and systematic reviews of scientific literature. 
The Community Guide directs purchasers to evidence-
based population health recommendations and other
activities that may complement their investments in
clinical preventive services. Some of these activities are
described in Appendix A. Implementing the Community
Guide’s evidence-based recommendations provides the
potential to improve community health by preventing
injury, disease, disability, and premature death. 
Employer Action in the Absence of Evidence-Based
Guidelines 
The presence of an evidence-based guideline generally means that objective measures of
several experiences have credibly and consistently shown that the intervention or policy
improves important health or behavioral outcomes. 
Evidence-based guidelines do not exist for every important topic because studies or
evaluations have not been conducted, such experiences have not been published or otherwise
shared, or results across interventions have not been synthesized. As a result, employers will
often have to consider how to act in the absence of an evidence-based guideline. When
making such judgments, employers should first consider whether there are evidence-based
guidelines that can meet some of their needs.
If there are no guidelines available, employers should consider using general advice (provided
below) to inform the design and implementation of interventions. Appendix B includes case
examples and of worksite population health interventions implemented by large employers.
These brief examples describe just a few of the many population health interventions that can
be effectively implemented in the workplace.
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Our understanding of opportunities
for population-level prevention is
growing. Therefore, the Community
Guide is a work in progress. As new
information on the effectiveness of
community level interventions is 
gathered the Community Guide will
evolve and expand. Community Guide
recommendations are published in
peer-reviewed journals and posted 
on the Community Guide website
(www.thecommunityguide.org) as
they are developed.
The Guide to Community Preventive
Services (www.thecommunityguide.org)
provides recommendations about
population interventions that have the
potential to positively affect community
health by preventing injury, disease,
disability, and premature death.
General Advice to Employers about Health Improvement
and Maximizing the Value of Health Coverage 
Employers can ensure health improvement and maximize coverage value in many ways. 
At a minimum, an employer’s healthcare strategy should include:
1. Educating beneficiaries about the importance of clinical preventive services and
healthy lifestyles.
2. Encouraging beneficiaries to use their covered preventive services appropriately. 
3. Supporting community-wide disease prevention and health promotion activities.
To promote the appropriate use of clinical preventive services among beneficiaries,
employers should:
• Provide referrals to community-based support services and prevention programs, 
as needed (e.g., tobacco quitlines). 
• Encourage health plans to promote clinical preventive services.
• Encourage providers to increase the use of appropriate preventive services 
(e.g., time-appropriate reminders to patients). 
• Increase preventive service access points (e.g., worksite immunization programs).
To more broadly promote health among their beneficiaries, employers should:
• Make information, data, and recommendations about prevention available to
employees and their families.
• Support employee participation in programs of clinical or community prevention
(e.g., incentives).
• Support healthy worksites (e.g., offer a healthy cafeteria program).
• Support evidence-based health policies (e.g., require smoke-free workplaces).
To promote health generally, employers can:
• Work to increase awareness of critical health problems among employees, health
plans, providers, beneficiaries, other purchasers, and the general public. 
• Provide in-kind or financial support to develop or continue evidence-based health
programs and policies benefiting broader communities. Consider: 
> Sponsoring or providing supplies for school health programs. 
> Partnering with other business and community agencies to develop environmental
health promotion strategies (e.g., changing the physical environment by creating
walking and biking trails, encouraging increases in cigarette taxes and banning of
cigarette smoking in public spaces). 463
Promoting and protecting the health of employees and beneficiaries is critical to the continued health
of American businesses. Providing coverage for clinical preventive services is the first step to improving
overall beneficiary health. Employers should carefully consider integrating population-level health programs 
and policies into both their coverage packages and their overall worksite health promotion plans. This
integrative effort should enhance the effectiveness of medical benefits and increase the likelihood that
beneficiaries will appropriately use the coverage they have.
• Promote public policies that aim to prevent illness, injury, and death (e.g., minimum
legal drinking age laws). 
• Encourage employees to participate in health promotion programs available in their
communities.
Appendix A: Links Between Selected Topics with Particular
Relevance to Purchasers and Community Guide
Recommendations 
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To increase cancer screenings (client-oriented):
• Use client reminders
• Use multicomponent interventions using media, education and enhanced
access
• Reduce structural barriers
• Use client incentives (with reminders)
• Use small media
• Reduce out-of-pocket costs
• Provide one-on-one education
• Offer provider reminder recalls
• Offer provider assessment and feedback
Note: these approaches have differential effectiveness for different types of screening.
Visit the Community Guide website for more information.
To improve the care of persons with type 2 diabetes: 
• Ensure that disease management and case management programs are
provided in healthcare systems.
• Provide diabetes self-management education in community gathering places
(e.g., community centers or faith institutions) for adults. 
Also see the entry for obesity (below) for more type 2 diabetes-related information.
To increase community demand for immunizations: 
• Provide client recalls and reminders 
• Institute multicomponent interventions with education 
• Require immunizations for attendance at child care and school 
To enhance access to immunization services: 
• Reduce out-of-pocket costs 
• Institute multicomponent interventions for expanding access 
• Offer via home visits 
To improve provider-based interventions: 
• Institute a provider reminder and recall system 
• Provide assessment and feedback for providers 
• Establish standing orders to vaccinate adults
Table 6.0: Community Guide Recommendations that may Complement Clinical Preventive
Services Recommended in the Purchaser’s Guide 
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TOPICS IN THE RELATED COMMUNITY GUIDE RECOMENDATIONS
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Note: Community Guide content is a work in progress. Additional content will become available over time. Please check






The Community Guide’s systematic review of the effectiveness of selected population-
based interventions addressing motor vehicle occupant injuries focused on
interventions within three areas: 
• Increasing the proper use of child safety seats 
• Increasing the use of safety belts 
• Reducing alcohol-impaired driving 
The Community Guide has recommended numerous population-based interventions
for families, schools, and communities, which are proven effective in promoting
physical activity. It also has a growing portfolio of work related to nutrition and
obesity. To increase physical activity, the Community Guide recommends:
• Use of community-wide campaigns
• Use of point-of-decision prompts to increase stair use
• Use of health behavior change programs adapted for individual needs
• School-based physical education
• Social support in community settings
• Creation and/or enhanced access to places for physical 
activity combined with informational outreach
To control overweight or obesity:
• Offer worksite programs combining nutrition and physical 
activity
To increase tobacco cessation: 
• Increase unit price for tobacco products 
• Develop mass media campaigns and use with other interventions (e.g., excise
tax increase, other community educational programs)
• Establish provider reminder systems 
• Establish provider reminder systems with provider education
• Reduce patient costs for treatments 
• Make available telephone support for quitting smoking and use with other
interventions (e.g., cessation counseling)
• Make available telephone support for quitting with the 
possible provision of cessation medications
To decrease environmental tobacco smoke (ETS):
• Implement smoking bans or restrictions 
Table 6.0: Community Guide Recommendations that may Complement Clinical Preventive
Services Recommended in the Purchaser’s Guide (Continued)
TOPICS IN THE RELATED COMMUNITY GUIDE RECOMENDATIONS
PURCHASER’S GUIDE
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Appendix B: Employer Case Examples, Success Stories,
and Action Examples
Many employers around the country have implemented programs, policies, or procedures to
promote their employees’ health. Some of the approaches used have been evaluated and
published. Other approaches have been reviewed systematically by the Community Guide or
through another systematic review mechanism. In 2005, the Community Guide began a set
of reviews to examine the effectiveness of interventions conducted in worksite settings or
made available by employers. The results of these reviews will begin to be available in late
2006.
Listed below are a few examples of evidence-based practices applied to worksite settings and
examples of worksite health promotion practices that will inform evidence-based practices in
the future. 
Employer Case Examples and Success Stories
Tobacco Cessation: Supporting Quit Attempts
Tobacco use, responsible for approximately 440,000 deaths per year, remains the leading
preventable cause of death in the United States.1 There is substantial evidence that smoking
cessation improves health by lowering an individual’s risk for diseases caused by smoking
such as heart disease, stroke, and cancer.4 Helping tobacco users to quit is one important
goal of a comprehensive effort to reduce morbidity and mortality associated with tobacco
use.2 Approximately 70% of tobacco users want to quit3 and efforts to quit are frequent,
although it is rare for a smoker to quit permanently on a single attempt.
Tobacco use affects productivity and absenteeism, increases use of disability leave, and
increases overall healthcare costs among workers.1 Good quality evidence-based
recommendations are available for clinical and community interventions designed to
motivate and assist the cessation efforts of tobacco users. Many community-based
interventions designed to assist smokers in quitting are directly applicable to the worksite. 
The Community Guide recommends providing coverage for tobacco use treatment and
routine treatment of tobacco use in healthcare systems as two effective interventions to
increase tobacco cessation.5 The Public Health Service Clinical Practice Guideline, Treating
Tobacco Use and Dependence, recommends individual, group, and proactive telephone
6 Leveraging Benefits: Opportunities to Promote the Delivery and Use of Preventive Services
Employer Success Story: Union Pacific Railroad
Union Pacific Railroad experienced a decrease from 40% to 25% in smoking prevalence
among its employees in the 7-year period during which it has offered a cessation benefit
as part of a comprehensive tobacco cessation program. The program included smoking
bans and restrictions and reduced beneficiary out-of-pocket costs for nonsmokers. The
program was implemented incrementally, starting with the removal of smoking areas,
the addition of coverage for tobacco dependence treatment, and finally the move to
smoke-free buildings.4
counseling along with the use of Food and Drug Administration (FDA) approved cessation
medications (e.g., bupropion—Wellbutrin® or Zyban® and varenicline—ChantixTM).7 The
USPSTF strongly recommends that clinicians screen all adults for tobacco use and provide
tobacco cessation interventions for those who use tobacco.5 There is also evidence that
nicotine replacement medications (e.g., Nicorette® gum) increase successful quit rates and
increase tobacco abstinence rates.6
Purchasers can support tobacco cessation efforts by implementing evidence-based guidelines: 
• Promote a smoke-free workplace and campus.7
• Provide coverage for the full range of counseling options (individual, group, and by
telephone) and reduce or eliminate copays and deductibles for counseling.6
• Ensure that all FDA-approved tobacco cessation medications are available in
formularies and reduce or eliminate copays and deductibles for medications.6
• Educate employees about using flexible spending account (FSA) funds to pay for
tobacco cessation medication and nicotine replacement products.
• Provide employees with tobacco quitline numbers and contract with a quitline vendor
to provide services for employees.
• Become active in the communities where workplaces exist: support implementation of
smoke-free workplace laws, appropriate school-based initiatives (including smoke-free
campuses and curricula), and increased excise taxes on cigarettes and tobacco
products.5
Purchasers can ensure that their health plans and delivery systems:
• Aggressively educate plans’ providers and enrollees about the availability of tobacco
cessation benefits.
Purchasers can ensure that their medical offices and employee clinics:
• Integrate tobacco dependence treatment into disease management initiatives.
• Follow the Public Health Service Clinical Practice Guideline, Treating Tobacco Use
and Dependence, which recommend that providers6:
• Ask every patient, at every visit, if they use tobacco
• Advise to quit
• Assess readiness to quit
• Assist with the quit process
• Arrange for follow-up with counseling and medications
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Employer Case Example: Centers for Disease Control and Prevention (CDC)7
The Centers for Disease Control and Prevention (CDC) recently implemented a tobacco-free
campus in all CDC-owned buildings nationwide. This included provision of free over-the-
counter nicotine replacement medications to federal employees, negotiations with labor
unions to remove previously negotiated smoking huts, provision of smoking cessation
classes, and encouraged access to the national network of tobacco quitlines 
(1-800-QUIT NOW).
Additional information about coverage for tobacco treatment can be found on the CDC
website (www.cdc.gov/tobacco/educational_materials/cessation/index.html.). Employers
interested in making their worksite smoke free can also reference Making Your Workplace
Smokefree – A Decision Makers Guide
(www.cdc.gov/tobacco/research_data/environmental/etsguide.htm.)
Lipid Disorders: Screening and Treatment Adherence
Lipid disorders, which result from abnormal levels of cholesterol in the blood, increase the
risk of cardiovascular disease (CVD), including coronary heart disease (CHD) and coronary
artery disease (CAD). Arteriosclerosis (a thickening or hardening of the arteries) is
particularly sensitive to lipid levels. From 1999 to 2002, about 17% of the U.S. adult
population had high cholesterol (total cholesterol 240 mg/dL or higher).
The National Cholesterol Education Program (NCEP) Adult Treatment Expert Panel-III
(ATP-III) recommends that clinicians routinely screen all adults aged 20 years and above 
for elevated blood cholesterol once every 5 years.9 The goal of screening is to identify and
treat individuals with lipid disorders in order to decrease their risk for CVD events, such as
heart attack. 
The NCEP ATP-III Treatment Guideline states that the first line of therapy for elevated
LDL cholesterol levels is therapeutic lifestyle changes (e.g., diet, exercise, weight loss,
smoking cessation). Drug therapy (e.g., cholesterol-lowering medication), may be used,
when appropriate, to further reduce cholesterol levels. Both therapeutic lifestyle changes 
and cholesterol-lowering medications are proven effective for improving lipid profiles and
reducing the risk of heart disease. Yet, the benefits of lowered cholesterol can only be
realized with quality care and adherence to treatment. 
NCEP ATP-III also includes a series of recommendations to increase adherence to
recommended treatments. The ATP III recommendations are based on large, randomized,
control clinical trials, prospective epidemiological studies, and smaller clinical trials.9 An
expert panel qualified each recommendation according to a category of evidence, which can
be found at the NCEP website: (http://nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm.)
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Employer Success Story: Fieldale Farms10
Fieldale Farms, a poultry processor in Georgia, offered mobile screening, a gift card, and
other incentives to all employees participating in its Wellness Program. Those with elevated
cholesterol were offered follow-up nutrition counseling and company-paid fitness 
memberships. Over a 5-year evaluation period, 26% of the participating employees with
high cholesterol normalized their cholesterol levels through diet changes, and/or 
medications. In 2004, the overall healthcare cost for an employee participating in the
Fieldale Farms Wellness Program was $3,052 per year — less than half the national 
average healthcare cost for a manufacturing employee ($6,900).
Employer Action Examples
Opportunities to Supporting Breastfeeding 
Human breast milk is universally recognized to be the optimal food for infants and is
nutritionally superior to formula. Breast milk confers immunity and protects infants from
infections and allergens. Further, research shows that children who were breastfed are at
significantly lower risk for many conditions and diseases such as childhood obesity and type
2 diabetes compared to non-breastfed children.12 Breastfeeding also has important short- and
long-term health benefits for the mother. A woman’s risk of breast cancer is decreased 4.3%
for every 12-month increment of breastfeeding over her lifetime. Her risk of ovarian and
endometrial cancer is decreased through breastfeeding as well.13-14 
Children who are not breastfed contribute to additional healthcare expenditures and
productivity losses for the employers of their parents. A 2001 U.S. Department of
Agriculture (USDA) study estimated that at least $500 million (in year 1998 dollars) could
be saved in healthcare costs if breastfeeding rates were increased to match those
recommended by the Surgeon General and the Healthy People 2010 goals.15
Breastfeeding and Employment: Barriers and Opportunities
Despite the well-documented benefits of breastfeeding, only 70% of new mothers initiate
breastfeeding and only 36% continue to breastfeed for the recommended 6-month
minimum.1 Women who — at the birth of their child — intend to return to work full-time
are even less likely to initiate breastfeeding.16  Employed women also have a shorter duration
of breastfeeding than do women who do not work outside the home.16 Low rates of
breastfeeding among working women should be of great concern to employers. Mothers are
the fastest growing segment of the U.S labor force and approximately 70% of employed
mothers with infants or toddlers work full-time.16 Further, one-third of working mothers
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Employer Success Story: Johnson & Johnson11
Johnson & Johnson, a manufacturer of healthcare products, offered a comprehensive
health and wellness program to its employees. The program offered on-site fitness centers,
an internet-based lifestyle management program, and a $500 premium incentive to those
who completed a health risk appraisal (HRA) and enrolled in a high-risk intervention
program (as needed). For those with chronic medical conditions, such as hyperlipidemia,
the program also offered lifestyle counseling with a registered nurse, and a comprehensive
disease and care management program. Over a 2.75 year period, the program yielded a
9% decrease in the number of participating employees with high cholesterol levels.
Medical expenses decreased by $225 per participating employee, per year, over four years.
As a result, Johnson & Johnson saw a savings of approximately $8.5 million per year
due to reduced inpatient hospital use, fewer mental health visits, and fewer
outpatient doctor’s office visits. Job absenteeism also decreased.
return to work within 3 months of the birth of their child and two-thirds return within 6
months, the exact time period when breastfeeding is most critical.16 The negative effect of
part- and full-time work on breastfeeding rates is not absolute. Employers who provide
employees with worksite lactation programs effectively increase the number of their
employees who continue breastfeeding after returning to work.
Employers can support breastfeeding mothers in multiple ways:
1. Purchasers can include breastfeeding counseling as a component of their medical
benefit plan. For more information about breastfeeding counseling, please refer to the 
breastfeeding subsection of the “Health Pregnancy” chapter located in Parts II and III
of the Purchaser’s Guide. 
2. Employers can ensure that their beneficiaries have access to baby-friendly hospitals
that promote the initiation of breastfeeding. The World Health Organization (WHO)
provides guidelines on hospital breastfeeding policies and several domestic
organizations track hospitals who comply with this well-recognized international
guideline.17 Employers can preferentially select baby-friendly hospitals to include in
their health plan networks and encourage their beneficiaries to choose baby-friendly
hospitals through education, incentives, or reduced copays/coinsurance. 
3. Employers can provide a worksite lactation program. 
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Employer Action Example: Worksite Lactation Program16
The implementation of a worksite lactation program is one way an employer can support its 
breastfeeding employees. The essential components of a worksite lactation program include:
SPACE
A nursing mother’s room (NMR) or other designated space that is centrally located, has 
adequate lighting, ventilation, and privacy; has a sink, an electrical outlet, and a designated 
refrigerator.
EQUIPMENT
Breast-pumps (employers may provide single or multi-user pumps, subsidize employee 
purchased pumps, or require employees to bring their own pumps).
WRITTEN COMPANY POLICIES REGARDING
• Breastfeeding
• Maternity leave
• Use of vacation days, flex time, sick days, personal time, and FMLA.
• Breaks for expressing milk (two breaks and a lunch period for each 8-hour work period).
EDUCATION
• Communicate the breastfeeding support policy to all employees.
• Provide a list of community resources available to support breastfeeding women.
• Train supervisors and managers on the company breastfeeding policy.
Other services such as access to a lactation specialist on an as needed basis at the 
worksite or in the beneficiary’s home can further support breastfeeding.
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Employer Action Example: Hospital Network Selections to Support Breastfeeding12,17
The World Health Organization (WHO)/UNICEF’s Baby-Friendly Hospital Initiative seeks to
acknowledge hospitals that promote breastfeeding through a variety of programs, policies,
and supports. To qualify as “baby-friendly,” hospitals and birthing centers must prove that
they follow the WHO’s Ten Steps to Successful Breastfeeding Guideline as follows:
• Have a written breastfeeding policy that is routinely communicated to all healthcare
staff.
• Train all healthcare staff in skills necessary to implement this policy.
• Inform all pregnant women about the benefits and management of breastfeeding.
• Help mothers initiate breastfeeding within one hour of birth.
• Show mothers how to breastfeed and how to maintain lactation even if they should
be separated from their infants.
• Give newborn infants no food or drink other than breast milk, unless medically indicated.
• Practice rooming-in (allowing mothers and infants to remain together 24 hours a day).
• Encourage breastfeeding on demand.
• Give no artificial treats or pacifiers to breastfeeding infants.
• Foster the establishment of breastfeeding support groups and refer mothers to them 
on discharge from the hospital or clinic.
To ensure beneficiary access to baby-friendly hospitals that comply with the WHO 
breastfeeding guideline, employers should:
• Direct health plans to include baby-friendly hospitals in-network.
• Work with healthcare consultants, health plans, and benefits staff to develop a
mechanism to encourage women to birth at baby-friendly hospitals. To steer
beneficiaries toward baby-friendly hospitals employers can:
> Educate beneficiaries on the benefits of delivering their baby at a baby-friendly
hospital.
> Educate beneficiaries on the importance of breastfeeding initiation and
maintenance.
> Provide monetary or other types of incentives (e.g., baby car-seats) to
beneficiaries who birth at baby-friendly hospitals.
> Reduce copayment/coinsurance amounts for services rendered at baby-friendly
hospitals.
A list of Baby-friendly hospitals located in the United States can be found at:
www.babyfriendlyusa.org
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Employer Success Story: CIGNA18
CIGNA, an insurance and benefits company based in Philadelphia, offers a corporate 
lactation program for all employees who breastfeed. The program was created in 1995
when CIGNA employees asked for assistance in continuing to breastfeed after returning
from maternity leave. To date, over 1,000 women have enrolled in the Working Well Moms
program in more than 250 CIGNA offices. The program provides consultation for mothers
with a professional lactation consultant before and after birth and access to a private room
equipped with a hospital-grade breast pump, refrigerator, carrying case, and supplies.
The Working Well Moms program has enabled CIGNA to surpass the Healthy People 2010
6-month breastfeeding objective by 45%. Breastfeeding duration for women enrolled in the
Working Well Moms program is 72.5% at 6 months post-birth (nationally only 21.1%
employed mothers continue breastfeeding for 6 months). And 36% of women enrolled in
the Working Well Moms continue to breastfeed through the first year of their baby’s life;
nationally only 10.1% of employed mothers breastfeed their babies to 1-year of age.
As a result of the Working Well Moms program, CIGNA saw a savings of $300,000 in
annual healthcare expenses for breastfeeding mothers and their children. The 
program also reduced absenteeism among breastfeeding mothers.
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Additional information for employers on
clinical preventive services, including:
• Life Course Maps
- Recommended Schedule of 
Preventive Care for Adults
- Recommended Schedule of Preventive 
Care for Children and Adolescents
- Recommended Schedule of 
Preventive Preconception, Prenatal and 
Postpartum Care
• Comparison of A Purchaser’s Guide
to Clinical Preventive Services,
USPSTF Recommendations, NCQA
HEDIS® Measures, NCQA Industry
Trends and Analysis, and Healthy
People 2010 Goals
• Glossary






Visual guides to clinical preventive services across the lifespan:
• Recommended Schedule of Preventive Care for Adults
• Recommended Schedule of Preventive Care for Children and Adolescents
• Recommended Schedule of Preventive Preconception, Prenatal, and Postpartum Care
Crosswalk
A crosswalk between the recommendations proposed in the Guide, the 2007 HEDIS®
Measures, the NCQA State of Healthcare Quality Report, and the Department of Health
and Human Service’s Healthy People 2010 Goals.
Clinical Preventive Services Glossary
Definitions and examples of scientific, medical, and business terms used throughout the
Purchaser’s Guide. 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A crosswalk between the recommendations proposed in the Guide, the 2007 HEDIS®
Measures, the NCQA State of Healthcare Quality Report, and the Department of Health
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Health Care Quality

















































• Screen men and
women 50 years 
















of adults aged 50
years and older.
Cancer 2000: 67% of women age 40
and above have had a




2000: 79% of women age 18
and above have had a pap
smear within the past 3 years^
2010 target: increase
proportion to 90%^
2000: 24% of adults age 50
and above have received a fecal




1998: 37% of adults age 50
and above have received a
sigmonoscopy at some point
during their life^
2010 target: increase
proportion to 50% 
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for men aged 65 to
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• Screen adults aged
18 and older for
high blood
pressure.
• Screen men aged
35 years and older
and women aged


















































2000: 26% of adults age 20
and above have high blood
pressure^
2010 target: reduce proportion
to 14%
2000: 25% of adults age 18
and above with high blood
pressure have it under control
2010 target: increase proportion
to 68%^
2000: 67% of adults age 18
and above have had their blood




2000: 64% of adults age 20
and above with diabetes have
been diagnosed^
2010 target: increase rate to
78%^
2000: there are 5.5 new cases of
diabetes per 1,000 population
aged 18-84
2010 target: reduce incidence
to 3.8 new caser per 











NCQA 2006 State of
Health Care Quality





































































• Flu shots for
adults age 50–64





• Well-child visits in
the first 15
months of life















































2002: 66% of adults age 65




2004: 56% of adults age 65




1998: 87% of children age 19
to 35 months received 3 does
of hepatitis B vaccine in 1998. 
2010: Increase proportion to
80%
2010 target: Ensure that all
newborns are screened at birth
for conditions mandated by their
State-sponsored newborn
screening programs^
1998: 87% of children age 19 to
35 months received 3 does of
hepatitis B vaccine in 1998. 
2010: Increase proportion to
90%
1994: 4.4% of children aged 1-5
years have blood lead levels
exceeding 10 mg/dL^
2010 target: reduce proportion
to 0%
1998: 73% of children receive all
vaccines that have been
recommended for universal
administration for at least 5 years
(DTaP, polio. MMR, Hib and
HepB vaccines)^
2010 target: increase proportion
to 90%^
1994: 131 per 10,000 children
born suffers from mental
retardation and 32.2 per 10,000
suffer from cerebral palsy^
2010 target: reduce rate of
mental retardation to 124 cases
per 10,000 live births and reduce
the rate of cerebral palsy to 31.5
cases per 10,000 live births^
2001: 66% of newborns receive
screenings for hearing loss before
age 1 month, 56% receive
audiologic evaluation before age
3 month, and 57% are enrolled
in appropriate intervention
services by age 6 months. 
2010 target: increase the
proportion of newborns who are
screened for hearing loss by age 1
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evaluation by age 3 months to
70%, and are enrolled in
appropriate intervention services
by age 6 months to 85%.
2002: 36% of children aged 5
years and under had ever had
their vision screened in 2002.
2010 target: increase the
Increase the proportion of
preschool children aged 5 years
and under who receive vision
screening to 52%. 
1997: 48% of adolescents aged
13-15 years received 3 or more
doses of hepatitis B vaccine,
89% received 2 or more doses
of MMR, 93% received 1 or
more tetanus –diphtheria
booster, and 45% received 1
or more doses of varicella (for
chicken pox)^
2010 target: increase
proportions for all vaccines to
90%^
2002: 26% of adolescents in
12th grade smoke1
2010 target: reduce smoking
rate to 16%
1997: 23% of Adults aged 18
years and older with
depression receive treatment
2010 target: increase
proportion to 50% 
2002: 51% of individuals age
12 and above consume
alcohol
2002: 17.6% of adolescents
ages 12-17 consume alcohol
2002: 10.7% of adolescents
aged 12 to 17 binge drink (5
or more drinks on the same
occasion within the past 30
days)
2010 target: Reduce
adolescents engaging in binge
drinking during the past
month to 3.1%^ 
1998: 24.3% of adults aged
18 and older binge drink^
2010 target: reduce
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• Screen all pregnant
women for HIV.

































2002: 65% of U.S. adults,
aged 20 and above, are
overweight
2010 target: reduce
proportion to 15% 
2002: 31% of adults aged 20
and above are overweight
2010 target: reduce
proportion to 15% 
2004: 84% of pregnant
women received timely
prenatal care
2010 target: increase rate to
90%





2002: 13% of mothers




1995: 93% of females 15 to
44 who are at risk of
unintended pregnancy use
contraception.
2010 target: increase rate to
100%
1994: 21% of non-pregnant
women ages 15 to 44 consume
at least 400 mg of folic acid
per day
2010 target: increase rate to
80%
2010 target: Increase the
proportion of pregnant females
screened for sexually
transmitted diseases (including
HIV infection and bacterial
vaginosis) during prenatal
health care visits, according to
recognized standards.
2000: 1,682 chronic hepatitis
B virus infections in children
under age 2 years were
reported in 1995.
2010 target: Reduce chronic
hepatitis B virus infections in
infants and young children
(perinatal infections) to 400
infections.
1996: 6 cases of spina bifida or
other NTD per 10,000 live
births
2010 target: reduce the
number of spina bifida cases to
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risk of infection. 
• Screen all sexually
active women




























screening: 16 to 20
years: 34.4% 







2002: 11% of pregnant
women smoke*, 1997: 14% of
pregnant women drink
alcohol, 1% binge drink, and
2% use illicit drugs
2010 target: reduce smoking
rate to 1%, alcohol use rate to
6%, binge drinking rate to
0%, and illicit drug use rate to
0% 
1997: fetal alcohol syndrome
occurs in 0.4 per 1,000 live
births^
2010 target: reduce incidence
to 0.1 cases per 1,000 live
births^
2002: 25% of sexually active
women aged 25 and under
enrolled in commercial
managed care organizations




2002: there are 279 new cases
of gonorrhea among women
age 15-44 per 100,000
population^
2010 target: reduce the
incidence to 42 new cases per
100,000 population^
1994: 17% of adults age 20-
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• Screen women aged



















































1995: 51% of pregnancies in
the U.S. are intended
2010 target: increase rate to
70%
2002: 8.4 per 100,000 deaths
result form a motor vehicle
accident (age-adjusted deaths)
2010 target: reduce rate to 8.0
deaths per 100,000^
2000: 10% of adults age 50
and above have osteoporosis^
2010 target: reduce
proportion to 8%^
2002: 26% of adolescents in
12th grade smoke1
2010 target: reduce smoking
rate to 16% 
1999: 20% of adult females
and 25% of adult males
smoke1
2010 target: reduce adult
smoking rate to 12%^
1998: 6.8 new cases of TB per
100,000 population^
2010 target: reduce incidence
to 1.0 new cases per 100,000
population^
1997: 62% of contacts and
other high-risk persons with
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1 Adolescent smoking definition: an adolescent in grade 9-12 who smoked one or more cigarettes in the past 30 days. Adult
smoking definition: an adult (≥18 years of age) who smoked more than 100 cigarettes in his/her lifetime and who smoked on
some or all days in the past month. 
2 The NCQA Report on the State of Health Care Quality is based on 500 health plans that voluntarily report HEDIS
measurements to NCQA. 
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Information Sources:
All information on the USPSTF recommendations was adapted from:
U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Pocket Guide; 2005. [cited
2006 Jun 5]. Available from: http://www.ahrq.gov/clinic/pocketgd.htm.  
All information related to the Healthy People 2010 guidelines, unless otherwise noted by * or a ^ was adapted
from: 
U.S. Department of Health and Human Services. Healthy People 2010. 2nd ed. With Understanding and
Improving Health and Objectives for Improving Health. 2 vols. Washington. DC: U.S. Government
Printing Office; November 2000.
^ U.S. Department of Health and Human Services. Healthy People 2010. Midcourse Review.
Washington, DC: U.S. Department of Health and Human Services. Office of Disease Prevention and
Health Promotion. [cited 2006 Jun 13]. Available from:
http://www.healthypeople.gov/data/midcourse/comments/objectives.asp.  
All information from NCQA was adapted from:
National Committee for Quality Assurance (NCQA). The State of Healthcare Quality: 2006. National
Committee for Quality Assurance (NCQA); Washington, DC; 2006. 
National Committee for Quality Assurance (NCQA). The State of Healthcare Quality: 2004. National
Committee for Quality Assurance (NCQA); Washington, DC; 2004.
National Committee for Quality Assurance (NCQA). HEDIS 2007 Summary Table of Measures and
Product Lines. Measure List. Washington, DC: National Committee for Quality Assurance; 2006.
[cited 2006 Sept 15]. Available from: http://www.ncqa.org/Programs/HEDIS/2007/MeasuresList.pdf.  
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Glossary
Absenteeism: Missing days from work. In terms of health-related absenteeism, it can be attributed to general
sickness, workers’ compensation, short-term disability, long-term disability, sick leave, Family Medical
Leave Act (FMLA), paid time off (PTO), unpaid leave, and death (premature mortality costs).1
Asymptomatic: Lacking symptoms of a disease or condition. 
At-work productivity decline (also see presenteeism): Reduced normal activity and job output due to a
health problem.2
Bed days: Number of days-of-stay in a healthcare facility (e.g., hospital) used to treat a condition or
population. “Hospital bed days per thousand,” for example, may describe the average number of inpatient
days used in a specified period of time for every 1,000 employees.
Chemoprophylaxis: The prevention of infectious disease through the use of chemical agents3; such as drugs;
also called preventive medication. 
Clinical preventive services: A comprehensive term referring to a variety of interventions delivered to an
individual (e.g., screenings, counseling, immunizations, and preventive medication) intended to detect
conditions for which the individual has no symptoms of disease or to prevent escalation of an established
disease or condition. 
Cohort: A defined group of individuals; a group of individuals with a common statistical factor (such as birth
year, age, or risk).3
Comorbidity: The presence of multiple diseases or conditions that are simultaneously present and not
necessarily caused by one another. For example, a patient with type 2 diabetes and depression is said to
have comorbid diabetes and depression. Comorbid disorders may interact to affect clinical course, severity,
risk factors for other conditions, or to alter the appropriateness of tests and treatments that are normally
used to manage a single condition. Comorbidity may be used as a prognostic indicator for length of
hospital stay, cost factors, and outcome or survival.5
Complication: A side effect, secondary condition, or adverse effect related to an underlying condition.
Complications may occur because of the natural course of a disease (e.g., death can be a complication of an
untreated heart attack) or may occur as the result of medical procedure or treatment (e.g., post-operative
infection). 
Cost, indirect: Expenses associated with an illness, condition, or disorder that are not immediately related to
treatment. These non-medical expenditures include lost wages, lost workdays, costs related to using
replacement workers, overtime premiums, productivity losses related to unscheduled absences, and
productivity losses of workers while on the job.1
Cost, direct: Dollars spent on health services. Direct costs include out-of-pocket payments, medical insurance
benefits (e.g., medical, pharmacy, dental, mental health), disability payments, and workers' compensation
losses.1
Cost-effective: A determination that the net cost per unit of health generated by an intervention is favorable
in comparison with other health services.
Cost-effectiveness: Minimum cost for a given benefit, the maximum benefit for a given cost, or a balance of
low cost and high benefit that has maximum utility.
Cost-effectiveness analysis (CEA): An economic analysis designed to compare the net cost (expense) of an
intervention with the net expense of one or more other interventions. CEAs usually use a common
outcome measure, such as years-of-extended life or quality-adjusted life years in which all expenditures are
related to a single, common effect, usually in terms of expense per outcome achieved.
Cost-effectiveness (CE) ratio: The ratio of total investment expenditures to total accrued benefits, in terms of
both dollars and benefit value. This is comparable to a Return-on-Investment (ROI) calculation.
Cost, out-of-pocket: Expenditures for a healthcare service that are not covered by a health plan or other third
party and for which an individual is directly responsible.
Cost-saving: The reduction in healthcare expenses resulting from an intervention or program after accounting
for the cost required to develop, implement, and maintain the given intervention or program.
Cost, total: The sum of all direct and indirect costs.
Counseling: An intervention during which a clinical provider gives information to an individual about
changes in personal behavior that can reduce the risk of illness or injury.
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Disability: Inability to pursue an occupation or perform job tasks because of physical or mental impairment.3
Direct medical expense: The economic value directly attributable to a particular clinical action, purchase,
program or initiative; the amount spent for diagnosis, treatment or prevention of medical problems. Direct
medical expenses include visits to physician’s offices and treatment expenditures. 
Evidence-based medicine: The conscientious, explicit, and judicious use of current best evidence in making
decisions about the care of individual patients. The practice of evidence-based medicine integrates
individual clinical expertise with the best available external clinical evidence from systematic research.4
Evidence-based recommendations: Require “First, good evidence that each test or procedure recommended is
medically effective in reducing morbidity or mortality; second, the medical benefits must outweigh the
risks; third, the cost of each test or procedure must be reasonable compared to its expected benefits; and
finally, the recommended actions must be practical and feasible.”8 [Note: The USPSTF does not consider cost
as a factor in its recommendations.] 
Excess medical costs: Any medical expenditure related to a preventable disease or health condition, for
example, spending for an amputation necessitated by poorly controlled diabetes or expenses related to a
hospital-acquired infection. 
Health economics: A branch of economics concerned with analyzing the costs and consequences of
healthcare. Health economics uses mathematical models to synthesize data from biostatistics and
epidemiology to support medical decision-making, both for individuals and for wider health policy.5
Health promotion program (also see wellness program): Any prevention initiative aimed at changing
lifestyle behaviors associated with greater risk of disease. These initiatives actively encourage healthy
activities such as substance abuse control, weight management, smoking cessation, stress management,
physical activity, or the like.
Health risk appraisal/Health risk assessment (HRA): A standardized assessment tool administered to
employees (or other groups of individuals) that measures an individual’s wellness and disease risk factors,
interest in participating in specific programs, and readiness to change unhealthy lifestyle habits.
Health Plan Employer Data and Information Set (HEDIS®): HEDIS® is a United States program from the
National Committee for Quality Assurance (NCQA) that consists of multiple, diverse measures of clinical
and administrative outcomes by which the performance of a health plan can be compared to other plans,
national or regional benchmarks, or the plan's performance from previous years.
Herd immunity: The immunity of a group or community. When a high proportion of a community is
immunized against a particular communicable disease, the entire community (including those who are
immunized) is resistant to the invasion and spread of an infectious agent because there are not enough non-
immune people to transmit the disease.
High-value: An intervention that is both evidence-based and cost-effective. 
Immunization (also see vaccination): The administration of a substance, usually by injection, oral, or nasal
administration, that produces protective immunity to one or more specific diseases.
Incidence: The number of new cases of a particular illness or condition reported in a given time period (e.g.,
day, week, year). 
Indirect medical expense: Money expenditures associated with an illness, condition, or disorder, but not
immediately related to treatment of that disorder. 
Life-years gained: A measure of value gained from a healthcare intervention: the average number of extra years
of life resulting from treatment when compared with non-treatment. It does not include measures of
quality of life or disability status (e.g., QALY, DALY).
Lost productivity: Total limitation in work experienced by an individual. It is a sum of lost workdays and
productivity decline.2
Lost workdays: Days for which an individual reports being unable to complete normal activities due to a
health condition.
Lost workday cases: Cases that involve consecutive or nonconsecutive days away from a job, on restricted
activity, or both as a result of injury or illness. Counting of lost workday cases should begin following the
day an injury occurs or a disease or illness commences.
Morbidity: The relative frequency and severity of a disease in a defined population; the result of experiencing
illness from a disease or condition (excluding death). For example, untreated type 2 diabetes may result in
morbidities such as blindness, infections, neuropathies, and other problems. 
Mortality: The number of deaths in a defined population or more specifically, the number of deaths
attributable to a particular type of illness or disease.
Premature mortality: The number of deaths of people aged 0 to 74 years. Premature mortality is an
important indicator of the general health of a population as a high premature mortality rate indicates poor
population health status.4
Presenteeism: Describes an employee who is at work but not fully functioning while there. In this context,
presenteeism refers to those situations whereby an employee’s job performance or productivity is impaired
by a health problem.1
Prevalence: The proportion of the general population affected by a specific illness or condition at a specific
point in time or during a defined period of time.
Preventive medication: A medication taken to prevent the occurrence or delay the onset of a disease or
condition.
Primary care: Clinical care provided by family physicians, pediatricians, internal medicine doctors, or
obstetrician/gynecologists who treat general illnesses, provide clinical preventive services, and triage patients
for specialized medical care.
Primary prevention: is aimed at preventing the onset of disease. One way of doing this is by controlling risk
factors in healthy people that may lead to disease. Examples of primary prevention include 1)
immunizations to prevent communicable diseases such as influenza or polio, and 2) promotion of physical
activity to prevent conditions such as obesity that can lead to disease (e.g., type 2 diabetes).
Primary preventive service: Any service, procedure, medication, counseling, or immunization aimed at
avoiding or delaying illness. 
Productivity: The amount of output produced by a worker in a given period of time (hour or day, etc.).2
Recommended guidance: A recommendation or guideline that is based on the best-available information for
a condition, disease, or health service, but that does not yet have the scientific research support to be
considered evidence-based.
Return-on-investment (ROI): A comparison of the money earned (or lost) on an investment to the amount
of money invested. For example, every $1 an employer spends on immunization produces a return of $3 in
avoided healthcare costs. It is important to note that ROI is not a proxy for cost-effectiveness or vice versa.
Interventions that are cost-effective or even cost-saving at the societal level do not necessarily yield a
positive ROI from the business perspective, although they may provide a better value than other services.6
Risk, at-: Possessing a chance of succumbing to a disease or condition due to specific genetic markers, personal
history, behaviors, or other factors.
Risk, high: Possessing a greater chance of succumbing to a disease or condition than the general population
due to specific genetic markers, personal history, behaviors, a lack of immunity, or other factors.
Risk, low: Possessing a lesser chance of succumbing to a disease or condition than the general population due
to specific genetic markers, personal history, behaviors, or other factors.
Screening: A test or examination designed to identify an individual’s risk of developing an illness or condition
(i.e. blood pressure measurement or cholesterol reading).
Secondary prevention: is aimed at treating a disease after its onset, but before it causes serious complications.
Secondary prevention includes 1) identifying individuals with established disease, and 2) treating those
individuals in a timely way so as to prevent further problems (e.g., mammography screening to detect and
treat breast cancer in its earliest stages).
Spontaneous abortion (miscarriage): A sudden unplanned miscarriage of the fetus from the womb. The
terms fetal death and stillborn refer to the spontaneous death of a fetus in later stages of pregnancy. 
Symptomatic: Having characteristics that indicate the presence of a disease or condition.
Tertiary prevention: is aimed at treating the late or final stages of a disease so as to minimize the degree of
disability caused by that disease (e.g., administering a foot check to a person with diabetes to identify
infections that would require amputation if left untreated).
Test: Any technique used to determine whether a condition is present or not or to measure its level of activity
or severity. Tests include, for example, maneuvers such as physical examinations, laboratory-based
examinations of blood and other tissues, X-ray examinations, and questionnaires, among others.
Vaccination (also see immunization): The administration of a substance, usually by injection, oral, or nasal
administration, that produces protective immunity to one or more specific diseases.
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Wellness program (also see health promotion program): Any prevention initiative aimed at changing
lifestyle behaviors associated with greater risk of disease. These initiatives actively encourage healthy
activities such as substance abuse control, weight management, smoking cessation, stress management,
physical activity, or the like.
Work loss: Time away from a job or an inability to perform normal work activities because of a health problem.
References:
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from: http://www.acoem.org/health_productivity/terms.asp. 
2. Center for Prevention and Health Services. Improving Health Improving Business: An Employer’s Guide to
Clinical Preventive Services. Washington, DC: National Business Group on Health; 2004.
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Links to Cost-Calculators and Additional Resources 
Cost-Calculators
Alcohol Misuse
• George Washington University Alcohol Treatment ROI Calculator,
http://www.alcoholcostcalculator.org/roi/
Diabetes
• Diabetes at Work, Conducting a Diabetes Assessment.  General Assessment Tool.
http://www.diabetesatwork.org/diabetesatwork/assessing_gen.cfm
Obesity and Physical Activity
• American Cancer Society ROI Calculator for Obesity and Physical Activity,
http://www.acsworkplacesolutions.com/obesitycalculator.asp
• Magellan Health Services Obesity Cost Calculator.
http://www.magellanassist.com/customer/services/obesitycost/default.asp
Tobacco
• American Cancer Society ROI Calculator for Tobacco,
http://www.acsworkplacesolutions.com/tobaccocalculator.asp
• America’s Health Insurance Plans (AHIP) and Center for Health Research, Kaiser
Permanente Tobacco ROI calculator, http://www.businesscaseroi.org/roi/default.aspx
• Free & Clear Employer and Health Plan ROI Calculator for Tobacco,
http://www.freeclear.com/case_for_cessation/econ_impact.aspx?nav_section=2#
Additional Resources
U.S. Department of Health and Human Services (Federal)
• Advisory Committee on Immunization Practices (ACIP),
http://www.cdc.gov/nip/ACIP/default.htm
- Standards for Child and Adolescent Immunization Practices:
http://www.cdc.gov/nip/publications/pink/appendices/H/standards-pediatric.pdf
- Standards for Adult Immunization Practices:
http://www.cdc.gov/nip/recs/rev_stds_adult_AJPM.pdf
• Agency for Healthcare Research and Quality (AHRQ), http://www.ahrq.gov
• Centers for Disease Control and Prevention (CDC), http://www.cdc.gov
• Healthy People 2010 Goals, http://www.healthypeople.gov/
• National Guidelines Clearinghouse, http://www.guideline.gov/
• National Healthcare Quality Report (AHRQ), http://www.qualitytools.ahrq.gov/
• National Institutes of Health (NIH), http://www.nih.gov
• Office of the U.S. Surgeon General, http://www.surgeongeneral.gov/
• Steps to a Healthier U.S., Prevention Portfolio, Department of Health and Human
Services (U.S. DHHS), http://www.healthierus.gov/steps/documents.html#portfolio
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• U.S. Department of Health and Human Services (USDHHS), http://www.dhhs.gov/
• U.S. Preventive Services Task Force (USPSTF), http://www.ahrq.gov/clinic/prevenix.htm
• U.S. Public Health Service (USPHS), http://www.usphs.gov
Professional Organizations
• American Academy of Family Physicians (AAFP), http://www.aafp.org
• American Academy of Pediatrics (AAP), http://www.aap.org
• American College of Obstetricians and Gynecologists (ACOG), http://www.acog.org
• American College of Occupational and Environmental Medicine (ACOEM),
http://www.acoem.org/
• American College of Preventive Medicine (ACPM), http://www.acpm.org/
• American Medical Association (AMA), http://www.ama.org
• American Speech-Language-Hearing Association (ASHA), http://www.asha.org
• American College of Allergy, Asthma, & Immunology (ACAAI), http://www.acaai.org
• American College of Cardiology, http://www.acc.org/
Other
• Institute of Medicine (IOM), http://www.iom.edu
• National Committee on Quality Assurance (NCQA), http://www.ncqa.org
• HEDIS Data Set, National Committee on Quality Assurance (NCQA),
http://www.ncqa.org/communications/publications/hedispub.htm
Condition/Disease Specific Resources (Federal)
• Joint National Committee on the Prevention, Detection, Evaluation, and Treatment
of High Blood Pressure (JNC 7),
http://hyper.ahajournals.org/cgi/content/full/hypertensionaha;41/6/1178
• National Cancer Institute (NCI), http://www.nci.nih.gov
• National Cholesterol Education Program (NCEP),
http://www.nhlbi.nih.gov/about/ncep/index.htm
• National Heart, Lung, and Blood Institute (NHLBI), http://www.nhlbi.nih.gov
> Dietary Approaches to Stop Hypertension (DASH) Eating Plan,
http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/.
> Framingham-based risk assessment tool,
http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.
> Healthy diet tip sheets, http://www.nhlbi.nih.gov/chd/Tipsheets/daily.htm.
> Hypertension risk assessment tool,
http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.
> Therapeutic lifestyle change tip sheets,
http://www.nhlbi.nih.gov/chd/Tipsheets/daily.htm.
> Your Guide to Lowering your Cholesterol Level with Therapeutic Lifestyle Changes,
http://www.nhlbi.nih.gov/health/public/heart/chol/chol_tlc.pdf.
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• National Institute of Alcohol Abuse and Alcoholism (NIAAA),
http://www.niaaa.nih.gov/
• National Institute of Occupational Health and Safety (NIOSH),
http://www.cdc.gov/niosh/homepage.html
Condition/Disease Specific Resources (Non-Federal)
• American Cancer Society (ACS), http://www.acs.org
• American Dental Association (ADA), http://www.ada.org
• American Diabetes Association (ADA), http://www.diabetes.org
• American Dietetics Association (ADA), http://www.eatright.org
• American Heart Association (AHA), http://www.americanheart.org
• American Lung Association (ALA), http://www.lungusa.org
• American Managed Behavioral Healthcare Association (AMBHA),
http://www.ambha.org
• American Stroke Association, http://www.strokeassociation.org
• March of Dimes, http://www.marchofdimes.com
• National Mental Health Association (NHMA), http://www.nmha.org
• National Stroke Association, http://www.stroke.org
Supplemental Guides and Resources
• Agency for Healthcare Research and Quality, The Pocket Guide to Clinical Preventive
Services 2005, http://www.ahrq.gov/clinic/pocketgd.htm
• Agency for Healthcare Research and Quality, 2005 National Healthcare Disparities
Report, http://www.ahrq.gov/qual/nhdr05/nhdr05.htm
• Centers for Disease Control and Prevention, The CDC Guide to Breastfeeding
Interventions, http://www.cdc.gov/breastfeeding/resources/guide.htm
• Centers for Disease Control and Prevention, The Community Guide to Preventive
Services, http://www.thecommunityguide.org/
National Business Group on Health Resources
• Improving Health, Improving Business: the Employer’s Guide to Health
Improvement and Preventive Services,
http://www.businessgrouphealth.org/services/index.cfm
• Consumer Drive Healthcare for Children: An Employer’s Guide to Developing Child
and Adolescent Benefits,
http://www.businessgrouphealth.org/prevention/et_childhealthcareconsumer.cfm
• An Employer’s Guide to Behavioral Health Services: A Roadmap and





Abdominal Aortic Aneurysm, Screening, 51, 73 107
Alcohol Misuse, Screening and Counseling, 51, 73, 113
Aspirin Therapy for the Prevention of Cardiovascular Disease, Counseling, 51, 73, 125
Breast Cancer, Screening, 52, 73, 131
Breast Cancer, Genetic Risk Assessment and BRCA Mutation Testing,
Counseling, testing, and preventive treatment, 52, 74, 132
Breast Cancer, Counseling and preventive medication, 52, 75, 133
Cervical Cancer, Screening, 53, 76, 145
Childhood Health Promotion, Child Development, Screening, 54, 77, 154
Childhood Health Promotion, Dental Caries, Preventive medication, 54, 77, 160 
Childhood Health Promotion, Immunizations, 54, 88, 337
Childhood Health Promotion, Lead, Elevated Blood Level, Screening, 54, 78, 164
Childhood Health Promotion, Newborn Screening for Genetic and Endocrine
Disorders, Screening, medical foods, and treatment, 55, 78, 169
Childhood Health Promotion, Newborn Hearing, Screening, 55, 78, 175
Childhood Health Promotion, Vision, Screening, 56, 78, 181
Colorectal Cancer, Screening, 57, 79, 195
Contraceptive Use, Counseling and preventive intervention, 57, 79, 201
Depression, Screening, 57, 79, 211
Diabetes (type 2), Screening, 58, 79, 217
Healthy Diet, Counseling, 58, 80, 227
Healthy Pregnancy, Alcohol Misuse, Screening and counseling, 58, 80, 243
Healthy Pregnancy, Asymptomatic Bacteriuria, Screening, 59, 81, 248
Healthy Pregnancy, Breastfeeding, Counseling, 59, 81, 252
Healthy Pregnancy, Folic Acid Supplementation, Counseling and preventive medication, 60, 81, 257
Healthy Pregnancy, Group B Streptococcal Disease (GBS), Screening and 
preventive medication, 60, 81, 262
Healthy Pregnancy, Hepatitis B Virus (HBV), Screening, immunization, and treatment, 61, 81, 266
Healthy Pregnancy, Human Immunodeficiency Virus (HIV), Screening, counseling,
and preventive medication, 62, 82, 272
Healthy Pregnancy, Influenza, Immunization, 63, 83, 277
Healthy Pregnancy, Preeclampsia, Screening, 63, 83, 281
Healthy Pregnancy, Prenatal Diagnosis of Chromosomal Abnormalities,
Screening and testing, 63, 83, 284
Healthy Pregnancy, Rh (D) Incompatibility, Screening and preventive medication, 64, 87, 290
Healthy Pregnancy, Rubella, Screening, 64, 87, 294
Healthy Pregnancy, Syphilis, Screening, 64, 87, 298
Healthy Pregnancy, Tetanus, Immunization, 65, 87, 302
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Healthy Pregnancy, Tobacco Use Treatment, Screening and counseling, 65, 88, 305
Hypertension, Screening, counseling and treatment, 65, 88, 323
Immunizations (Child, Adolescent, Adult), 66, 88, 337
Lipid Disorders, Screening, counseling, and treatment, 66, 92, 349
Motor Vehicle-Related Injury Prevention, Counseling, 67, 92, 363
Obesity, Screening, counseling, and treatment, 67, 93, 373
Osteoporosis, Screening and treatment, 68, 94, 383
Sexually Transmitted Infections (STIs), Counseling to Prevent STIs, Counseling, 69, 94, 393
Sexually Transmitted Infections (STIs), Chlamydia, Screening, 69, 95, 395
Sexually Transmitted Infections (STIs), Gonorrhea, Screening, 69, 95, 398
Sexually Transmitted Infections (STIs), Human Immunodeficiency Virus (HIV),
Screening and counseling, 70, 96, 401
Sexually Transmitted Infections (STIs), Syphilis, Screening, 70, 96, 407
Tobacco Use Treatment, Screening, counseling, and treatment, 71, 96, 415
Tuberculosis, Screening, 71, 97, 427
